0001437749-21-006778.txt : 20210322 0001437749-21-006778.hdr.sgml : 20210322 20210322170415 ACCESSION NUMBER: 0001437749-21-006778 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 88 CONFORMED PERIOD OF REPORT: 20201231 FILED AS OF DATE: 20210322 DATE AS OF CHANGE: 20210322 FILER: COMPANY DATA: COMPANY CONFORMED NAME: InfuSystem Holdings, Inc CENTRAL INDEX KEY: 0001337013 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 203341405 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35020 FILM NUMBER: 21761998 BUSINESS ADDRESS: STREET 1: 31700 RESEARCH PARK DRIVE CITY: MADISON HEIGHTS STATE: MI ZIP: 48071 BUSINESS PHONE: (248) 291-1210 MAIL ADDRESS: STREET 1: 31700 RESEARCH PARK DRIVE CITY: MADISON HEIGHTS STATE: MI ZIP: 48071 FORMER COMPANY: FORMER CONFORMED NAME: HAPC, Inc. DATE OF NAME CHANGE: 20060425 FORMER COMPANY: FORMER CONFORMED NAME: Healthcare Acquisition Partners Corp. DATE OF NAME CHANGE: 20050824 10-K 1 infu20201119_10k.htm FORM 10-K infu20201119_10k.htm
 

Table of Contents

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C., 20549


 

FORM 10-K


 

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2020

OR

 

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

For the transition period from _________________ to ___________________

 

Commission File Number: 001-35020


 

infulogo.jpg

INFUSYSTEM HOLDINGS, INC.

(Exact Name of Registrant as Specified in its Charter)


Delaware

20-3341405

(State or Other Jurisdiction of

Incorporation or Organization)

(I.R.S. Employer Identification No.)

3851 West Hamlin Road

Rochester Hills, Michigan 48309

(Address of Principal Executive Offices) (Zip Code)

 

Registrants Telephone Number, including Area Code:

(248) 291-1210


 

Securities Registered Pursuant to Section 12(b) of the Act:

 

Title of Each Class

Trading Symbol(s)

Name of Each Exchange on which Registered

Common Stock, par value $0.0001 per share

INFU

NYSE American LLC

 

Securities Registered Pursuant to Section 12(g) of the Act:

None

(Title of Class)


 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    YES  ☐    NO   ☒

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.    YES  ☐    NO   ☒

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods as the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.    YES  ☒    NO   ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    YES  ☒    NO   ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☒ Smaller reporting company ☒
       
Emerging growth company ☐      

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    YES  ☐    NO   ☒

 

The aggregate market value of the registrant’s voting equity held by non-affiliates of the registrant, computed by reference to the price at which the common stock was last sold as of the last business day of the registrants most recently completed second fiscal quarter, was $150,739,346. In determining the market value of the voting equity held by non-affiliates, securities of the registrant beneficially owned by directors and officers of the registrant and persons who hold 10% or more of the outstanding common stock of the registrant have been excluded. This determination of affiliate status is not necessarily a conclusive determination for other purposes. The number of shares of the registrant’s common stock outstanding as of March 16, 2021 was 20,336,671.

 

 

DOCUMENTS INCORPORATED BY REFERENCE

Portions of the registrant’s definitive proxy statement to be filed with the Securities and Exchange Commission in connection with the solicitation of proxies for its 2021 Annual Meeting of Stockholders are incorporated by reference in Part III of this Form 10-K.

 

 

 

 

TABLE OF CONTENTS

 

 

PART I

 
       
 

Item 1.

Business

3
       
 

Item 1A.

Risk Factors

10
       
 

Item 1B.

Unresolved Staff Comments

20
       
 

Item 2.

Properties

20
       
 

Item 3.

Legal Proceedings

20
   
 

Item 4.

Mine Safety Disclosures

20
       

PART II

 
       
 

Item 5.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

21
       
 

Item 6.

Selected Financial Data

22
       
 

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

22
       
 

Item 7A.

Quantitative and Qualitative Disclosure About Market Risk

34
       
 

Item 8.

Financial Statements and Supplementary Data

35
       
 

Item 9.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosures

66
       
 

Item 9A.

Controls and Procedures

66
       
 

Item 9B.

Other Information

67
   

PART III

 
       
 

Item 10.

Directors, Executive Officers and Corporate Governance

67
       
 

Item 11.

Executive Compensation

67
       
 

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

68
       
 

Item 13.

Certain Relationships and Related Transactions and Director Independence

68
       
 

Item 14.

Principal Accounting Fees and Services

68
   

PART IV

 
       
 

Item 15.

Exhibits, Financial Statement Schedules

69
       
 

Item 16.

Form 10-K Summary

73

 

 

 

References in this Form 10-K to we, us, or the Company are to InfuSystem Holdings, Inc. (InfuSystem) and our wholly owned subsidiaries, as appropriate to the context.

 

Cautionary Statement About Forward-Looking Statements

 

Certain statements contained in this Form 10-K are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” “strategy,” “future,” “likely,” variations of such words, and other similar expressions, as they relate to the Company, are intended to identify forward-looking statements. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. In connection with the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, the Company is identifying certain factors that could cause actual results to differ, perhaps materially, from those indicated by these forward-looking statements. InfuSystem does not intend and does not undertake any obligation to update any forward-looking statement to reflect future events or circumstances after the date of such statements, except as may be required by law. Important factors that could cause our actual results and financial condition to differ materially from the forward-looking statements include, without limitation, those described in “Risk Factors” and elsewhere in this Form 10-K, and the following:

 

 

changes in third-party reimbursement processes, rates, contractual relationships and payer mix;

 

our dependence on estimates of collectible revenue from third-party reimbursement;

 

risks associated with the loss of a relationship with one or more third-party payers;

 

risks associated with a federal government shutdown;

 

risks associated with the federal government’s sequestration;

 

physicians’ acceptance of infusion pump therapy over alternative therapies and focus on early detection and diagnostics;

 

our dependence on our Medicare Suppler Number, which allows us to bill Medicare for services provided to Medicare patients;

 

availability of chemotherapy drugs used in our infusion pump systems;

 

our expectations regarding enacted and potential legislative and regulatory changes impacting, among other things, the level of reimbursement received from the Medicare and state Medicaid programs including the Center for Medicare and Medicaid Services (“CMS”) competitive bidding;

 

our dependence upon our suppliers;

 

periodic reviews and billing audits from governmental and private payers;

 

our ability to maintain controls and processes over billing and collection and the adequacy of our allowance for doubtful accounts and customer concessions;

 

our ability to comply with state licensure laws for Durable Medical Equipment suppliers;

 

risks associated with our allowance for doubtful accounts and customer concessions;

 

our ability to execute our business strategies to grow our business, including our ability to introduce new products and services;

 

industry competition;

 

compliance with regulatory guidelines affecting our billing practices;

 

defective products manufactured by third-party suppliers;

 

our ability to execute on acquisition and joint-venture opportunities and integrate any acquired businesses;

 

our ability to maintain relationships with health care professionals and organizations;

 

our ability to comply with changing health care regulations;

 

our ability to remain in compliance with our credit agreement or future debt agreements;

 

general economic uncertainty;

 

changes in tax laws or challenges to our tax positions;

 

volatility in the market price of our stock;

 

the future price our stock may be negatively affected by not paying dividends;

 

potential dilution to current stockholders from the issuance of equity awards; and

 

we may be subject to limitations on net operating loss carryforwards and certain built-in losses following an ownership change.

 

the effect of the coronavirus (COVID-19) pandemic on our business;

 

 

 

litigation in which we may be involved from time to time;

 

risks associated with the collection of sales or consumption taxes;

 

our ability to implement, both internally and externally, information technology improvements and to respond to technological changes, interruptions and security breaches;

 

natural disasters, pandemics, acts of war or terrorism and other external events affecting us, our customers or our suppliers;

 

our ability to protect our intellectual property;

 

our ability to hire and retain key employees;

 

These risks are not exhaustive. Other sections of this Form 10-K include additional factors which could adversely impact our business and financial performance. Moreover, we operate in a very competitive and changing environment. New risk factors emerge from time to time and it is not possible for us to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. All forward-looking statements made in this Form 10-K speak only as of the date of this report. We do not intend, and do not undertake any obligation, to update any forward-looking statements to reflect future events or circumstances after the date of such statements, except as required by law.

 

You should not rely upon forward-looking statements as predictions of future events. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Therefore, you should not rely on any of the forward-looking statements. In addition, with respect to all of our forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

 

Market and Industry Data

 

This Form 10-K contains market, industry and government data and forecasts that have been obtained from publicly available information, various industry publications and other published industry sources. We have not independently verified the information and cannot make any representation as to the accuracy or completeness of such information. None of the reports and other materials of third-party sources referred to in this Form 10-K were prepared for use in, or in connection with, this report.

 

Trademarks and Tradenames

 

We have a number of registered trademarks, including Ambulatory Infusion Made Easy®, Biomed Made Easy®, BlockPain Dashboard®, EXPRESSTech® and Infusion Made Easy®. These and other trademarks of ours appearing in this report are our property. Solely for convenience, trademarks and trade names of ours referred to in this Form 10-K may appear without the ® or ™ symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks and trade names. This report may contain additional trade names and trademarks of other companies. We do not intend our use or display of other companies' trade names or trademarks to imply an endorsement or sponsorship of us by such companies, or any relationship with any of these companies.

 

 

 

PART I

 

Item1.         Business.

 

Background

 

The Company is a Delaware corporation, formed in 2005. It operates through operating subsidiaries, including InfuSystem Holdings USA, Inc., a Delaware corporation (“Holdings”), InfuSystem, Inc., a California corporation (“ISI”), First Biomedical, Inc., a Kansas corporation (“First Biomedical”) and IFC, LLC, a Delaware limited liability company (“IFC”).

 

Business Concept and Strategy

 

We are a leading national health care service provider, facilitating outpatient care for Durable Medical Equipment manufacturers and health care providers. We provide our products and services to hospitals, oncology practices, ambulatory surgery centers, and other alternate site health care providers. Our headquarters is in Rochester Hills, Michigan, and we operate our business from a total of five locations in the United States and Canada.

 

Our services are provided under a two-platform model. Our lead platform, Integrated Therapy Services (“ITS”), provides the last-mile solution for clinic-to-home healthcare where the continuing treatment involves complex Durable Medical Equipment and services. Our second platform, Durable Medical Equipment Services (“DME Services”), supports our ITS platform and leverages strong service orientation to win incremental business from our direct payer clients. Starting in the fourth quarter of 2019, we reorganized the Company’s segment reporting to reflect this two-platform approach and changes made to our internal reporting and the information evaluated by our chief operating decision-maker.

 

We believe InfuSystem has a lot to offer the healthcare community. Over the last 30 plus years, we have developed a unique expertise and service offering that Durable Medical Equipment manufacturers and health care providers are using to reduce costs, improve service, and most importantly, provide welcome options for patients who want to continue their healthcare treatments from home. We perfected our ITS model in oncology and have proven that we can extend this model into other Durable Medical Equipment therapies. Key is the ability to leverage our existing platforms – the new therapies do not require building a new infrastructure, we simply add incrementally to the systems already in place (e.g., sales, clinical, logistics, revenue cycle management, and biomedical services).

 

ITS is presented as a “turnkey” solution allowing our health care provider customers to focus on the practice of medicine. InfuSystem provides the Durable Medical Equipment and treatment consumables, handles the logistics around orders and deliveries, provides 24x7 nursing support relating to the provided equipment, assumes responsibility for third-party payer Durable Medical Equipment billing, and handles biomedical services (inspection, repair, certification and replacement) for the Durable Medical Equipment. DME Services are provided as a “concierge” offering, whereby InfuSystem leverages its strong service orientation to provide incremental services to our health care provider customers on a direct payer model. DME Services include equipment rental and sales, consumable sales, and biomedical support services.

 

InfuSystem competes for and retains its business primarily on the basis of its long participation and strong reputation in the Durable Medical Equipment space, its long-standing relationships with Durable Medical Equipment manufacturers and its health care provider customers, and the high levels of service it provides. Current barriers to entry for potential competitors are created by our: (i) growing number of third-party payer networks under contract, which included nearly 728 third-party payer networks for the fiscal year ended December 31, 2020, an increase of 8% over the prior year period; (ii) economies of scale, which allow for predictable reimbursement and less costly purchase and management of the pumps, respectively; (iii) established, long-standing relationships as a provider of pumps to outpatient oncology practices in the U.S. and Canada; (iv) pump fleet of ambulatory and large volume infusion pumps for rent and for sale, which may allow us to be more responsive to the needs of physicians, outpatient oncology practices, hospitals, outpatient surgery centers, homecare practices, patient rehabilitation centers and patients than a new market entrant; (v) five geographic locations in the U.S. and Canada that allow for same-day or next-day delivery of pumps; and (vi) pump repair and service capabilities at all of these facilities. We do not perform any research and development on pumps, but we have made, and continue to make, investments in our information technology.

 

 

ITS Segment

 

Our ITS segment’s core purpose is to seek opportunities to leverage our unique know-how in clinic-to-home health care involving Durable Medical Equipment, our logistics and billing capabilities, our growing network of third-party payers under contract, and our clinical and biomedical capabilities. This leverage may take the form of new products and/or services, strategic alliances, joint ventures and/or acquisitions. The leading service within our ITS segment is to supply electronic ambulatory infusion pumps and associated disposable supply kits to private oncology clinics, infusion clinics and hospital outpatient oncology clinics to be utilized in the treatment of a variety of cancers including colorectal cancer and other disease states (“Oncology Business”). Colorectal cancer is the third most prevalent form of cancer in the United States, according to the American Cancer Society, and the standard of care for the treatment of colorectal cancer relies upon continuous chemotherapy infusions delivered via ambulatory infusion pumps. One of the primary goals for the ITS segment is to expand into treatment of other cancers. In 2020, our Oncology Business approximated 95% of our total ITS net revenues. In 2020, we generated approximately 50% of our total ITS net revenues from treatments for colorectal cancer and 45% of our ITS net revenues from treatments for non-colorectal disease states. There are a number of approved treatment protocols for pancreatic, head and neck, esophageal and other cancers, as well as other disease states which present opportunities for growth. There are also a number of other drugs currently approved by the U.S. Food and Drug Administration (the “FDA”), as well as agents in the pharmaceutical development pipeline, which we believe could potentially be used with continuous infusion protocols for the treatment of diseases other than colorectal cancer. Additional drugs or protocols currently in clinical trials may also obtain regulatory approval over the next several years. If these new drugs or protocols obtain regulatory approval for use with continuous infusion protocols, we expect the pharmaceutical companies to focus their sales and marketing efforts on promoting the new drugs and protocols to physicians.

 

Furthermore, our Oncology Business focuses mainly on the continuous infusion of chemotherapy. Continuous infusion of chemotherapy can be described as the gradual administration of a drug via a small, lightweight, portable infusion pump over a prolonged period of time. A cancer patient can receive his or her medicine anywhere from one to 30 days per month depending on the chemotherapy regimen that is most appropriate to that individual’s health status and disease state. This may be followed by periods of rest and then repeated cycles with treatment goals of progression-free disease survival. This drug administration method has replaced intravenous push or bolus administration in specific circumstances. The advantages of slow continuous low doses of certain drugs are well documented. Clinical studies support the use of continuous infusion chemotherapy for decreased toxicity without loss of anti-tumor efficacy. The 2015 National Comprehensive Cancer Network (“NCCN”) Guidelines recommend the use of continuous infusion for treatment of numerous cancer diagnoses. We believe that the growth of continuous infusion therapy is driven by three factors: evidence of improved clinical outcomes; lower toxicity and side effects; and a favorable reimbursement environment.

 

The use of continuous infusion has been demonstrated to decrease or alter the toxicity of a number of cytotoxic, or cell killing, agents. Higher doses of drugs can be infused over longer periods of time, leading to improved tolerance and decreased toxicity. For example, the cardiotoxicity (heart muscle damage) of the chemotherapy drug Doxorubicin is decreased by schedules of administration according to The Chemotherapy Source Book by Michael C. Perry. Nausea, vomiting, diarrhea and decreased white blood cell and platelet counts are all affected by duration of delivery. Continuous infusion can lead to improved tolerance and patient comfort while enhancing the patient’s ability to remain on the chemotherapy regimen. Additionally, the lower toxicity profile and resulting reduction in side effects enables patients undergoing continuous infusion therapy to continue a relatively normal lifestyle, which may include continuing to work, going shopping, and caring for family members. We believe that the partnering of physician management and patient autonomy provide for the highest quality of care with the greatest patient satisfaction.

 

We believe that oncology practices have a heightened sensitivity to providing quality service and whether they are reimbursed for services they provide. Simultaneously, CMS and private insurers are increasingly focused on evidence-based medicine to inform their reimbursement decisions — that is, aligning reimbursement with clinical outcomes and adherence to standards of care. Continuous infusion therapy is a main component of the standard of care for certain cancer types because clinical evidence demonstrates superior outcomes. Payers’ recognition of this benefit is reflected in their relative reimbursement policies for clinical services related to the delivery of this care.

 

Additional areas of focus for our ITS segment are as follows:

 

 

Pain Management - providing our ambulatory pumps, products, and services for pain management in the area of post-surgical continuous peripheral nerve block.

 

Negative Pressure Wound Therapy (“NPWT”) - as announced in February 2020, includes providing the Durable Medical Equipment, overseeing logistics, biomedical services, and managing third-party billing of the U.S. home health care market, which as a subset of the broader NPWT market, has an estimated addressable home health care market of $600 million per year.

 

Acquisitions - we believe there are opportunities to acquire smaller, regional health care service providers, in whole or part that perform similar services to us but do not have the national market access, network of third-party payer contracts or operating economies of scale that we currently enjoy. We may also pursue acquisition opportunities of companies that perform similar services, but offer different therapies or utilize different devices.

 

Information technology-based services - we also plan to continue to capitalize on key new information technology-based services such as EXPRESS, InfuSystem Mobile, InfuBus or InfuConnect, Pump Portal and BlockPain Dashboard®.

 

 

The payer environment within our ITS segment is in a constant state of change. We continue to extend our considerable breadth of payer networks under contract as patients move into different insurance coverages, including Medicaid and Insurance Marketplace products. In some cases, this may slightly reduce our aggregate billed revenues payment rate but result in an overall increase in collected revenues, due to a reduction in concessions. Consequently, we are increasingly focused on revenues net of concessions.

 

DME Services Segment

 

Our DME Services segment’s core service is to (i) sell or rent new and pre-owned pole-mounted and ambulatory infusion pumps and other durable medical equipment, (ii) sell treatment-related consumables, and (iii) provide biomedical recertification, maintenance and repair services for oncology practices as well as other alternate site settings including home care and home infusion providers, skilled nursing facilities, pain centers and others. We also provide these products and services to customers in the hospital market. We purchase new and pre-owned pole-mounted and ambulatory infusion pumps from a variety of sources on a non-exclusive basis. We repair, refurbish and provide biomedical certification for the devices as needed. The pumps are then available for sale, rental or to be used within our ambulatory infusion pump management service.

 

Services

 

ITS Segment

 

Our core service within our ITS segment is our Oncology Business. After providing ambulatory pumps to oncology offices, infusion clinics and hospital and outpatient chemotherapy clinics, we then directly bill and collect payment from payers and patients for the use of these pumps. At any given time, our pumps are in the possession of these facilities, on a patient, in transit, or in our facilities for cleaning, calibration and storage as reserves for increased demand.

 

After a physician determines that a patient is eligible for ambulatory infusion pump therapy, the physician arranges for the patient to receive an infusion pump and provides the necessary chemotherapy drugs. The physician and nursing staff train the patient in the use of the pump and initiate service. The physician bills the payers, which may include Medicare, Medicaid, third-party payer companies or patients for the physician’s professional services associated with initiating and supervising the infusion pump administration, as well as the supply of drugs. We directly bill (i) payers, (ii) facilities of our Medicare patients, and (iii) patients for the use of the pump and related disposable supplies. Billing to payers requires coordination with patients and physicians who initiate the service, as physicians’ offices must provide us with appropriate documentation (patient’s insurance information, physician’s order, an acknowledgement of benefits that shows receipt of equipment by the patient, and, in some cases, physician’s progress notes) in order for us to submit a bill to the payers. We provide assistance to those that cannot afford our pumps via our financial hardship program – a program that usually matches what our physician practices provide as long as the uninsured patients meet certain criteria. This billing process is handled from our Rochester Hills, Michigan location.

 

In addition to providing high quality and convenient care, we believe that our business offers significant economic benefits for patients, providers and payers.

 

 

We support our patients throughout the treatment process by providing patients with 24x7 service and support. InfuSystem Mobile provides patients with secure, two-way communication with our clinical support team, the latest infusion safety technology, and infusion therapy expertise in a convenient and easy-to-use app.

 

 

Physicians use our services to outsource the capital commitment, pump service, maintenance and billing and administrative burdens associated with pump ownership. Our services also allow the doctor to continue a direct relationship with the patient and to receive professional service fees for setting up the treatment and administering the drugs.

 

 

Our clinical support team employs oncology, pain, Intravenous Certified, and Oncology Certified registered nurses trained on ambulatory infusion pump equipment who staff our 24x7 hotline to address questions that patients may have about their pump treatment, the infusion pumps or other medical or technical questions related to the pumps.

 

 

We provide methods for the physician offices to deliver the appropriate paperwork for billing through a number of electronic means including EXPRESS and InfuConnect reducing the required effort on the employees of the physician offices.

 

 

We believe our services are attractive to payers because such services are generally less expensive than hospitalization or standalone home health care.

 

 

Also, within ITS, we offer pain management services via electronic ambulatory infusion pumps for post-operative pain management using our pumps along with a numbing agent and a continuous nerve block catheter – continuous peripheral nerve block (“CPNB”). Using CPNB for the management of post-operative pain, which usually lasts two to three days after surgery, can result in reduced pain for the patient, increased satisfaction scores for the surgical center or hospital, and reduced need for post-operative opioid pain medication. These services include our patient care call center interaction offering support to patients and the review and collection of pain score patient outcome data for outpatient surgery centers using our proprietary BlockPain Dashboard®.

 

DME Services Segment

 

Other services we offer are classified under our DME Services segment and include the rental, sale or leasing of pole-mounted and ambulatory infusion pumps to oncology practices, hospitals and other clinical settings. These pumps are available for daily, weekly, monthly or annual rental periods. We also sell treatment consumables that can be used in conjunction with the pumps we sell and rent.

 

In addition to sales, rental and leasing services, we also provide biomedical maintenance, repair and certification services for the devices we offer as well as for devices owned by customers but not acquired from us. We operate pump service and repair “Centers of Excellence” from all of our locations across the United States and Canada and employ a staff of highly-trained technicians to provide these services. Our main Center of Excellence for service is our Lenexa, Kansas facility.

 

As of December 31, 2020, our rental fleet of pole-mounted pumps, ambulatory pumps and NPWT medical equipment for both our ITS and DME Services segments had a historical cost of $83.4 million, up from $75.9 million at the end of 2019, and included approximately 111 makes and models of equipment dedicated to our rental services. Additionally, as of December 31, 2020 and 2019, we had a fleet of new and used pole-mounted pumps, ambulatory pumps and NPWT medical equipment with a historical cost of $1.6 million and $1.3 million, respectively, for sale or rental.

 

Information Technology

 

Our Information Technology (“IT”) department is focused on not only supporting our internal IT infrastructure needs, but also supporting our revenue cycle management infrastructure including our electronic medical record technology (“EMR”) that allows medical facilities to use our infusion pumps and services via our solutions such as EXPRESS and InfuConnect. This focus has enabled current billing information to be transferred to us from participating facilities electronically and automatically. Our focus on IT solutions resulted in the development of EXPRESS, a product powered by our InfuBus data integration platform, and provides for paperless delivery of the appropriate information for InfuSystem to bill payers that:

 

 

eliminates all paper;

 

provides an enhanced visibility as a result of real time status and reporting;

 

reduces risk of error;

 

automates treatment logs, pump assignments, tracking and physician’s orders;

 

provides a secure scanner for easy pump assignment to patients; and

 

removes interruptions from physician practices’ daily schedules, and standardizes data flow for clinics and hospitals with multiple locations.

 

Relationships with Physician Offices

 

As of December 31, 2020, we had business relationships with clinical oncologists in over 2,100 outpatient oncology clinics. Although this represents a substantial number of the oncologists in the United States, we believe that we can continue to expand our network to further penetrate the oncology market. Based on our retention rates and the positive results of our professional customer satisfaction research, we believe our relationships with physician offices are strong.

 

We believe that, in general, we do not compete directly with hospitals and physician offices to treat patients. Rather, by providing products and services to hospitals and physician offices and other care facilities and providers, we believe that we assist other providers in meeting increasing patient demand and managing institutional constraints on capital and manpower due to the nature of limited resources in hospitals and physician offices.

 

 

Physician practices in the oncology field are following the overall healthcare practices trend to consolidate. However, as of December 31, 2020, we had gained more facilities than we had lost. We expect this trend to continue for the foreseeable future.

 

Employees

 

As of December 31, 2020, we had 292 employees, including 282 full-time employees and 10 part-time or contract employees. None of our employees are unionized.

 

Material Suppliers

 

We supply a wide variety of pumps and associated equipment, as well as disposables and ancillary supplies. The majority of our pumps are electronic infusion pumps. Smiths Medical, Inc. and Moog Medical Devices Group each supplied more than 10% of the ambulatory pumps purchased by us in 2020. The Company has a supply agreement in place with each of these suppliers. Certain “spot” purchases are made on the open market subject to individual negotiation. We also supply NPWT medical equipment, as well as related disposables and ancillary supplies. Cardinal Health, Inc. supplied more than 10% of the NPWT medical equipment purchased by us in 2020. The Company has a supply agreement in place with Cardinal Health, Inc.

 

Seasonality

 

Revenues may be seasonal due to the impact of co-pays and deductibles for patients’ insurance that traditionally reset each January. This has been further impacted by changes in the insurance industry as it responds to increased government regulation. Also, rental customers tend to make buy versus rent decisions late in the year as customer capital budgets are being finalized, impacting sales revenue in the second half of the year, predominantly in the fourth quarter. Furthermore, as the Company’s liquidity has improved, opportunistic pump purchases are made from time to time. These opportunistic pump purchases also allow for opportunistic pump sales, which could be material. The timing of such purchases and sales vary within the course of a year.

 

Environmental Laws

 

We are required to comply with applicable federal, state and local environmental laws regulating the disposal of cleaning agents used in the process of cleaning our ambulatory infusion pumps and NPWT medical equipment, as well as the disposal of sharps and blood products used in connection with the pumps and medical equipment. We do not believe that compliance with such laws has a material effect on our business.

 

Significant Customers

 

We have sought to establish contracts with as many third-party payer organizations as commercially practicable, in an effort to ensure that reimbursement is not a significant obstacle for providers who recommend continuous infusion therapy and wish to utilize our services. A third-party payer organization is a health care payer or a group of medical services payers that contracts to provide a wide variety of health care services to enrolled members through participating providers such as us. A payer is any entity that pays on behalf of a member patient.

 

As of December 31, 2020, we had contracts with nearly 728 third-party payer networks, an increase of 8% over the prior year period. Material terms of contracts with third-party payer organizations are typically a pre-negotiated fee schedule rate or a then-current proprietary fee schedule rate for equipment and supplies provided. The majority of these contracts generally provide for a term of one year, with automatic one-year renewals, unless we or the contracted payer elect not to renew. For 2020 and 2019, our largest contracted payer was a national payer which accounted for approximately 14% and 8% of our ITS net revenues for 2020 and 2019, respectively, and approximately 9% and 5% of our total consolidated net revenues for 2020 and 2019, respectively.

 

We also contract with various other third-party payer organizations, Medicaid, commercial Medicare replacement plans, self-insured plans, facilities of our Medicare patients and numerous other insurance carriers. Other than the payer noted above, no other single payer represented more than 7% of ITS net revenue in 2020.

 

 

Competitors

 

We believe that our competition primarily consists of national, regional, and hospital-owned Durable Medical Equipment providers, physician providers and home care infusion providers and the competitive products and services they offer. An estimate of the number of competitors is not known or reasonably available, due to the wide variety in type and size of the market participants described below. We are not aware of any industry reports with respect to the competitive market described below. The description of market segments and business activities within those market segments is based on our experiences in the industry.

 

 

National Durable Medical Equipment Providers: Other national providers have offerings similar to us. These products and service offerings include, but are not limited to, third-party reimbursement, direct rental and sale of infusion electronic and disposal pumps and related products and services for patients in the home, oncology clinics, ambulatory surgery centers, and other sites of care.

 

 

Regional Durable Medical Equipment Providers: Regional Durable Medical Equipment providers act as distributors for a variety of medical products. We believe regional Durable Medical Equipment provider sales forces generally consist of a relatively small number of salespeople, usually covering several states. Regional Durable Medical Equipment providers tend to carry a limited selection of infusion pumps and their salespeople generally have limited resources. Regional Durable Medical Equipment providers usually do not have 24x7 nursing services. We believe that Regional Durable Medical Equipment providers have relatively few third-party payer contracts, which may prevent these providers from being paid at acceptable levels and may also result in higher out-of-pocket costs for patients.

 

 

Hospital-owned Durable Medical Equipment Providers: Many hospitals have in-house Durable Medical Equipment providers to supply basic equipment. In general, however, these providers have limited capital and tend to stock a small inventory of infusion pumps. We believe that hospital-owned providers have limited ability to grow because of limited patient populations. Growth from outside of the hospital may pose a challenge because hospitals typically will not provide referrals to competitors, instead preferring to offer patients a choice of non-hospital-affiliated Durable Medical Equipment providers.

 

 

Physician Providers: A limited number of physicians maintain an inventory of their own infusion pumps and provide them to patients for a fee. However, we believe that pump utilization in this area tends to be low and the costs associated with ongoing supplies, preventative maintenance and repairs can be relatively high. Moreover, we believe that a high percentage of Durable Medical Equipment claims by doctors are rejected by payers upon first submission, requiring a physician’s staff to spend significant time and effort to resubmit claims and receive payment for treatment. The numerous service and technical questions from patients may present another significant cost to a physician provider’s staff.

 

 

Home Care Infusion Providers: Home care infusion providers provide chemotherapy drugs and services to allow for in-home patient treatment. We believe that home care infusion treatment can be very costly and that many patients do not carry insurance coverage that covers home-based infusion services, resulting in larger out-of-pocket costs. Because home care treatments may take as long as six months, these costs can be high and can result in higher patient co-payments. We believe that home care providers may also be reluctant to offer 24x7 coverage or additional patient visits, due to capped fees.

 

Regulation of Our Business

 

Our business is subject to various regulations. Specifically, as a registered Medicare supplier of Durable Medical Equipment and related supplies, we must comply with supplier standards established by CMS regulating Medicare suppliers of Durable Medical Equipment, Prosthetics, Orthotics and Supplies (“DMEPOS Supplier Standards”). The DMEPOS Supplier Standards consist of 30 requirements that must be met in order for a DMEPOS supplier to be eligible to receive payment for a Medicare-covered item. Some of the more significant DMEPOS Supplier Standards require us to (i) advise Medicare beneficiaries of their option to purchase certain equipment, (ii) honor all warranties under state law and not charge Medicare beneficiaries for the repair or replacement of equipment or for services covered under warranty, (iii) permit CMS agents to conduct on-site inspections to ascertain compliance with the DMEPOS Supplier Standards, (iv) maintain liability insurance in prescribed amounts, (v) refrain from contacting Medicare beneficiaries by telephone, except in certain limited circumstances, (vi) answer questions and respond to complaints of beneficiaries regarding the supplied equipment, (vii) disclose the DMEPOS Supplier Standards to each Medicare beneficiary to whom we supply equipment, (viii) maintain a complaint resolution procedure and record certain information regarding each complaint, (ix) maintain accreditation from a CMS approved accreditation organization, and (x) meet certain specified surety bond requirements.

 

We are also subject to the provisions of the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), which are designed to protect the security and confidentiality of certain protected health information. Under HIPAA, we must provide patients access to certain records and must notify patients of our use of protected health information and patient privacy rights. Moreover, HIPAA sets limits on how we may use individually identifiable health information and prohibits the use of patient information for marketing purposes. The adoption of the American Recovery and Reinvestment Act of 2009 (“ARRA”) includes a new breach notification requirement that applies to breaches of unsecured health information occurring on or after September 23, 2009. We are subject to regulations in the various states in which we operate. We believe we are in material compliance with all such regulations.

 

In addition, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, imposes a 2.3% excise tax on medical devices that applies to sales within the United States of a majority of our pump products that we purchase. This law imposes an excise tax on the first sale of medical devices by a manufacturer, producer, or importer equal to 2.3% of the sales price. This tax only applies directly to new pumps that we purchase from manufacturers. Taxable medical devices include any device as defined in Section 201(h) of the Federal Food, Drug, and Cosmetic Act intended for humans, with the exception of eyeglasses, contact lenses, hearing aids and any other device determined by the Secretary of Health and Human Services to be a type which is generally purchased by the general public at retail for individual use. On December 18, 2015, under the Consolidated Appropriations Act, 2016 (Pub. L. 114-113), a two-year moratorium on the medical device excise tax was imposed by Section 4191 of the Internal Revenue Code (the “Code”). On January 22, 2018, the H.R. 195: Extension of Continuing Appropriations Act Bill extended the existing suspensions of the ACA’s medical device excise tax through 2019. The Further Consolidated Appropriations Act, 2020 H.R. 1865 (Pub. L. 116-94), signed into law on December 20, 2019, has repealed the medical device excise tax. As a result of the repeal and the prior moratorium, sales of taxable medical devices after December 31, 2015, are not subject to the tax. Though the repeal and prior moratorium are favorable for our Company, future legislation could have a material effect on our business, cash flows, financial condition and results of operations.

 

 

Recent Events in Our Business

 

Acquisition

 

On February 3, 2021, the Company announced that it had acquired FilAMed, a privately held biomedical services company based in Bakersfield, California. This acquisition will supplement the Company’s existing biomedical recertification, maintenance and repair services for acute care facilities and other alternate site settings including home care and home infusion providers, skilled nursing facilities, pain centers and others.

 

Credit Agreement

 

On February 5, 2021, the Company entered into a Credit Agreement (the “2021 Credit Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent (the “Agent”), sole bookrunner and sole lead arranger, and the lenders party thereto. The borrowers under the 2021 Credit Agreement are the Company, Holdings, ISI, First Biomedical, and IFC (collectively, the “Borrowers”).

 

The 2021 Credit Agreement provides for a revolving credit facility (the “Revolving Facility”) of $75 million, maturing on February 5, 2026. The Revolving Facility may be increased by $25 million, subject to certain conditions, including the consent of the Agent and obtaining necessary commitments. The lenders under the 2021 Credit Agreement may issue up to $7 million in letters of credit subject to the satisfaction of certain conditions. On February 5, 2021, the Borrowers made an initial borrowing of $30 million under the Revolving Facility. Proceeds from the loan, along with approximately $8.2 million in cash, were used to repay all amounts due under the Company’s existing credit facility dated March 23, 2015 (the “2015 Credit Agreement”).

 

Amounts outstanding under the Revolving Facility bear interest at a variable rate equal to, at the Company's election, a LIBO Rate for Eurodollar loans or an Alternate Base Rate for ABR loans, as defined by the 2021 Credit Agreement, plus a spread that will vary depending upon the Company's leverage ratio. The spread ranges from 2.00% to 3.00% for Eurodollar Loans and 1.00% to 2.00% for base rate loans. The initial spread under the 2021 Credit Agreement is 2.00% for Eurodollar loans and 1.00% for ABR loans.

 

The 2021 Credit Agreement has customary representations and warranties, and the ability to borrow under the facility is subject to ongoing compliance with a number of customary affirmative and negative covenants, including limitations on indebtedness, liens, mergers, acquisitions, investments, asset sales, affiliate transactions and restricted payments, as well as financial covenants, including the following:

 

 

a minimum fixed charge coverage ratio (defined as the ratio of consolidated EBITDA (as defined in the 2021 Credit Agreement) less 50% of depreciation expense), to consolidated fixed charges (as defined in the 2021 Credit Agreement)) for the prior four most recently ended calendar quarters of 1.20 to 1.00; and

 

a maximum leverage ratio (defined as total indebtedness to EBITDA for the prior four most recently ended calendar quarters) of 3.50 to 1.00.

 

The 2021 Credit Agreement includes customary events of default, and the occurrence of an event of default will permit the lenders to terminate commitments to lend under the Revolving Facility and accelerate payment of all amounts outstanding thereunder.

 

Pledge and Security Agreement

 

Simultaneous with the execution of the 2021 Credit Agreement, the Company entered into a Pledge and Security Agreement to secure repayment of the obligations of the Borrowers. Under the Pledge and Security Agreement, each Borrower has granted to the Agent, for the benefit of various secured parties, a first priority security interest in substantially all of the personal property assets of each of the Borrowers, including the shares of each of Holdings, ISI and First Biomedical and the equity interests of IFC.

 

2015 Credit Agreement

 

On February 5, 2021, in connection with the execution and closing of the 2021 Credit Agreement, the Company, along with its wholly owned subsidiaries as borrowers, terminated the 2015 Credit Agreement. All outstanding loans under the 2015 Credit Agreement have been repaid and all liens under the 2015 Credit Agreement have been released, except that a letter of credit originally issued under the 2015 Credit Agreement in the amount of approximately $0.8 million was transferred to the 2021 Credit Agreement. 

 

Available Information

 

Our Internet address is www.infusystem.com. On this Web site, we post the following filings as soon as reasonably practicable after they are electronically filed with or furnished to the U.S. Securities and Exchange Commission (the “SEC”): our Annual Reports on Form 10-K; our Quarterly Reports on Form 10-Q; our Current Reports on Form 8-K; our proxy statements related to our annual stockholders’ meetings; and any amendments to those reports or statements. All such filings are available on our Web site free of charge. The charters of our audit, nominating and governance and compensation committees and our Code of Business Conduct and Ethics Policy are also available on our Web site and in print to any stockholder who requests them. The content on our Web site is not incorporated by reference into this Form 10-K unless expressly noted.

 

 

Item 1A.      Risk Factors.

 

An investment in our securities involves a high degree of risk. You should consider carefully all of the material risks described below, together with the other information contained in this Form 10-K. If any of the following events occur, our business, financial condition, results of operations and cash flows may be materially adversely affected.

 

RISK FACTORS RELATING TO OUR BUSINESS AND THE INDUSTRY IN WHICH WE OPERATE

 

Our business is substantially dependent on third-party reimbursement. Any change in the overall health care reimbursement system may adversely impact our business.

 

Our revenues are substantially dependent on third-party reimbursement. We are paid directly by private insurers and, in some cases, governmental agencies, often on a fixed fee basis, for the use of continuous infusion equipment and related disposable supplies provided to patients. If the average fees allowable by private insurers or governmental agencies were reduced, the negative impact on revenues could have a material effect on our business, financial condition, results of operations and cash flows. Also, if amounts owed to us by patients and insurers are reduced or not paid on a timely basis, we may be required to increase our concessions and/or decrease our revenues.

 

Changes in the health care reimbursement system often create financial incentives and disincentives that encourage or discourage the use of a particular type of product, therapy or clinical procedure. Such changes may be impacted by the growth in ACOs, reduction of providers by payers, the use of lower cost rental networks and other factors. Market acceptance of continuous infusion therapy may be adversely affected by changes or trends within the health care reimbursement system. Changes to the health care reimbursement system that favor other technologies or treatment regimens that reduce reimbursements to providers or treatment facilities, including increasing competitive pressures from home health care and other companies that use our services, may adversely affect our ability to market our services profitably. Overall, such dependency and potential changes could materially and adversely affect our business, financial condition, results of operations and cash flows.

 

Our business is substantially dependent on estimates of collectible revenue from third-party reimbursement.

 

Our revenues are substantially dependent on estimates of collectible revenue from third-party reimbursement. Due to the complex nature of third-party reimbursement for the use of continuous infusion equipment and related disposable supplies provided to patients, we must estimate, based upon historical averages, the amount of collectible revenue that may be derived from each patient treatment. If average reimbursement rates diverge from historical levels, the estimates of such revenue may diverge from actual collections.

 

We utilize statistical methods to account for such changes, but there can be no assurance that the revenue reported in any period will ultimately be collected. Any recognized revenue related to third-party reimbursement from prior periods, which remains uncollected until written off from accounts receivable, will negatively impact revenues in the period in which it is written off. Thus, over time, recognized revenue net of concessions will approximate total collections.

 

The loss of a relationship with one or more third-party payers could negatively impact our business.

 

Our contracts for reimbursement with third-party payers are often for a term of one year, with automatic one-year renewals, unless we or the contracted payer elect not to renew. These evergreen contracts are subject to termination upon written notice. One or more terminations could have a material and adverse effect on our business, financial condition, results of operations and cash flows.

 

Any federal government shutdown may adversely impact our business.

 

Our revenues are dependent on private insurers and governmental agencies. In the absence of any bipartisan agreement in the federal government with respect to payments from governmental agencies, our revenues could be reduced. In addition, any federal government shutdown could also have a material and adverse impact on our business, financial condition, results of operations and cash flows.

 

Our business has and may continue to be adversely impacted by the U.S. federal governments sequestration.

 

On March 1, 2013, most agencies of the U.S. federal government automatically reduced their budgets according to an agreement made by Congress in 2012 known as “sequestration”. Originally devised as an incentive to force Congressional agreement on budget issues, the sequestration order was approved on March 1, 2013 by the President of the United States. Beginning in 2013, we were impacted by the sequestration order, which affects Medicare payments. For the years ended December 31, 2020 and 2019, the impact on our net revenues was approximately $0.0 million and $0.1 million, respectively. Sequestration mainly applied to payments received from Medicare Advantage plans by the Company. As of the date of this report, it is our understanding that the mandatory payment reduction of 2% will continue until further notice, although it has currently been suspended temporarily from May 2020 through March 2021. We also believe that the cuts will likely continue until definitive action is taken by the U.S federal government on this issue.

 

 

Payer concentration may adversely impact our business.

 

As of December 31, 2020, we had contracts with nearly 728 third-party payer networks, an increase of 8% over the prior year period. Material terms of contracts with third-party payer organizations are typically a pre-negotiated fee schedule rate or a then-current proprietary fee schedule rate for equipment and supplies provided. The majority of these contracts generally provide for a term of one year, with automatic one-year renewals, unless we or the contracted payer elect not to renew. For 2020 and 2019, our largest contracted payer was a national payer which accounted for approximately 14% and 8% of our ITS net revenues for 2020 and 2019, respectively, and approximately 9% and 5% of our total consolidated net revenues for 2020 and 2019, respectively.

 

We also contract with various other third-party payer organizations, Medicaid, commercial Medicare replacement plans, self-insured plans, facilities of our Medicare patients and numerous other insurance carriers. Other than the payer noted above, no other single payer represented more than 7% of ITS net revenue in 2020. To the extent such dependency continues, significant fluctuations in revenues, results of operations and liquidity could arise if any other significant contracted payer reduces its reimbursement for the services we provide.

 

Our billing process is dependent on meeting payer claims processing guidelines which are subject to change at the discretion of the payers. Such changes would materially impact our ability to bill and the timing of such billings, which could materially and adversely impact our net revenues and cash flows, which impact would be even greater if such changes are made by one of our larger payers.

 

The continued consolidation of physician practices, outpatient infusion clinics, oncology clinics, homecare providers and hospitals, increases the concentration of decision makers whom either choose to use our ambulatory electronic pumps within our Oncology Business or directly rent, lease or purchase pumps or supplies directly from us.

 

While we make every effort to benefit from such concentration, it could materially and adversely affect our business, financial condition, results of operations and cash flows.

 

Increased focus on early detection and diagnostics may adversely affect our business.

 

An increased focus on lowering health care spending via improved diagnostic testing (i.e., defensive medicine) and patient monitoring could materially and negatively affect our business. A large portion of our ambulatory infusion pumps are dedicated to a specific form of cancer (i.e., colorectal). As a result of rising health care costs, there may be a demand for more cost-effective approaches to disease management, specifically for colorectal cancer, as well as for emphasis on screening and accurate diagnostic testing to facilitate early detection of potentially costly, severe afflictions. Any change in the approach to treatment of colorectal cancer could have a material and adverse impact on our business, financial condition, results of operations and cash flows.

 

If future clinical studies demonstrate that oral medications or other therapies that do not use our electronic ambulatory pumps are at least as effective as continuous infusion therapy, our business could be adversely affected.

 

Ongoing clinical trials are currently evaluating and comparing the therapeutic benefits of current continuous infusion-based regimens with various oral medication regimens. If these clinical trials demonstrate that oral medications provide equal or greater therapeutic benefits and/or demonstrate reduced side effects compared to prior oral medication regimens, our revenues and overall business could be materially and adversely affected. Additionally, if new oral medications or other therapies that do not utilize our ambulatory electronic pumps are introduced to the market that are superior to existing oral therapies, physicians’ willingness to prescribe continuous infusion-based regimens could decline, which would materially and adversely affect our business, financial condition, results of operations and cash flows.

 

Our success is impacted by the availability of the chemotherapy drugs that are used in our continuous infusion pump systems.

 

We primarily derive our revenues from the rental of ambulatory infusion pumps to oncology patients through physicians’ offices and chemotherapy clinics. A shortage in the availability of chemotherapy drugs that are used in the continuous infusion pump system, which has occurred in the past, could have a material and adverse effect on our business, financial condition, results of operations and cash flows.

 

 

We are dependent on our Medicare Supplier Number.

 

We are required to have a Medicare Supplier Number in order to have the ability to bill Medicare for services provided to Medicare patients. Furthermore, all third-party and Medicaid contracts require us to have a Medicare Supplier Number. We are required to comply with Medicare DMEPOS Supplier Standards in order to maintain such number. If we are unable to comply with the relevant standards, we could lose our Medicare Supplier Number. Without such number, we would be unable to continue our various third-party and Medicaid contracts. A significant portion of our revenues are dependent upon our Medicare Supplier Number, the loss of which would materially and adversely affect our business, financial condition, results of operations and cash flows.

 

The CMS requires that all Durable Medical Equipment providers must be accredited by a CMS-approved accreditation organization. On February 17, 2009, we initially received accreditation from CHAP, and we have remained accredited to date. If we lost our accredited status, our business, financial condition, revenues and results of operations would be materially and adversely affected.

 

The impact of United States health care reform legislation on us remains uncertain.

 

The ACA has perpetuated the development of alternative provider payment models by CMS and the major national commercial payers. These payment models do not replace the current fee-for-service models nor replace current payer contracts, but rather provide additional financial incentives to certain “accountable” providers to improve quality and lower cost. The implications for the Company will come from the provider networks that are forming in order to integrate and coordinate care under these alternative models with CMS and the commercial payers. These provider networks include ACOs, patient-centered primary care medical homes, specialty medical homes, networks accepting bundled payment programs, and other “performance” networks that contract with CMS and commercial payers under alternative payment models that financially reward improved quality and lower medical cost. The relationship between us and our provider practices and facilities that are participating in these provider networks under alternative payment models will depend on (i) the extent to which these provider networks give priority to the medical cost associated with our Durable Medical Equipment services and (ii) whether our services are seen as part of a care delivery model that delivers higher value – higher quality at a lower cost.

 

Our failure to perform under these alternative payment models, or under similar models or conditions introduced by future legislation, could have a material adverse impact on our business, financial condition, results of operations and cash flows.

 

We rely on independent suppliers for our products. Any delay or disruption in the supply of products, particularly our supply of electronic ambulatory pumps, may negatively impact our operations.

 

Our infusion pumps are obtained from outside vendors. The majority of our new pumps are electronic infusion pumps which are supplied to us by two major suppliers: Smiths Medical, Inc. and Moog Medical Devices Group. The loss or disruption of our relationships with outside vendors, including pumps, parts, or supply recall or pump end-of-life announcements or availability of related proprietary consumable supplies, could subject us to substantial delays in the delivery of pumps or services provided to customers. From time to time, we or our suppliers may experience supply chain disruptions due to circumstances beyond our or our suppliers’ control, such as the 2020 outbreak of COVID-19. Significant delays in the delivery or service of pumps or related proprietary consumable supplies could result in possible cancellation of orders and the loss of customers. Our inability to provide pumps to meet delivery schedules could have a material adverse effect on our reputation in the industry, as well as on our business, financial condition, results of operations and cash flows.

 

We face periodic reviews and billing audits from governmental and private payers and these audits could have adverse results that may negatively impact our business.

 

As a result of our participation in the Medicaid program and our registration in the Medicare program, we are subject to various governmental reviews and audits to verify our compliance with these programs and applicable laws and regulations. We also are subject to audits under various government programs in which third-party firms engaged by CMS conduct extensive reviews of claims data and medical and other records to identify potential improper payments under the Medicare program. Private pay sources also reserve the right to conduct audits. If billing errors are identified in the sample of reviewed claims, the billing error can be extrapolated to all claims filed which could result in a larger overpayment than originally identified in the sample of reviewed claims. Our costs to respond to and defend reviews and audits may be significant and could have a material adverse effect on our business, financial condition, results of operations and cash flows. Moreover, an adverse review or audit could result in:

 

• required refunding or retroactive adjustment of amounts we have been paid by governmental or private payers;

 

 

• state or Federal agencies imposing fines, penalties and other sanctions on us;

• loss of our right to participate in the Medicare program, state programs, or one or more private payer networks; or
• damage to our business and reputation in various markets.

 

Any one of these results could have a material adverse effect on our business, financial condition, results of operations and cash flows.

 

Our failure to maintain controls and processes over billing and collecting could have a significant negative impact on our Consolidated Financial Statements.

 

The collection of accounts receivable is a significant challenge and requires constant focus and involvement by management and ongoing enhancements to information systems, billing center operating procedures and proper staffing levels. If we are unable to properly bill and collect our accounts receivable, our results could be materially and adversely affected. While management believes that our staffing, controls and processes are satisfactory, there can be no assurance that accounts receivable collectability will remain at current levels.

 

State licensure laws for Durable Medical Equipment suppliers are subject to change. If we fail to comply with any state laws, we will be unable to operate as a Durable Medical Equipment supplier in such state and our business operations will be adversely affected.

 

As a Durable Medical Equipment supplier operating in all 50 states, we are subject to each state’s licensure laws regulating Durable Medical Equipment suppliers. State licensure laws for Durable Medical Equipment suppliers are subject to change and we must ensure that we are continually in compliance with the laws of all 50 states. In the event that we fail to comply with any state’s laws governing the licensing of Durable Medical Equipment suppliers, we will be unable to operate as a Durable Medical Equipment supplier in such state until we regain compliance. We may also be subject to certain fines and/or penalties and our business operations could be materially and adversely affected.

 

Our customer concessions may not be adequate to cover actual losses.

 

Our third-party payer contracts do not guarantee annual inflationary increases, typical of the Durable Medical Equipment payer contracting environment. Contracted reimbursement rates are either subject to increases or decreases in CMS program rates or, if not indexed to government rates, are frozen until those payer contracts are reopened and renegotiated. While we monitor reimbursement levels to identify specific payer reimbursement rates that have eroded and renegotiate such rates, we may not be able to maintain or improve overall reimbursement levels, thereby compromising the adequacy of the predicted customer concessions.

 

We may also face reduced reimbursements from private third-party payers. As a result, our customers may be unable to make timely payments to us. Although we maintain allowances for estimated losses resulting from the inability of our customers to make required payments, we cannot guarantee that we will continue to experience the same loss rates that we have in the past. If we begin to experience an increase in our loss rates in excess of our allowances, it could materially and adversely impact our business, financial condition, results of operations and cash flows.

 

Our growth strategy includes expanding into treatment for cancers other than colorectal cancer. There can be no assurance that continuous infusion-based regimens for these other cancers will become standards of care for large numbers of patients or that we will be successful in penetrating these different markets.

 

An aspect of our growth strategy is to expand into the treatment of other cancers, such as head, neck and gastric cancers. This population of patients will expand only if clinical trial results for new drugs and new combinations of drugs demonstrate superior outcomes for regimens that include continuous infusion therapy relative to alternatives. No assurances can be given that these new drugs and drug combinations will be approved or will prove superior to oral medication or other treatment alternatives. In addition, no assurances can be given that we will be able to penetrate successfully any new markets that may develop in the future or manage the growth in additional resources that would be required.

 

 

The industry in which we operate is intensely competitive and ever-changing. If we are unable to successfully compete with our competitors, our business operations may suffer.

 

The drug infusion industry is highly competitive. Some of our competitors and potential competitors, including some of the practices that we service, have significantly greater resources than we do for information technology, marketing and sales. As a result, they may be better able to compete for market share, even in areas in which our services may be superior. The industry is subject to technological changes and such changes may put our current fleet of pumps, smart pump licensing, our information technology solutions or our other technological-based solutions at a competitive disadvantage. Furthermore, the healthcare industry, in general, is experiencing market consolidation, reducing the number of decision makers. If we are unable to effectively compete in our market, our business, financial condition, results of operations and cash flows may be materially and adversely affected.

 

Our industry is dependent on regulatory guidelines that affect our billing practices. If our competitors do not comply with these regulatory guidelines, our business could be adversely affected.

 

Aggressive competitors may not fully comply with rules regarding CMS and other payers’ billing and documentation requirements. Competitors, who do not meet the same standards of compliance that we do with respect to billing regulations, may put us at a potential competitive disadvantage. We are a participating provider with Medicare and as of December 31, 2020, we were under contract with nearly 728 third-party payer networks, all of which have very stringent guidelines. If our competitors do not comply with these regulatory guidelines, we could be put at a potential competitive disadvantage and our business, financial condition, results of operations and cash flows could be material and adversely affected.

 

Although we do not manufacture the products we distribute, if one of the products distributed by us proves to be defective or is misused by a health care practitioner or patient, we may be subject to liability that could adversely affect our financial condition and results of operations.

 

Although we do not manufacture the pumps that we distribute, a defect in the design or manufacture of a pump distributed or serviced by us, or a failure of pumps distributed by us to perform for the use specified, could have a material and adverse effect on our reputation in the industry and subject us to claims of liability for injuries and otherwise. Misuse of the pumps distributed by us by a practitioner or patient that results in injury could similarly subject us to liability. Any substantial underinsured loss could have a material and adverse effect on our business, financial condition, results of operations and cash flows. Furthermore, any impairment of our reputation could have a material and adverse effect on our revenues and prospects for future business.

 

We intend to continue to pursue opportunities for the further expansion of our business through strategic alliances and/or joint ventures. Future strategic alliances and/or joint ventures may require significant resources and/or result in significant unanticipated costs or liabilities to us.

 

We intend to continue to pursue opportunities for the further expansion of our business through strategic alliances and/or joint ventures. Any future strategic alliances or joint ventures will depend on our ability to identify suitable partners, negotiate acceptable terms for such transactions and obtain financing, if necessary. These investments require significant managerial attention, which may be diverted from our other operations.

 

If we engage in strategic acquisitions, we may experience significant costs and difficulty in assimilating operations or personnel, which could threaten our future growth.

 

If we make any acquisitions, we could have difficulty assimilating operations, technologies and products and services. In addition, we could have difficulty integrating or retaining personnel and maintaining employee morale as we take steps to combine the personnel and business cultures of separate organizations into one and to eliminate duplicate positions and functions. It may also be difficult for us to preserve important relationships with others, such as strategic partners, customers, and suppliers, who may delay or defer decisions on agreements with us, or seek to change existing agreements with us, because of the acquisition. In addition, acquisitions may involve entering markets in which we have no or limited direct prior experience. The occurrence of any one or more of these factors could disrupt our ongoing business, distract our management’s and employees’ attention from our ongoing business operations, result in decreased operating performance and increase our expenses. Moreover, our profitability may suffer because of acquisition-related costs or amortization of intangible assets. Furthermore, we may have to incur debt or issue equity securities in future acquisitions. The issuance of equity securities would dilute our existing stockholders.

 

We may be unable to maintain adequate working relationships with health care professionals.

 

We seek to maintain close working relationships with respected physicians and medical personnel in hospitals and universities. We rely on these professionals to assist us in the development of proprietary service and improvements to complement and expand our existing service and product lines. If we are unable to maintain these relationships, our ability to market and sell new and improved products and services could decrease and future operating results could be unfavorably affected.

 

 

If we fail to comply with applicable governmental or accrediting bodies regulations, we could face substantial penalties and our business, operations and financial condition could be adversely affected.

 

Certain federal, state health care, and accreditation bodies’ laws and regulations, including those pertaining to fraud and abuse and patients’ rights, are applicable to our business. The laws that are applicable to our business include:

 

 

the federal health care program Anti-Kickback Statute, which prohibits, among other things, soliciting, receiving or providing remuneration, directly or indirectly, to induce (i) the referral of an individual, for an item or service or (ii) the purchasing or ordering of a good or service, for which payment may be made under federal health care programs such as the Medicare and Medicaid programs;

 

 

federal false claims laws which prohibit, among other things, knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payers that are false or fraudulent, and which may apply to entities like us that promote medical devices, provide medical device management services and may provide coding and billing advice to customers;

 

 

HIPAA, which prohibits executing a scheme to defraud any health care benefit program or making false statements relating to health care matters and which also imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information; and

 

 

state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payer, including commercial insurers, and state laws governing the privacy and security of health information in certain circumstances, many of which differ in significant ways from state to state and often are not preempted by HIPAA, thus complicating compliance efforts.

 

If our operations are found to be in violation of any of the laws described above or any other regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines and the curtailment or restructuring of our operations. Any penalties, damages, fines, curtailment or restructuring of our operations could materially and adversely affect our business, financial condition, results of operations and cash flows. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business. Moreover, achieving and sustaining compliance with applicable federal and state privacy, security and fraud laws may prove costly.

 

Failure to protect our intellectual property could substantially harm our business and operating results.

 

In order to protect our trade secrets and other confidential information, we rely in part on confidentiality agreements with our employees, consultants and third parties with whom we have relationships. These agreements may not effectively prevent disclosure of trade secrets and other confidential information and may not provide an adequate remedy in the event of misappropriation of trade secrets or any unauthorized disclosure of trade secrets and other confidential information. In addition, others may independently discover our trade secrets and confidential information and, in such cases, we could not assert any trade secret rights against such parties. Costly and time-consuming litigation could be necessary to enforce or determine the scope of our trade secret rights and related confidentiality and nondisclosure provisions. Failure to obtain or maintain trade secret protection, or our competitors' acquisition of our trade secrets, could materially and adversely affect our competitive business position.

 

Covenants in our current and any future debt agreement restrict our business.

 

Our 2021 Credit Agreement contains, our 2015 Credit Agreement contained, and the agreements that govern our future indebtedness may contain, covenants that restrict our ability to and the ability of our subsidiaries to, among other things:

 

 

engage in a transaction that results in a change of control, as defined by the 2021 Credit Agreement;

 

create, incur, assume or suffer to exist any lien upon any of our property, assets or revenues;

 

make certain investments or acquisitions;

 

create, incur, assume or suffer to exist certain indebtedness;

 

merge, dissolve, liquidate, consolidate or sell all or substantially all of our assets;

 

make any disposition or enter into any agreement to make any disposition;

 

repurchase outstanding stock from the open market; and

 

declare or make, directly or indirectly, any dividend or other restricted payment, or incur any obligation (contingent or otherwise) to do so.

 

 

These covenants may restrict our ability to operate our business. Our failure to comply with these covenants could result in an event of default that, if not cured or waived, could result in reduced liquidity for the Company and could have a material and adverse effect on our ability to operate our business, financial condition, results of operations and cash flows. Additionally, our ability to pay interest and repay the principal for our indebtedness is dependent upon our ability to manage our business operations, generate sufficient cash flows to service such debt and the other factors discussed in this section. Our 2021 Credit Agreement also contains, and our 2015 Credit Agreement contained, certain financial covenants. As of December 31, 2020, we were in compliance with all the covenants contained in the 2015 Credit Agreement, however, there can be no assurance that we will be able to manage any of the risks associated with debt agreements successfully.

 

Economic uncertainty or economic deterioration could adversely affect us.

 

There continues to be global economic uncertainty. Political changes in the U.S. and abroad, such as the United Kingdom’s recent withdrawal of its membership from the European Union, have contributed to volatility in the global financial markets. In addition, the recent outbreak of COVID-19 has also contributed to economic uncertainty. Continued economic uncertainty may continue to drive stock market and interest rate volatility and adversely impact consumer confidence, product demand, and our ability to refinance our debt. Economic conditions, along with our operating performance, may also materially and adversely impact our ability to access the financial markets. Accordingly, our future business and financial results are subject to uncertainty. If economic conditions deteriorate in the future, our future revenues and financial results could be materially and adversely affected.

 

Changes in tax laws or challenges to our tax positions could adversely affect our business, results of operations and financial condition.

 

We are subject to income taxes as well as non-income based taxes in federal and various state jurisdictions. Changes in tax laws, including, for example, those resulting from the U.S. federal tax legislation commonly referred to as the Tax Cuts and Jobs Act of 2017 (“Tax Act”) or the Coronavirus Aid, Relief, and Economic Security (CARES) Act, as well as other factors, could cause us to experience fluctuations in our tax obligations and effective tax rates in future periods and otherwise adversely affect our tax positions and/or our tax liabilities. The full impact of the Tax Act or CARES Act on us may change significantly as regulations, interpretations and rulings relating to the Tax Act or CARES Act are issued and additional changes in U.S. federal and state tax laws are made in the future. There can be no assurance that our effective tax rates, tax payments, tax credits or incentives will not be adversely affected by these or other initiatives.

 

We are subject to audits by tax authorities from time to time in federal and state jurisdictions. Tax authorities may disagree with certain positions we have taken and assess additional taxes and penalties. We regularly assess the likely outcomes of these audits in order to determine the appropriateness of our tax provision. However, there can be no assurance that we will accurately predict the outcomes of these audits, and the actual outcomes of these audits could have a material impact on our results of operations.

 

 

RISK FACTORS RELATING SPECIFICALLY TO OUR COMMON STOCK

 

The market price of our common stock has been, and is likely to remain, volatile, subject to low trading volume and may decline in value.

 

The market price of our common stock has been and may continue to be volatile. Market prices for securities of health care services companies, including ours, have historically been volatile, and the market has from time to time experienced significant price and volume fluctuations that appear unrelated to the operating performance of particular companies. The following factors, among others, can have a significant effect on the market price of our common stock:

 

 

announcements of technological innovations, new products, or clinical studies by others;

 

government regulation;

 

changes in the coverage or reimbursement rates of private insurers and governmental agencies;

 

announcements regarding new products or services;

 

announcements or speculation regarding strategic alliances, mergers, acquisitions or other transactions;

 

developments in patent or other proprietary rights;

 

the liquidity of the market for our common stock;

 

news of other healthcare events or announcements;

 

changes in health care policies in the United States or globally;

 

global financial conditions; and

 

comments by securities analysts and general market conditions.

 

 

The realization of any risks described in these “Risk Factors” could also have a negative effect on the market price of our common stock.

 

We do not pay dividends and this may negatively affect the price of our stock.

 

Under the terms of our 2015 Credit Agreement and 2021 Credit Agreement, our ability to pay dividends on our common stock is limited and we do not anticipate paying dividends on our common stock in the foreseeable future. The future price of our common stock may be adversely impacted because we do not pay dividends.

 

Restricted stock awards, performance-based restricted stock units and the exercise of stock options may depress our stock price and may result in dilution to our common stockholders.

 

There are a significant number of shares of restricted stock awards (“RSUs”), performance-based restricted stock units (“PSUs”) and outstanding options to purchase our stock. If the market price of our common stock rises above the exercise price of outstanding options, holders of those securities may be likely to exercise their options and sell the common stock acquired upon exercise in the open market. Sales of a substantial number of shares of our common stock in the public market by holders of options may depress the prevailing market price for our common stock and could impair our ability to raise capital through the future sale of our equity securities. Additionally, if the holders of outstanding options exercise those options, our common stockholders will incur dilution in their relative percentage ownership.

 

As of December 31, 2020, options to purchase 1.9 million shares of common stock were outstanding, at a weighted average exercise price of $4.26 per share, of which 1.4 million were exercisable at a weighted average exercise price of $3.33 per share. In addition, RSUs of 0.2 million shares, with a weighted average grant date fair value of $9.78 per share, were outstanding and were issuable upon the vesting of certain time restrictions and PSUs of 0.2 million shares, with a weighted average grant date fair value of $9.06 per share, were outstanding and were issuable upon meeting certain performance-based vesting criteria.

 

We may be subject to limitations on net operating loss carryforwards and certain built-in losses following an ownership change.

 

If we experience an ownership change, either via a major transaction or a series of trades where a substantial percentage of our ownership changes, which may be less than a majority of our ownership in certain cases, we may be limited in our ability to use our net operating loss carryforwards.

 

The Company continues to monitor shifts in past ownership (as defined under Section 382 of the Code). A definitive analysis necessary to quantify the effect of an ownership change was performed on the net operating loss carryforwards generated prior to December 31, 2019. Based on the analysis, we are subject to an annual limitation of $1.8 million on our use of remaining pre-ownership change net operating loss carryforwards of $4.5 million (and certain other pre-change tax attributes). Our U.S. federal net operating loss carryforwards of approximately $31.5 million will begin to expire in various years beginning in 2029 and $3.4 million of our U.S. federal net operating loss carryforward has an indefinite life. There can be no assurance that we will not experience an ownership change in the future, in which case we may be limited in our ability to use our deferred tax assets. At December 31, 2020, management has determined that the valuation allowance against the U.S. federal and state deferred taxes is no longer required and the valuation allowance of $11.2 million was released, which is described under the heading “Income Taxes” in Note 8 to our Consolidated Financial Statements included in this Form 10-K.

 

 

GENERAL RISK FACTORS

 

The effects of the COVID-19 pandemic could disrupt our operations and adversely affect our business, financial condition, results of operations and cash flows.

 

The widespread outbreak of COVID-19 has created significant volatility, uncertainty, and disruption in economic activity and financial markets globally. Although the outbreak of COVID-19 has not had any material unfavorable effect on our results of operations to date, there can be no assurance that COVID-19 will not have a material adverse effect on our future operational and financial performance. The extent to which COVID-19 could impact our operational and financial performance in future periods is currently uncertain and will depend on numerous evolving factors and future developments that we may not be able to accurately predict and to which we may not be able to respond. Such factors and developments include, but are not limited to: the duration, severity and spread of the outbreak; actions taken by government authorities to contain and mitigate COVID-19 and the effectiveness of such actions (including the efficacy and distribution of any vaccines); the effect on the U.S. and global economies and actions taken in response; the overall impact on the businesses of our customers, partners, vendors and suppliers; the health of and effect on our workforce; the future effects to our operational and financial results of the changes we have made to protect the safety and well-being of our employees and future operational disruptions or challenges we may face; increased cybersecurity and information security risk as a result of the transition of our employees to a remote work environment; and how quickly and to what extent normal economic and operating conditions may resume. Further, our management has been intensely focused on mitigating COVID-19 impacts, which has required and will continue to require, a large investment of time, attention and resources. Although we have yet to experience a significant disruption of our operations as a result of the COVID-19 pandemic, a prolonged outbreak could, among other things, strain our business continuity plans, create delays in our growth and strategic initiatives, reduce our sales and marketing activities, limit our sales peoples’ access to our clients, limit our access to financing on favorable terms, increase our exposure to potential impairment charges related to long-lived and intangible assets, hinder our ability to support our clients and operate our business effectively, heighten the risk of disruption to our information and reporting systems and internal controls, including those over financial reporting and other risk management systems, or require us to incur substantial costs. We cannot predict the degree to which COVID-19 will ultimately impact our operations, however, the effects of the COVID-19 pandemic, alone or taken together, could adversely affect our future business, financial condition, results of operations and cash flows, and may also heighten other risks to which the Company is subject, including other risks discussed in this annual report on Form 10-K.

 

We may become subject to legal and regulatory proceedings that could have a material adverse impact on our business, results of operations and financial condition.

 

From time to time and in the ordinary course of our business, we and certain of our subsidiaries may become involved in various legal and regulatory proceedings. All such proceedings are inherently unpredictable and, regardless of the merits of the claims, litigation and regulatory proceedings may be expensive, time-consuming and disruptive to our operations and distracting to management. If resolved against us, such proceedings could result in excessive verdicts, injunctive relief or other equitable relief that may affect how we operate our business. Similarly, if we settle such proceedings, it may affect how we operate our business. Future court decisions, alternative dispute resolution awards, business expansion or legislative activity may increase our exposure to litigation and regulatory investigations. In some cases, substantial non-economic remedies or punitive damages may be sought. Although we maintain liability insurance coverage, there can be no assurance that such coverage will cover any particular verdict, judgment or settlement that may be entered against us, that such coverage will prove to be adequate or that such coverage will continue to remain available on acceptable terms, if at all. If we incur liability that exceeds our insurance coverage or that is not within the scope of the coverage in proceedings brought against us, it could have a material adverse effect on our business, results of operations and financial condition.

 

We do not collect sales or consumption taxes in some jurisdictions.

 

Our core services are exempt from sales tax or its equivalent in many states. However, there are several states that consider pump rentals, sales and services taxable regardless of method of payment. We are collecting sales tax or its equivalent in numerous jurisdictions. A successful assertion by one or more states or localities requiring us to collect taxes where we currently do not, could result in substantial tax liabilities, including for past sales, as well as penalties and interest.

 

If we are unsuccessful in our efforts to implement and support information technology improvements or respond to technological changes, our growth, prospects and results of operations could be adversely affected.

 

To remain competitive, we must continue to enhance and improve the functionality and features of our technology solutions and services. We have implemented a service to support EMR technology with some of our outpatient infusion practices that enables billing information to be transferred between us and medical facilities electronically and automatically, thus eliminating the current use of mail, email and/or faxes. We have also implemented a web portal that supports our rental and service customers. If these efforts cease to be successful, our reputation and ability to attract and retain customers and contributors will be adversely affected. Furthermore, we are likely to incur expenses in connection with continuously updating and improving our technology infrastructure and services. Without such improvements, our operations might suffer from unanticipated system disruptions, slow application performance or unreliable service levels, any of which could negatively affect our reputation and ability to attract and retain customers and contributors. We may face significant delays in introducing new services, products and enhancements.

 

If competitors introduce new products and services using new technologies or if new industry standards and practices emerge, our existing technology and systems may become obsolete or less competitive, and our business may be harmed. In addition, the expansion and improvement of our systems and infrastructure will require us to commit substantial financial, operational and technical resources, with no assurance that our business will improve.

 

All of these factors could have a material adverse impact on our business, financial condition, results of operations and cash flows.

 

 

Cybersecurity risks and cyber incidents could adversely affect our business and disrupt operations.

 

Cyber incidents can result from deliberate attacks or unintentional events. These incidents can include, but are not limited to, gaining unauthorized access to digital systems for purposes of misappropriating assets or sensitive information, corrupting data, or causing operational disruption. The result of these incidents could include, but are not limited to, disrupted operations, misstated financial data, liability for stolen assets or information, increased cybersecurity protection costs, litigation and reputational damage adversely affecting customer or investor confidence. We have implemented systems and processes to focus on identification, prevention, mitigation and resolution. However, these measures cannot provide absolute security, and our systems may be vulnerable to cybersecurity breaches such as viruses, hacking, and similar disruptions from unauthorized intrusions. In addition, we rely on third party service providers to perform certain services, such as payroll and tax services. Any failure of our systems or third-party systems may compromise our sensitive information and/or personally identifiable information of our employees or patient health information subject to HIPAA confidentiality requirements. While we have secured cyber insurance to potentially cover certain risks associated with cyber incidents, there can be no assurance the insurance will be sufficient to cover any such liability.

 

Technological interruptions or the efficiency of our website and technology solutions could damage our reputation and brand and adversely affect our results of operations.

 

The satisfactory performance, security, reliability and availability of our network infrastructure are critical to our reputation, our ability to attract, communicate with and retain customers and our ability to maintain adequate customer service levels. Any system interruptions, outside intrusions, or security breaches could result in negative publicity, damage our reputation and brand or adversely affect our results of operations. We may experience temporary system interruptions for a variety of reasons, including security breaches and other security incidents, viruses, telecommunication and other network failures, power failures, software errors or data corruption. We rely upon third-party service providers, such as co-location and cloud service providers, for our data centers and application hosting, and we are dependent on these third parties to provide continuous power, cooling, internet connectivity and physical security for our servers. In the event that these third-party providers experience any interruption in operations or cease business for any reason, or if we are unable to agree on satisfactory terms for continued hosting relationships, our business could be harmed and we could be forced to enter into a relationship with other service providers or assume hosting responsibilities ourselves. Although we operate two data centers in an active/standby configuration for geographic and vendor redundancy and even though we maintain a third disaster recovery facility to back up our content collection, a system disruption at the active data center could result in a noticeable disruption of our services. Because some of the causes of system interruptions may be outside of our control, we may not be able to remedy such interruptions in a timely manner, or at all.

 

All of these factors could have a material adverse impact on our business, financial condition, results of operations and cash flows.

 

Natural disasters, pandemics, acts of war or terrorism and other external events could significantly impact our business.

 

Natural disasters, including hurricanes, earthquakes, floods, excessive snowfall and other unfavorable weather conditions, pandemics, such as the recent outbreak of COVID-19, acts of war or terrorism and other adverse external events may affect our operations. Such events may have a detrimental effect on our gross revenue, preventing many patients from visiting a facility to obtain our ambulatory infusion pumps or receive treatment. Similarly, such events could impact key suppliers or vendors, disrupting the services or materials they provide us. The severity of these occurrences, should they ever occur, will determine the extent to which and if our business, financial condition, results of operations and cash flows is materially and adversely affected.

 

We are dependent upon executive officers and other key personnel. The loss of any of our executive officers or other key personnel could reduce our ability to manage our businesses and achieve our business plan, which could cause our sales to decline and our operating results and cash flows to suffer.

 

Our success is substantially dependent on the continued services of our executive officers and other key personnel who generally have extensive experience in our industry. Our future success also will depend in large part upon our ability to identify, attract and retain other highly qualified executive officers, managerial, finance, technical, clinical, customer service and sales and marketing personnel. Competition for these individuals is intense, more so in the current labor market. The loss of the services of any executive officer or other key employee, or our failure to attract and retain other qualified and experienced personnel on acceptable terms, could have a material and adverse effect on our business, financial condition, results of operations and cash flows.

 

 

Item 1B.      Unresolved Staff Comments.

 

None.

 

Item 2.         Properties.

 

We do not own any real property. We lease office and warehouse space at the following locations:

 

City

 

State/Country

     

Rochester Hills

 

Michigan

Lenexa

 

Kansas

Canton

 

Massachusetts

Bakersfield

 

California

Santa Fe Springs

 

California

Mississauga

 

Ontario, Canada

 

We believe that such office and warehouse space is suitable and adequate for our business.

 

Item 3.         Legal Proceedings.

 

From time to time in the ordinary course of our business, we may be involved in legal and regulatory proceedings, the outcomes of which may not be determinable. The results of litigation and regulatory proceedings are inherently unpredictable. Any claims against us, whether meritorious or not, could be time consuming, result in costly litigation, require significant amounts of management time and result in diversion of significant resources. We are not able to estimate an aggregate amount or range of reasonably possible losses for those legal matters for which losses are not probable and estimable, primarily for the following reasons: (i) many of the relevant legal proceedings are in preliminary stages and until such proceedings develop further, there is often uncertainty regarding the relevant facts and circumstances at issue and potential liability; and (ii) many of these proceedings involve matters of which the outcomes are inherently difficult to predict. We have insurance policies covering certain potential losses where such coverage is cost effective.

 

We are not at this time involved in any proceedings that we believe could have a material effect on our business, financial condition, results of operations or cash flows.

 

Item 4.         Mine Safety Disclosures.

 

Not applicable.

 

 

PART II

 

Item 5.         Market for Registrants Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

 

Our common stock is listed on the NYSE American under the symbol INFU.

 

Holders of Common Equity

 

As of March 16, 2021, we had approximately 296 stockholders of record of our common stock. This does not include beneficial owners of our common stock. None of our preferred stock is issued or outstanding.

 

Common Share Repurchase Program

 

On September 30, 2019, our Board of Directors approved a stock repurchase program (the “Share Repurchase Program”) authorizing the Company to repurchase up to $5.0 million of the Company’s outstanding common stock through 2020. Repurchases under the Share Repurchase Program will be subject to market conditions, the periodic capital needs of the Company’s operating activities, and the continued satisfaction of all covenants under the Company’s existing credit agreement. Our ability to repurchase stock is subject to the restrictions and limitations of our credit agreements. Repurchases under the program may take place in the open market or in privately negotiated transactions and may be made under a Rule 10b5-1 plan. The Share Repurchase Program does not obligate the Company to repurchase shares and may be suspended, terminated, or modified at any time.

 

As of December 31, 2020, the Company had not repurchased any shares under the Share Repurchase Program.

 

Shares Forgone to Satisfy Minimum Statutory Withholdings

 

During the years ended December 31, 2020 and 2019, shares of common stock were issued to employees and directors as their restricted stock awards vested or stock options were exercised. Under the terms of our stock plans, at the election of each employee, we can authorize a net settlement of distributable shares to employees after satisfaction of an individual employees' tax withholding obligations. For both the years ended December 31, 2020 and 2019, we received 0.1 million shares from employees for tax withholding obligations.

 

During the year ended December 31, 2020, we acquired and cancelled shares of common stock surrendered by employees to pay income taxes due upon the vesting of restricted stock as follows:

 

Period   

Total Number of Shares Purchased

   

Average Price Paid per Share

   

Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs

   

Maximum Number (or Approximate Dollar Value) of Shares that May Yet Be Purchased Under the Plans or Programs

 

February 6, 2020

    6,062     $ 8.85       N/A       N/A  

May 20, 2020

    756     $ 11.68       N/A       N/A  

Total

    6,818     $ 9.16       N/A       N/A  

 

 

During the year ended December 31, 2019, we acquired and cancelled shares of common stock surrendered by employees to pay income taxes due upon vesting of restricted stock as follows:

Period  

Total Number of Shares Purchased

   

Average Price Paid per Share

   

Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs

   

Maximum Number (or Approximate Dollar Value) of Shares that May Yet Be Purchased Under the Plans or Programs

 

March 12, 2019

    8,892     $ 4.14       N/A       N/A  

September 17, 2019

    16,368     $ 5.31       N/A       N/A  

October 21, 2019

    46,008     $ 6.50       N/A       N/A  

Total

    71,268     $ 5.93       N/A       N/A  

 

Unregistered Sales of Equity Securities and Use of Proceeds

 

We did not sell any unregistered securities during the fiscal year ended December 31, 2020.

 

Equity Compensation Plan Information

 

See Part III, Item 12 to this Form 10-K for information relating to securities authorized for issuance under our equity compensation plans.

 

Stock Performance Graph

 

InfuSystem is a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and is not required to provide the information required under this item.

 

Item 6.         Selected Financial Data.

 

InfuSystem is a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and is not required to provide the information required under this item.

 

Item 7.         Managements Discussion and Analysis of Financial Condition and Results of Operations.

 

The following discussion should be read in conjunction with the Consolidated Financial Statements and Notes thereto included in this Form 10-K. The forward-looking statements included in this discussion and elsewhere in this Form 10-K involve risks and uncertainties, including those set forth under Cautionary Statement About Forward-Looking Statements. Actual results and experience could differ materially from the anticipated results and other expectations expressed in our forward-looking statements as a result of a number of factors, including but not limited to those discussed in this Item and in Item 1A - Risk Factors.

 

 

Overview

 

We are a leading national health care service provider, facilitating outpatient care for Durable Medical Equipment manufacturers and health care providers. We provide our products and services to hospitals, oncology practices, ambulatory surgery centers, and other alternate site health care providers. Our headquarters is in Rochester Hills, Michigan, and we operate our business from a total of five locations in the United States and Canada. We deliver local, field-based customer support as well as operate pump service and repair Centers of Excellence in Michigan, Kansas, California, Massachusetts and Ontario, Canada. ISI is accredited by the Community Health Accreditation Partner (CHAP) while First Biomedical is ISO certified.

 

InfuSystem competes for and retains its business primarily on the basis of its long participation and strong reputation in the Durable Medical Equipment space, its long-standing relationships with Durable Medical Equipment manufacturers and its health care provider customers, and the high levels of service it provides. Current barriers to entry for potential competitors are created by our: (i) growing number of third-party payer networks under contract, which included nearly 728 third-party payer networks for the fiscal year ended December 31, 2020, an increase of 8% over the prior year period; (ii) economies of scale, which allow for predictable reimbursement and less costly purchase and management of the pumps, respectively; (iii) established, long-standing relationships as a provider of pumps to outpatient oncology practices in the U.S. and Canada; (iv) pump fleet of ambulatory and large volume infusion pumps for rent and for sale, which may allow us to be more responsive to the needs of physicians, outpatient oncology practices, hospitals, outpatient surgery centers, homecare practices, patient rehabilitation centers and patients than a new market entrant; (v) five geographic locations in the U.S. and Canada that allow for same day or next day delivery of pumps; and (vi) pump repair and service capabilities at all of these facilities. We do not perform any research and development on pumps, but we have made, and continue to make investments in our information technology.

 

During the fourth quarter of 2019, the Company reorganized its segment reporting from one reportable segment to two reportable segments, ITS and DME Services, due to changes in our internal reporting and the information evaluated by our chief operating decision-maker.

 

ITS Segment

 

Our ITS segment’s core purpose is to seek opportunities to leverage our unique know-how in clinic-to-home health care involving Durable Medical Equipment, our logistics and billing capabilities, our growing network of third-party payers under contract, and our clinical and biomedical capabilities. This leverage may take the form of new products and/or services, strategic alliances, joint ventures and/or acquisitions. The leading service within our ITS segment is to supply electronic ambulatory infusion pumps and associated disposable supply kits to private oncology clinics, infusion clinics and hospital outpatient oncology clinics to be utilized in the treatment of a variety of cancers including colorectal cancer and other disease states (“Oncology Business”). Colorectal cancer is the third most prevalent form of cancer in the United States, according to the American Cancer Society, and the standard of care for the treatment of colorectal cancer relies upon continuous chemotherapy infusions delivered via ambulatory infusion pumps. One of the primary goals for the ITS segment is to expand into treatment of other cancers. In 2020, our Oncology Business approximated 95% of our total ITS revenues. In 2020, we generated approximately 50% of our total ITS revenues from treatments for colorectal cancer and 45% of our ITS revenues from treatments for non-colorectal disease states. There are a number of approved treatment protocols for pancreatic, head and neck, esophageal and other cancers, as well as other disease states which present opportunities for growth. There are also a number of other drugs currently approved by the U.S. Food and Drug Administration (the “FDA”), as well as agents in the pharmaceutical development pipeline, which we believe could potentially be used with continuous infusion protocols for the treatment of diseases other than colorectal cancer. Additional drugs or protocols currently in clinical trials may also obtain regulatory approval over the next several years. If these new drugs or protocols obtain regulatory approval for use with continuous infusion protocols, we expect the pharmaceutical companies to focus their sales and marketing efforts on promoting the new drugs and protocols to physicians.

 

Furthermore, our Oncology Business focuses mainly on the continuous infusion of chemotherapy. Continuous infusion of chemotherapy can be described as the gradual administration of a drug via a small, lightweight, portable infusion pump over a prolonged period of time. A cancer patient can receive his or her medicine anywhere from one to 30 days per month depending on the chemotherapy regimen that is most appropriate to that individual’s health status and disease state. This may be followed by periods of rest and then repeated cycles with treatment goals of progression-free disease survival. This drug administration method has replaced intravenous push or bolus administration in specific circumstances. The advantages of slow continuous low doses of certain drugs are well documented. Clinical studies support the use of continuous infusion chemotherapy for decreased toxicity without loss of anti-tumor efficacy. The 2015 National Comprehensive Cancer Network (“NCCN”) Guidelines recommend the use of continuous infusion for treatment of numerous cancer diagnoses. We believe that the growth of continuous infusion therapy is driven by three factors: evidence of improved clinical outcomes; lower toxicity and side effects; and a favorable reimbursement environment.

 

 

The use of continuous infusion has been demonstrated to decrease or alter the toxicity of a number of cytotoxic, or cell killing agents. Higher doses of drugs can be infused over longer periods of time, leading to improved tolerance and decreased toxicity. For example, the cardiotoxicity (heart muscle damage) of the chemotherapy drug Doxorubicin is decreased by schedules of administration according to The Chemotherapy Source Book by Michael C. Perry. Nausea, vomiting, diarrhea and decreased white blood cell and platelet counts are all affected by duration of delivery. Continuous infusion can lead to improved tolerance and patient comfort while enhancing the patient’s ability to remain on the chemotherapy regimen. Additionally, the lower toxicity profile and resulting reduction in side effects enables patients undergoing continuous infusion therapy to continue a relatively normal lifestyle, which may include continuing to work, going shopping, and caring for family members. We believe that the partnering of physician management and patient autonomy provide for the highest quality of care with the greatest patient satisfaction.

 

We believe that oncology practices have a heightened sensitivity to providing quality service and whether they are reimbursed for services they provide. Simultaneously, CMS and private insurers are increasingly focused on evidence-based medicine to inform their reimbursement decisions — that is, aligning reimbursement with clinical outcomes and adherence to standards of care. Continuous infusion therapy is a main component of the standard of care for certain cancer types because clinical evidence demonstrates superior outcomes. Payers’ recognition of this benefit is reflected in their relative reimbursement policies for clinical services related to the delivery of this care.

 

Additional areas of focus for our ITS segment are as follows:

 

 

Pain Management - providing our ambulatory pumps, products, and services for pain management in the area of post-surgical continuous peripheral nerve block.

 

Negative Pressure Wound Therapy (“NPWT”) - as announced in February 2020, includes providing the Durable Medical Equipment, overseeing logistics, biomedical services, and managing third-party billing of the U.S. home health care market, which as a subset of the broader NPWT market, has an estimated addressable home health care market of $600 million per year.

 

Acquisitions - we believe there are opportunities to acquire smaller, regional health care service providers, in whole or part that perform similar services to us but do not have the national market access, network of third-party payer contracts or operating economies of scale that we currently enjoy. We may also pursue acquisition opportunities of companies that perform similar services, but offer different therapies or utilize different devices.

 

Information technology-based services - we also plan to continue to capitalize on key new information technology-based services such as EXPRESS, InfuSystem Mobile, InfuBus or InfuConnect, Pump Portal and BlockPain Dashboard®.

 

The payer environment within our ITS segment is in a constant state of change. We continue to extend our considerable breadth of payer networks under contract as patients move into different insurance coverages, including Medicaid and Insurance Marketplace products. In some cases, this may slightly reduce our aggregate billed revenues payment rate but result in an overall increase in collected revenues, due to a reduction in concessions. Consequently, we are increasingly focused on net revenues less concessions.

 

DME Services Segment

 

Our DME Services segment’s core service is to (i) sell or rent new and pre-owned pole-mounted and ambulatory infusion pumps and other durable medical equipment, (ii) sell treatment-related consumables; and (iii) provide biomedical recertification, maintenance and repair services for oncology practices as well as other alternate site settings including home care and home infusion providers, skilled nursing facilities, pain centers and others. We also provide these products and services to customers in the hospital market. We purchase new and pre-owned pole-mounted and ambulatory infusion pumps from a variety of sources on a non-exclusive basis. We repair, refurbish and provide biomedical certification for the devices as needed. The pumps are then available for sale, rental or to be used within our ambulatory infusion pump management service.

 

Key Business Metrics

 

Our management monitors a number of financial and non-financial measures and ratios on a regular basis in order to track the progress of our business and make adjustments as necessary. We believe that the most important of these measures and ratios include net revenues and our order-to-cash process, fleet utilization, operating margin, operating expenses, profitability, cash and cash equivalents, and debt levels including available credit and leverage ratios. These measures and ratios are compared to standards or objectives set by management, so that actions can be taken, as necessary, in order to achieve the standards and objectives.

 

 

COVID-19 Update

 

On March 11, 2020, the World Health Organization declared the outbreak of COVID-19 as a pandemic, which spread globally and throughout the United States. In response, we took a number of precautionary and preemptive steps to protect the safety and well-being of our employees while ensuring continuity of service to our clients, including, transitioning our employees to a remote work environment, suspending employee travel, canceling participation in industry events and in-person group meetings, promoting social distancing and enhanced cleaning and sanitization efforts across office locations, and implementing protocols to quarantine employees who may have been exposed to COVID-19, or show relevant symptoms. We also continued to undertake preparedness plans at our facilities to maintain continuity of operations, which provide for flexible work arrangements without any significant disruptions to our business or control processes. Our management team is continuing to actively monitor the situation and is in constant communication with our workforce as well as with our customers and vendors. While the COVID-19 pandemic has not had any material unfavorable effect on our operations to date, the extent and nature of the impact in the future, if any, will depend on future developments, which are highly uncertain, cannot be predicted and could have a material adverse impact on our financial position, operating results and cash flows. We are continuing to closely monitor the impact of the COVID-19 pandemic on all aspects of our business and may take further actions as may be required by federal, state or local authorities, or that we determine are in the best interests of our employees, customers and partners. As the conditions surrounding the COVID-19 pandemic continue to evolve, we will continue to actively manage our response in collaboration with customers, government officials and stakeholders, and assess any potential impacts to our financial position and operating results, as well as adverse developments in our business. For further information regarding the effect of the COVID-19 pandemic on the Company, please see Note 14 to our Consolidated Financial Statements included in this Form 10-K.

 

COVID-19 Comprehensive Financial Impacts

 

The COVID-19 global pandemic has caused significant disruption to the United States and global economies and has severely impacted the overall healthcare industry and the related supply chain. The focus on preparing and treating large numbers of COVID-19 patients resulted in significant shifts in demand and related shortages in certain types of medical equipment, including infusion pumps, while at the same time reducing capacity for non-COVID-19 services such as elective surgeries. These impacts created a significant net favorable dynamic for InfuSystem resulting in increased net revenues and margins in certain of our service lines only partially offset by reductions in others during 2020. Some of these benefits are not expected to occur in the future, such as elevated levels of sales of new and pre-owned medical equipment, whereas some are expected to continue but partially diminish over time, including a portion of the increased volume of rental revenues. The COVID-19 pandemic has also heightened potential risks that did not impact the Company in 2020 but may impact the Company on a delayed basis such as an unfavorable impact to payer mix caused by extended periods of high unemployment rates in the United States and an increased number of uninsured patients. We continue to prepare for disruptions in the current and future periods, both positive and negative.

 

 

InfuSystem Holdings, Inc. Results of Operations for the year ended December 31, 2020 compared to the year ended December 31, 2019

 

   

Year Ended

   

Year Ended

         
   

December 31,

   

December 31,

   

Increase/

 

(in thousands, except share and per share data)

 

2020

   

2019

   

(Decrease)

 
                         

Net revenues:

                       

ITS

  $ 61,072     $ 51,540     $ 9,532  

DME Services (inclusive of inter-segment revenues)

    41,686       33,363       8,323  

Less: elimination of inter-segment revenues

    (5,370 )     (3,788 )     (1,582 )

Total

    97,388       81,115       16,273  

Gross profit (inclusive of certain inter-segment allocations) (a):

                       

ITS

    39,773       33,063       6,710  

DME Services

    18,986       13,819       5,167  

Total

    58,759       46,882       11,877  
                         

Selling, general and administrative expenses

                       

Provision for doubtful accounts

    791       37       754  

Amortization of intangibles

    4,285       4,402       (117 )

Selling and marketing

    9,661       9,932       (271 )

General and administrative

    35,195       28,986       6,209  

Total selling, general and administrative expenses

    49,932       43,357       6,575  
                         

Operating income

    8,827       3,525       5,302  
                         

Other expense

    (1,284 )     (2,001 )     717  
                         

Income before income taxes

    7,543       1,524       6,019  

Benefit from (provision for) income taxes

    9,789       (163 )     9,952  
                         

Net income

  $ 17,332     $ 1,361     $ 15,971  
                         

Net income per share:

                       

Basic

  $ 0.86     $ 0.07     $ 0.79  

Diluted

  $ 0.80     $ 0.07     $ 0.73  

Weighted average shares outstanding:

                       

Basic

    20,106,940       19,731,498       375,442  

Diluted

    21,717,216       20,839,396       877,820  

 

(a) Inter-segment allocations are for cleaning and repair services performed on medical equipment.

 

 

Net Revenues

 

Net revenues for the year ended December 31, 2020 were $97.4 million, an increase of $16.3 million, or 20.1%, compared to $81.1 million for the year ended December 31, 2019. The increase was due to continued market penetration in Oncology and a net favorable impact from the COVID-19 pandemic. The COVID-19 pandemic effects were favorable to the current period net revenues due to strong market demand for infusion pumps including those needed to treat COVID-19 patients which increased both medical equipment sales and medical equipment rental revenues in the DME Services segment. Increased net revenues were achieved in both the ITS and DME Services segments.

 

ITS

 

ITS net revenue of $61.1 million increased $9.5 million, or 18.5%, during the year ended December 31, 2020 as compared to the prior year. This increase was primarily attributable to growth in the Company’s customer base due to favorable changes in the competitive environment for oncology services, improved third-party payer billing throughput, growth in the pain management business, net revenues from the new NPWT therapy and other market related organic growth. The pain management business net revenue for 2020 increased despite significant country-wide, government-mandated COVID-19 pandemic-related deferrals in elective surgeries during the early months of the COVID-19 outbreak. Decreases in the number of surgeries during the 2020 second quarter were partially offset by an improved revenue volume during the 2020 third and fourth quarters as the number of surgeries recovered during those periods and by an increase in the customer base for 2020 attributable to customer penetration achieved in the fourth quarter of 2019 and the first quarter of 2020.

 

DME Services

 

DME Services net revenue of $36.3 million increased $6.7 million, or 22.8%, during 2020 as compared to the prior year. DME Services net revenue excludes inter-segment revenues for both periods. This performance was driven by strong market demand for infusion pumps needed to treat high numbers of COVID-19 patients, expansion of our market share with national home infusion service providers and the addition of new devices to our product offerings stemming from new partnerships with certain medical device manufacturers. The demand benefited both sales of new and pre-owned medical equipment, which increased by $2.6 million, and higher rental revenues, which increased by $3.7 million.

 

Gross Profit (inclusive of certain inter-segment allocations)

 

Gross profit for the year ended December 31, 2020 of $58.8 million increased $11.9 million, or 25.3%, from $46.9 million during the year ended December 31, 2019. The increase was driven by the increase in net revenues and a higher gross margin. These improvements were attributable to increases in both operating segments. Gross margin increased to 60.3% during 2020, as compared to 57.8% during the prior year period, an increase of 2.5%.

 

ITS

 

ITS gross profit was $39.8 million, during 2020, representing an increase of $6.7 million, or 20.3%, compared to the prior year. The improvement reflected an increase in net revenues and a higher gross margin which improved to 65.1%, an increase of 1.0%, from the prior year. The higher gross margin was the result of improved leverage of fixed costs, including medical equipment depreciation, and a better payer rate mix.

 

DME Services

 

DME Services gross profit during 2020 was $19.0 million, representing an increase of $5.2 million, or 37.4%, over the prior year. This increase was due to the COVID-19 pandemic-related increase in net revenues from medical equipment sales and rental revenue and a higher gross margin. The DME gross margin was 52.3% during 2020, which was 5.6% higher than the prior year. This increase was the result of both the improved gross margin mix associated with a greater portion of the generally higher margin rental revenues and higher than average gross margin from sales of medical equipment. Medical equipment sales during 2020 had a higher weighting of pre-owned equipment sales, a typically higher margin business, as compared with sales of new equipment.

 

 

Provision for Doubtful Accounts

 

Provision for doubtful accounts for the year ended December 31, 2020 was $0.8 million, an increase of $0.8 million, compared to the prior year. The provision for doubtful accounts during the current period was mainly attributable to reserves related to our DME Services segment and included provisions recorded for slow paying customers. We did not incur any significant disruptions to payments from our customers during 2020 that can be directly associated with the COVID-19 pandemic; however, we cannot be certain that business disruptions associated with the COVID-19 pandemic will not unfavorably impact future customer collections or our ability to recover unreserved accounts receivable balances.

 

Amortization of Intangible Assets

 

Amortization of intangible assets for the year ended December 31, 2020 was $4.3 million representing a decrease of $0.1 million, or 2.7%, compared to 2019. The decrease is attributable to certain intangible assets becoming fully amortized.

 

Selling and Marketing Expenses

 

Selling and marketing expenses for the year ended December 31, 2020 were $9.7 million, a decrease of $0.3 million, compared to 2019. Selling and marketing expenses as a percentage of net revenues decreased to 9.9% compared to 2019, which was 12.2%. This decrease reflected COVID-19 pandemic-related lower customer travel and entertainment expenses, a shift in the proportion of net revenue favoring the DME Services segment, which has a lower commission to sales ratio than the ITS Services segment, and improved net revenue leverage of fixed selling and marketing expenses. Selling and marketing expenses during these periods consisted of sales personnel salaries, commissions and associated fringe benefit and payroll-related items, marketing, overall travel and entertainment and other miscellaneous expenses.

 

General and Administrative (G&A) Expenses

 

G&A expenses for the year ended December 31, 2020 were $35.2 million, an increase of 21.4% from $29.0 million for the year ended December 31, 2019. G&A expenses during these periods consisted primarily of accounting, administrative, third-party payer billing and contract services, customer service, nurses on staff, new product services, service center personnel salaries, fringe benefits and other payroll-related items, professional fees, legal fees, stock-based compensation, insurance and other miscellaneous items. The increase of $6.2 million was largely due to an increase in employee compensation related expenses of $5.7 million and higher general business expenses of $0.5 million. The higher personnel expenses reflect higher staff levels supporting the increase in revenues, higher short- and long-term management incentive compensation and annual inflationary increases. The higher general business expenses include higher rent and depreciation associated with the relocation of our headquarters in 2019, higher costs for telecommunication services, higher office expenses and increased premiums associated with the Company’s general risk insurance policies. These increases were partially offset by lower outside services expenses and lower travel and entertainment expenses totaling $0.6 million. G&A expenses as a percentage of net revenues for 2020 increased to 36.1% compared to 35.7% for the prior year mainly reflecting the year-over-year increases offset partially by improved net revenue leverage over fixed costs.

 

Other Income and Expenses

 

During the year ended December 31, 2020, we incurred interest expense of $1.3 million, a decrease of $0.6 million, or 34.1%, compared to the year ended December 31, 2019. This was a net result of lower weighted average interest rates on our outstanding debt in 2020 as compared to 2019, which was partially offset by interest on our increased average outstanding borrowings during 2020.

 

Provision for Income Taxes

 

As of December 31, 2020, the Company has generated significant pre-tax income on a three-year cumulative basis prompting management to assess available positive and negative evidence regarding the recovery of our net deferred tax assets. Due to this assessment, it was determined that it is more likely than not that the Company will recognize the benefits of its federal and state net deferred tax assets and, as a result, a previously recorded valuation allowance was released totaling $11.2 million. During the year ended December 31, 2020, the Company recorded a benefit for income taxes of $9.8 million, which included the valuation allowance reversal, representing a negative effective tax rate of 130% on pre-tax income of $7.5 million. Without the valuation reserve reversal, the Company would have recorded a provision for income taxes of $1.5 million which would have represented an effective tax rate of 19.4%. This adjusted effective tax rate differed from the U.S. statutory rate mainly due to permanent differences in the amounts of equity compensation expense recognized for book versus tax purposes. During the year ended December 31, 2019, the Company recorded a provision for income taxes of $0.2 million, representing an effective tax rate of 10.7% on pre-tax income totaling $1.5 million. This effective tax rate for 2019 differed from the U.S. statutory rate mainly due to the availability of net operating losses which almost fully offset the current tax provision in most jurisdictions in which we operate and a decrease in the valuation reserve recorded on our net deferred tax assets prior to the current year reversal. On March 27, 2020, the Coronavirus Aid, Relief and Economic Securities (CARES) Act was enacted in response to the COVID-19 pandemic, which provides numerous tax provisions and other stimulus measures. The Company assessed the impact of these CARES Act provisions and the subsequently released government guidance related to the COVID-19 pandemic on our financial position and results of operations and determined their impact was not material.

 

 

Inflation

 

Management believes that there has been no material effect on the results of operations or financial condition as a result of inflation or changing prices of our ambulatory infusion pumps during the period from January 1, 2019 through December 31, 2020.

 

Subsequent Events

 

We have evaluated subsequent events through the date that our consolidated financial statements are issued.

 

On February 3, 2021, the Company acquired FilAMed, a privately held biomedical services company based in Bakersfield, California. This acquisition will supplement the Company’s existing biomedical recertification, maintenance and repair services for acute care facilities and other alternate site settings including home care and home infusion providers, skilled nursing facilities, pain centers and others.

 

On February 5, 2021, the Company entered into a new credit agreement (the “2021 Credit Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent and other lenders. The 2021 Credit Agreement provides for a revolving credit facility (the “Revolving Facility”) of $75 million, maturing on February 5, 2026. On February 5, 2021, the company made an initial borrowing of $30 million under the Revolving Facility. Proceeds from the loan, along with approximately $8.2 million in cash, were used to repay all amounts due under the Company’s existing credit facility dated March 23, 2015 (the “2015 Credit Agreement”). Further details are described under the heading “Subsequent Events” in Note 15 to the Company’s Consolidated Financial Statements included in this Form 10-K.

 

 

Liquidity and Capital Resources

 

Overview:

 

We finance our operations and capital expenditures with cash generated from operations and borrowings under our existing credit agreements. As of December 31, 2020, we had cash and cash equivalents of $9.6 million and $10.8 million of availability on our revolving credit facility under the 2015 Credit Agreement compared to $2.6 million of cash and cash equivalents and $9.9 million of revolving credit availability December 31, 2019. Our liquidity and borrowing plans are established to align with our financial and strategic planning processes and ensure we have the necessary funding to meet our operating commitments, which primarily include the purchase of pumps, inventory, payroll and general expenses. We also take into consideration our overall capital allocation strategy which includes investment for future organic growth, potential acquisitions and share repurchases. We believe we have adequate sources of liquidity and funding available for at least the next year from the filing date of this report. However, any projections of future earnings and cash flows are subject to substantial uncertainty, including factors such as the successful execution of our business plan and general economic conditions, particularly in light of the rapidly changing market and economic conditions created by the COVID-19 pandemic. We may need to access debt and equity markets in the future if unforeseen costs or opportunities arise, to meet working capital requirements, fund acquisitions or investments or repay indebtedness under our credit agreements. If we need to obtain new debt or equity financing in the future, the terms and availability of such financing may be impacted by economic and financial market conditions as well as our financial condition and results of operations at the time we seek additional financing. While we did not incur significant disruptions or significant direct unusual expenses during the year ended December 31, 2020 from the COVID-19 pandemic, during the initial stages of the COVID-19 pandemic we used cash and drew on our revolving loan and 2019 Equipment Line (as defined below) to fund an acceleration of our capital expenditures for medical equipment and to increase our inventory levels of disposable medical supplies in conjunction with our COVID-19 pandemic preparedness activities. These amounts leveled off during the 2020 third and fourth quarters approaching normal amounts by December 31, 2020.

 

 

Long-Term Debt Activities:

 

On February 5, 2019, the Company and its primary lender entered into the fifth amendment (the “Fifth Amendment”) to its 2015 Credit Agreement. The Fifth Amendment amended the 2015 Credit Agreement to, among other things:

 

 

increase our borrowing capacity under the equipment line to $8.0 million, which allows for capital expenditure financing to the Company for the sole purpose of purchasing medical equipment (the “Equipment Line”);

 

revise the definition of earnings before interest, taxes, depreciation and amortization (“EBITDA”), a non-GAAP financial measure, to include additional add-back adjustments for the years ended December 31, 2018 and 2019;

 

revise the definition of fixed charge coverage ratio for the year ended December 31, 2019 to include an unfinanced portion of capital expenditures of up to $7.0 million for the year ended December 31, 2019;

 

revise the 2015 Credit Agreement’s maximum permitted indebtedness to finance the acquisition, construction or improvement of any fixed or capital assets; and

 

revise the maximum leverage ratio for each of the quarters during December 31, 2018 and December 31, 2019.

 

On April 15, 2019, the Company sold for $2.0 million and immediately leased back certain medical equipment in rental service to a third party specializing in such transactions. The leaseback term is 36 months. Because the arrangement contains a purchase option that the Company is reasonably certain to exercise, this transaction did not qualify for the sale-leaseback accounting under ASC 842. The medical equipment remains recorded on the accompanying condensed consolidated balance sheet and the proceeds received have been classified as an Other Financing liability, which is being paid off monthly over the term of the lease. The balance of Other Financing as of December 31, 2020 was $0.9 million.

 

On November 7, 2019, the Company and its primary lender entered into the sixth amendment (the “Sixth Amendment”) to its 2015 Credit Agreement. The Sixth Amendment amended the 2015 Credit Agreement to, among other things:

 

 

provide for a 2019 capital expenditure loan (the “2019 Equipment Line”) commitment of $10.0 million (in addition to the existing Equipment Line of $8.0 million), which may be drawn upon until the earlier of the full commitment being advanced or December 31, 2020, to be used solely to purchase eligible equipment to be used in our business and in amounts not to exceed 90.0% of the invoiced hard costs of such acquired equipment;

 

 

increase the commitment under the revolving facility (the “Revolver”) under the 2015 Credit Agreement to $11.8 million;

 

 

revise the definition of EBITDA to include the following additional or revised add-back adjustments: (i) one-time charges in an aggregate amount not to exceed $0.3 million and incurred prior to December 31, 2019 relating to our integration of business previously served by another major provider of electronic oncology pumps; (ii) one-time charges in an aggregate amount not to exceed $0.3 million and incurred prior to December 31, 2019 relating to our facility move; (iii) lease buyout expenses not to exceed: (x) $0.1 million incurred on or prior to December 31, 2018; (y) $0.2 million incurred after December 31, 2018 but on or prior to March 31, 2019; and (z) $0.2 million incurred after September 30, 2019 but on or prior to December 31, 2020; and (iv) any other non-cash charges for such period (but excluding certain non-cash charges);

 

 

revise the definition of Fixed Charge Coverage Ratio to mean, for any period, the ratio of (a) EBITDA minus Maintenance Capital Expenditures (defined to mean, for any period, 50.0% of depreciation expense) to (b) Fixed Charges, all calculated for the Company and its subsidiaries on a consolidated basis in accordance with GAAP;

 

 

revise the definitions of Revolving Credit Maturity Date and Term Maturity Date to mean the date five years after the Sixth Amendment Effective Date and add a definition for the 2019 Equipment Line Maturity Date to provide for the same maturity date;

 

 

reflect the refinancing of the Term A Loans, Term B Loans and Term C Loan as a single term loan (the “Term Loan”) on the Sixth Amendment Effective Date and, commencing on the last Business Day of December 2019, the consecutive quarterly principal installment payments changed to approximately $1.2 million; and

 

 

revise Section 5.01(e) of the 2015 Credit Agreement, which governs our obligation to deliver financial statements to the lender, to require us to provide the financial statements (x) as soon as possible but in any event within 30 days of the end of each fiscal quarter, or within 30 days of the end of each calendar month if any revolving loans were outstanding in month, (y) in connection with, and prior to, requesting any letter of credit and (z) at such other times as may be requested by the lender.

 

These debt amendments were accounted for as debt modifications. As of December 31, 2020, the Company was in compliance with all covenants under the 2015 Credit Agreement.

 

 

As of December 31, 2020, the Company’s Term Loan, Equipment Line and 2019 Equipment line under the 2015 Credit Agreement had balances of $21.9 million, $6.0 million and $10.0 million, respectively. The availability under the Revolver was subject to a borrowing base, which is calculated as the sum of the Company’s eligible accounts receivable and eligible inventory as defined by the 2015 Credit Agreement. As of December 31, 2020, the borrowing base was approximately $15.6 million, which exceeded the gross available borrowing amount of $11.8 million. The following table illustrates the net availability under the Revolver as of the applicable balance sheet date (in thousands):

 

   

December 31,

   

December 31,

 
   

2020

   

2019

 

Revolver:

               

Gross Availability

  $ 11,750     $ 11,750  

Outstanding Draws

    -       -  

Letters of Credit

    (800 )     (1,750 )

Landlord Reserves

    (162 )     (150 )

Availability on Revolver

  $ 10,788     $ 9,850  

 

As of December 31, 2020, interest on the credit facility is payable at our option as a (i) Eurodollar Loan, which bears interest at a per annum rate equal to the applicable 30-day London Interbank Offered Rate (“LIBOR”) plus a margin ranging from 2.00% to 3.00% or (ii) CB Floating Rate (“CBFR”) Loan, which bears interest at a per annum rate equal to the greater of (a) the lender’s prime rate or (b) LIBOR plus 2.50%, in each case, plus a margin ranging from -1.00% to 0.25% based on our leverage ratio as defined in the 2015 Credit Agreement. The actual Eurodollar Loan rate at December 31, 2020 was 2.19% (LIBOR of 0.19% plus 2.00%). The actual CBFR Loan rate at December 31, 2020 was 2.25% (lender’s prime rate of 3.25% minus 1.00%).

 

As discussed above, subsequent to December 31, 2020, the Company entered into the 2021 Credit Agreement, which replaced the 2015 Credit Agreement.

 

Share Repurchases

 

As described previously, on September 30, 2019, our Board of Directors approved the Share Repurchase Program. As of December 31, 2020, the Company has not repurchased any shares under the Share Repurchase Program.

 

Cash Flows:

 

Operating Cash Flow.  Net cash provided by operating activities for the year ended December 31, 2020 was $20.3 million compared to $13.9 million for the year ended December 31, 2019. This $6.4 million, or 46.2%, increase was primarily attributable to the positive cash flow effect of increases in net income adjusted for non-cash items of $7.5 million, which was partially offset by an incremental increase in accounts receivable totaling $1.1 million.

 

Investing Cash Flow. Net cash used in investing activities was $12.2 million for the year ended December 31, 2020 compared to $19.6 million for the year ended December 31, 2019. The decrease in net cash used was primarily due to a $3.8 million decrease in cash used to purchase medical equipment, $1.8 million decrease in cash used to purchase other property and equipment and a $1.8 million increase in proceeds from the sales of medical equipment.

 

Financing Cash Flow.  Net cash used in financing activities for the year ended December 31, 2020 was $1.1 million compared to cash provided of $4.1 million for the year ended December 31, 2019. The decrease was primarily attributable to cash used to repurchase common stock to satisfy statutory withholding on stock-based compensation of $1.7 million and a net increase in outstanding borrowing under the 2015 Credit Agreement and other financing totaling $0.4 million. The increase in 2015 Credit Agreement borrowings included $8.4 million in borrowings under the 2019 Equipment Line offset by amortization installments on term notes and other financing totaling $8.0 million.

 

Contractual Obligations

 

InfuSystem is a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and is not required to provide this information.

 

Contingent Liabilities

 

We are not aware of any contingent liabilities.

 

 

Off-Balance Sheet Arrangements

 

We do not have any material off-balance sheet arrangements.

 

Critical Accounting Policies and Estimates

 

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements, including the notes thereto. We consider critical accounting policies to be those that require more significant judgments and estimates in the preparation of our consolidated financial statements, including the following: revenue recognition; leases; accounts receivable and allowance for doubtful accounts; income taxes; and long-lived asset valuations. Management relies on historical experience and other assumptions believed to be reasonable in making its judgments and estimates. Actual results could differ materially from those estimates.

 

Management believes its application of accounting policies, and the estimates inherently required therein, are reasonable. These accounting policies and estimates are periodically reevaluated, and adjustments are made when facts and circumstances dictate a change.

 

Our accounting policies are more fully described under the heading “Summary of Significant Accounting Policies” in Note 2 to our Consolidated Financial Statements included in this Form 10-K. We believe the following critical accounting estimates are the most significant to the presentation of our financial statements and require the most difficult, subjective and complex judgments:

 

Revenue Recognition

 

On January 1, 2018 the Company adopted the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 606 - Revenue from Contracts with Customers (“ASC 606”) and concluded that, consistent with prior reporting, the Company has two separate revenue streams: rentals and product sales. The adoption of ASC 606 requires certain customer concessions associated with rental revenues reported in accordance with ASC 605 - Revenue Recognition, previously reported in selling, general and administrative expenses as “provision for doubtful accounts” to now be recorded as a reduction of net rental revenues as they are considered price concessions of the transaction price under the new revenue guidance. ASC 606 was adopted on a modified retrospective method.

 

ASC 606 stipulates revenue recognition at the time and in an amount that reflects the consideration expected to be received for the performance obligations that have been provided. ASC 606 defines contracts as written, oral and through customary business practice. Under this definition, the Company considers contracts to be created at the time that the rental service is authorized or an order to purchase product is agreed upon regardless of whether or not there is a written contract.

 

The Company has two separate and distinct performance obligations offered to its customers: a rental service performance obligation or a product sale performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is defined as the unit of account for revenue recognition under ASC 606. These performance obligations are related to separate revenue streams and at no point are they combined into a single transaction. Sources of net revenues include commercial insurance payers, government insurance payers, medical facilities and patients.

 

The Company generates the majority of its revenue from the rental of infusion pumps to its customers and a minority of its revenue from product sales. For the rental service performance obligation, revenue is based on its standalone price, determined by using reimbursement rates established by third-party payer or other contracts. Revenue is recognized in the period in which the related performance obligation is satisfied, which is typically at the point in time that a patient concludes a treatment, or in certain arrangements, based on the number of pumps that a facility has onsite. The Company’s revenues related to product sales is recognized at the time that control of the product has been transferred to the customer; either at the time the product is shipped or the time the product has been received by the customer, depending on the delivery terms. The Company does not commit to long-term contracts to sell customers a certain minimum quantity of products.

 

The Company employs certain significant judgments to estimate the dollar amount of revenue, and related concessions, allocated to the rental service and sale of products. These judgments include, among others, the estimation of variable consideration. Variable consideration, specifically related to the Company’s third-party payer rental revenues, is estimated as implied price concessions resulting from differences between the rates charged for services performed and the expected reimbursements for commercial payers and other implied customer concessions. The estimates for variable consideration are based on historical collections with similar payers, aged accounts receivable by payer class and payer correspondence using the portfolio approach, which provide a reasonable basis for estimating the variable portion of a transaction. The Company doesn’t believe it is probable that a significant reversal of revenue will occur in future periods because (i) there is no significant uncertainty about the amount of considerations that are expected to be collected based on collection history and (ii) the large number of sufficiently similar contracts allows the Company to adequately estimate the component of variable consideration.

 

 

Net revenues are adjusted when changes in estimates of variable consideration occur. Changes in estimates typically arise as a result of new information obtained, such as actual payment receipt or denial, or pricing adjustments by payers. Subsequent changes to estimates of transaction prices are recorded as adjustments to net revenue in the period of the change. Subsequent changes that are determined to be the result of an adverse change in the payer’s ability to pay are recorded as an allowance for doubtful accounts.

 

Leases

 

On January 1, 2019 (the “Effective Date”), the Company adopted Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842); ASU 2018-10, Codification Improvements to Topic 842, Leases; and ASU 2018-11, Targeted Improvements (collectively, “Topic 842”) using a modified retrospective transition approach, which requires Topic 842 to be applied to all leases existing at the date of initial application. Under Topic 842, lessees are required to recognize a lease liability and right-of-use asset (“ROU asset”) for all leases and to disclose key information about leasing arrangements. Additionally, leases are classified as either financing or operating; the classification determines the pattern of expense recognition and classification within the statement of operations. The Company elected to apply its lease accounting policy only to leases with a term greater than twelve months.

 

Topic 842 provides several optional practical expedients that we adopted at transition. We elected the “package of practical expedients”, which does not require us to reassess our prior conclusions regarding lease identification, lease classification and initial direct costs. We did not elect the practical expedient of hindsight to the evaluation of lease options (e.g. renewal).

 

Topic 842 also provides practical expedients for an entity’s ongoing accounting. We elected the “combining lease and non-lease components” practical expedient and also elected to apply the short-term lease recognition exemption to certain leases; therefore, we did not recognize ROU assets and lease liabilities for these leases.

 

In adopting Topic 842, we determined and will continue to determine whether an arrangement is a lease at inception. Our operating leases are primarily for office space, service facility centers and equipment under operating lease arrangements that expire at various dates over the next ten years. Our leases do not contain any restrictive covenants. Our office leases generally contain renewal options for periods ranging from one to five years. Because we are not reasonably certain to exercise these renewal options, the options are not considered in determining the lease term, and payments associated with the option years are excluded from lease payments. Our office leases do not contain any material residual value guarantees. Our equipment leases generally do not contain renewal options. We are not reasonably certain to exercise the renewal options for those equipment leases that do contain renewal options, thus, the options are not considered in determining the lease term and payments associated with the option years are excluded from lease payments.

 

For our equipment leases, we used and will use the implicit rate in the lease as the discount rate, when available. Otherwise, we use our incremental borrowing rate as the discount rate. For our office leases, the implicit rate is typically not available, so we used and will use our incremental borrowing rate as the discount rate. Our lease agreements include both lease and non-lease components. We elected the practical expedient that allows us to combine lease and non-lease components for all of our leases.

 

Payments due under our operating leases include fixed payments as well as variable payments. For our office leases, variable payments include amounts for the Company’s proportionate share of operating expenses, utilities, property taxes, insurance, common area maintenance and other facility-related expenses. For our equipment leases, variable payments may consist of sales taxes, property taxes and other fees.

 

Accounts Receivable and Allowance for Doubtful Accounts

 

Amounts billed that have not yet been collected that also meet the conditions for unconditional right to payment are presented as accounts receivable. Accounts receivable related to rental service and delivery of products are reported at their estimated transaction prices, inclusive of adjustments for variable consideration, based on the amounts expected to be collected from payers. The Company writes off accounts receivable once collection efforts have been exhausted and an account is deemed to be uncollectible. Subsequent to the adoption of ASC 606, an allowance for doubtful accounts is established only as a result of an adverse change in the Company’s payers’ ability to pay outstanding billings. The allowance for doubtful accounts was $1.0 million and $0.4 million as of December 31, 2020 and 2019, respectively.

 

 

Income Taxes

 

We recognize deferred income tax liabilities and assets based on (i) the differences between the financial statement carrying amounts and the tax basis of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse and (ii) the tax credit carryforwards. Deferred income tax (expense) benefit results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when, in the opinion of management, it is more likely than not that some or all of any deferred tax assets will not be realized. To make this assessment, we consider the historical and projected future taxable income or loss in each tax jurisdiction and we review our tax planning strategies. In the fourth quarter of 2020 we determined that our valuation allowance against U.S. federal and state deferred taxes is no longer required and the valuation allowance of $11.2 million that existed was released. Management has weighed all of the positive and negative evidence and determined that it was more likely than not that the Company would generate sufficient taxable income in the near future to realize all of the deferred tax assets before they expire. The Company turned profitable in 2019 and is profitable in 2020, putting the Company in a three-year cumulative income position. The Company is projecting sufficient pre-tax book income over the next several years to be able to utilize net operating loss carryforwards. Since future financial results may differ from previous estimates, periodic adjustments to our valuation allowance positions may be necessary.

 

Provisions for federal, state and foreign taxes are calculated based on reported pre-tax earnings based on current tax law and include the cumulative effect of any changes in tax rates from those used previously in determining deferred tax assets and liabilities. Certain items of income and expense are recognized in different time periods for financial reporting than for income tax purposes; thus, such provisions differ from the amounts currently receivable or payable.

 

We estimate the impact of uncertain income tax positions on our income tax return. These estimates impact income taxes receivable, accounts payable and accrued liabilities on the balance sheet and provision for income taxes on the income statement. We follow a two-step approach for recognizing uncertain tax positions. First, management evaluates the tax position for recognition by determining if the weight of available evidence indicates it is more-likely-than-not that the position will be sustained upon examination. Second, for positions that are determined are more-likely-than-not to be sustained, we recognize the tax benefit as the largest benefit that has a greater than 50% likelihood of being sustained. We establish a reserve for uncertain tax positions liability that is comprised of unrecognized tax benefits and related interest and penalties. We adjust this liability in the period in which an uncertain tax position is effectively settled, the statute of limitations expires for the relevant taxing authority to examine the tax position, or more information becomes available. For more information, refer to the “Income Taxes” discussion included in Note 8 in the Notes to the Consolidated Financial Statements.

 

The Company adopted ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, in the fourth quarter of 2019. This guidance simplifies various aspects related to accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted, including adoption in any interim period for which financial statements have not yet been issued. Certain amendments may be applied on a retrospective, modified retrospective or prospective basis. As permitted, the Company elected to early adopt this guidance for the year ended December 31, 2019. The adoption of this guidance did not have a significant impact on the Company’s financial statements and primarily resulted in the reclassification of an immaterial amount from non-income tax expense to income tax expense related to the accounting for franchise taxes, with no impact to the Company’s consolidated net income, equity or cash flows.

 

Long-lived Asset Valuation

 

We evaluate the carrying value of long-lived assets for impairment by analyzing the operating performance and anticipated future cash flows for those assets, whenever events or changes in circumstances indicate that the carrying amounts of such assets may not be recoverable. We evaluate the need to adjust the carrying value of the underlying assets if the sum of the expected cash flows is less than the carrying value. Our projection of future cash flows, the level of actual cash flows, the methods of estimation used for determining fair values and salvage values can impact impairment. Any changes in management’s judgments could result in greater or lesser annual depreciation and amortization expense or impairment charges in the future. Depreciation and amortization of long-lived assets is calculated using the straight-line method over the estimated useful lives of the assets.

 

We performed our annual impairment analysis of all indefinite-lived intangible assets in October 2020 and determined that the fair value of all the assets was greater than the carrying value, resulting in no impairment of indefinite-lived assets.

 

The Company assesses impairment indicators related to its internally-developed, internal-use software, specifically looking at the effectiveness and useful lives of each project and sub-project to determine if impairment indicators are present. In December 2020 and 2019, respectively, the Company assessed the impairment indicators and found none to be present.

 

For more information, refer to the “Intangible Assets” discussion included in Note 6 in the Notes to the Consolidated Financial Statements included in this Form 10-K.

 

Item 7A.      Quantitative and Qualitative Disclosure About Market Risk.

 

InfuSystem is a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and is not required to provide the information required under this item.

 

 

Item 8.         Financial Statements and Supplementary Data.

 

 

Index to Financial Statements

 

 

Page 

Report of Independent Registered Public Accounting Firm

36

Consolidated Balance Sheets as of December 31, 2020 and 2019

38

Consolidated Statements of Operations for the years ended December 31, 2020 and 2019

39

Consolidated Statements of Stockholders’ Equity for the years ended December 31, 2020 and 2019

40

Consolidated Statements of Cash Flows for the years ended December 31, 2020 and 2019

41

Notes to Consolidated Financial Statements

43

 

 

Report of Independent Registered Public Accounting Firm

 

Shareholders and Board of Directors

InfuSystem Holdings, Inc.

Rochester Hills, Michigan

 

Opinion on the Consolidated Financial Statements

 

We have audited the accompanying consolidated balance sheets of InfuSystem Holdings, Inc. (the “Company”) as of December 31, 2020 and 2019, the related consolidated statements of operations, stockholders’ equity, and cash flows for each of the two years in the period ended December 31, 2020, and the related notes (collectively referred to as the “consolidated financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the two years in the period December 31, 2020, in conformity with accounting principles generally accepted in the United States of America.

 

Basis for Opinion

 

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

 

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matters

 

The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.

 

36

 

Third-Party Payer Rental Revenue

 

As described in Note 2 of the Company’s consolidated financial statements, variable consideration related to third-party payer rentals is estimated as implied price concessions resulting from differences between the rates charged for services performed and the expected reimbursements for commercial payers and other implied customer concessions (“payer reimbursement rates”).  Such payer reimbursement rates are based on historical collections with similar payers, aged accounts receivable by payer class and payer correspondence using the portfolio approach. For the year ended December 31, 2020, the Company’s consolidated revenues attributable to third-party payer rentals was $49.3 million. 

 

We identified the estimation of payer reimbursement rates used in the determination of variable consideration from third-party payer rental revenue as a critical audit matter.  Significant assumptions, including rates charged and collection, are used to determine payer reimbursement rates. Auditing management’s estimates involved subjective auditor judgment due to the nature and extent of audit effort required to address these matters.

 

The primary procedures we performed to address this critical audit matter included:

 

 

Testing the inputs to the payer reimbursement rates through tracing to source documents.

 

 

Testing the calculation of payer reimbursement rates through checking the mathematical accuracy of the calculations.

 

 

Evaluating management’s estimated payer reimbursement rates by performing a retrospective review of historical estimated payer reimbursement rates to actual reimbursements received.

 

Income Taxes Valuation Allowance

 

As discussed in Note 8 to the Company’s consolidated financial statements, the release of the valuation allowance during fiscal year ended December 31, 2020 was $11.2 million.  In assessing the realizability of deferred tax assets, management determined there was sufficient positive evidence that it was more-likely-than-not that its deferred tax assets would be realized and therefore, released the full valuation allowance against the deferred tax assets.

 

We identified management’s judgments related to the determination of the valuation allowance as a critical audit matter due to significant judgments related to: (i) evaluating the positive and negative evidence available in the determination of the amount of deferred tax assets that were more-likely-than-not to be realized in the future, and (ii) evaluating whether sufficient projected future taxable income will be generated to support the full valuation allowance release.  Auditing these judgments involved especially challenging auditor judgment due to the nature and extent of audit evidence and effort required to address these matters, including the extent of specialized skills or knowledge needed.

 

The primary procedures we performed to address this critical audit matter included:

 

 

Assessing the reasonableness and the appropriateness of management’s judgments and assumptions used to support projected taxable income against historical performance of the Company and management’s plans.

 

 

Utilizing personnel with specialized knowledge and skill in income taxes to assist in the evaluation of the appropriateness of the Company’s tax positions and analysis of the realizability of the deferred tax assets and the conclusions reached.

 

/s/ BDO USA, LLP

 

We have served as the Company's auditor since 2013.

 

Troy, Michigan

 

March 22, 2021

 

 

 

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

 

   

December 31,

   

December 31,

 

(in thousands, except par value and share data)

 

2020

   

2019

 
                 

ASSETS

               

Current assets:

               

Cash and cash equivalents

  $ 9,648     $ 2,647  

Accounts receivable, net

    14,720       12,097  

Inventories

    3,001       2,899  

Other current assets

    2,402       1,662  
                 

Total current assets

    29,771       19,305  

Medical equipment for sale or rental

    1,603       1,306  

Medical equipment in rental service, net of accumulated depreciation

    35,611       33,225  

Property & equipment, net of accumulated depreciation

    4,296       4,037  

Intangible assets, net

    11,177       15,463  

Operating lease right of use assets

    4,461       5,733  

Deferred income taxes

    9,967       -  

Other assets

    105       155  
                 

Total assets

  $ 96,991     $ 79,224  
                 

LIABILITIES AND STOCKHOLDERS EQUITY

               

Current liabilities:

               

Accounts payable

  $ 6,779     $ 7,962  

Current portion of long-term debt

    9,423       8,082  

Other current liabilities

    6,795       5,803  
                 

Total current liabilities

    22,997       21,847  
                 

Long-term debt, net of current portion

    29,378       30,295  

Deferred income taxes

    -       104  

Operating lease liabilities, net of current portion

    3,864       4,644  
                 

Total liabilities

  $ 56,239     $ 56,890  
                 

Stockholders’ equity:

               

Preferred stock, $.0001 par value: authorized 1,000,000 shares; none issued

    -       -  

Common stock, $.0001 par value: authorized 200,000,000 shares; issued and outstanding 23,816,193 and 20,297,704, as of December 31, 2020, respectively, and issued and outstanding 23,400,625 and 19,882,136, as of December 31, 2019, respectively.

    2       2  

Additional paid-in capital

    84,785       83,699  

Retained deficit

    (44,035 )     (61,367 )
                 

Total stockholders’ equity

    40,752       22,334  
                 

Total liabilities and stockholders’ equity

  $ 96,991     $ 79,224  

 

See accompanying notes to consolidated financial statements.

 

 

 

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

 

   

Year Ended

   

Year Ended

 
   

December 31,

   

December 31,

 

(in thousands, except share and per share data)

 

2020

   

2019

 
                 

Net revenues

  $ 97,388     $ 81,115  

Cost of revenues

    38,629       34,233  

Gross profit

    58,759       46,882  
                 

Selling, general and administrative expenses:

               

Provision for doubtful accounts

    791       37  

Amortization of intangibles

    4,285       4,402  

Selling and marketing

    9,661       9,932  

General and administrative

    35,195       28,986  
                 

Total selling, general and administrative

    49,932       43,357  
                 

Operating income

    8,827       3,525  
                 

Other expense:

               

Interest expense

    (1,255 )     (1,904 )

Other expense

    (29 )     (97 )
                 

Income before income taxes

    7,543       1,524  

Benefit from (provision for) income taxes

    9,789       (163 )
                 

Net income

  $ 17,332     $ 1,361  
                 

Net income per share:

               

Basic

  $ 0.86     $ 0.07  

Diluted

  $ 0.80     $ 0.07  

Weighted average shares outstanding:

               

Basic

    20,106,940       19,731,498  

Diluted

    21,717,216       20,839,396  

 

See accompanying notes to consolidated financial statements.

 

 

 

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF

STOCKHOLDERS EQUITY

 

   

Common Stock

   

Additional

           

Treasury Stock

   

Total

 
           

Par Value

   

Paid in

   

Retained

           

Par Value

   

Stockholders

 

(in thousands)

 

Shares

   

Amount

   

Capital

   

Deficit

   

Shares

   

Amount

   

Equity

 

Balances at January 1, 2019

    23,096     $ 2     $ 83,167     $ (62,728 )     (3,518 )   $ -     $ 20,441  

Stock-based shares issued upon vesting - gross

    394       -       139       -       -       -       139  

Stock-based compensation expense

    -       -       997       -       -       -       997  

Employee stock purchase plan

    33       -       113       -       -       -       113  

Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation

    (122 )     -       (717 )     -       -       -       (717 )

Net income

    -       -       -       1,361       -       -       1,361  

Balances at December 31, 2019

    23,401       2       83,699       (61,367 )     (3,518 )     -       22,334  

Stock-based shares issued upon vesting - gross

    505       -       -       -       -       -       -  

Stock-based compensation expense

    -       -       2,610       -       -       -       2,610  

Employee stock purchase plan

    29       -       190       -       -       -       190  

Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation

    (147 )     -       (1,714 )     -       -       -       (1,714 )

Common stock - issued

    28       -       -       -       -       -       -  

Net income

    -       -       -       17,332       -       -       17,332  

Balances at December 31, 2020

    23,816     $ 2     $ 84,785     $ (44,035 )     (3,518 )   $ -     $ 40,752  

 

See accompanying notes to consolidated financial statements.

 

 

 

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

   

Year Ended

   

Year Ended

 
   

December 31,

   

December 31,

 

(in thousands)

 

2020

   

2019

 

OPERATING ACTIVITIES

               

Net income

  $ 17,332     $ 1,361  

Adjustments to reconcile net income to net cash provided by operating activities:

               

Provision for doubtful accounts

    791       37  

Depreciation

    9,740       7,940  

Loss on disposal of medical equipment and other assets

    418       638  

Gain on sale of medical equipment

    (3,577 )     (1,453 )

Amortization of intangible assets

    4,285       4,402  

Amortization of deferred debt issuance costs

    17       37  

Stock-based compensation

    2,610       997  

Deferred income taxes

    (10,071 )     104  

Changes in Assets - Increase:

               

Accounts receivable

    (2,631 )     (1,560 )

Inventories

    (102 )     (645 )

Other current assets

    (740 )     (290 )

Other assets

    (186 )     (129 )

Changes in Liabilities - Increase:

               

Accounts payable and other liabilities

    2,394       2,436  

NET CASH PROVIDED BY OPERATING ACTIVITIES

    20,280       13,875  

INVESTING ACTIVITIES

               

Purchase of medical equipment

    (15,820 )     (19,669 )

Purchase of property and equipment

    (1,094 )     (2,926 )

Proceeds from sale of medical equipment, property and equipment

    4,752       2,952  

NET CASH USED IN INVESTING ACTIVITIES

    (12,162 )     (19,643 )

FINANCING ACTIVITIES

               

Principal payments on term loans, equipment line, revolving credit facility and other financing

    (37,180 )     (4,868 )

Cash proceeds from 2019 equipment line, equipment line, revolving credit facility and other financing

    37,587       9,436  

Debt issuance costs

    -       (6 )

Common stock repurchased to satisfy statutory withholding on employee stock-based compensation plans

    (1,714 )     (717 )

Cash proceeds from stock plans

    190       252  

NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES

    (1,117 )     4,097  

Net change in cash and cash equivalents

    7,001       (1,671 )

Cash and cash equivalents, beginning of year

    2,647       4,318  

Cash and cash equivalents, end of year

  $ 9,648     $ 2,647  

 

See accompanying notes to consolidated financial statements.

 

 

The following table presents certain supplementary cash flow information for the years ended December 31 (in thousands):

 

(in thousands)

 

2020

   

2019

 
                 

SUPPLEMENTAL DISCLOSURES

               

Cash paid for interest

  $ 1,214     $ 1,705  

Cash paid for income taxes

    102       111  

NON-CASH TRANSACTIONS

               

Additions to medical equipment and property (a)

  $ 793     $ 2,773  

 

(a) Amounts consist of current liabilities for medical equipment that have not been included in investing activities. These amounts have not been paid for as of December 31, 2020 and 2019, respectively, but will be included as a cash outflow from investing activities for purchases of medical equipment and property when paid. 

 

See accompanying notes to consolidated financial statements.

 

 

INFUSYSTEM HOLDINGS, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

 

 

1.         Basis of Presentation and Nature of Operations

 

InfuSystem Holdings, Inc. and its consolidated subsidiaries (the “Company”) are a leading provider of infusion pumps and related products and services for patients in the home, oncology clinics, ambulatory surgery centers, and other sites of care from five locations in the United States and Canada. The Company provides products and services to hospitals, oncology practices and facilities and other alternate site health care providers. Headquartered in Rochester Hills, Michigan, the Company delivers local, field-based customer support, and also operates pump service and repair Centers of Excellence in Michigan, Kansas, California, Massachusetts and Ontario, Canada. InfuSystem Inc. (“ISI”), which is an operating subsidiary of the Company, is accredited by the Community Health Accreditation Program while First Biomedical, Inc. (First Biomedical), which is an operating subsidiary of the Company, is ISO certified.

 

The Company’s core service is to supply electronic ambulatory infusion pumps and associated disposable supply kits to oncology clinics, infusion clinics and hospital outpatient chemotherapy clinics to be utilized in the treatment of a variety of cancers including colorectal cancer, pain management and other disease states. The majority of the Company’s pumps are electronic infusion pumps. Smiths Medical, Inc. and Moog Medical Devices Group each supplied more than 10% of the ambulatory pumps purchased by the Company in 2020. The Company has a supply agreement in place with each of these suppliers. Certain “spot” purchases are made on the open market subject to individual negotiation. The Company also supplies Negative Pressure Wound Therapy (“NPWT”) medical equipment, as well as related disposables and ancillary supplies. Cardinal Health, Inc. supplied more than 10% of the NPWT medical equipment purchased by the Company in 2020. The Company has a supply agreement in place with Cardinal Health, Inc.

 

In addition, the Company sells or rents new and pre-owned pole-mounted and ambulatory infusion pumps to, and provides biomedical recertification, maintenance and repair services for oncology practices, as well as other alternate site settings including home care and home infusion providers, skilled nursing facilities, pain centers and others. The Company also provides these products and services to customers in the hospital market.

 

The Company purchases new and pre-owned pole-mounted and ambulatory infusion pumps from a variety of sources on a non-exclusive basis. The Company repairs, refurbishes and provides biomedical certification for the devices as needed. The pumps are then available for sale, rental or to be used within the Company’s ambulatory infusion pump management service.

 

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”).

 

 

 

2.         Summary of Significant Accounting Policies

 

Reclassifications

 

Certain prior period reclassifications were made to conform with the current period presentation. These reclassifications had no effect on reported income (loss), overall cash flows, total assets, total liabilities or stockholders’ equity as previously reported.

 

Presentation in the Consolidated Statements

 

The Company rents and sells medical equipment. The Company purchases medical equipment directly for sale as well as medical equipment that is purchased for either rental or sale and that is unallocated at the time of purchase (“Unallocated Assets”). Management believes that the predominant source of revenues and cash flows from the Unallocated Assets is from rentals and most equipment purchased is likely to be rented prior to being sold. The Company concluded that (i) the assets specifically supporting its two primary revenue streams should be separately disclosed on the balance sheet; (ii) the purchase and sale of Unallocated Assets should be classified solely in investing cash flows based on their predominant source while medical equipment purchased specifically for sales activity should be classified in operating cash flows; and (iii) other activities ancillary to the rental process should be consistently classified.

 

Principles of Consolidation

 

The consolidated financial statements include the accounts of the Company and all wholly owned organizations. All intercompany transactions and account balances have been eliminated in consolidation.

 

 

Segments

 

During the fourth quarter of 2019, the Company reorganized its segment reporting from one reportable segment to two reportable segments, Integrated Therapy Services (“ITS”) and Durable Medical Equipment Services (“DME Services”), due to changes in our internal reporting and the information evaluated by our chief operating decision-maker. See Note 12 for segment disclosures.

 

The Company’s approach is to make operational decisions and assess performance based on delivering products and services that together provide solutions to its customer base utilizing a functional management structure. Based upon this business model, the Company’s Chief Executive Officer, whom the Company has determined to be its chief operating decision-maker, reviews segment financial information.

 

Use of Estimates

 

The preparation of financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements, including the notes thereto. The Company considers critical accounting policies to be those that require more significant judgments and estimates in the preparation of its consolidated financial statements, including the following: revenue recognition, leases, accounts receivable and allowance for doubtful accounts, income taxes, and long-lived asset valuations. Management relies on historical experience and other assumptions believed to be reasonable in making its judgments and estimates. Actual results could differ materially from those estimates.

 

Business Combinations

 

The Company accounts for all business combinations using the acquisition method of accounting, which allocates the fair value of the purchase consideration to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values. The excess of the purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. When determining the fair values of assets acquired and liabilities assumed, management makes significant estimates and assumptions. The Company may utilize third-party valuation specialists to assist the Company in the allocation. Initial purchase price allocations are subject to revision within the measurement period, not to exceed one year from the date of acquisition. Acquisition-related expenses and transaction costs associated with business combinations are expensed as incurred.

 

Cash and Cash Equivalents

 

The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. The Company maintains its cash and cash equivalents primarily with two financial institutions that are insured with the Federal Deposit Insurance Corporation (“FDIC”). At times throughout the year, cash and cash equivalents balances might exceed FDIC insurance limits.

 

Accounts Receivable and Allowance for Doubtful Accounts

 

Amounts billed that have not yet been collected that also meet the conditions for unconditional right to payment are presented as accounts receivable. Accounts receivable related to rental service and delivery of products are reported at their estimated transaction prices, inclusive of adjustments for variable consideration, based on the amounts expected to be collected from payers. The Company writes off accounts receivable once collection efforts have been exhausted and an account is deemed to be uncollectible. An allowance for doubtful accounts is established as a result of an adverse change in the Company’s payers’ ability to pay outstanding billings. The allowance for doubtful accounts was $1.0 million and $0.4 million as of December 31, 2020 and 2019, respectively.

 

Inventories

 

The Company’s inventories consist of disposable medical supplies, replacement parts and other supplies used in conjunction with medical equipment and are stated at the lower of cost (first-in, first-out basis) or net realizable value. The Company periodically performs an analysis of slow-moving inventory and records a reserve based on estimated obsolete inventory, which was $0.1 million as of December 31, 2020 and 2019.

 

 

Medical Equipment

 

Medical Equipment (“Equipment”) consists of equipment that the Company purchases from third-parties and is (1) for sale or rent, and (2) used in service to generate rental revenue. Equipment, once placed into service, is depreciated using the straight-line method over the estimated useful lives of the equipment which is typically seven years. The Company does not depreciate Equipment held for sale or rent. When Equipment in rental service assets are sold, or otherwise disposed, the cost and related accumulated depreciation are removed from the accounts and a sale is recorded in the current period. The Company periodically performs an analysis of slow-moving Equipment used in service to generate rental revenue and records a reserve based on estimated obsolescence, which was $0.9 and $0.7 million as of December 31, 2020 and 2019, respectively. The Company performs a similar analysis of slow-moving Equipment for sale or rent and records a reserve, which was less than $0.1 million as of December 31, 2020 and 2019.

 

Property and Equipment

 

Property and equipment is stated at acquired cost and depreciated using the straight-line method over the estimated useful lives of the related assets, ranging from three to seven years. Externally purchased information technology software and hardware are depreciated over three and five years, respectively. Leasehold improvements are amortized using the straight-line method over the life of the asset or the remaining term of the lease, whichever is shorter. Maintenance and minor repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is recorded in the current period.

 

Intangible Assets

 

Intangible assets consist of trade names, physician and customer relationships and software. The physician and customer relationships arose primarily from previous acquisitions. The Company amortizes the value assigned to the physician and customer relationships on a straight-line basis over the period of expected benefit, which ranges from fifteen to twenty years. The acquired physician and customer relationship base represents a valuable asset of the Company due to the expectation of future business opportunities to be leveraged from the existing relationship with each physician and customer. The Company has long-standing relationships with numerous oncology clinics, physicians, home care and home infusion providers, skilled nursing facilities, pain centers and others. The useful lives of these relationships are based on minimal attrition experienced to date by the Company and expectations of continued minimal attrition. Acquired software is amortized on a straight-line basis over three years. Trade names associated with the original acquisition of InfuSystem are not amortized.

 

Management tests indefinite life trade names for impairment annually or more frequently if deemed necessary. The impairment test for intangible assets with indefinite lives consists of a comparison of the fair value of the intangible assets with their carrying amounts. If the carrying value of the intangible assets exceeds the fair value, an impairment loss is recognized in an amount equal to that excess. The Company determines the fair value for trade names with indefinite lives through the royalty relief income valuation approach. The Company performed its annual impairment analysis as of the last day of October 2020 and determined that the fair value of the trade names with indefinite lives was greater than their carrying value, resulting in no impairment.

 

Software Capitalization and Depreciation

 

The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software, including payroll and payroll-related costs for employees who are directly associated with the internal-use software project, external direct costs of materials and services and interest costs while developing the software. Capitalized software costs are included in intangible assets, net and are amortized using the straight-line method over the estimated useful life of three to five years. Capitalization of such costs ceases when the project is substantially complete and ready for its intended purpose. Costs incurred during the preliminary project and post-implementation stages, as well as software maintenance and training costs, are expensed in the period in which they are incurred. The Company did not capitalize any internal-use software for the years ended December 31, 2020 and 2019, respectively. Amortization expense for capitalized software was $1.9 million in 2020 and $2.0 million in 2019.

 

Impairment of Long-Lived Assets

 

Long-lived assets held for use, which includes medical equipment in rental service, property and equipment and amortizable intangible assets, are reviewed for impairment when events or changes in circumstances indicate that their carrying value may not be recoverable. If an impairment indicator exists, the Company assesses the asset or asset group for recoverability. Recoverability of these assets is determined based upon the expected undiscounted future net cash flows from the operations to which the assets relate, utilizing management’s best estimates, appropriate assumptions and projections at the time. If the carrying value is determined not to be recoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair market value of the asset or asset group.

 

 

The Company assesses impairment indicators related to its internally-developed, internal-use software, specifically looking at the effectiveness and useful lives of each project and sub-project to determine if impairment indicators are present. In December 2020 and 2019, respectively, the Company assessed the impairment indicators and found none to be present.

 

Leases

 

On January 1, 2019 (the “Effective Date”), the Company adopted Accounting Standards Update (“ASU”) 2016-02, Leases (Topic 842); ASU 2018-10, Codification Improvements to Topic 842, Leases; and ASU 2018-11, Targeted Improvements (collectively, “Topic 842”) using a modified retrospective transition approach, which requires Topic 842 to be applied to all leases existing at the date of initial application. Under Topic 842, lessees are required to recognize a lease liability and right-of-use asset (“ROU asset”) for all leases and to disclose key information about leasing arrangements. Additionally, leases are classified as either financing or operating; the classification determines the pattern of expense recognition and classification within the statement of operations. The Company elected to apply its lease accounting policy only to leases with a term greater than twelve months.

 

Topic 842 provides several optional practical expedients that we adopted at transition. The Company elected the “package of practical expedients”, which does not require it to reassess its prior conclusions regarding lease identification, lease classification and initial direct costs. The Company did not elect the practical expedient of hindsight to the evaluation of lease options (e.g. renewal).

 

Topic 842 also provides practical expedients for an entity’s ongoing accounting. The Company elected the “combining lease and non-lease components” practical expedient and also elected to apply the short-term lease recognition exemption to certain leases; therefore, the Company did not recognize ROU assets and lease liabilities for these leases.

 

In adopting Topic 842, the Company determined and will continue to determine whether an arrangement is a lease at inception. The Company’s operating leases are primarily for office space, service facility centers and equipment under operating lease arrangements that expire at various dates over the next ten years. The Company’s leases do not contain any restrictive covenants. The Company’s office leases generally contain renewal options for periods ranging from one to five years. Because the Company is not reasonably certain to exercise these renewal options, the options are not considered in determining the lease term, and payments associated with the option years are excluded from lease payments. The Company’s office leases do not contain any material residual value guarantees. The Company’s equipment leases generally do not contain renewal options. The Company is not reasonably certain to exercise the renewal options for those equipment leases that do contain renewal options, thus, the options are not considered in determining the lease term and payments associated with the option years are excluded from lease payments.

 

For the Company’s equipment leases, the Company used and will use the implicit rate in the lease as the discount rate, when available. Otherwise, the Company uses its incremental borrowing rate as the discount rate. For the Company’s office leases, the implicit rate is typically not available, so the Company used and will use its incremental borrowing rate as the discount rate. The incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments. The Company’s lease agreements include both lease and non-lease components. The Company elected the practical expedient that allows it to combine lease and non-lease components for all of its leases.

 

Payments due under the Company’s operating leases include fixed payments as well as variable payments. For the Company’s office leases, variable payments include amounts for the Company’s proportionate share of operating expenses, utilities, property taxes, insurance, common area maintenance and other facility-related expenses. For the Company’s equipment leases, variable payments may consist of sales taxes, property taxes and other fees.

 

Revenue Recognition

 

Revenue is recognized at the time and in an amount that reflects the consideration expected to be received for the performance obligations that have been provided. Accounting Standards Codification (“ASC”) Topic 606 – Revenue from Contracts with Customers (“ASC 606”) defines contracts as written, oral and through customary business practice. Under this definition, the Company considers contracts to be created at the time that the rental service is authorized or an order to purchase product is agreed upon regardless of whether or not there is a written contract.

 

The Company has two separate and distinct performance obligations offered to its customers: a rental service performance obligation or a product sale performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is defined as the unit of account for revenue recognition under ASC 606. These performance obligations are related to separate revenue streams and at no point are they combined into a single transaction. Sources of net revenues include commercial insurance payers, government insurance payers, medical facilities and patients.

 

 

The Company generates the majority of its revenue from the rental of infusion pumps to its customers and a minority of its revenue from product sales. For the rental service performance obligation, revenue is based on its standalone price, determined by using reimbursement rates established by third-party payer or other contracts. Revenue is recognized in the period in which the related performance obligation is satisfied, which is typically at the point in time that a patient concludes a treatment, or in certain arrangements, based on the number of pumps that a facility has onsite. The Company’s revenues related to product sales are recognized at the time that control of the product has been transferred to the customer; either at the time the product is shipped or the time the product has been received by the customer, depending on the delivery terms. The Company does not commit to long-term contracts to sell customers a certain minimum quantity of products.

 

The Company employs certain significant judgments to estimate the dollar amount of revenue, and related concessions, allocated to the rental service and sale of products. These judgments include, among others, the estimation of variable consideration. Variable consideration, specifically related to the Company’s third-party payer rental revenues, is estimated as implied price concessions resulting from differences between the rates charged for services performed and the expected reimbursements for commercial payers and other implied customer concessions. The estimates for variable consideration are based on historical collections with similar payers, aged accounts receivable by payer class and payer correspondence using the portfolio approach, which provide a reasonable basis for estimating the variable portion of a transaction. The Company doesn’t believe it is probable that a significant reversal of revenue will occur in future periods because (i) there is no significant uncertainty about the amount of considerations that are expected to be collected based on collection history and (ii) the large number of sufficiently similar contracts allows the Company to adequately estimate the component of variable consideration.

 

Net revenues are adjusted when changes in estimates of variable consideration occur. Changes in estimates typically arise as a result of new information obtained, such as actual payment receipt or denial, or pricing adjustments by payers. Subsequent changes to estimates of transaction prices are recorded as adjustments to net revenue in the period of the change. Subsequent changes that are determined to be the result of an adverse change in the payer’s ability to pay are recorded as an allowance for doubtful accounts.

 

Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenues and accounts receivable at their net realizable values. Inherent in these estimates is the risk that the estimates will have to be revised or updated as additional information becomes available. Specifically, the complexity of many third-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payers may result in adjustments to amounts originally recorded. Due to continuing changes in the health care industry and third-party reimbursement, it is possible that management’s estimates could change in the near term, which could have a material impact on the Company’s results of operations and cash flows.

 

Cost of Revenues

 

Cost of revenues include the costs of servicing and maintaining pumps, products sold, shipping and other direct and indirect costs related to net revenues. Shipping and handling costs incurred after control over a product has transferred to a customer are accounted for as a fulfillment cost.

 

Customer Concentration

 

For 2020 and 2019, the Company’s largest contracted payer was a national payer which accounted for approximately 14% and 8% of ITS net revenues for 2020 and 2019, respectively, and approximately 9% and 5% of total consolidated net revenues for 2020 and 2019, respectively.

 

The Company also contracts with various other third-party payer organizations, Medicaid, commercial Medicare replacement plans, self-insured plans, facilities of our Medicare patients and numerous other insurance carriers. Other than the payer noted above, no other single payer represented more than 7% of the Company’s ITS net revenue.

 

Income Taxes

 

The Company recognizes deferred income tax liabilities and assets based on (i) the differences between the financial statement carrying amounts and the tax basis of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse and (ii) the tax credit carryforwards. Deferred income tax (expense) benefit results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when it is more likely than not that some or all of any deferred tax assets will not be realized.

 

Provisions for federal, state and foreign taxes are calculated based on reported pre-tax earnings based on current tax law and include the cumulative effect of any changes in tax rates from those used previously in determining deferred tax assets and liabilities. Certain items of income and expense are recognized in different time periods for financial reporting than for income tax purposes; thus, such provisions differ from the amounts currently receivable or payable.

 

 

The Company follows a two-step approach for recognizing uncertain tax positions. First, it evaluates the tax position for recognition by determining if the weight of available evidence indicates it is more-likely-than-not that the position will be sustained upon examination. Second, for positions that are determined are more-likely-than-not to be sustained, it recognizes the tax benefits as the largest benefit that has a greater than 50% likelihood of being sustained. The Company establishes a reserve for uncertain tax positions liability that is comprised of unrecognized tax benefits and related interest and penalties. The Company adjusts this liability in the period in which an uncertain tax position is effectively settled, the statute of limitations expires for the relevant taxing authority to examine the tax position, or more information becomes available.

 

The Company adopted ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes, in the fourth quarter of 2019. This guidance simplifies various aspects related to accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted, including adoption in any interim period for which financial statements have not yet been issued. Certain amendments may be applied on a retrospective, modified retrospective or prospective basis. As permitted, the Company elected to early adopt this guidance for the year ended December 31, 2019. The adoption of this guidance did not have a significant impact on the Company’s financial statements and primarily resulted in the reclassification of an immaterial amount from non-income tax expense to income tax expense related to the accounting for franchise taxes, with no impact to the Company’s consolidated net income, equity or cash flows.

 

Treasury Stock

 

The Company periodically repurchases shares of its common stock. These repurchases take place either as part of a board-authorized program, which may include open market transactions or privately negotiated transactions and may be made under a Rule 10b5-1 plan, or in targeted stock purchase agreements approved by the board. Treasury stock is accounted for using the par value method.

 

Share-Based Payments

 

The Company determines the fair value of stock option awards, restricted stock awards and stock appreciation rights (collectively, “Share-Based Awards”) on the date of grant using option-pricing models which are affected by the Company’s stock price, as well as assumptions regarding a number of other inputs using the Black-Scholes pricing model. These variables include the Company’s expected stock price volatility over the expected term of the Share-Based Awards, actual and projected employee stock option exercise behaviors, risk-free interest rates and expected dividends. The expected volatility is based on the historical volatility. The Company uses historical data to estimate Share-Based Awards exercise rates. The expected term represents the period over which the Share-Based Awards are expected to be outstanding. The dividend yield is an estimate of the expected dividend yield on the Company’s stock. The risk-free rate is based on U.S. Treasury yields in effect at the time of the grant for the expected term of the Share-Based Awards. All Share-Based Awards are amortized based on their graded vesting over the requisite service period of the awards. Compensation costs are recognized over the requisite service period using the accelerated method and included in general and administrative expenses.

 

Additionally, the Company also determines the fair value of performance-based restricted stock units (“PSUs”) based upon the type of performance measure. These awards typically vest after the Company’s achievement of either Company performance relative to specified performance measure goals for a specific fiscal period or when the market value of the Company’s stock price reaches a target value for a minimum number of consecutive trading days. Under Financial Accounting Standards Board (“FASB”) ASC Topic 718, the provisions of the PSUs that vest upon achievement of a target market value are considered a market condition, and therefore the effect of that market condition is reflected in the grant date fair value for this type of award. A third-party valuation expert was engaged to complete a “Monte Carlo simulation” to account for the market condition. That simulation takes into account the beginning stock price of the Company’s common stock, the expected volatilities for the Company’s stock price and the expected risk-free rate of return. The single grant-date fair value computed by this valuation method is recognized by the Company in accounting for the awards regardless of the actual future outcome of the market condition. The grant date fair value of the other PSUs is calculated as the closing price of the Company’s common stock on the grant date multiplied by the number of shares subject to the award. Company performance measure goals are considered a performance condition and the grant-date fair value for those PSUs corresponds with management’s expectation of the probable outcome of the performance conditions as of the grant date.

 

 

Deferred Debt Issuance Costs

 

Capitalized debt issuance costs as of December 31, 2020 and 2019 relate to the Company’s credit facility. The costs related to the agreement are netted against current and non-current debt. The Company amortizes these costs using the interest method through the maturity date of the underlying debt.

 

Earnings Per Share

 

The Company reports its earnings per share in accordance with ASU 2017-11, Earnings Per Share (Topic 260), which requires the presentation of both basic and diluted earnings per share on the statements of operations. The diluted weighted average common shares include adjustments for the potential effects of outstanding stock options but only in the periods in which such effect is dilutive under the treasury stock method. Included in our basic and diluted weighted average common shares are those stock options and restricted stock awards due to participants granted from the 2014 stock incentive plan. Anti-dilutive stock awards are comprised of stock options and unvested restricted stock awards, which would have been anti-dilutive in the application of the treasury stock method in accordance with ASU 2017-11, Earnings Per Share (Topic 260). In periods where the Company records a net loss, the diluted per share amount is the same as the basic per share amount.

 

In accordance with this topic, the following table reconciles income and share amounts utilized to calculate basic and diluted net income per common share as of December 31 (in thousands, except shares):

 

   

2020

   

2019

 

Numerator:

               

Net income (in thousands)

  $ 17,332     $ 1,361  

Denominator:

               

Weighted average common shares outstanding:

               

Basic

    20,106,940       19,731,498  

Dilutive effect of restricted shares and options

    1,610,276       1,107,898  

Diluted

    21,717,216       20,839,396  

 

Stock options of less than 0.1 million shares were not included in the calculations for both the years ended December 31, 2020 and 2019 because they would have an anti-dilutive effect.

 

Fair Value of Financial Instruments

 

The carrying amounts reported in the consolidated balance sheets as of December 31, 2020 and 2019 for cash, accounts receivable, accounts payable and other current liabilities approximate fair value because of the short-term nature of these instruments (Level I). The carrying value of the Company’s long-term debt with variable interest rates approximates fair value based on instruments with similar terms (Level II).

 

The Company has adopted ASC 820, Fair Value Measurements, which defines fair value, establishes a framework for assets and liabilities being measured and reported at fair value and appends disclosures about fair value measurements.

 

For financial assets and liabilities measured at fair value on a recurring basis, fair value is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date. A three-level fair value hierarchy prioritizes the inputs used to measure fair value as follows:

 

 

Level I:

quoted prices in active markets for identical instruments;

 

 

Level II:

quoted prices in active markets for similar instruments, quoted prices for identical instruments in markets that are not active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the instrument; and

 

 

Level III:

significant inputs to the valuation model are unobservable.

 

 

Recent Accounting Pronouncements and Developments

 

In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments (Topic 326) Credit Losses”. Topic 326 changes the impairment model for most financial assets and certain other instruments. Under the new standard, entities holding financial assets and net investment in leases that are not accounted for at fair value through net income are to be presented at the net amount expected to be collected. An allowance for credit losses will be a valuation account that will be deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected on the financial asset. Topic 326 was originally effective as of January 1, 2020, although in November 2019, the FASB delayed the effective date until fiscal years beginning after December 15, 2022 for SEC filers eligible to be smaller reporting companies under the SEC’s definition. The Company qualifies as a smaller reporting company under the SEC’s definition. Early adoption is permitted. The Company is currently evaluating the impact of Topic 326 on its consolidated balance sheets, statements of operations, statements of cash flows and related disclosures.

 

 

 

3.         Revenue Recognition

 

The following table presents the Company’s disaggregated revenue by offering type as of December 31 (in thousands):

 

   

2020

   

2019

 
                 

Third-Party Payer Rentals

  $ 49,266     $ 40,510  

Direct Payer Rentals

  $ 30,765     $ 26,269  

Product Sales

  $ 17,357     $ 14,336  
                 

Total - Net revenues

  $ 97,388     $ 81,115  

 

Third-Party Payer Rentals are entirely attributed to revenues of the ITS segment. Product Sales are entirely attributed to revenues of the DME Services segment. For the year ended December 31, 2020, $11.8 million and $19.0 million of Direct Payer Rentals were attributed to the ITS and DME Services segments, respectively. For the year ended December 31, 2019, $11.0 million and $15.3 million were attributed to the ITS and DME Services segments, respectively.

 

The following table presents the Company’s disaggregated revenue by offering type as a percentage of total net revenues as of December 31:

 

   

2020

   

2019

 
                 

Third-Party Payer Rentals

    50.6 %     49.9 %

Direct Payer Rentals

    31.6 %     32.4 %

Product Sales

    17.8 %     17.7 %
                 

Total - Net revenues

    100.0 %     100.0 %

 

 

 

4.         Medical Equipment

 

Medical equipment consisted of the following as of December 31 (in thousands):

 

   

2020

   

2019

 

Medical Equipment for sale or rental

  $ 1,636     $ 1,334  

Medical Equipment for sale or rental - pump reserve

    (33 )     (28 )

Medical Equipment for sale or rental - net

    1,603       1,306  
                 

Medical Equipment in rental service

    83,411       75,853  

Medical Equipment in rental service - pump reserve

    (893 )     (720 )

Accumulated depreciation

    (46,907 )     (41,908 )

Medical Equipment in rental service - net

    35,611       33,225  
                 

Total

  $ 37,214     $ 34,531  

 

Depreciation expense for medical equipment for the years ended December 31, 2020 and 2019 was $8.9 million and $7.5 million, respectively, which were recorded in “cost of revenues” for each period.

 

 

 

5.         Property and Equipment

 

Property and equipment consisted of the following as of December 31 (in thousands):

 

   

2020

 
   

Gross Assets

   

Accumulated

Depreciation

   

Total

 

Furniture, fixtures, and equipment

  $ 3,742     $ (2,018 )   $ 1,724  

Automobiles

    117       (102 )     15  

Leasehold improvements

    3,416       (859 )     2,557  
                         

Total

  $ 7,275     $ (2,979 )   $ 4,296  

 

   

2019

 
   

Gross Assets

   

Accumulated

Depreciation

   

Total

 

Furniture, fixtures, and equipment

  $ 3,202     $ (1,928 )   $ 1,274  

Automobiles

    117       (90 )     27  

Leasehold improvements

    3,366       (630 )     2,736  
                         

Total

  $ 6,685     $ (2,648 )   $ 4,037  

 

Depreciation expense for property and equipment for each of the years ended December 31, 2020 and 2019 was $0.8 million and $0.5 million, respectively. This expense was recorded in “general and administrative expenses” for each period.

 

 

 

6.         Intangible Assets

 

The carrying amount and accumulated amortization of intangible assets as of December 31, 2020 and 2019 were as follows (in thousands):

 

   

2020

 
   

Gross Assets

   

Accumulated Amortization

   

Net

 

Nonamortizable intangible assets

                       

Trade names

  $ 2,000     $ -     $ 2,000  

Amortizable intangible assets

                       

Trade names

    23       (23 )     -  

Physician and customer relationships

    36,534       (28,924 )     7,610  

Software

    11,230       (9,663 )     1,567  
                         

Total nonamortizable and amortizable intangible assets

  $ 49,787     $ (38,610 )   $ 11,177  

 

 

   

2019

 
   

Gross Assets

   

Accumulated Amortization

   

Net

 

Nonamortizable intangible assets

                       

Trade names

  $ 2,000     $ -     $ 2,000  

Amortizable intangible assets

                       

Trade names

    23       (23 )     -  

Physician and customer relationships

    36,534       (26,550 )     9,984  

Software

    11,230       (7,751 )     3,479  
                         

Total nonamortizable and amortizable intangible assets

  $ 49,787     $ (34,324 )   $ 15,463  

 

The weighted average remaining lives of physician and customer relationships and software were seven years and one year, respectively, as of December 31, 2020.

 

The Company assesses impairment indicators related to its internally-developed, internal-use software, specifically looking at the effectiveness and useful lives of each project and sub-project to determine if impairment indicators are present. In December 2020 and 2019, respectively, the Company assessed the impairment indicators and found none to be present.

 

Amortization expense for intangible assets for the years ended December 31, 2020 and 2019 was $4.3 million and $4.4 million, respectively, which was recorded in operating expenses. Expected annual amortization expense for the next five years for intangible assets recorded as of December 31, 2020 is as follows (in thousands):

 

   

2021

   

2022

   

2023

   

2024

   

2025

   

2026 and

thereafter

 

Amortization expense

  $ 3,930     $ 2,051     $ 548     $ 548     $ 367     $ 1,733  

 

 

 

7.         Debt

 

On February 5, 2019, the Company and its primary lender entered into the fifth amendment (the “Fifth Amendment”) to its Credit Agreement entered into on March 23, 2015 (as amended, the “2015 Credit Agreement”). The Fifth Amendment amended the 2015 Credit Agreement to, among other things:

 

 

increase our borrowing capacity under the equipment line to $8.0 million, which allows for capital expenditure financing to the Company for the sole purpose of purchasing medical equipment (the “Equipment Line”);

 

revise the definition of earnings before interest, taxes, depreciation and amortization (“EBITDA”), a non-GAAP financial measure, to include additional add-back adjustments for the years ended December 31, 2018 and 2019;

 

revise the definition of fixed charge coverage ratio for the year ended December 31, 2019 to include an unfinanced portion of capital expenditures of up to $7.0 million for the year ended December 31, 2019;

 

revise the 2015 Credit Agreement’s maximum permitted indebtedness to finance the acquisition, construction or improvement of any fixed or capital assets; and

 

revise the maximum leverage ratio for each of the quarters during December 31, 2018 and December 31, 2019.

 

On April 15, 2019, the Company sold for $2.0 million and immediately leased back certain medical equipment in rental service to a third party specializing in such transactions. The leaseback term is 36 months. Because the arrangement contains a purchase option that the Company is reasonably certain to exercise, this transaction did not qualify for the sale-leaseback accounting under ASC 842. The medical equipment remains recorded on the accompanying consolidated balance sheet and the proceeds received have been classified as an Other Financing liability, which is being paid off monthly over the term of the lease. The balance of Other Financing as of December 31, 2020 was $0.9 million.

 

On November 7, 2019, the Company and its primary lender entered into the sixth amendment (the “Sixth Amendment”) to its 2015 Credit Agreement. The Sixth Amendment amended the 2015 Credit Agreement to, among other things:

 

 

provide for a 2019 capital expenditure loan (the “2019 Equipment Line”) commitment of $10.0 million (in addition to the existing Equipment Line of $8.0 million), which may be drawn upon until the earlier of the full commitment being advanced or December 31, 2020, to be used solely to purchase eligible equipment to be used in the Company’s business and in amounts not to exceed 90.0% of the invoiced hard costs of such acquired equipment;

 

increase the commitment for the revolving credit facility (the “Revolver”) under the 2015 Credit Agreement to $11.8 million;

 

revise the definition of EBITDA to include the following additional or revised add-back adjustments: (i) one-time charges in an aggregate amount not to exceed $0.3 million and incurred prior to December 31, 2019 relating to the Company’s integration of business previously served by another major provider of electronic oncology pumps; (ii) one-time charges in an aggregate amount not to exceed $0.3 million and incurred prior to December 31, 2019 relating to the Company’s facility move; (iii) lease buyout expenses not to exceed: (x) $0.1 million incurred on or prior to December 31, 2018; (y) $0.2 million incurred after December 31, 2018 but on or prior to March 31, 2019; and (z) $0.2 million incurred after September 30, 2019 but on or prior to December 31, 2020; and (iv) any other non-cash charges for such period (but excluding certain non-cash charges);

 

revise the definition of Fixed Charge Coverage Ratio to mean, for any period, the ratio of (a) EBITDA minus Maintenance Capital Expenditures (defined to mean, for any period, 50.0% of depreciation expense) to (b) Fixed Charges, all calculated for the Company and its subsidiaries on a consolidated basis in accordance with GAAP;

 

revise the definitions of Revolving Credit Maturity Date and Term Maturity Date to mean the date five years after the Sixth Amendment Effective Date and add a definition for the 2019 Equipment Line Maturity Date to provide for the same maturity date;

 

reflect the refinancing of the Term A Loans, Term B Loans and Term C Loan as a single term loan (the “Term Loan”) on the Sixth Amendment Effective Date and, commencing on the last Business Day of December 2019, the consecutive quarterly principal installment payments changed to approximately $1.2 million; and

 

revise Section 5.01(e) of the 2015 Credit Agreement, which governs the Company’s obligation to deliver financial statements to the lender, to require the Company to provide financial statements (x) as soon as possible but in any event within 30 days of the end of each fiscal quarter, or within 30 days of the end of each calendar month if any revolving loans were outstanding in month, (y) in connection with, and prior to, requesting any letter of credit and (z) at such other times as may be requested by the lender.

 

These debt amendments were accounted for as debt modifications. As of December 31, 2020, the Company was in compliance with all financial covenants under the 2015 Credit Agreement.

 

 

As of December 31, 2020, the Company’s Term Loan, Equipment Line and 2019 Equipment line under the 2015 Credit Agreement had balances of $21.9 million, $6.0 million and $10.0 million, respectively. The availability under the Revolver is subject to a borrowing base, which is calculated as the sum of the Company’s eligible accounts receivable and eligible inventory as defined by the 2015 Credit Agreement. As of December 31, 2020, the borrowing base was approximately $15.6 million, which exceeded the gross available borrowing amount of $11.8 million. The following table illustrates the net availability under the Revolver as of the applicable balance sheet date (in thousands):

 

   

December 31,

   

December 31,

 
   

2020

   

2019

 

Revolver:

               

Gross availability

  $ 11,750     $ 11,750  

Outstanding draws

    -       -  

Letters of credit

    (800 )     (1,750 )

Landlord reserves

    (162 )     (150 )

Availability on Revolver

  $ 10,788     $ 9,850  

 

The Company had future maturities of loans as of December 31, 2020 as follows (in thousands):

 

   

2021

   

2022

   

2023

   

2024

   

2025 and

thereafter

   

Total

 

Term Loan

  $ 4,615     $ 4,615     $ 4,615     $ 8,075     $ -     $ 21,920  

Equipment Line

    1,600       1,600       1,600       1,200       -       6,000  

2019 Equipment Line

    2,500       2,000       2,000       3,500       -       10,000  

Unamortized value of debt issuance costs

    (17 )     (17 )     (17 )     (15 )     -       (66 )

Other financing

    725       222       -       -       -       947  

Total

  $ 9,423     $ 8,420     $ 8,198     $ 12,760     $ -     $ 38,801  

 

The following is a breakdown of the Company’s current and long-term debt as of December 31, 2020 and December 31, 2019 (in thousands):

 

   

December 31, 2020

   

December 31, 2019

 
   

Current

Portion

   

Long-Term

Portion

   

Total

   

Current

Portion

   

Long-Term

Portion

   

Total

 

Term Loan

  $ 4,615     $ 17,305     $ 21,920     $ 5,768     $ 21,919     $ 27,687  

Equipment Line

    1,600       4,400       6,000       1,600       6,000       7,600  

2019 Equipment Line

    2,500       7,500       10,000       79       1,495       1,574  

Unamortized value of debt issuance costs

    (17 )     (49 )     (66 )     (17 )     (66 )     (83 )

Other financing

    725       222       947       652       947       1,599  

Total

  $ 9,423     $ 29,378     $ 38,801     $ 8,082     $ 30,295     $ 38,377  

 

As of December 31, 2020, interest on the credit facility is payable at our option as a (i) Eurodollar Loan, which bears interest at a per annum rate equal to the applicable 30-day London Interbank Offered Rate (“LIBOR”) plus an applicable margin ranging from 2.00% to 3.00% or (ii) CB Floating Rate (“CBFR”) Loan, which bears interest at a per annum rate equal to the greater of (a) the lender’s prime rate or (b) LIBOR plus 2.50%, in each case, plus a margin ranging from -1.00% to 0.25% based on our leverage ratio as defined in the 2015 Credit Agreement. The actual Eurodollar Loan rate at December 31, 2020 was 2.19% (LIBOR of 0.19% plus 2.00%). The actual CBFR Loan rate at December 31, 2020 was 2.25% (lender’s prime rate of 3.25% minus 1.00%).

 

Subsequent to December 31, 2020, the Company entered into the 2021 Credit Agreement, which replaced the 2015 Credit Agreement. For more information regarding the 2021 Credit Agreement, refer to the “Subsequent Events” discussion included in Note 15 in the Notes to the Consolidated Financial Statements included in this Form 10-K.

 

 

 

8.         Income Taxes

 

The following table summarizes the Company’s income before income taxes for the years ended December 31 (in thousands):

 

   

2020

   

2019

 

U.S income

  $ 6,623     $ 1,413  

Non-U.S. income

    920       111  

Income before income taxes

  $ 7,543     $ 1,524  

 

The following table summarizes the Company’s components of the consolidated benefit from (provision for) income taxes for the years ended December 31 (in thousands):

 

   

2020

   

2019

 

U.S Federal income tax benefit (expense)

               

Current

  $ (11 )   $ -  

Deferred

    8,346       (104 )

Total U.S. Federal income tax benefit (expense)

    8,335       (104 )

State and local income tax benefit (expense)

               

Current

    (66 )     (29 )

Deferred

    1,725       -  

Total state and local income tax benefit (expense)

    1,659       (29 )

Foreign income tax expense

               

Current

    (205 )     (30 )

Total income tax benefit (expense)

  $ 9,789     $ (163 )

 

The following table summarizes activity related to the Company’s valuation allowance for the years ended December 31 (in thousands):

 

   

2020

   

2019

 

Valuation allowance at the Beginning of Period

  $ (11,250 )   $ (11,370 )

Income tax expense

    -       -  

Release of valuation allowance

    11,250       120  

Valuation allowance at the End of Period

  $ -     $ (11,250 )

 

The following table summarizes a reconciliation of the Company’s effective income tax rate to the U.S. federal statutory rate for the years ended December 31:

 

   

2020

   

2019

 

Income tax expense at the statutory rate

    21.0 %     21.0 %

State and local income tax expense

    5.1 %     2.0 %

Foreign income tax

    0.2 %     2.0 %

Permanent differences

    (8.4 %)     (5.8 %)

Decrease in valuation allowance

    (149.2 %)     (7.9 %)

Other adjustments

    1.5 %     (0.6 %)

Effective income tax rate

    (129.8 %)     10.7 %

 

 

The following table summarizes the temporary differences and carryforwards that give rise to deferred tax assets and liabilities as of December 31 (in thousands):

 

   

2020

   

2019

 

Deferred Federal tax assets –

               

Bad debt reserves

  $ 1,570     $ 1,459  

Stock-based compensation

    656       443  

Net operating loss

    7,337       7,991  

Operating lease liabilities

    1,014       1,271  

Accrued compensation

    757       451  

Inventories

    214       27  

Goodwill and intangible assets

    832       1,688  

Research & development credits

    533       533  

Other credits

    30       25  

Other

    54       194  

Total deferred Federal tax assets

    12,997       14,082  

Less: valuation allowance

    -       (9,553 )

Net deferred Federal tax assets

    12,997       4,529  

Deferred Federal tax liabilities –

               

Depreciation and asset basis differences

    (3,393 )     (3,366 )

Right-of-use assets

    (937 )     (1,204 )

Total deferred Federal tax liabilities

    (4,330 )     (4,570 )

Net deferred Federal tax assets (liabilities)

    8,667       (41 )

Total deferred state and local tax assets (a)

    1,300       1,634  

Less: valuation allowance

    -       (1,697 )

Net deferred state and local tax assets (liabilities)

    1,300       (63 )

Net deferred tax assets (liabilities)

  $ 9,967     $ (104 )

 

(a) at December 31, 2020 and 2019, this includes state and local net operating losses of $1.2 million and $1.4 million, respectively.

 

The Company’s U.S. federal net operating loss carryforward for tax purposes was $34.9 million at December 31, 2020, resulting in a federal deferred tax asset of $7.3 million. Approximately $31.5 million of the Company’s U.S. federal net operating loss carryforwards will begin to expire in various years beginning in 2029. $3.4 million of U.S. federal net operating loss carryforwards have an indefinite life. The Company’s state net operating loss carryforward of approximately $1.2 million is comprised of various jurisdictions. These state net operating losses can be used for a period of 5 to 20 years and vary by state, and if unused, begin to expire in 2021, though a substantial portion expires beyond 2021. Approximately $0.1 million of the state net operating loss carryforwards have an indefinite life. Tax benefits of operating loss and tax credit carryforwards are evaluated on an ongoing basis, including a review of historical and projected future operating results, the eligible carryforward period, and other circumstances.

 

The Company continues to monitor shifts in past ownership (as defined under Section 382 of the Code). A definitive analysis necessary to quantify the effect of an ownership change was performed on the net operating loss carryforwards generated prior to December 31, 2019. Based on the analysis, the Company is subject to an annual limitation of $1.8 million on its use of remaining pre-ownership change net operating loss carryforwards of $4.5 million (and certain other pre-change tax attributes).

 

In the fourth quarter of 2020 it was determined that the valuation allowance against the U.S. federal and state deferred taxes is no longer required and the valuation allowance of $11.2 million that existed was released. The Company’s realization of its deferred tax assets is dependent upon many factors, including, but not limited to, the Company’s ability to generate sufficient taxable income. Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. Cumulative income in recent years and projected future taxable income is the basis for the Company’s assessment that the deferred tax assets no longer require a full valuation allowance.

 

 

The Company had no uncertain tax positions for the years ended December 31, 2020 and 2019.

 

The Company is subject to taxation for Federal and various state jurisdictions in the United States and Canada. The Federal income tax returns of the Company for the years 2017 through 2020 are open to examination by the Internal Revenue Service. The Company currently has an open audit with the Internal Revenue Service in relation to the Company’s 2018 federal income tax return. Under examination, the Internal Revenue Service may redetermine the correct taxable income for a closed year (pre-2017) to determine either the amount of the federal net operating loss carryforward deduction reported in the open years or the amount of a federal net operating loss deduction that is absorbed in a closed year and supports the determination of the available federal net operating loss deduction for the open years under examination. The state income tax returns and other state tax filings of the Company are subject to examination by the state taxing authorities, for various periods generally up to four years after they are filed. Canadian income tax returns of the Company for the years 2016 through 2020 are subject to examination by the Canada Revenue Agency.

 

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security (CARES) Act was enacted in response to the COVID-19 pandemic. The CARES Act among other things, allows employers to defer the deposit and payment of the employer's share of Social Security taxes. The Company, under the CARES Act, deferred paying $0.7 million of applicable gross payroll taxes as of December 31, 2020, which is included in other liabilities. The $0.7 million balance of the deferred Social Security taxes is expected to be paid in two equal annual installments during the years ending December 31, 2021 and 2022, respectively. On April 15, 2020, the Company received a $4.1 million loan under the Federal Paycheck Protection Program (“PPP”) created under the CARES Act. In response to revised eligibility guidelines announced by the U.S. Small Business Administration shortly thereafter, the Company repaid this loan in full on May 7, 2020.

 

 

 

9.         Commitments and Contingencies

 

From time to time in the ordinary course of its business, the Company may be involved in legal and regulatory proceedings, the outcomes of which may not be determinable. The results of litigation and regulatory proceedings are inherently unpredictable. Any claims against the Company, whether meritorious or not, could be time consuming, result in costly litigation, require significant amounts of management time and result in diversion of significant resources. The Company is not able to estimate an aggregate amount or range of reasonably possible losses for those legal matters for which losses are not probable and estimable, primarily for the following reasons: (i) many of the relevant legal proceedings are in preliminary stages, and until such proceedings develop further, there is often uncertainty regarding the relevant facts and circumstances at issue and potential liability; and (ii) many of these proceedings involve matters of which the outcomes are inherently difficult to predict. The Company has insurance policies covering potential losses where such coverage is cost effective.

 

The Company is not at this time involved in any proceedings that the Company believes could have a material effect on the Company’s financial condition, results of operations or cash flows.

 

 

 

10.       Leases

 

The Company has historically entered into a number of lease agreements under which the Company is the lessee for equipment and office leases. During the year ended December 31, 2020, the Company entered into four leases for equipment.

 

The components of the Company’s lease costs consisted of the following as of December 31 (in thousands):

 

   

2020

   

2019

 

Operating lease cost

  $ 1,617     $ 1,948  

Variable lease cost

    315       291  

Total lease cost

  $ 1,932     $ 2,239  

 

Lease costs for the year ended December 31, 2020 of approximately $1.3 million and $0.6 million, were recorded to G&A expenses and cost of revenues, respectively. Lease costs for the year ended December 31, 2019 of approximately $1.2 million and $1.0 million, were recorded to G&A expenses and cost of revenues, respectively.

 

 

Supplemental cash flow information and non-cash activity related to the Company’s leases was as follows (in thousands):

 

   

2020

   

2019

 

Cash paid for amounts included in the measurement of lease liabilities and ROU assets:

               

Operating cash flow from operating leases

  $ 1,603     $ 1,610  
                 

ROU assets obtained in exchange for lease obligations:

               

Operating leases

  $ 264     $ 4,545  
                 

Reductions to ROU assets resulting from reductions to lease obligations:

               

Operating leases

  $ -     $ 22  

 

Weighted average remaining lease terms and discount rates for the Company’s leases as of December 31, 2019 are as follows:

 

   

2020

   

2019

 
                 
   

Years

   

Years

 

Weighted average remaining lease term:

               

Operating leases

    7.0       7.4  
   

Rate

   

Rate

 

Weighted average discount rate:

               

Operating leases

    7.8 %     7.7 %

 

Future maturities of lease liabilities as of December 31, 2020 are as follows (in thousands):

 

   

Operating Leases

 

2021

  $ 1,108  

2022

    1,045  

2023

    941  

2024

    949  

2025

    914  

Thereafter

    2,253  

Total undiscounted lease payments

    7,210  

Less: Imputed interest

    (2,380 )

Total lease liabilities

  $ 4,830  

 

 

 

11.       Share-based Compensation

 

All stock option awards are amortized based on their graded vesting over the requisite service period of the awards. Compensation costs are recognized over the requisite service period using the accelerated method and included in general and administrative expenses.

 

Stock Incentive Plan

 

The Company has various stock option and stock-based incentive plans and agreements whereby stock options, restricted stock awards (“RSUs”) and PSUs were made available to certain employees, directors and others approved by the Company’s Board of Directors (the “Board”) or Compensation Committee. Stock options are granted at, or above, fair market value and generally expire in five to ten years from the grant date. RSUs are granted at the fair market value on the date of grant and generally become exercisable over a period of up to three years. PSUs are granted at the fair market value on the date of grant and generally become exercisable over a period of up to three years based on the performance of a specific achievement. Awards typically vest and are issued only if the participants remain employed by the Company through the vesting date. Stock options, RSUs and PSUs are issued from shares under the Company’s plan described below. Grants may be made in the form of stock options, restricted stock awards, performance-based restricted stock units, unrestricted common stock or stock appreciation rights (“SARs”).

 

 

On April 23, 2014, the Company’s Board adopted the 2014 Amended and Restated Stock Incentive Plan (the “2014 Plan”). The 2014 Plan was approved by the Company’s shareholders at the 2014 Annual Meeting and became effective as of the date it was adopted by the Board of Directors. The 2014 Plan provided for the issuance of a maximum of 2.0 million shares of common stock in connection with the grant of stock-based or stock-denominated awards. On July 19, 2018, the Company’s stockholders approved the reservation of an additional 1.0 million shares to be issued under the 2014 Plan. On May 15, 2019, the Company’s stockholders approved the reservation of an additional 1.0 million shares to be issued under the 2014 Plan. As of December 31, 2020, a total of approximately 0.4 million common shares remained available for future grant under the 2014 Plan.

 

The Company granted stock options under the 2014 Plan during the years ended December 31, 2020 and 2019, respectively.

 

Shares Forgone to Satisfy Minimum Statutory Withholdings

 

During the years ended December 31, 2020 and 2019, shares of common stock were issued to employees and directors as their restricted stock awards vested or stock options were exercised. Under the terms of the Company’s stock plans, at the election of each employee, the Company can authorize a net settlement of distributable shares to employees after satisfaction of an individual employees' tax withholding obligations. For both of the years ended December 31, 2020 and 2019, the Company received 0.1 million shares from employees for tax withholding obligations.

 

Restricted Stock Awards

 

During the year ended December 31, 2020, the Company granted 0.2 million restricted stock awards. During the year ended December 31, 2019, the Company granted less than 0.1 million restricted stock awards. Restricted stock awards entitle the holder to receive, upon meeting certain time-based vesting criteria, a specified number of shares of the Company’s common stock. Stock-based compensation cost of restricted stock awards is measured by the market value of the Company’s common stock on the date of grant.

 

The following table summarizes the Company’s restricted share activity, excluding the Company’s employee stock purchase plan, for the years ended December 31:

 

           

Weighted

         
           

average

         
           

grant

         
   

Number of

   

date fair

   

Aggregate

 
   

shares

   

value

   

fair value

 
                         

Unvested at December 31, 2018

    129,583     $ 1.42          
                         

Granted

    26,000       7.04          

Vested

    (58,314 )     3.17     $ 712,969  

Vested shares forgone to satisfy minimum statutory withholding

    (71,269 )     3.17     $ 422,779  

Forfeitures

    -       -          
                         

Unvested at December 31, 2019

    26,000       7.04          

Granted

    156,250       10.12          

Vested

    (28,432 )     9.28     $ 367,273  

Vested shares forgone to satisfy minimum statutory withholding

    (6,818 )     9.28     $ 62,479  

Forfeitures

    (2,000 )     11.68          

Unvested at December 31, 2020

    145,000     $ 9.78          

 

As of December 31, 2020, there was $1.0 million of pre-tax total unrecognized compensation cost related to non-vested restricted stock awards, which will be adjusted for future forfeitures, if any. The Company expects to recognize such cost over the period ending in 2023.

 

 

Performance-Based Restricted Stock Units

 

During the year ended December 31, 2020, the Company granted approximately 0.2 million PSUs. During the year ended December 31, 2019, the Company did not grant any PSUs. PSUs entitle the holder to receive, upon meeting certain performance-based vesting criteria, a specified number of shares of the Company’s common stock. These awards typically vest after the Company’s achievement of either Company performance relative to specified performance measure goals for a specific fiscal period or when the Company’s stock price reaches a target value for a minimum number of consecutive trading days. Approximately three-fourths of the PSUs granted in 2020 are earned based on the market-based condition, while the other one-fourth are earned based on specified Company performance measure conditions. In the case of the market-based condition, awards are paid in stock immediately upon achievement of the performance condition or expire without any payment after the third anniversary of the grant date. In the case of the specified Company performance measure, awards can be earned at 50% of the target number of shares for achieving a minimum threshold or up to 200% of the target number of shares for exceeding the target, with a linear adjustment between threshold and target or between target and stretch performance goals.

 

Under FASB ASC Topic 718, the provisions of the PSUs that vest upon achievement of a target market value are considered a market condition, and therefore the effect of that market condition is reflected in the grant date fair value for this type of award. A third-party valuation expert was engaged to complete a “Monte Carlo simulation” to account for the market condition. That simulation takes into account the beginning stock price of the Company’s common stock, the expected volatilities for the Company’s stock price and the expected risk-free rate of return. The single grant-date fair value computed by this valuation method is recognized by the Company in accounting for the awards regardless of the actual future outcome of the market condition. The grant date fair value of the other PSUs is calculated as the closing price of the Company’s common stock on the grant date multiplied by the number of shares subject to the award. Company performance measure goals are considered a performance condition and the grant-date fair value for those PSUs corresponds with management’s expectation of the probable outcome of the performance conditions as of the grant date.

 

The following table summarizes the Company’s PSU activity for the years ended December 31:

 

           

Weighted

         
           

average

         
           

grant

         
   

Number of

   

date fair

   

Aggregate

 
   

shares

   

value

   

fair value

 
                         

Unvested at December 31, 2019

    -       -          

Granted

    232,500       9.06          

Unvested at December 31, 2020

    232,500     $ 9.06          

 

As of December 31, 2020, there was $1.7 million of pre-tax total unrecognized compensation cost related to non-vested PSUs, which will be adjusted for future forfeitures and changes to management’s expectations of the probable outcomes of the performance conditions, if any. The Company expects to recognize such cost over the period ending in 2022.

 

Employee Stock Purchase Plan

 

In May 2014, the Company received approval from stockholders to adopt an employee stock purchase plan ("ESPP") effective October 2014 (collectively the “Original ESPP”). Under the Original ESPP, 200,000 shares of common stock were authorized for purchase by eligible employees at a 15% discount through payroll deductions during the six-month offering periods. Shares were purchased in whole numbers and generally would be the last day of the offering period. On September 7, 2016, the Company received approval from shareholders for an additional 350,000 shares. No employee may purchase more than $25,000 worth of fair market value shares in any calendar year. As allowed under the ESPP, a participant may elect to withdraw from the plan, effective for the purchase period in progress at the time of the election with all accumulated payroll deductions returned to the participant at the time of withdrawal. As of December 31, 2020, there were 187,676 shares remaining available for future issuance. The following table summarizes the activity relating to the Company’s ESPP program for the years ended December 31:

 

   

2020

   

2019

 

Compensation expense

  $ 108,589     $ 43,030  

Shares of stock sold to employees

    30,012       33,742  

Weighted average fair value per ESPP award

  $ 7.43     $ 3.94  

 

 

Stock Options

 

The Company calculates the fair value of stock option awards using the Black-Scholes option pricing model, which incorporates various assumptions including volatility, expected term, risk-free interest rates and dividend yields. The expected volatility assumption is based on historical volatility of the Company’s common stock over the most recent period commensurate with the expected life of the stock option granted. The Company uses historical volatility because management believes such volatility is representative of prospective trends. The risk-free interest rate assumption is based upon observed interest rates appropriate for the expected life of the stock option awarded. The Company uses historical exercise data to determine the expected lives. Dividend yields have not been a factor in determining fair value of stock options granted as the Company has never issued cash dividends and does not anticipate issuing cash dividends in the future.

 

During the year ended December 31, 2020, the Company granted 0.3 million stock options, of which 0.1 million were issued to Board members at exercise prices based on a preceding five-day average price on the date of grant with a vesting period of 12 months. During the year ended December 31, 2019, the Company granted 0.7 million stock options, of which 0.1 million were issued to Board members at exercise prices based on the stock price as of the date of grant with a vesting period of 12 months. The following tables detail the various stock option and inducement stock option activity for the years ended December 31:

 

 

                   

Weighted-

         
                   

Average

         
   

Number

   

Weighted-

   

Remaining

   

Aggregate

 
   

of Authorized

   

Average Exercise

   

Contractual

   

Intrinsic

 

2014 Plan (Options)

 

Shares

   

Price

   

Term (in Years)

   

Value

 

Outstanding at December 31, 2018

    2,224,167     $ 2.67       3.01     $ -  
                                 

Granted

    670,000     $ 3.77       4.40          

Exercised

    (213,056 )     2.33               624,462  

Exercised shares forgone to satisfy minimum statutory withholding

    (51,339 )     2.33                  

Cashless exercise

    (184,493 )     2.33                  

Forfeited

    (101,946 )     3.63                  
                                 

Outstanding at December 31, 2019

    2,343,333     $ 2.99       1.81     $ 12,989,767  
                                 

Exercisable at December 31, 2019

    1,501,750     $ 2.69                  
                                 

Granted

    331,000       10.38       8.59          

Exercised

    (334,184 )     2.77               3,135,211  

Exercised shares forgone to satisfy minimum statutory withholding

    (125,714 )     2.77                  

Cashless exercise

    (164,751 )     2.77                  

Forfeited

    (90,336 )     3.96                  
                                 

Outstanding at December 31, 2020

    1,959,348     $ 4.26       4.42     $ 28,449,362  
                                 

Exercisable at December 31, 2020

    1,362,932     $ 3.33                  

 

Aggregate Intrinsic Value = Excess of market value over the option exercise price of all in-the-money stock options.

 

                   

Weighted-

         
                   

Average

         
   

Number

   

Weighted-

   

Remaining

   

Aggregate

 

Inducement

 

of Authorized

   

Average Exercise

   

Contractual

   

Intrinsic

 

Options

 

Shares ( 1 )

   

Price

   

Term (in Years)

   

Value

 

Outstanding at December 31, 2018

    125,000     $ 2.55       5.42     $ 111,250  
                                 

Granted

    -       -       -       -  

Exercised

    -       -       -       -  

Forfeited

    -       -       -       -  
                                 

Outstanding at December 31, 2019

    125,000     $ 2.55       4.42     $ 747,500  
                                 

Granted

    -       -       -       -  

Exercised

    (27,940 )     2.55       -       242,519  

Exercised shares forgone to satisfy minimum statutory withholding

    (12,417 )     2.55       -       -  

Cashless exercise

    (14,330 )     2.55       -       -  

Forfeited

    (70,313 )     2.55       -       -  
                                 

Outstanding at December 31, 2020

    -     $ -       -     $ -  
                                 

Exercisable at December 31, 2020

    -     $ -                  

 

Aggregate Intrinsic Value = Excess of market value over the option exercise price of all in-the-money stock options.

 

(1) Represents inducement stock options to purchase shares of the Company's Common Stock to executive level managers.

 

The following table summarizes information about stock options outstanding at December 31, 2020:

 

       

Options Outstanding

   

Options Exercisable

 

2014 Plan (Options):

                                       

Range of Exercise Prices

 

Number of Shares Outstanding

   

Weighted-Average Remaining Contractual Life

   

Weighted-Average Exercise Price

   

Number of Shares Exercisable

   

Weighted-Average Exercise Price

 
                                             
$2.01 -

$3.00

    870,011       3.20     $ 2.26       784,178     $ 2.26  
$3.01 -

$4.00

    423,336       2.74     $ 3.23       301,669     $ 3.21  
$4.01 -

$5.00

    335,001       5.60     $ 4.70       198,335     $ 4.70  
$6.01 -

$7.00

    50,000       4.21     $ 6.82       -     $ -  
$8.01 -

$9.00

    20,000       9.02     $ 8.55       -     $ -  
$11.01 -

$12.00

    245,000       9.38     $ 11.07       78,750     $ 11.07  
$13.01 -

$14.00

    16,000       9.62     $ 13.30       -     $ -  
                                             

Outstanding at December 31, 2020

    1,959,348       4.42     $ 4.26       1,362,932     $ 3.33  

 

 

The following is the average fair value per share estimated on the date of grant and the assumptions used for options granted during the years ended December 31:

 

Stock Options:

 

2020

   

2019

 

Expected volatility

   42% to 51%      36% to  38%  

Risk free interest rate

   0.20% to  1.56%      1.80% to 2.36%  

Expected lives at date of grant (in years)

    3.25         4.63    

Weighted average fair value of options granted

    $3.87         $1.61    

 

Stock-based compensation expense

 

The following table presents the total stock-based compensation expense, which is included in selling, general and administrative expenses for the years ended December 31 (in thousands):

 

   

2020

   

2019

 

Restricted share expense

  $ 1,687     $ 190  

Stock option and SARs expense

    923       807  

Total stock-based compensation expense

  $ 2,610     $ 997  

 

Share Repurchase Program

 

On September 30, 2019, the Company’s Board of Directors approved a stock repurchase program (the “Share Repurchase Program”) authorizing the Company to repurchase up to $5.0 million of the Company’s outstanding common stock through 2020. Repurchases under the Share Repurchase Program will be subject to market conditions, the periodic capital needs of the Company’s operating activities, and the continued satisfaction of all covenants under the Company’s credit agreements. The Company’s ability to repurchase stock is subject to the restrictions and limitations of its credit agreements. Repurchases under the program may take place in the open market or in privately negotiated transactions and may be made under a Rule 10b5-1 plan. The Share Repurchase Program does not obligate the Company to repurchase shares and may be suspended, terminated, or modified at any time.

 

As of December 31, 2020, the Company had not repurchased any shares under the Share Repurchase Program.

 

 

 

12.       Business Segment Information

 

During the fourth quarter of 2019, the Company reorganized its segment reporting from one reportable segment to two reportable segments, ITS and DME Services, due to changes in the Company’s internal reporting and the information evaluated by its chief operating decision-maker. The Company’s reportable segments are organized based on service platforms, with the ITS segment reflecting higher margin rental revenues that generally include payments made by third-party and direct payers and the DME Services segment reflecting lower margin product sales and direct payer rental revenues. Resources are allocated and performance is assessed for these segments by the Company’s Chief Executive Officer, whom the Company has determined to be its chief operating decision-maker. The Company believes that reporting performance at the gross profit level is the best indicator of segment performance.

 

 

The financial information summarized below is presented by reportable segment:

 

2020

                               
                   

Corporate/

         

(in thousands)

 

ITS

   

DME Services

   

Eliminations

   

Total

 
                                 

Net revenues - external

  $ 61,072     $ 36,316     $ -     $ 97,388  

Net revenues - internal

    -       5,370       (5,370 )     -  

Total net revenues

    61,072       41,686       (5,370 )     97,388  

Gross profit

    39,773       18,986       -       58,759  
                                 

Selling , general and administrative expenses

                    49,932       49,932  

Interest expense

                    (1,255 )     (1,255 )

Other expense

                    (29 )     (29 )

Benefit from income taxes

                    9,789       9,789  
                                 

Net income

                          $ 17,332  
                                 

Total assets

  $ 68,472     $ 26,519     $ 2,000     $ 96,991  

Purchases of medical equipment

  $ 9,583     $ 6,237     $ -     $ 15,820  

Depreciation and amortization of intangible assets

  $ 10,708     $ 3,317     $ -     $ 14,025  

 

 

2019

                               
                   

Corporate/

         

(in thousands)

 

ITS

   

DME Services

   

Eliminations

   

Total

 
                                 

Net revenues - external

  $ 51,540     $ 29,575     $ -     $ 81,115  

Net revenues - internal

    -       3,788       (3,788 )     -  

Total net revenues

    51,540       33,363       (3,788 )     81,115  

Gross profit

    33,063       13,819       -       46,882  
                                 

Selling, general and administrative expenses

                    43,357       43,357  

Interest expense

                    (1,904 )     (1,904 )

Other expense

                    (97 )     (97 )

Provision for income taxes

                    (163 )     (163 )
                                 

Net income

                          $ 1,361  
                                 

Total assets

  $ 54,292     $ 22,932     $ 2,000     $ 79,224  

Purchases of medical equipment

  $ 14,216     $ 5,453     $ -     $ 19,669  

Depreciation and amortization of intangible assets

  $ 9,457     $ 2,885     $ -     $ 12,342  

 

The presentation of gross profit above was revised from the 2019 Consolidated Financial Statements to include inter-segment revenues in the DME Services segment column from the prior presentation within the Corporate/Eliminations column. This revision is considered immaterial to the prior period based on the Company’s assessment.

 

 

13.       Employee Benefit Plans and Other

 

The Company has a defined contribution plan in which the Company makes discretionary matching contributions for a certain percentage of employee contributions. For the years ended December 31, 2020 and 2019, the Company’s matching contributions were $0.8 million and $0.7 million, respectively. The Company does not provide other post-retirement or post-employment benefits to its employees. As of December 31, 2020 and 2019, accrued payroll liabilities included in Other current liabilities were $2.8 million and $3.5 million, respectively.

 

 

 

14.       COVID-19

 

On March 11, 2020, the World Health Organization declared the outbreak of COVID-19 as a pandemic, which has spread globally and throughout the United States. With the exception of in-person visits to our customer facilities by our sales staff, the Company has continued to operate despite stay-at-home orders and other government mandated shutdowns across the United States and Canada under exceptions allowed by those orders for the healthcare industry.

 

We have taken a number of precautionary and preemptive steps to protect the safety and well-being of our employees while ensuring continuity of service to our clients, including, transitioning our employees to a remote work environment, suspending employee travel, canceling participation in industry events and in-person group meetings, promoting social distancing and enhanced cleaning and sanitization efforts across office locations, and implementing protocols to quarantine employees who may have been exposed to COVID-19, or show relevant symptoms. We also continued to undertake preparedness plans at our facilities to maintain continuity of operations, which provide for flexible work arrangements without any significant disruptions to our business or control processes. Our management team is continuing to actively monitor the situation and is in constant communication with our workforce as well as with our customers and vendors. Other specific actions we have taken include purchasing additional inventory of supplies and pumps, as well as purchasing personal protective equipment for our employees. While the Company’s business is considered critical, we are unable to predict the impact that the COVID-19 pandemic will have on future periods due to numerous uncertainties. While the COVID-19 pandemic has not had any material unfavorable effects in our financial results for the year ended December 31, 2020, the extent of the impact in the future, if any, will depend on future developments, which are highly uncertain, cannot be predicted and could have a material adverse impact on our financial position, operating results and cash flows. A prolonged outbreak could, among other things, strain our business continuity plans, create delays in our growth and strategic initiatives, reduce our sales and marketing activities, limit our access to financing on favorable terms, increase our exposure to potential impairment charges related to long-lived and intangible assets, hinder our ability to support our clients and operate our business effectively, heighten the risk of disruption to our information and reporting systems and internal controls, including those over financial reporting and other risk management systems, or require us to incur substantial costs. We are closely monitoring the impact of the COVID-19 pandemic on all aspects of our business and may take further actions as may be required by federal, state or local authorities, or that we determine are in the best interests of our employees, customers and partners. As the conditions surrounding the COVID-19 pandemic continue to evolve rapidly, we will continue to actively manage our response in collaboration with customers, government officials and stakeholders, and assess any potential impacts to our financial position and operating results, as well as adverse developments in our business.

 

 

 

15.       Subsequent Events

 

Acquisition

 

On February 3, 2021, the Company announced that it had acquired FilAMed, a privately held biomedical services company based in Bakersfield, California, for an approximate purchase price of $1.4 million.  The initial accounting for the business combination, including the estimated fair value of the assets and liabilities acquired, is incomplete as a result of the timing of the acquisition. This acquisition will supplement the Company’s existing biomedical recertification, maintenance and repair services for acute care facilities and other alternate site settings including home care and home infusion providers, skilled nursing facilities, pain centers and others.

 

Credit Agreement

 

On February 5, 2021, the Company entered into a Credit Agreement (the “2021 Credit Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent (the “Agent”), sole bookrunner and sole lead arranger, and the lenders party thereto. The borrowers under the 2021 Credit Agreement are the Company, InfuSystem Holdings USA, Inc. (“Holdings”), ISI, First Biomedical, , and IFC LLC (“IFC” and, collectively with the Company, Holdings, ISI and First Biomedical, the “Borrowers”).

 

The 2021 Credit Agreement provides for a revolving credit facility (the “Revolving Facility”) of $75 million, maturing on February 5, 2026. The Revolving Facility may be increased by $25 million, subject to certain conditions, including the consent of the Agent and obtaining necessary commitments. The lenders under the 2021 Credit Agreement may issue up to $7 million in letters of credit subject to the satisfaction of certain conditions. On February 5, 2021, the Borrowers made an initial borrowing of $30 million under the Revolving Facility. Proceeds from the loan, along with approximately $8.2 million in cash, were used to repay all amounts due under the Company’s existing credit facility dated March 23, 2015 (the “2015 Credit Agreement”).

 

Amounts outstanding under the Revolving Facility bear interest at a variable rate equal to, at the Company's election, a LIBO Rate for Eurodollar loans or an Alternate Base Rate for ABR loans, as defined by the 2021 Credit Agreement, plus a spread that will vary depending upon the Company's leverage ratio. The spread ranges from 2.00% to 3.00% for Eurodollar Loans and 1.00% to 2.00% for base rate loans. The initial spread under the 2021 Credit Agreement is 2.00% for Eurodollar loans and 1.00% for ABR loans.

 

 

The 2021 Credit Agreement has customary representations and warranties, and the ability to borrow under the facility is subject to ongoing compliance with a number of customary affirmative and negative covenants, including limitations on indebtedness, liens, mergers, acquisitions, investments, asset sales, affiliate transactions and restricted payments, as well as financial covenants, including the following:

 

 

a minimum fixed charge coverage ratio (defined as the ratio of consolidated EBITDA (as defined in the 2021 Credit Agreement) less 50% of depreciation expense), to consolidated fixed charges (as defined in the 2021 Credit Agreement)) for the prior four most recently ended calendar quarters of 1.20 to 1.00; and

 

a maximum leverage ratio (defined as total indebtedness to EBITDA for the prior four most recently ended calendar quarters) of 3.50 to 1.00.

 

The 2021 Credit Agreement includes customary events of default, and the occurrence of an event of default will permit the lenders to terminate commitments to lend under the Revolving Facility and accelerate payment of all amounts outstanding thereunder.

 

Pledge and Security Agreement

 

Simultaneous with the execution of the 2021 Credit Agreement, the Company entered into a Pledge and Security Agreement to secure repayment of the obligations of the Borrowers. Under the Pledge and Security Agreement, each Borrower has granted to the Agent, for the benefit of various secured parties, a first priority security interest in substantially all of the personal property assets of each of the Borrowers, including the shares of each of Holdings, ISI and First Biomedical and the equity interests of IFC.

 

2015 Credit Agreement

 

On February 5, 2020, in connection with the execution and closing of the 2021 Credit Agreement, the Company, along with its wholly owned subsidiaries as borrowers, terminated the 2015 Credit Agreement. All outstanding loans under the 2015 Credit Agreement have been repaid and all liens under the 2015 Credit Agreement have been released, except that a letter of credit originally issued under the 2015 Credit Agreement in the amount of approximately $0.8 million was transferred to the 2021 Credit Agreement.

 

 

 

Item 9.         Changes in and Disagreements with Accountants on Accounting and Financial Disclosures.

 

None.

 

 

Item 9A.      Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

Management, with the participation of our Chief Executive Officer (“CEO”) and our Chief Financial Officer (“CFO”), evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2020. The term “disclosure controls and procedures,” as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives. Based on this evaluation, management, including our CEO and CFO, concluded as of December 31, 2020 that our disclosure controls and procedures were effective.

 

Managements Annual Report on Internal Control Over Financial Reporting

 

Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rule 13a-15(f). The Company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles (“US GAAP”).

 

 

Internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, is a process designed by, or under the supervision of, the CEO and CFO and is effected by the Board of Directors, management and other personnel to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external reporting purposes in accordance with US GAAP. Internal control over financial reporting includes those policies and procedures that:

 

 

pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company;

 

provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with US GAAP, and that the receipts and expenditures of the Company are being made only in accordance with appropriate authorization of management and the board of directors; and

 

provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company’s assets that could have a material effect on the financial statements.

 

Management conducted an evaluation of the effectiveness of internal control over financial reporting based on the framework in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission.

 

Based on our evaluation under the criteria set forth in Internal Control — Integrated Framework (2013), our management concluded that, as of December 31, 2020, our internal control over financial reporting was effective.

 

This annual report does not include an attestation report of the Company’s independent registered public accounting firm regarding internal control over financial reporting because that requirement under Section 404 of the Sarbanes-Oxley Act of 2002 was permanently removed for smaller reporting companies pursuant to the provisions of Section 989G(a) set forth in the Dodd-Frank Wall Street Reform and Consumer Protection Act enacted into federal law in July 2010.

 

Changes in Internal Control over Financial Reporting

 

There have been no material changes in our internal controls over financial reporting as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act, during the quarter ended December 31, 2020 identified in connection with our evaluation that has materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

 

Item 9B.      Other Information.

 

None.

 

PART III

 

Item 10.       Directors, Executive Officers and Corporate Governance

 

The information required by Part III, Item 10 is incorporated herein by reference to the sections titled “Election of Directors”, “Board of Directors and Committees of the Board of Directors”, “Executive Officers”, and “Security Ownership of Certain Beneficial Owners and Management” in our definitive proxy statement relating to the 2021 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K.

 

Item 11.       Executive Compensation

 

The information required by Part III, Item 11 is incorporated herein by reference to the sections titled “Advisory Vote Regarding Executive Compensation”, and “Executive Compensation” in our definitive proxy statement relating to the 2021 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K.

 

 

Item 12.       Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

 

Equity Compensation Plan Information

 

The following table provides information as of December 31, 2020 with respect to compensation plans, including individual compensation arrangements, under which our equity securities are authorized for issuance:

 

   

Number of securities to be issued upon exercise of outstanding options and rights
( a )

   

WeightedAverage Exercise Price of options and rights
( b )

   

Number of securities remaining available for future issuance under equity compensation plans (excluding securites reflected in column (a)) (2)
( c )

 

Plan Category:

                       

Equity compensation plans approved by security holders:

(1)                      

2014 Plan

    2,341,848     $ 5.09       417,477  

Total

    2,341,848     $ 5.09       417,477  

 

(1) This amount includes 0.4 million shares of common stock issuable upon the vesting of certain restricted stock awards and performance-based restricted stock units and 1.9 million shares of common stock issuable upon the exercise of vested stock option awards.

 

(2) Includes 2.0 million shares authorized as part of our 2014 Annual Meeting of Stockholders held in May 2014, 1.0 million shares authorized as part of our 2018 Annual Meeting of Stockholders held in August 2018 and 1.0 million shares authorized as part of our 2019 Annual Meeting of Stockholders held in May 2019, less just under 3.6 million shares that were made available to certain employees, directors and others.

 

The other information required by Part III, Item 12 is incorporated herein by reference to the section titled “Security Ownership of certain Beneficial Owners and Management” in our definitive proxy statement relating to the 2021 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K.

 

Item 13.       Certain Relationships and Related Transactions, and Director Independence

 

The information required by Part III, Item 13 is incorporated herein by reference to the sections titled “Election of Directors – Director Independence” and “Certain Relationships and Related Party Transactions” in our definitive proxy statement relating to the 2021 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K.

 

Item 14.       Principal Accounting Fees and Services

 

The information required by Part III, Item 14 is incorporated herein by reference to the sections titled “Ratification of Independent Registered Public Accounting Firm” and “Independent Auditor’s Fees” in our definitive proxy statement relating to the 2021 Annual Meeting of Stockholders to be filed with the SEC within 120 days after the end of the fiscal year covered by this Annual Report on Form 10-K.

 

 

PART IV

 

Item 15.       Exhibits, Financial Statement Schedules

 

 

(a)

The following documents are filed or furnished as part of this Form 10-K:

 

 

1.

Financial Statements

     
    Reference is made to the Index to Financial Statements under Item 8, Part II hereof.

 

 

2.

Financial Statement Schedules

     
    The Financial Statement Schedules have been omitted either because they are not required or because the information has been included in the financial statements or the notes thereto included in this Annual Report on Form 10-K.

 

 

3.

Exhibits

     
    Reference is made to the accompanying Exhibit Index set forth below. Pursuant to the rules and regulations of the Securities and Exchange Commission, the Company has filed, furnished or incorporated by reference the documents referenced in the Exhibit Index as exhibits to this Form 10-K. The documents include agreements to which the Company is a party or has a beneficial interest. The agreements have been filed to provide investors with information regarding their respective terms. The agreements are not intended to provide any other factual information about the Company or its business or operations. In particular, the assertions embodied in any representations, warranties and covenants contained in the agreements may be subject to qualifications with respect to knowledge and materiality different from those applicable to investors and may be qualified by information in confidential disclosure schedules not included with the exhibits. These disclosure schedules may contain information that modifies, qualifies and creates exceptions to the representations, warranties and covenants set forth in the agreements. Moreover, certain representations, warranties and covenants in the agreements may have been used for the purpose of allocating risk between the parties, rather than establishing matters as facts. In addition, information concerning the subject matter of the representations, warranties and covenants may have changed after the date of the respective agreement, which subsequent information may or may not be fully reflected in the Company's public disclosures. Accordingly, investors should not rely on the representations, warranties and covenants in the agreements as characterizations of the actual state of facts about the Company or its business or operations on the date hereof. The Company will furnish to any stockholder, upon written request, any exhibit listed in the Exhibit Index upon payment by such stockholder of the Company's reasonable expenses in furnishing any such exhibit.

 

 

Exhibit Index

 

Exhibit
Number

 

Description of Document

     3.1

 

Amended and Restated Certificate of Incorporation, as amended (incorporated by reference to Exhibit 3.1 to the Company’s current report on Form 8-K (File No. 1-35020) filed on May 12, 2014).

     

     3.2

 

Amended and Restated By-Laws (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K (File No. 1-35020) filed on July 9, 2018).

     

     4.1

 

Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.2 to the Company’s Registration Statement on Form S-1/A (File No. 333-129035) filed on March 3, 2006).

     

     4.2

 

Description of Securities Registered Under Section 12 of the Exchange Act (incorporated by reference to Exhibit 4.2 to the Company’s Annual Report on Form 10-K (File No. 1-35020) filed on March 30, 2020.

     

   10.1**

 

InfuSystem Holdings, Inc. 2007 Stock Incentive Plan (incorporated by reference to Exhibit 4.1 to the Company’s Registration Statement on Form S-8 (File No. 333-150066) filed on April 3, 2008).

     

   10.2

 

Amended and Restated Registration Rights Agreement, dated as of October 17, 2007 by and among InfuSystem Holdings, Inc., Wayne Yetter, John Voris, Jean-Pierre Millon, Erin Enright, Sean McDevitt, Pat LaVecchia and Great Point Partners LLC (incorporated by reference to Exhibit 10.1 to the Company’s Annual Report on Form 10-K (File No. 0-51902) filed on March 3, 2009).

     

   10.3

 

Credit Agreement by and among InfuSystem Holdings, Inc., its subsidiaries and JPMorgan Chase Bank, N.A., dated as of March 23, 2015 (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q (File No. 1-35020) filed on May 12, 2015).

     

   10.4

 

Pledge and Security Agreement by and among InfuSystem Holdings, Inc., its subsidiaries and JPMorgan Chase Bank, N.A., dated as of March 23, 2015 (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q (File No. 1-35020) filed on May 12, 2015).

     

   10.5

 

Patent and Trademark Agreement by and among InfuSystem Holdings, Inc., its subsidiaries and JPMorgan Chase Bank, N.A., dated as of March 23, 2015 (incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q (File No. 1-35020) filed on May 12, 2015).

     
   10.6   First Amendment to Credit Agreement and Waiver, dated as of December 5, 2016, among the InfuSystem Holdings, Inc., and its direct and indirect subsidiaries, with JPMorgan Chase Bank, N.A. as Lender (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 1-35020) filed on December 9, 2016).
     

   10.7**

 

First Amended and Restated Employment Agreement by and between Jan Skonieczny and InfuSystem Holdings, Inc., effective January 2, 2013 (incorporated by reference to Exhibit 10.16 to the Company’s Annual Report on Form 10-K (File No. 1-35020) filed on March 28, 2013).

     

   10.8**

 

Form of Stock Option Award Agreement (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q (File No. 1-35020) filed on November 10, 2014).

     

   10.9**

 

Form of Restricted Stock Award Agreement (incorporated by reference to Exhibit 10.4 to the Company’s Quarterly Report on Form 10-Q (File No. 1-35020) filed on May 12, 2015).

     

   10.10**

 

Employment Agreement by and between InfuSystem Holdings, Inc. and Richard DiIorio, effective November 15, 2017 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 1-35020) filed on November 20, 2017).

     

   10.11**

 

Stock Option Award Agreement by and between InfuSystem Holdings, Inc. and Richard DiIorio, dated as of November 15, 2017 (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K (File No. 1-35020) filed on November 20, 2017).

 

 

Exhibit
Number
  Description of Document

  10.12**

 

Stock Appreciation Right Award Agreement by and between InfuSystem Holdings, Inc. and Richard DiIorio, dated as of November 15, 2017 (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K (File No. 1-35020) filed on November 20, 2017).

     

  10.13

 

Second Amendment to Credit Agreement by and between InfuSystem Holdings, Inc., InfuSystem Holdings USA, Inc., InfuSystem, Inc., First Biomedical, Inc., IFC LLC and JPMorgan Chase Bank, N.A. as the Lender, dated March 22, 2017 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 1-35020) filed on March 23, 2017).

     

  10.14

 

Limited Waiver by and between InfuSystem Holdings, Inc., InfuSystem Holdings USA, Inc., InfuSystem, Inc., First Biomedical, Inc., IFC LLC and JPMorgan Chase Bank, N.A. as the Lender, dated May 10, 2017 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 1-35020) filed on May 11, 2017).

     

  10.15**

 

Separation Agreement and General Release by and between InfuSystem Holdings, Inc. and Eric Steen, dated June 7, 2017 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K/A (File No. 1-35020) filed on June 14, 2017).

     

  10.16

 

Third Amendment to Credit Agreement by and between InfuSystem Holdings, Inc., InfuSystem Holdings USA, Inc., InfuSystem, Inc., First Biomedical, Inc., IFC LLC and JPMorgan Chase Bank as the Lender, dated June 28, 2017 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 1-35020) filed on June 29, 2017).

     

  10.17

 

Patent and Trademark Security Agreement by and between InfuSystem Holdings, Inc., InfuSystem Holdings USA, Inc., InfuSystem, Inc., First Biomedical, Inc. and JPMorgan Chase Bank, N.A. as the Lender, dated June 28, 2017 (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K (File No. 1-35020) filed on June 29, 2017).

     

  10.18**

 

Employment Agreement by and between InfuSystem Holdings, Inc. and Gregory Schulte, effective May 7, 2018 (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q (File No. 1-35020) filed on May 14, 2018).

     

  10.19**

 

Equity Settlement Agreement by and between InfuSystem Holdings, Inc. and Christopher Downs, effective May 11, 2018 (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q (File No. 1-35020) filed on May 14, 2018).

     

  10.20**

 

Inducement Stock Option Award Agreement by and between InfuSystem Holdings, Inc. and Gregory Schulte, effective May 7, 2018 (incorporated by reference to Exhibit 10.3 to the Company’s Quarterly Report on Form 10-Q (File No. 1-35020) filed on May 14, 2018).

     

  10.21**

 

Equity Settlement Agreement by and between InfuSystem Holdings, Inc. and Jan Skonieczny, effective June 5, 2018 (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q (File No. 1-35020) filed on August 14, 2018).

     

  10.22**

 

Equity Settlement Agreement by and between InfuSystem Holdings, Inc. and Trent Smith, effective June 5, 2018 (incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q (File No. 1-35020) filed on August 14, 2018).

     

  10.23

 

Fourth Amendment to the Credit Agreement, dated as of July 31, 2018, among InfuSystem Holdings, Inc. and its direct subsidiaries with JPMorgan Chase Bank, N.A. as Lender (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 1-35020) filed on August 2, 2018).

     

  10.24

 

Stock Purchase and Settlement Agreement, dated as of July 31, 2018, among InfuSystem Holdings, Inc., Ryan J. Morris and Meson Capital, L.P. (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K (File No. 1-35020) filed on August 2, 2018).

 

 

Exhibit
Number
  Description of Document

  10.25**

 

InfuSystem Holdings, Inc. 2014 Equity Plan (as amended through May 15, 2019) (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 1-35020) filed on May 17, 2019).

     

  10.26

 

Fifth Amendment to the Credit Agreement, dated as of February 5, 2019, among InfuSystem Holdings, Inc. and its direct and indirect subsidiaries with JPMorgan Chase Bank, N.A. as Lender (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 1-35020) filed on February 12, 2019).

     

  10.27**

 

Employment Agreement by and between InfuSystem Holdings, Inc. and Carrie Lachance, effective October 1, 2019 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 1-35020) filed on October 2, 2019).

     

  10.28

  Sixth Amendment to the Credit Agreement, dated as of November 7, 2019, among InfuSystem Holdings, Inc. and its direct and indirect subsidiaries with JPMorgan Chase Bank, N.A. as Lender (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 1-35020) filed on November 12, 2019).
     

  10.29**

 

Employment Agreement by and between InfuSystem Holdings, Inc. and Thomas Ruiz, effective January 3, 2018 (incorporated by reference to Exhibit 10.30 to the Company’s Annual Report on Form 10-K (File No. 1-35020) filed on March 30, 2020).

     

  10.31**

 

Independent Contractor Agreement, effective February 5, 2020, by and between the Company and Wesley W. Winnekins (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 1-35020) filed on February 7, 2020).

     

  10.32**

 

Separation Agreement, dated March 5, 2020, by and between the Company and Greg Schulte (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K/A (File No. 1-35020) filed on March 9, 2020).

     

  10.33**

 

Employment Agreement, effective March 11, 2020, by and between the Company and Barry G. Steele (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 1-35020) filed on March 12, 2020).

     

  10.34**

 

Form of Performance Unit Award Agreement under the 2014 Equity Plan (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 1-35020) filed on May 27, 2020).

     

  10.35**

 

Composite Copy of InfuSystem Holdings, Inc. Employee Stock Purchase Plan, as amended (incorporated by reference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q (File No. 1-35020) filed on November 13, 2020).

     

  10.36**

 

Amendment to Employment Agreement, dated August 24, 2020, between the Company and Richard DiIorio (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K (File No. 1-35020) filed on August 25, 2020).

     

  10.37**

 

Restricted Stock Unit Agreement (Service-Based), dated August 24, 2020, between the Company and Richard DiIorio (incorporated by reference to Exhibit 10.2 to the Company’s Current Report on Form 8-K (File No. 1-35020) filed on August 25, 2020).

     

  10.38**

 

Restricted Stock Unit Agreement (Performance-Based), dated August 24, 2020, between the Company and Richard DiIorio (incorporated by reference to Exhibit 10.3 to the Company’s Current Report on Form 8-K (File No. 1-35020) filed on August 25, 2020).

     

  21.1*

 

Subsidiaries of InfuSystem Holdings, Inc.

     

  23.1*

 

Consent of BDO USA, LLP

     

  31.1*

 

Certification of Chief Executive Officer pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as amended

 

 

Exhibit
Number
  Description of Document

31.2*

 

Certification of Principal Financial Officer pursuant to Rule 13a-14 of the Securities Exchange Act of 1934, as amended

     

32.1*

 

Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

     

32.2*

 

Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

     

101.INS

 

XBRL Instance Document*

     

101.SCH

 

XBRL Taxonomy Extension Schema Document*

     

101.CAL

 

XBRL Taxonomy Extension Calculation Linkbase Document*

     

101.DEF

 

XBRL Taxonomy Extension Definition Linkbase Document*

     

101.LAB

 

XBRL Taxonomy Extension Label Linkbase Document*

     

101.PRE

 

XBRL Taxonomy Extension Presentation Linkbase Document*

     

 

*           Filed herewith.

 

**         Management contract or compensatory plan, contract or arrangement.

 

Item 16.         10-K Summary

 

None.

 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

     
 

INFUSYSTEM HOLDINGS, INC.

     

Date: March 22, 2021

By:

/s/    RICHARD DiIORIO        

   

Richard DiIorio

   

Chief Executive Officer and Director

(Principal Executive Officer)

 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the Registrant and in the capacity and on the dates indicated.

 

 

   

Date: March 22, 2021

 

By:

/s/    RICHARD DiIORIO        

     

Richard DiIorio

     

Chief Executive Officer and Director

(Principal Executive Officer)

   

Date: March 22, 2021

/s/    BARRY STEELE         

 

Barry Steele

 

Chief Financial Officer

(Principal Accounting and Financial Officer)

   

Date: March 22, 2021

/s/    SCOTT SHUDA         

 

Scott Shuda

 

Chairman of the Board

Director

   

Date: March 22, 2021

/s/    GREGG LEHMAN        

 

Gregg Lehman

 

Vice Chairman of the Board

Director

   

Date: March 22, 2021

/s/    PAUL GENDRON        

 

Paul Gendron

 

Director

   

Date: March 22, 2021

/s/    DARRELL MONTGOMERY         

 

Darrell Montgomery

 

Director

   

Date: March 22, 2021

/s/    CHRISTOPHER SANSONE         

 

Christopher Sansone

 

Director

 

 

74
EX-21.1 2 ex_233059.htm EXHIBIT 21.1 ex_233059.htm

EXHIBIT 21.1

 

 

Subsidiaries of the Registrant

 

     

Name                    

 

Jurisdiction of Organization                                                         

   

InfuSystem, Inc.

 

California

   

First Biomedical, Inc.

 

Kansas

   

IFC, LLC

 

Delaware

   

InfuSystem Holdings USA, Inc.            

 

Delaware

 

 

 

 
EX-23.1 3 ex_233060.htm EXHIBIT 23.1 ex_233060.htm

EXHIBIT 23.1

 

 

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

 

We hereby consent to the incorporation by reference, in the Registration Statements on Form S-8 (Nos. 333-195929, 333-195930, 333-217090, 333-226872 and 333-232146) of InfuSystem Holdings, Inc. of our report dated March 22, 2021, relating to the consolidated financial statements, which appears in this Form 10-K.

 

 

/s/ BDO USA, LLP

 

Troy, Michigan

March 22, 2021

 

 

 

 
EX-31.1 4 ex_233061.htm EXHIBIT 31.1 ex_233061.htm

EXHIBIT 31.1

 

CERTIFICATION BY OFFICER

 

I, Richard DiIorio, certify that:

 

1.

I have reviewed this Form 10-K for the year ended December 31, 2020 of InfuSystem Holdings, Inc.;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

a.

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

b.

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

c.

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

d.

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

 

a.

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

b.

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

         

Date: March 22, 2021

 

By:

/s/    RICHARD DiIORIO        

       

Richard DiIorio

       

Chief Executive Officer and Director

 

 

 
EX-31.2 5 ex_233062.htm EXHIBIT 31.2 ex_233062.htm

EXHIBIT 31.2

 

CERTIFICATION BY OFFICER

 

I, Barry Steele, certify that:

 

1.

I have reviewed this Form 10-K for the year ended December 31, 2020 of InfuSystem Holdings, Inc.;

 

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

 

 

a.

designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

 

b.

designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

 

c.

evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

 

d.

disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5.

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

 

a.

all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

 

b.

any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

         

Date: March 22, 2021

 

By:

/s/    BARRY STEELE        

       

Barry Steele

       

Chief Financial Officer

 

 

 
EX-32.1 6 ex_233063.htm EXHIBIT 32.1 ex_233063.htm

EXHIBIT 32.1

 

CERTIFICATION OF OFFICER

 

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

 

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of InfuSystem Holdings, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

 

The Form 10-K for the year ended December 31, 2020 (the “Report”) of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

         

Date: March 22, 2021

 

By:

/s/    RICHARD DiIORIO        

       

Richard DiIorio

       

Chief Executive Officer and Director

 

 
EX-32.2 7 ex_233064.htm EXHIBIT 32.2 ex_233064.htm

EXHIBIT 32.2

 

CERTIFICATION OF OFFICER

 

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)

 

Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of InfuSystem Holdings, Inc., a Delaware corporation (the “Company”), does hereby certify, to such officer’s knowledge, that:

 

The Form 10-K for the year ended December 31, 2020 (the “Report”) of the Company fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

         

Date: March 22, 2021

 

By:

/s/    BARRY STEELE        

       

Barry Steele

       

Chief Financial Officer

 

 
EX-101.INS 8 infu-20201231.xml XBRL INSTANCE DOCUMENT false --12-31 FY 2020 2020-12-31 10-K 0001337013 20336671 Yes false Non-accelerated Filer Yes 150739346 InfuSystem Holdings, Inc false true No No Common Stock, par value $0.0001 per share infu <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; margin-left: 5%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Gross Assets</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Accumulated Amortization</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Net</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Nonamortizable intangible assets</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Trade names</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Amortizable intangible assets</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Trade names</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">23</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(23</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Physician and customer relationships</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">36,534</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(28,924</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">7,610</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Software</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">11,230</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(9,663</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,567</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total nonamortizable and amortizable intangible assets</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">49,787</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(38,610</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">11,177</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; margin-left: 5%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Gross Assets</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Accumulated Amortization</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Net</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Nonamortizable intangible assets</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Trade names</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Amortizable intangible assets</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Trade names</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">23</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(23</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Physician and customer relationships</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">36,534</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(26,550</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">9,984</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Software</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">11,230</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(7,751</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">3,479</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total nonamortizable and amortizable intangible assets</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">49,787</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(34,324</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">15,463</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> </tr> </table></div> 184493 164751 14330 0.025 3.5 1.2 1014000 1271000 11250000 120000 937000 1204000 8900000 7500000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">14.</div></div>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<div style="display: inline; font-weight: bold;">COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div></div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 25pt;">On <div style="display: inline; font-style: italic; font: inherit;"> March 11, 2020, </div>the World Health Organization declared the outbreak of COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> as a pandemic, which has spread globally and throughout the United States. With the exception of in-person visits to our customer facilities by our sales staff, the Company has continued to operate despite stay-at-home orders and other government mandated shutdowns across the United States and Canada under exceptions allowed by those orders for the healthcare industry.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 25pt;">We have taken a number of precautionary and preemptive steps to protect the safety and well-being of our employees while ensuring continuity of service to our clients, including, transitioning our employees to a remote work environment, suspending employee travel, canceling participation in industry events and in-person group meetings, promoting social distancing and enhanced cleaning and sanitization efforts across office locations, and implementing protocols to quarantine employees who <div style="display: inline; font-style: italic; font: inherit;"> may </div>have been exposed to COVID-<div style="display: inline; font-style: italic; font: inherit;">19,</div> or show relevant symptoms. We also continued to undertake preparedness plans at our facilities to maintain continuity of operations, which provide for flexible work arrangements without any significant disruptions to our business or control processes. Our management team is continuing to actively monitor the situation and is in constant communication with our workforce as well as with our customers and vendors. Other specific actions we have taken include purchasing additional inventory of supplies and pumps, as well as purchasing personal protective equipment for our employees. While the Company's business is considered critical, we are unable to predict the impact that the COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic will have on future periods due to numerous uncertainties. While the COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic has <div style="display: inline; font-style: italic; font: inherit;">not</div> had any material unfavorable effects in our financial results for the year ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020, </div>the extent of the impact in the future, if any, will depend on future developments, which are highly uncertain, cannot be predicted and could have a material adverse impact on our financial position, operating results and cash flows. A prolonged outbreak could, among other things, strain our business continuity plans, create delays in our growth and strategic initiatives, reduce our sales and marketing activities, limit our access to financing on favorable terms, increase our exposure to potential impairment charges related to long-lived and intangible assets, hinder our ability to support our clients and operate our business effectively, heighten the risk of disruption to our information and reporting systems and internal controls, including those over financial reporting and other risk management systems, or require us to incur substantial costs. We are closely monitoring the impact of the COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic on all aspects of our business and <div style="display: inline; font-style: italic; font: inherit;"> may </div>take further actions as <div style="display: inline; font-style: italic; font: inherit;"> may </div>be required by federal, state or local authorities, or that we determine are in the best interests of our employees, customers and partners. As the conditions surrounding the COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic continue to evolve rapidly, we will continue to actively manage our response in collaboration with customers, government officials and stakeholders, and assess any potential impacts to our financial position and operating results, as well as adverse developments in our business.</div></div> -0.084 -0.058 25000 0.15 7.43 3.94 0.0019 162000 150000 0.0325 25000000 10000000 15600000 0.9 100000 200000 200000 300000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">4.</div></div>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<div style="display: inline; font-weight: bold;">Medical Equipment</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">Medical equipment consisted of the following as of <div style="display: inline; font-style: italic; font: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font: inherit;">31</div> (in thousands):</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 7.5%; margin-left: 7.5%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 64%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Medical Equipment for sale or rental</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,636</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,334</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Medical Equipment for sale or rental - pump reserve</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(33</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(28</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Medical Equipment for sale or rental - net</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,603</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,306</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Medical Equipment in rental service</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">83,411</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">75,853</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Medical Equipment in rental service - pump reserve</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(893</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(720</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accumulated depreciation</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(46,907</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(41,908</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Medical Equipment in rental service - net</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">35,611</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">33,225</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">37,214</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">34,531</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table> </div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">Depreciation expense for medical equipment for the years ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019</div> was <div style="display: inline; font-style: italic; font: inherit;">$8.9</div> million and <div style="display: inline; font-style: italic; font: inherit;">$7.5</div> million, respectively, which were recorded in &#x201c;cost of revenues&#x201d; for each period.</div></div> 100000 100000 33000 28000 1603000 1306000 1636000 1334000 35611000 33225000 46907000 41908000 83411000 75853000 893000 720000 P7Y 37214000 34531000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Medical Equipment</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">Medical Equipment (&#x201c;Equipment&#x201d;) consists of equipment that the Company purchases from <div style="display: inline; font-style: italic; font: inherit;">third</div>-parties and is (<div style="display: inline; font-style: italic; font: inherit;">1</div>) for sale or rent, and (<div style="display: inline; font-style: italic; font: inherit;">2</div>) used in service to generate rental revenue. Equipment, once placed into service, is depreciated using the straight-line method over the estimated useful lives of the equipment which is typically <div style="display: inline; font-style: italic; font: inherit;">seven</div> years. The Company does <div style="display: inline; font-style: italic; font: inherit;">not</div> depreciate Equipment held for sale or rent. When Equipment in rental service assets are sold, or otherwise disposed, the cost and related accumulated depreciation are removed from the accounts and a sale is recorded in the current period. The Company periodically performs an analysis of slow-moving Equipment used in service to generate rental revenue and records a reserve based on estimated obsolescence, which was <div style="display: inline; font-style: italic; font: inherit;">$0.9</div> and <div style="display: inline; font-style: italic; font: inherit;">$0.7</div> million as of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> respectively. The Company performs a similar analysis of slow-moving Equipment for sale or rent and records a reserve, which was less than <div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">$0.1</div></div> million as of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019.</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div> 1800000 2 4 5 P5Y P20Y 31500000 100000 3400000 15820000 19669000 9583000 6237000 14216000 5453000 0.5 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Presentation in the Consolidated Statements</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">The Company rents and sells medical equipment. The Company purchases medical equipment directly for sale as well as medical equipment that is purchased for either rental or sale and that is unallocated at the time of purchase (&#x201c;Unallocated Assets&#x201d;). Management believes that the predominant source of revenues and cash flows from the Unallocated Assets is from rentals and most equipment purchased is likely to be rented prior to being sold. The Company concluded that (i) the assets specifically supporting its <div style="display: inline; font-style: italic; font: inherit;">two</div> primary revenue streams should be separately disclosed on the balance sheet; (ii) the purchase and sale of Unallocated Assets should be classified solely in investing cash flows based on their predominant source while medical equipment purchased specifically for sales activity should be classified in operating cash flows; and (iii) other activities ancillary to the rental process should be consistently classified.</div></div></div></div></div></div></div></div></div></div></div></div></div></div> 22000 4500000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Cost of Revenues</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">Cost of revenues include the costs of servicing and maintaining pumps, products sold, shipping and other direct and indirect costs related to net revenues. Shipping and handling costs incurred after control over a product has transferred to a customer are accounted for as a fulfillment cost.</div></div></div></div></div></div></div></div></div></div></div></div></div></div> 61072000 36316000 97388000 51540000 29575000 81115000 5370000 -5370000 3788000 -3788000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 7.5%; margin-left: 7.5%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 64%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Medical Equipment for sale or rental</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,636</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,334</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Medical Equipment for sale or rental - pump reserve</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(33</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(28</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Medical Equipment for sale or rental - net</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,603</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,306</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Medical Equipment in rental service</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">83,411</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">75,853</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Medical Equipment in rental service - pump reserve</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(893</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(720</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accumulated depreciation</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(46,907</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(41,908</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Medical Equipment in rental service - net</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">35,611</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">33,225</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">37,214</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">34,531</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div> 71269 6818 3.17 9.28 P4Y146D P8Y215D 0.5 2 2.33 2.77 2.55 624462 3135211 422779 62479 2.55 187676 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Treasury Stock</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The Company periodically repurchases shares of its common stock. These repurchases take place either as part of a board-authorized program, which <div style="display: inline; font-style: italic; font: inherit;"> may </div>include open market transactions or privately negotiated transactions and <div style="display: inline; font-style: italic; font: inherit;"> may </div>be made under a Rule <div style="display: inline; font-style: italic; font: inherit;">10b5</div>-<div style="display: inline; font-style: italic; font: inherit;">1</div> plan, or in targeted stock purchase agreements approved by the board. Treasury stock is accounted for using the par value method.</div></div></div></div></div></div></div></div></div></div></div></div></div></div> 17000 17000 49000 66000 17000 15000 17000 17000 6779000 7962000 14720000 12097000 700000 2018000 102000 859000 2979000 1928000 90000 630000 2648000 84785000 83699000 717000 717000 1714000 1714000 113000 113000 190000 190000 997000 997000 2610000 2610000 1000000 400000 17000 37000 4285000 4402000 100000 100000 96991000 79224000 68472000 26519000 2000000 54292000 22932000 2000000 29771000 19305000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;text-indent:-25pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">1.</div></div>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<div style="display: inline; font-weight: bold;">Basis of Presentation and Nature of Operations</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">InfuSystem Holdings, Inc. and its consolidated subsidiaries (the &#x201c;Company&#x201d;) are a leading provider of infusion pumps and related products and services for patients in the home, oncology clinics, ambulatory surgery centers, and other sites of care from <div style="display: inline; font-style: italic; font: inherit;">five</div> locations in the United States and Canada. The Company provides products and services to hospitals, oncology practices and facilities and other alternate site health care providers. Headquartered in Rochester Hills, Michigan, the Company delivers local, field-based customer support, and also operates pump service and repair Centers of Excellence in Michigan, Kansas, California, Massachusetts and Ontario, Canada. InfuSystem Inc. (&#x201c;ISI&#x201d;), which is an operating subsidiary of the Company, is accredited by the Community Health Accreditation Program while First Biomedical, Inc. (First Biomedical), which is an operating subsidiary of the Company, is ISO certified.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The Company's core service is to supply electronic ambulatory infusion pumps and associated disposable supply kits to oncology clinics, infusion clinics and hospital outpatient chemotherapy clinics to be utilized in the treatment of a variety of cancers including colorectal cancer, pain management and other disease states. The majority of the Company's pumps are electronic infusion pumps. Smiths Medical, Inc. and Moog Medical Devices Group each supplied more than <div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">10%</div></div> of the ambulatory pumps purchased by the Company in <div style="display: inline; font-style: italic; font: inherit;">2020.</div> The Company has a supply agreement in place with each of these suppliers. Certain &#x201c;spot&#x201d; purchases are made on the open market subject to individual negotiation. The Company also supplies Negative Pressure Wound Therapy (&#x201c;NPWT&#x201d;) medical equipment, as well as related disposables and ancillary supplies. Cardinal Health, Inc. supplied more than <div style="display: inline; font-style: italic; font: inherit;">10%</div> of the NPWT medical equipment purchased by the Company in <div style="display: inline; font-style: italic; font: inherit;">2020.</div> The Company has a supply agreement in place with Cardinal Health, Inc.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">In addition, the Company sells or rents new and pre-owned pole-mounted and ambulatory infusion pumps to, and provides biomedical recertification, maintenance and repair services for oncology practices, as well as other alternate site settings including home care and home infusion providers, skilled nursing facilities, pain centers and others. The Company also provides these products and services to customers in the hospital market.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">The Company purchases new and pre-owned pole-mounted and ambulatory infusion pumps from a variety of sources on a non-exclusive basis. The Company repairs, refurbishes and provides biomedical certification for the devices as needed. The pumps are then available for sale, rental or to be used within the Company's ambulatory infusion pump management service.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and the rules and regulations of the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;).</div></div> 1400000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Business Combinations</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The Company accounts for all business combinations using the acquisition method of accounting, which allocates the fair value of the purchase consideration to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values. The excess of the purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. When determining the fair values of assets acquired and liabilities assumed, management makes significant estimates and assumptions. The Company <div style="display: inline; font-style: italic; font: inherit;"> may </div>utilize <div style="display: inline; font-style: italic; font: inherit;">third</div>-party valuation specialists to assist the Company in the allocation. Initial purchase price allocations are subject to revision within the measurement period, <div style="display: inline; font-style: italic; font: inherit;">not</div> to exceed <div style="display: inline; font-style: italic; font: inherit;">one</div> year from the date of acquisition. Acquisition-related expenses and transaction costs associated with business combinations are expensed as incurred.</div></div></div></div></div></div></div></div></div></div></div></div></div></div> 7000000 793000 2773000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Software Capitalization and Depreciation</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software, including payroll and payroll-related costs for employees who are directly associated with the internal-use software project, external direct costs of materials and services and interest costs while developing the software. Capitalized software costs are included in intangible assets, net and are amortized using the straight-line method over the estimated useful life of <div style="display: inline; font-style: italic; font: inherit;">three</div> to <div style="display: inline; font-style: italic; font: inherit;">five</div> years. Capitalization of such costs ceases when the project is substantially complete and ready for its intended purpose. Costs incurred during the preliminary project and post-implementation stages, as well as software maintenance and training costs, are expensed in the period in which they are incurred. The Company did <div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">not</div></div> capitalize any internal-use software for the years ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> respectively. Amortization expense for capitalized software was <div style="display: inline; font-style: italic; font: inherit;">$1.9</div> million in <div style="display: inline; font-style: italic; font: inherit;">2020</div> and <div style="display: inline; font-style: italic; font: inherit;">$2.0</div> million in <div style="display: inline; font-style: italic; font: inherit;">2019.</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div> 1900000 2000000 0 0 9648000 2647000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Cash and Cash Equivalents</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The Company considers all highly liquid investments with original maturities of <div style="display: inline; font-style: italic; font: inherit;">three</div> months or less to be cash equivalents. The Company maintains its cash and cash equivalents primarily with <div style="display: inline; font-style: italic; font: inherit;">two</div> financial institutions that are insured with the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;). At times throughout the year, cash and cash equivalents balances might exceed FDIC insurance limits.</div></div></div></div></div></div></div></div></div></div></div></div></div></div> 2647000 4318000 9648000 7001000 -1671000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;text-indent:-25pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">9.</div></div>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<div style="display: inline; font-weight: bold;">Commitments and Contingencies</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">From time to time in the ordinary course of its business, the Company <div style="display: inline; font-style: italic; font: inherit;"> may </div>be involved in legal and regulatory proceedings, the outcomes of which <div style="display: inline; font-style: italic; font: inherit;"> may </div><div style="display: inline; font-style: italic; font: inherit;">not</div> be determinable. The results of litigation and regulatory proceedings are inherently unpredictable. Any claims against the Company, whether meritorious or <div style="display: inline; font-style: italic; font: inherit;">not,</div> could be time consuming, result in costly litigation, require significant amounts of management time and result in diversion of significant resources. The Company is <div style="display: inline; font-style: italic; font: inherit;">not</div> able to estimate an aggregate amount or range of reasonably possible losses for those legal matters for which losses are <div style="display: inline; font-style: italic; font: inherit;">not</div> probable and estimable, primarily for the following reasons: (i) many of the relevant legal proceedings are in preliminary stages, and until such proceedings develop further, there is often uncertainty regarding the relevant facts and circumstances at issue and potential liability; and (ii) many of these proceedings involve matters of which the outcomes are inherently difficult to predict. The Company has insurance policies covering potential losses where such coverage is cost effective.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The Company is <div style="display: inline; font-style: italic; font: inherit;">not</div> at this time involved in any proceedings that the Company believes could have a material effect on the Company's financial condition, results of operations or cash flows.</div></div> 0.0001 0.0001 200000000 200000000 23816193 23400625 20297704 19882136 2000 2000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Customer Concentration</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">For <div style="display: inline; font-style: italic; font: inherit;">2020</div> and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> the Company's largest contracted payer was a national payer which accounted for approximately <div style="display: inline; font-style: italic; font: inherit;">14%</div> and <div style="display: inline; font-style: italic; font: inherit;">8%</div> of ITS net revenues for <div style="display: inline; font-style: italic; font: inherit;">2020</div> and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> respectively, and approximately <div style="display: inline; font-style: italic; font: inherit;">9%</div> and <div style="display: inline; font-style: italic; font: inherit;">5%</div> of total consolidated net revenues for <div style="display: inline; font-style: italic; font: inherit;">2020</div> and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> respectively.</div> <div style=" font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The Company also contracts with various other <div style="display: inline; font-style: italic; font: inherit;">third</div>-party payer organizations, Medicaid, commercial Medicare replacement plans, self-insured plans, facilities of our Medicare patients and numerous other insurance carriers. Other than the payer noted above, <div style="display: inline; font-style: italic; font: inherit;">no</div> other single payer represented more than <div style="display: inline; font-style: italic; font: inherit;">7%</div> of the Company's ITS net revenue.</div></div></div></div></div></div></div></div></div></div></div></div></div></div> 0.1 0.1 0.1 0.14 0.08 0.09 0.05 0.506 0.499 0.316 0.324 0.178 0.177 1 1 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Principles of Consolidation</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The consolidated financial statements include the accounts of the Company and all wholly owned organizations. All intercompany transactions and account balances have been eliminated in consolidation.</div></div></div></div></div></div></div></div></div></div></div></div></div></div> 38629000 34233000 11000 205000 30000 66000 29000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">7.</div></div>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<div style="display: inline; font-weight: bold;">Debt</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">On <div style="display: inline; font-style: italic; font: inherit;"> February 5, 2019, </div>the Company and its primary lender entered into the <div style="display: inline; font-style: italic; font: inherit;">fifth</div> amendment (the &#x201c;Fifth Amendment&#x201d;) to its Credit Agreement entered into on <div style="display: inline; font-style: italic; font: inherit;"> March 23, 2015 (</div>as amended, the <div style="display: inline; font-style: italic; font: inherit;">&#x201c;2015</div> Credit Agreement&#x201d;). The Fifth Amendment amended the <div style="display: inline; font-style: italic; font: inherit;">2015</div> Credit Agreement to, among other things:</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <table border="0" cellpadding="0" cellspacing="0" style=";font-family:Times New Roman;font-size:10pt; min-width: 700px;"> <tr> <td style="width:45pt;">&nbsp;</td> <td style="vertical-align:top;width:18pt;"> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</div> </td> <td style="vertical-align:top;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">increase our borrowing capacity under the equipment line to <div style="display: inline; font-style: italic; font: inherit;">$8.0</div> million, which allows for capital expenditure financing to the Company for the sole purpose of purchasing medical equipment (the &#x201c;Equipment Line&#x201d;);</div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style=";font-family:Times New Roman;font-size:10pt; min-width: 700px;"> <tr> <td style="width:45pt;">&nbsp;</td> <td style="vertical-align:top;width:18pt;"> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</div> </td> <td style="vertical-align:top;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">revise the definition of earnings before interest, taxes, depreciation and amortization (&#x201c;EBITDA&#x201d;), a non-GAAP financial measure, to include additional add-back adjustments for the years ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2018 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019;</div></div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style=";font-family:Times New Roman;font-size:10pt; min-width: 700px;"> <tr> <td style="width:45pt;">&nbsp;</td> <td style="vertical-align:top;width:18pt;"> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</div> </td> <td style="vertical-align:top;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">revise the definition of fixed charge coverage ratio for the year ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019 </div>to include an unfinanced portion of capital expenditures of up to <div style="display: inline; font-style: italic; font: inherit;">$7.0</div> million for the year ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019;</div></div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style=";font-family:Times New Roman;font-size:10pt; min-width: 700px;"> <tr> <td style="width:45pt;">&nbsp;</td> <td style="vertical-align:top;width:18pt;"> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</div> </td> <td style="vertical-align:top;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">revise the <div style="display: inline; font-style: italic; font: inherit;">2015</div> Credit Agreement's maximum permitted indebtedness to finance the acquisition, construction or improvement of any fixed or capital assets; and</div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style=";font-family:Times New Roman;font-size:10pt; min-width: 700px;"> <tr> <td style="width:45pt;">&nbsp;</td> <td style="vertical-align:top;width:18pt;"> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</div> </td> <td style="vertical-align:top;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">revise the maximum leverage ratio for each of the quarters during <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2018 </div>and <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019.</div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">On <div style="display: inline; font-style: italic; font: inherit;"> April 15, 2019, </div>the Company sold for <div style="display: inline; font-style: italic; font: inherit;">$2.0</div> million and immediately leased back certain medical equipment in rental service to a <div style="display: inline; font-style: italic; font: inherit;">third</div> party specializing in such transactions. The leaseback term is <div style="display: inline; font-style: italic; font: inherit;">36</div> months. Because the arrangement contains a purchase option that the Company is reasonably certain to exercise, this transaction did <div style="display: inline; font-style: italic; font: inherit;">not</div> qualify for the sale-leaseback accounting under ASC <div style="display: inline; font-style: italic; font: inherit;">842.</div> The medical equipment remains recorded on the accompanying consolidated balance sheet and the proceeds received have been classified as an Other Financing liability, which is being paid off monthly over the term of the lease. The balance of Other Financing as of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>was <div style="display: inline; font-style: italic; font: inherit;">$0.9</div> million.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">On <div style="display: inline; font-style: italic; font: inherit;"> November 7, 2019, </div>the Company and its primary lender entered into the <div style="display: inline; font-style: italic; font: inherit;">sixth</div> amendment (the &#x201c;Sixth Amendment&#x201d;) to its <div style="display: inline; font-style: italic; font: inherit;">2015</div> Credit Agreement. The Sixth Amendment amended the <div style="display: inline; font-style: italic; font: inherit;">2015</div> Credit Agreement to, among other things:</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <table border="0" cellpadding="0" cellspacing="0" style=";font-family:Times New Roman;font-size:10pt; min-width: 700px;"> <tr> <td style="width:54pt;">&nbsp;</td> <td style="vertical-align:top;width:18pt;"> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</div> </td> <td style="vertical-align:top;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">provide for a <div style="display: inline; font-style: italic; font: inherit;">2019</div> capital expenditure loan (the <div style="display: inline; font-style: italic; font: inherit;">&#x201c;2019</div> Equipment Line&#x201d;) commitment of <div style="display: inline; font-style: italic; font: inherit;">$10.0</div> million (in addition to the existing Equipment Line of <div style="display: inline; font-style: italic; font: inherit;">$8.0</div> million), which <div style="display: inline; font-style: italic; font: inherit;"> may </div>be drawn upon until the earlier of the full commitment being advanced or <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020, </div>to be used solely to purchase eligible equipment to be used in the Company's business and in amounts <div style="display: inline; font-style: italic; font: inherit;">not</div> to exceed <div style="display: inline; font-style: italic; font: inherit;">90.0%</div> of the invoiced hard costs of such acquired equipment;</div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style=";font-family:Times New Roman;font-size:10pt; min-width: 700px;"> <tr> <td style="width:54pt;">&nbsp;</td> <td style="vertical-align:top;width:18pt;"> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</div> </td> <td style="vertical-align:top;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">increase the commitment for the revolving credit facility (the &#x201c;Revolver&#x201d;) under the <div style="display: inline; font-style: italic; font: inherit;">2015</div> Credit Agreement to <div style="display: inline; font-style: italic; font: inherit;">$11.8</div> million;</div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style=";font-family:Times New Roman;font-size:10pt; min-width: 700px;"> <tr> <td style="width:54pt;">&nbsp;</td> <td style="vertical-align:top;width:18pt;"> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</div> </td> <td style="vertical-align:top;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">revise the definition of EBITDA to include the following additional or revised add-back adjustments: (i) <div style="display: inline; font-style: italic; font: inherit;">one</div>-time charges in an aggregate amount <div style="display: inline; font-style: italic; font: inherit;">not</div> to exceed <div style="display: inline; font-style: italic; font: inherit;">$0.3</div> million and incurred prior to <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019 </div>relating to the Company's integration of business previously served by another major provider of electronic oncology pumps; (ii) <div style="display: inline; font-style: italic; font: inherit;">one</div>-time charges in an aggregate amount <div style="display: inline; font-style: italic; font: inherit;">not</div> to exceed <div style="display: inline; font-style: italic; font: inherit;">$0.3</div> million and incurred prior to <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019 </div>relating to the Company's facility move; (iii) lease buyout expenses <div style="display: inline; font-style: italic; font: inherit;">not</div> to exceed: (<div style="display: inline; font-style: italic; font: inherit;">x</div>) <div style="display: inline; font-style: italic; font: inherit;">$0.1</div> million incurred on or prior to <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2018; (</div>y) <div style="display: inline; font-style: italic; font: inherit;">$0.2</div> million incurred after <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2018 </div>but on or prior to <div style="display: inline; font-style: italic; font: inherit;"> March 31, 2019; </div>and (z) <div style="display: inline; font-style: italic; font: inherit;">$0.2</div> million incurred after <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2019 </div>but on or prior to <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020; </div>and (iv) any other non-cash charges for such period (but excluding certain non-cash charges);</div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style=";font-family:Times New Roman;font-size:10pt; min-width: 700px;"> <tr> <td style="width:54pt;">&nbsp;</td> <td style="vertical-align:top;width:18pt;"> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</div> </td> <td style="vertical-align:top;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">revise the definition of Fixed Charge Coverage Ratio to mean, for any period, the ratio of (a) EBITDA minus Maintenance Capital Expenditures (defined to mean, for any period, <div style="display: inline; font-style: italic; font: inherit;">50.0%</div> of depreciation expense) to (b) Fixed Charges, all calculated for the Company and its subsidiaries on a consolidated basis in accordance with GAAP;</div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style=";font-family:Times New Roman;font-size:10pt; min-width: 700px;"> <tr> <td style="width:54pt;">&nbsp;</td> <td style="vertical-align:top;width:18pt;"> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</div> </td> <td style="vertical-align:top;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">revise the definitions of Revolving Credit Maturity Date and Term Maturity Date to mean the date <div style="display: inline; font-style: italic; font: inherit;">five</div> years after the Sixth Amendment Effective Date and add a definition for the <div style="display: inline; font-style: italic; font: inherit;">2019</div> Equipment Line Maturity Date to provide for the same maturity date;</div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style=";font-family:Times New Roman;font-size:10pt; min-width: 700px;"> <tr> <td style="width:54pt;">&nbsp;</td> <td style="vertical-align:top;width:18pt;"> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</div> </td> <td style="vertical-align:top;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">reflect the refinancing of the Term A Loans, Term B Loans and Term C Loan as a single term loan (the &#x201c;Term Loan&#x201d;) on the Sixth Amendment Effective Date and, commencing on the last Business Day of <div style="display: inline; font-style: italic; font: inherit;"> December 2019, </div>the consecutive quarterly principal installment payments changed to approximately <div style="display: inline; font-style: italic; font: inherit;">$1.2</div> million; and</div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style=";font-family:Times New Roman;font-size:10pt; min-width: 700px;"> <tr> <td style="width:54pt;">&nbsp;</td> <td style="vertical-align:top;width:18pt;"> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</div> </td> <td style="vertical-align:top;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">revise Section <div style="display: inline; font-style: italic; font: inherit;">5.01</div>(e) of the <div style="display: inline; font-style: italic; font: inherit;">2015</div> Credit Agreement, which governs the Company's obligation to deliver financial statements to the lender, to require the Company to provide financial statements (<div style="display: inline; font-style: italic; font: inherit;">x</div>) as soon as possible but in any event within <div style="display: inline; font-style: italic; font: inherit;">30</div> days of the end of each fiscal quarter, or within <div style="display: inline; font-style: italic; font: inherit;">30</div> days of the end of each calendar month if any revolving loans were outstanding in month, (y) in connection with, and prior to, requesting any letter of credit and (z) at such other times as <div style="display: inline; font-style: italic; font: inherit;"> may </div>be requested by the lender.</div> </td> </tr> </table> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">These debt amendments were accounted for as debt modifications. As of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020, </div>the Company was in compliance with all financial covenants under the <div style="display: inline; font-style: italic; font: inherit;">2015</div> Credit Agreement.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">As of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020, </div>the Company's Term Loan, Equipment Line and <div style="display: inline; font-style: italic; font: inherit;">2019</div> Equipment line under the <div style="display: inline; font-style: italic; font: inherit;">2015</div> Credit Agreement had balances of <div style="display: inline; font-style: italic; font: inherit;">$21.9</div> million, <div style="display: inline; font-style: italic; font: inherit;">$6.0</div> million and <div style="display: inline; font-style: italic; font: inherit;">$10.0</div> million, respectively. The availability under the Revolver is subject to a borrowing base, which is calculated as the sum of the Company's eligible accounts receivable and eligible inventory as defined by the <div style="display: inline; font-style: italic; font: inherit;">2015</div> Credit Agreement. As of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020, </div>the borrowing base was approximately <div style="display: inline; font-style: italic; font: inherit;">$15.6</div> million, which exceeded the gross available borrowing amount of <div style="display: inline; font-style: italic; font: inherit;">$11.8</div> million. The following table illustrates the net availability under the Revolver as of the applicable balance sheet date (in thousands):</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Revolver:</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Gross availability</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">11,750</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">11,750</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Outstanding draws</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Letters of credit</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(800</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(1,750</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Landlord reserves</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(162</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(150</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Availability on Revolver</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">10,788</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">9,850</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table> </div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The Company had future maturities of loans as of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>as follows (in thousands):</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div> <table cellpadding="0pt" cellspacing="0pt" style="margin-right: 5%; margin-left: 5%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 22%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2021</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2022</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2023</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2024</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2025 and </div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">thereafter</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Total</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 22%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Term Loan</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">4,615</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">4,615</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">4,615</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">8,075</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">21,920</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 22%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Equipment Line</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,600</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,600</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,600</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,200</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">6,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 22%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2019 Equipment Line</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">3,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">10,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 22%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unamortized value of debt issuance costs</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(17</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(17</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(17</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(15</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(66</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 22%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other financing</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">725</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">222</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">947</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 22%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">9,423</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">8,420</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">8,198</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">12,760</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">38,801</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> </tr> </table> </div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 25pt;">The following is a breakdown of the Company's current and long-term debt as of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019 (</div>in thousands):</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div> <table cellpadding="0pt" cellspacing="0pt" style="margin-right: 7.5%; margin-left: 7.5%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 28%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 25%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2020</div></div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 25%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2019</div></div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 28%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Current </div></div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Portion</div> </div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Long-Term </div></div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Portion</div></div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Total</div></div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Current </div></div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Portion</div></div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Long-Term </div></div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Portion</div></div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Total</div></div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 28%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Term Loan</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">4,615</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">17,305</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">21,920</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">5,768</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">21,919</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">27,687</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 28%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Equipment Line</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,600</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">4,400</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,600</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7,600</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 28%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2019 Equipment Line</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">10,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">79</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,495</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,574</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 28%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unamortized value of debt issuance costs</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(17</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(49</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(66</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(17</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(66</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(83</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 28%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other financing</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">725</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">222</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">947</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">652</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">947</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,599</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 28%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">9,423</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">29,378</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">38,801</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">8,082</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">30,295</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">38,377</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table> </div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">As of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020, </div>interest on the credit facility is payable at our option as a (i) Eurodollar Loan, which bears interest at a per annum rate equal to the applicable <div style="display: inline; font-style: italic; font: inherit;">30</div>-day London Interbank Offered Rate (&#x201c;LIBOR&#x201d;) plus an applicable margin ranging from <div style="display: inline; font-style: italic; font: inherit;">2.00%</div> to <div style="display: inline; font-style: italic; font: inherit;">3.00%</div> or (ii) CB Floating Rate (&#x201c;CBFR&#x201d;) Loan, which bears interest at a per annum rate equal to the greater of (a) the lender's prime rate or (b) LIBOR plus <div style="display: inline; font-style: italic; font: inherit;">2.50%,</div> in each case, plus a margin ranging from -<div style="display: inline; font-style: italic; font: inherit;">1.00%</div> to <div style="display: inline; font-style: italic; font: inherit;">0.25%</div> based on our leverage ratio as defined in the <div style="display: inline; font-style: italic; font: inherit;">2015</div> Credit Agreement. The actual Eurodollar Loan rate at <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>was <div style="display: inline; font-style: italic; font: inherit;">2.19%</div> (LIBOR of <div style="display: inline; font-style: italic; font: inherit;">0.19%</div> plus <div style="display: inline; font-style: italic; font: inherit;">2.00%</div>). The actual CBFR Loan rate at <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>was <div style="display: inline; font-style: italic; font: inherit;">2.25%</div> (lender's prime rate of <div style="display: inline; font-style: italic; font: inherit;">3.25%</div> minus <div style="display: inline; font-style: italic; font: inherit;">1.00%</div>).</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Subsequent to <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020, </div>the Company entered into the <div style="display: inline; font-style: italic; font: inherit;">2021</div> Credit Agreement, which replaced the <div style="display: inline; font-style: italic; font: inherit;">2015</div> Credit Agreement. For more information regarding the <div style="display: inline; font-style: italic; font: inherit;">2021</div> Credit Agreement, refer to the &#x201c;Subsequent Events&#x201d; discussion included in Note <div style="display: inline; font-style: italic; font: inherit;">15</div> in the Notes to the Consolidated Financial Statements included in this Form <div style="display: inline; font-style: italic; font: inherit;">10</div>-K.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div></div> 0.02 0.03 -0.01 0.0025 0.02 -0.01 0.02 0.03 0.01 0.02 0.02 0.01 0.0219 0.0225 1200000 P3Y <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Deferred Debt Issuance Costs</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">Capitalized debt issuance costs as of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019</div> relate to the Company's credit facility. The costs related to the agreement are netted against current and non-current debt. The Company amortizes these costs using the interest method through the maturity date of the underlying debt.</div></div></div></div></div></div></div></div></div></div></div></div></div></div> -8346000 104000 66000 9967000 -10071000 104000 4330000 4570000 104000 -1725000 832000 1688000 12997000 14082000 1300000 1634000 214000 27000 8667000 1300000 9967000 12997000 4529000 7337000 7991000 54000 194000 30000 25000 533000 533000 757000 451000 656000 443000 1570000 1459000 11250000 11370000 9553000 1697000 41000 63000 104000 3393000 3366000 800000 700000 9740000 7940000 10708000 3317000 14025000 9457000 2885000 12342000 800000 500000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 7.5%; margin-left: 7.5%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 64%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Third-Party Payer Rentals</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">49,266</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">40,510</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Direct Payer Rentals</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">30,765</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">26,269</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Product Sales</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">17,357</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">14,336</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total - Net revenues</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">97,388</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">81,115</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 7.5%; margin-left: 7.5%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 64%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Third-Party Payer Rentals</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">50.6</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">49.9</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Direct Payer Rentals</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">31.6</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">32.4</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Product Sales</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">17.8</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">17.7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total - Net revenues</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">100.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">100.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">11.</div></div>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<div style="display: inline; font-weight: bold;">Share-based Compensation </div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">All stock option awards are amortized based on their graded vesting over the requisite service period of the awards. Compensation costs are recognized over the requisite service period using the accelerated method and included in general and administrative expenses.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Stock Incentive Plan</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The Company has various stock option and stock-based incentive plans and agreements whereby stock options, restricted stock awards (&#x201c;RSUs&#x201d;) and PSUs were made available to certain employees, directors and others approved by the Company's Board of Directors (the &#x201c;Board&#x201d;) or Compensation Committee. Stock options are granted at, or above, fair market value and generally expire in <div style="display: inline; font-style: italic; font: inherit;">five</div> to <div style="display: inline; font-style: italic; font: inherit;">ten</div> years from the grant date. RSUs are granted at the fair market value on the date of grant and generally become exercisable over a period of up to <div style="display: inline; font-style: italic; font: inherit;">three</div> years. PSUs are granted at the fair market value on the date of grant and generally become exercisable over a period of up to <div style="display: inline; font-style: italic; font: inherit;">three</div> years based on the performance of a specific achievement. Awards typically vest and are issued only if the participants remain employed by the Company through the vesting date. Stock options, RSUs and PSUs are issued from shares under the Company's plan described below. Grants <div style="display: inline; font-style: italic; font: inherit;"> may </div>be made in the form of stock options, restricted stock awards, performance-based restricted stock units, unrestricted common stock or stock appreciation rights (&#x201c;SARs&#x201d;).</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">On <div style="display: inline; font-style: italic; font: inherit;"> April 23, 2014, </div>the Company's Board adopted the <div style="display: inline; font-style: italic; font: inherit;">2014</div> Amended and Restated Stock Incentive Plan (the <div style="display: inline; font-style: italic; font: inherit;">&#x201c;2014</div> Plan&#x201d;). The <div style="display: inline; font-style: italic; font: inherit;">2014</div> Plan was approved by the Company's shareholders at the <div style="display: inline; font-style: italic; font: inherit;">2014</div> Annual Meeting and became effective as of the date it was adopted by the Board of Directors. The <div style="display: inline; font-style: italic; font: inherit;">2014</div> Plan provided for the issuance of a maximum of <div style="display: inline; font-style: italic; font: inherit;">2.0</div> million shares of common stock in connection with the grant of stock-based or stock-denominated awards. On <div style="display: inline; font-style: italic; font: inherit;"> July 19, 2018, </div>the Company's stockholders approved the reservation of an additional <div style="display: inline; font-style: italic; font: inherit;">1.0</div> million shares to be issued under the <div style="display: inline; font-style: italic; font: inherit;">2014</div> Plan. On <div style="display: inline; font-style: italic; font: inherit;"> May 15, 2019, </div>the Company's stockholders approved the reservation of an additional <div style="display: inline; font-style: italic; font: inherit;">1.0</div> million shares to be issued under the <div style="display: inline; font-style: italic; font: inherit;">2014</div> Plan. As of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020, </div>a total of approximately <div style="display: inline; font-style: italic; font: inherit;">0.4</div> million common shares remained available for future grant under the <div style="display: inline; font-style: italic; font: inherit;">2014</div> Plan.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The Company granted stock options under the <div style="display: inline; font-style: italic; font: inherit;">2014</div> Plan during the years ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> respectively.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Shares Forgone to Satisfy Minimum Statutory Withholdings</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">During the years ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> shares of common stock were issued to employees and directors as their restricted stock awards vested or stock options were exercised. Under the terms of the Company's stock plans, at the election of each employee, the Company can authorize a net settlement of distributable shares to employees after satisfaction of an individual employees' tax withholding obligations. For both of the years ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> the Company received <div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">0.1</div></div> million shares from employees for tax withholding obligations.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Restricted Stock Awards</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 25pt;">During the year ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020, </div>the Company granted <div style="display: inline; font-style: italic; font: inherit;">0.2</div> million restricted stock awards. During the year ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019, </div>the Company granted less than <div style="display: inline; font-style: italic; font: inherit;">0.1</div> million restricted stock awards. Restricted stock awards entitle the holder to receive, upon meeting certain time-based vesting criteria, a specified number of shares of the Company's common stock. Stock-based compensation cost of restricted stock awards is measured by the market value of the Company's common stock on the date of grant.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 25pt;">The following table summarizes the Company's restricted share activity, excluding the Company's employee stock purchase plan, for the years ended <div style="display: inline; font-style: italic; font: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font: inherit;">31:</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 54pt; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">average</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">grant</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Number of</div></div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">date fair</div></div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Aggregate</div></div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">shares</div></div> </div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">value</div></div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">fair value</div></div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unvested at December 31, 2018</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">129,583</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1.42</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">26,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7.04</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Vested</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(58,314</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3.17</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">712,969</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Vested shares forgone to satisfy minimum statutory withholding</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(71,269</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3.17</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">422,779</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeitures</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unvested at December 31, 2019</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">26,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7.04</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">156,250</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">10.12</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Vested</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(28,432</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">9.28</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">367,273</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Vested shares forgone to satisfy minimum statutory withholding</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(6,818</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">9.28</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">62,479</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeitures</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(2,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">11.68</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unvested at December 31, 2020</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">145,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">9.78</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> </table> </div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">As of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020, </div>there was <div style="display: inline; font-style: italic; font: inherit;">$1.0</div> million of pre-tax total unrecognized compensation cost related to non-vested restricted stock awards, which will be adjusted for future forfeitures, if any. The Company expects to recognize such cost over the period ending in <div style="display: inline; font-style: italic; font: inherit;">2023.</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Performance-Based Restricted Stock Units</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 25pt;">During the year ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020, </div>the Company granted approximately <div style="display: inline; font-style: italic; font: inherit;">0.2</div> million PSUs. During the year ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019, </div>the Company did <div style="display: inline; font-style: italic; font: inherit;">not</div> grant any PSUs. PSUs entitle the holder to receive, upon meeting certain performance-based vesting criteria, a specified number of shares of the Company's common stock. These awards typically vest after the Company's achievement of either Company performance relative to specified performance measure goals for a specific fiscal period or when the Company's stock price reaches a target value for a minimum number of consecutive trading days. Approximately <div style="display: inline; font-style: italic; font: inherit;">three</div>-fourths of the PSUs granted in <div style="display: inline; font-style: italic; font: inherit;">2020</div> are earned based on the market-based condition, while the other <div style="display: inline; font-style: italic; font: inherit;">one</div>-<div style="display: inline; font-style: italic; font: inherit;">fourth</div> are earned based on specified Company performance measure conditions. In the case of the market-based condition, awards are paid in stock immediately upon achievement of the performance condition or expire without any payment after the <div style="display: inline; font-style: italic; font: inherit;">third</div> anniversary of the grant date. In the case of the specified Company performance measure, awards can be earned at <div style="display: inline; font-style: italic; font: inherit;">50%</div> of the target number of shares for achieving a minimum threshold or up to <div style="display: inline; font-style: italic; font: inherit;">200%</div> of the target number of shares for exceeding the target, with a linear adjustment between threshold and target or between target and stretch performance goals.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 25pt;">Under FASB ASC Topic <div style="display: inline; font-style: italic; font: inherit;">718,</div> the provisions of the PSUs that vest upon achievement of a target market value are considered a market condition, and therefore the effect of that market condition is reflected in the grant date fair value for this type of award. A <div style="display: inline; font-style: italic; font: inherit;">third</div>-party valuation expert was engaged to complete a &#x201c;Monte Carlo simulation&#x201d; to account for the market condition. That simulation takes into account the beginning stock price of the Company's common stock, the expected volatilities for the Company's stock price and the expected risk-free rate of return. The single grant-date fair value computed by this valuation method is recognized by the Company in accounting for the awards regardless of the actual future outcome of the market condition. The grant date fair value of the other PSUs is calculated as the closing price of the Company's common stock on the grant date multiplied by the number of shares subject to the award. Company performance measure goals are considered a performance condition and the grant-date fair value for those PSUs corresponds with management's expectation of the probable outcome of the performance conditions as of the grant date.</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 25pt;">The following table summarizes the Company's PSU activity for the years ended <div style="display: inline; font-style: italic; font: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font: inherit;">31:</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 54pt; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">average</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">grant</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Number of</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">date fair</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Aggregate</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">shares</div></div> </div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">value</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">fair value</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unvested at December 31, 2019</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 14%; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">232,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">9.06</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unvested at December 31, 2020</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">232,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">9.06</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> </tr> </table> </div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">As of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020, </div>there was <div style="display: inline; font-style: italic; font: inherit;">$1.7</div> million of pre-tax total unrecognized compensation cost related to non-vested PSUs, which will be adjusted for future forfeitures and changes to management's expectations of the probable outcomes of the performance conditions, if any. The Company expects to recognize such cost over the period ending in <div style="display: inline; font-style: italic; font: inherit;">2022.</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Employee Stock Purchase Plan</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">In <div style="display: inline; font-style: italic; font: inherit;"> May 2014, </div>the Company received approval from stockholders to adopt an employee stock purchase plan ("ESPP") effective <div style="display: inline; font-style: italic; font: inherit;"> October 2014 (</div>collectively the &#x201c;Original ESPP&#x201d;). Under the Original ESPP, <div style="display: inline; font-style: italic; font: inherit;">200,000</div> shares of common stock were authorized for purchase by eligible employees at a <div style="display: inline; font-style: italic; font: inherit;">15%</div> discount through payroll deductions during the <div style="display: inline; font-style: italic; font: inherit;">six</div>-month offering periods. Shares were purchased in whole numbers and generally would be the last day of the offering period. On <div style="display: inline; font-style: italic; font: inherit;"> September 7, 2016, </div>the Company received approval from shareholders for an additional <div style="display: inline; font-style: italic; font: inherit;">350,000</div> shares. <div style="display: inline; font-style: italic; font: inherit;">No</div> employee <div style="display: inline; font-style: italic; font: inherit;"> may </div>purchase more than <div style="display: inline; font-style: italic; font: inherit;">$25,000</div> worth of fair market value shares in any calendar year. As allowed under the ESPP, a participant <div style="display: inline; font-style: italic; font: inherit;"> may </div>elect to withdraw from the plan, effective for the purchase period in progress at the time of the election with all accumulated payroll deductions returned to the participant at the time of withdrawal. As of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020, </div>there were <div style="display: inline; font-style: italic; font: inherit;">187,676</div> shares remaining available for future issuance. The following table summarizes the activity relating to the Company's ESPP program for the years ended <div style="display: inline; font-style: italic; font: inherit;"> December 31:</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Compensation expense</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">108,589</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">43,030</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Shares of stock sold to employees</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">30,012</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">33,742</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average fair value per ESPP award</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">7.43</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">3.94</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table> </div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Stock Options</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The Company calculates the fair value of stock option awards using the Black-Scholes option pricing model, which incorporates various assumptions including volatility, expected term, risk-free interest rates and dividend yields. The expected volatility assumption is based on historical volatility of the Company's common stock over the most recent period commensurate with the expected life of the stock option granted. The Company uses historical volatility because management believes such volatility is representative of prospective trends. The risk-free interest rate assumption is based upon observed interest rates appropriate for the expected life of the stock option awarded. The Company uses historical exercise data to determine the expected lives. Dividend yields have <div style="display: inline; font-style: italic; font: inherit;">not</div> been a factor in determining fair value of stock options granted as the Company has never issued cash dividends and does <div style="display: inline; font-style: italic; font: inherit;">not</div> anticipate issuing cash dividends in the future.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">During the year ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020, </div>the Company granted <div style="display: inline; font-style: italic; font: inherit;">0.3</div> million stock options, of which <div style="display: inline; font-style: italic; font: inherit;">0.1</div> million were issued to Board members at exercise prices based on a preceding <div style="display: inline; font-style: italic; font: inherit;">five</div>-day average price on the date of grant with a vesting period of <div style="display: inline; font-style: italic; font: inherit;">12</div> months. During the year ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019, </div>the Company granted <div style="display: inline; font-style: italic; font: inherit;">0.7</div> million stock options, of which <div style="display: inline; font-style: italic; font: inherit;">0.1</div> million were issued to Board members at exercise prices based on the stock price as of the date of grant with a vesting period of <div style="display: inline; font-style: italic; font: inherit;">12</div> months. The following tables detail the various stock option and inducement stock option activity for the years ended <div style="display: inline; font-style: italic; font: inherit;"> December 31:</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 54pt; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted-</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Average</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Number</div></div> </div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Weighted-</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Remaining</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Aggregate</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">of Authorized</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Average Exercise</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Contractual</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Intrinsic</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 44%; border-bottom: 1px solid black;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">2014 Plan (Options)</div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Shares</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Price</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Term (in Years)</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Value</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2018</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2,224,167</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2.67</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">3.01</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">670,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">3.77</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">4.40</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(213,056</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2.33</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">624,462</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised shares forgone to satisfy minimum statutory withholding</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(51,339</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2.33</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cashless exercise</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(184,493</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2.33</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(101,946</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3.63</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2019</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2,343,333</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2.99</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1.81</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">12,989,767</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at December 31, 2019</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,501,750</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2.69</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">331,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">10.38</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">8.59</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(334,184</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2.77</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">3,135,211</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised shares forgone to satisfy minimum statutory withholding</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(125,714</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2.77</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cashless exercise</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(164,751</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2.77</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(90,336</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3.96</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2020</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,959,348</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">4.26</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">4.42</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">28,449,362</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at December 31, 2020</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,362,932</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">3.33</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> </table> </div> <div style=" margin: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">&nbsp;</div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 54pt; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Aggregate Intrinsic Value = Excess of market value over the option exercise price of all in-the-money stock options.</div> </td> </tr> </table> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 54pt; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted-</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Average</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Number</div></div> </div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Weighted-</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Remaining</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Aggregate</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">Inducement</div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">of Authorized</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Average Exercise</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Contractual</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Intrinsic</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">Options</div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Shares</div> <div style="display: inline; font-weight: bold;"> ( 1 )</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Price</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Term (in Years)</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Value</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2018</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">125,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2.55</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">5.42</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">111,250</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2019</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">125,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2.55</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">4.42</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">747,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(27,940</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2.55</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">242,519</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised shares forgone to satisfy minimum statutory withholding</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(12,417</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2.55</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cashless exercise</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(14,330</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2.55</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(70,313</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">2.55</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2020</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at December 31, 2020</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> </table> </div> <div style=" margin: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">&nbsp;</div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 54pt; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Aggregate Intrinsic Value = Excess of market value over the option exercise price of all in-the-money stock options.</div> </td> </tr> <tr style="vertical-align: bottom;"> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="1" style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">(<div style="display: inline; font-style: italic; font: inherit;">1</div>) Represents inducement stock options to purchase shares of the Company's Common Stock to executive level managers.</div> </td> </tr> </table> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The following table summarizes information about stock options outstanding at <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020:</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 4%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 35%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 25%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Options Outstanding</div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 13%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Options Exercisable</div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="3" rowspan="1" style="font-family: Times New Roman; font-size: 10pt; width: 4%; border-bottom: 1px solid black;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2014 Plan (Options):</div> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="3" rowspan="1" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black; width: 4%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Range of Exercise Prices</div> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Number of Shares Outstanding</div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Weighted-Average Remaining Contractual Life</div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Weighted-Average Exercise Price</div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Number of Shares Exercisable</div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Weighted-Average Exercise Price</div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="width: 4%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 35%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 9%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 9%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 9%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 9%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 9%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 4%;">$2.01</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 35%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">$3.00</div></div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">870,011</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">3.20</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2.26</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">784,178</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2.26</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 4%;">$3.01</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 35%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">$4.00</div></div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">423,336</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2.74</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">3.23</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">301,669</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">3.21</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 4%;">$4.01</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 35%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">$5.00</div></div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">335,001</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">5.60</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">4.70</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">198,335</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">4.70</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 4%;">$6.01</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 35%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">$7.00</div></div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">50,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">4.21</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">6.82</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 4%;">$8.01</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 35%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">$9.00</div></div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">20,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">9.02</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">8.55</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 4%;">$11.01</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 35%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">$12.00</div></div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">245,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">9.38</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">11.07</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">78,750</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">11.07</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 4%;">$13.01</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 35%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">$14.00</div></div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">16,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">9.62</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">13.30</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 4%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 35%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); width: 9%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); width: 9%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); width: 9%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); width: 9%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); width: 9%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="3" rowspan="1" style="font-family: Times New Roman; font-size: 10pt; width: 4%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">Outstanding at December 31, 2020</div></div></div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,959,348</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">4.42</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">4.26</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,362,932</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">3.33</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table> </div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The following is the average fair value per share estimated on the date of grant and the assumptions used for options granted during the years ended <div style="display: inline; font-style: italic; font: inherit;"> December 31:</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; margin-left: 5%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 64%; border-bottom: 1px solid black;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock Options:</div> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 64%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Expected volatility</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: Times New Roman; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;42%</div></td> <td style="width: 4%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">to</div></td> <td style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">51%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: Times New Roman; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;36%</div></td> <td style="width: 4%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">to</div></td> <td style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;38%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 64%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Risk free interest rate</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: Times New Roman; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;0.20%</div></td> <td style="width: 4%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">to</div></td> <td style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;1.56%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: Times New Roman; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;1.80%</div></td> <td style="width: 4%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">to</div></td> <td style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2.36%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 64%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Expected lives at date of grant (in years)</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="width: 4%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">3.25</div></td> <td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="width: 4%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">4.63</div></td> <td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 64%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Weighted average fair value of options granted</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="width: 4%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">$3.87</div></td> <td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="width: 4%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">$1.61</div></td> <td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table> </div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Stock-based compensation expense</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The following table presents the total stock-based compensation expense, which is included in selling, general and administrative expenses for the years ended <div style="display: inline; font-style: italic; font: inherit;"> December 31 (</div>in thousands):</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Restricted share expense</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,687</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">190</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock option and SARs expense</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">923</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">807</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total stock-based compensation expense</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">2,610</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">997</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> </tr> </table> </div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Share Repurchase Program</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">On <div style="display: inline; font-style: italic; font: inherit;"> September 30, 2019, </div>the Company's Board of Directors approved a stock repurchase program (the &#x201c;Share Repurchase Program&#x201d;) authorizing the Company to repurchase up to <div style="display: inline; font-style: italic; font: inherit;">$5.0</div> million of the Company's outstanding common stock through <div style="display: inline; font-style: italic; font: inherit;">2020.</div> Repurchases under the Share Repurchase Program will be subject to market conditions, the periodic capital needs of the Company's operating activities, and the continued satisfaction of all covenants under the Company's credit agreements. The Company's ability to repurchase stock is subject to the restrictions and limitations of its credit agreements. Repurchases under the program <div style="display: inline; font-style: italic; font: inherit;"> may </div>take place in the open market or in privately negotiated transactions and <div style="display: inline; font-style: italic; font: inherit;"> may </div>be made under a Rule <div style="display: inline; font-style: italic; font: inherit;">10b5</div>-<div style="display: inline; font-style: italic; font: inherit;">1</div> plan. The Share Repurchase Program does <div style="display: inline; font-style: italic; font: inherit;">not</div> obligate the Company to repurchase shares and <div style="display: inline; font-style: italic; font: inherit;"> may </div>be suspended, terminated, or modified at any time.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020, </div>the Company had <div style="display: inline; font-style: italic; font: inherit;">not</div> repurchased any shares under the Share Repurchase Program.</div></div> 0.86 0.07 0.80 0.07 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Earnings Per Share</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The Company reports its earnings per share in accordance with ASU <div style="display: inline; font-style: italic; font: inherit;">2017</div>-<div style="display: inline; font-style: italic; font: inherit;">11,</div> Earnings Per Share (Topic <div style="display: inline; font-style: italic; font: inherit;">260</div>), which requires the presentation of both basic and diluted earnings per share on the statements of operations. The diluted weighted average common shares include adjustments for the potential effects of outstanding stock options but only in the periods in which such effect is dilutive under the treasury stock method. Included in our basic and diluted weighted average common shares are those stock options and restricted stock awards due to participants granted from the <div style="display: inline; font-style: italic; font: inherit;">2014</div> stock incentive plan. Anti-dilutive stock awards are comprised of stock options and unvested restricted stock awards, which would have been anti-dilutive in the application of the treasury stock method in accordance with ASU <div style="display: inline; font-style: italic; font: inherit;">2017</div>-<div style="display: inline; font-style: italic; font: inherit;">11,</div> Earnings Per Share (Topic <div style="display: inline; font-style: italic; font: inherit;">260</div>). In periods where the Company records a net loss, the diluted per share amount is the same as the basic per share amount.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">In accordance with this topic, the following table reconciles income and share amounts utilized to calculate basic and diluted net income per common share as of <div style="display: inline; font-style: italic; font: inherit;"> December 31 (</div>in thousands, except shares):</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 15%; margin-left: 72pt; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 64%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Numerator:</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Net income <div style="display: inline; font-style: italic;">(in thousands)</div></div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">17,332</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,361</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Denominator:</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Weighted average common shares outstanding:</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Basic</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">20,106,940</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">19,731,498</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Dilutive effect of restricted shares and options</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,610,276</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,107,898</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Diluted</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">21,717,216</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">20,839,396</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table> </div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">Stock options of less than <div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">0.1</div></div> million shares were <div style="display: inline; font-style: italic; font: inherit;">not</div> included in the calculations for both the years ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019</div> because they would have an anti-dilutive effect.</div></div></div></div></div> -1.298 0.107 0.21 0.21 -1.492 -0.079 0.002 0.02 0.015 -0.006 0.051 0.02 2800000 3500000 1000000 1700000 108589 43030 200000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Fair Value of Financial Instruments</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">The carrying amounts reported in the consolidated balance sheets as of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019</div> for cash, accounts receivable, accounts payable and other current liabilities approximate fair value because of the short-term nature of these instruments (Level I). The carrying value of the Company's long-term debt with variable interest rates approximates fair value based on instruments with similar terms (Level II).</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">The Company has adopted ASC <div style="display: inline; font-style: italic; font: inherit;">820,</div> Fair Value Measurements, which defines fair value, establishes a framework for assets and liabilities being measured and reported at fair value and appends disclosures about fair value measurements.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">For financial assets and liabilities measured at fair value on a recurring basis, fair value is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date. A <div style="display: inline; font-style: italic; font: inherit;">three</div>-level fair value hierarchy prioritizes the inputs used to measure fair value as follows:</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 54pt;">&nbsp;</td> <td style="width: 54pt;"> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; text-decoration: underline;">Level I</div>:</div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">quoted prices in active markets for identical instruments;</div> </td> </tr> </table> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:27pt;">&nbsp;</div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 54pt;">&nbsp;</td> <td style="width: 54pt;"> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; text-decoration: underline;">Level II</div>:</div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">quoted prices in active markets for similar instruments, quoted prices for identical instruments in markets that are <div style="display: inline; font-style: italic; font: inherit;">not</div> active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the instrument; and</div> </td> </tr> </table> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 54pt;">&nbsp;</td> <td style="width: 54pt;"> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; text-decoration: underline;">Level III</div>:</div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">significant inputs to the valuation model are unobservable.</div> </td> </tr> </table></div></div></div></div></div></div></div></div></div></div></div></div></div> -8335000 104000 P15Y P20Y P3Y 23000 28924000 9663000 38610000 23000 26550000 7751000 34324000 1733000 3930000 367000 548000 548000 2051000 23000 36534000 11230000 23000 36534000 11230000 7610000 1567000 9984000 3479000 P7Y P1Y 3577000 1453000 35195000 28986000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Intangible Assets</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">Intangible assets consist of trade names, physician and customer relationships and software. The physician and customer relationships arose primarily from previous acquisitions. The Company amortizes the value assigned to the physician and customer relationships on a straight-line basis over the period of expected benefit, which ranges from <div style="display: inline; font-style: italic; font: inherit;">fifteen</div> to <div style="display: inline; font-style: italic; font: inherit;">twenty</div> years. The acquired physician and customer relationship base represents a valuable asset of the Company due to the expectation of future business opportunities to be leveraged from the existing relationship with each physician and customer. The Company has long-standing relationships with numerous oncology clinics, physicians, home care and home infusion providers, skilled nursing facilities, pain centers and others. The useful lives of these relationships are based on minimal attrition experienced to date by the Company and expectations of continued minimal attrition. Acquired software is amortized on a straight-line basis over <div style="display: inline; font-style: italic; font: inherit;">three</div> years. Trade names associated with the original acquisition of InfuSystem are <div style="display: inline; font-style: italic; font: inherit;">not</div> amortized.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">Management tests indefinite life trade names for impairment annually or more frequently if deemed necessary. The impairment test for intangible assets with indefinite lives consists of a comparison of the fair value of the intangible assets with their carrying amounts. If the carrying value of the intangible assets exceeds the fair value, an impairment loss is recognized in an amount equal to that excess. The Company determines the fair value for trade names with indefinite lives through the royalty relief income valuation approach. The Company performed its annual impairment analysis as of the last day of <div style="display: inline; font-style: italic; font: inherit;"> October 2020 </div>and determined that the fair value of the trade names with indefinite lives was greater than their carrying value, resulting in <div style="display: inline; font-style: italic; font: inherit;">no</div> impairment.</div></div></div></div></div></div></div></div></div></div></div></div></div></div> 58759000 46882000 39773000 18986000 33063000 13819000 0 0 0 0 0 418000 638000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Impairment of Long-Lived Assets</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">Long-lived assets held for use, which includes medical equipment in rental service, property and equipment and amortizable intangible assets, are reviewed for impairment when events or changes in circumstances indicate that their carrying value <div style="display: inline; font-style: italic; font: inherit;"> may </div><div style="display: inline; font-style: italic; font: inherit;">not</div> be recoverable. If an impairment indicator exists, the Company assesses the asset or asset group for recoverability. Recoverability of these assets is determined based upon the expected undiscounted future net cash flows from the operations to which the assets relate, utilizing management's best estimates, appropriate assumptions and projections at the time. If the carrying value is determined <div style="display: inline; font-style: italic; font: inherit;">not</div> to be recoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair market value of the asset or asset group.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The Company assesses impairment indicators related to its internally-developed, internal-use software, specifically looking at the effectiveness and useful lives of each project and sub-project to determine if impairment indicators are present. In <div style="display: inline; font-style: italic; font: inherit;"> December 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> respectively, the Company assessed the impairment indicators and found <div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">none</div></div> to be present.</div></div></div></div></div></div></div></div></div></div></div></div></div></div> 6623000 1413000 7543000 1524000 920000 111000 7543000 1524000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">8.</div></div>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<div style="display: inline; font-weight: bold;">Income Taxes</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The following table summarizes the Company's income before income taxes for the years ended <div style="display: inline; font-style: italic; font: inherit;"> December 31 (</div>in thousands):</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">U.S income</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">6,623</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,413</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Non-U.S. income</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">920</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">111</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Income before income taxes</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">7,543</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,524</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table> </div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The following table summarizes the Company's components of the consolidated benefit from (provision for) income taxes for the years ended <div style="display: inline; font-style: italic; font: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font: inherit;">31</div> (in thousands):</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; margin-left: 5%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">U.S Federal income tax benefit&nbsp;(expense)</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Current</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(11</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Deferred</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">8,346</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(104</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">Total U.S. Federal income tax benefit (expense)</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">8,335</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(104</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">State and local income tax benefit&nbsp;(expense)</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Current</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(66</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(29</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Deferred</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,725</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">Total state and local income tax benefit (expense)</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,659</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(29</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Foreign income tax expense</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Current</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(205</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(30</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">Total income tax benefit (expense)</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">9,789</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(163</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> </tr> </table> </div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The following table summarizes activity related to the Company's valuation allowance for the years ended <div style="display: inline; font-style: italic; font: inherit;"> December 31 (</div>in thousands):</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Valuation allowance at the Beginning of Period</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(11,250</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(11,370</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Income tax expense</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Release of valuation allowance</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">11,250</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">120</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Valuation allowance at the End of Period</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(11,250</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> </tr> </table> </div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The following table summarizes a reconciliation of the Company's effective income tax rate to the U.S. federal statutory rate for the years ended <div style="display: inline; font-style: italic; font: inherit;"> December 31:</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 60%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 2%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 2%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 60%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Income tax expense at the statutory rate</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">21.0</div></td> <td nowrap="nowrap" style="width: 2%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">21.0</div></td> <td nowrap="nowrap" style="width: 2%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 60%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">State and local income tax expense</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">5.1</div></td> <td nowrap="nowrap" style="width: 2%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2.0</div></td> <td nowrap="nowrap" style="width: 2%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 60%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Foreign income tax</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">0.2</div></td> <td nowrap="nowrap" style="width: 2%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2.0</div></td> <td nowrap="nowrap" style="width: 2%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 60%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Permanent differences</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(8.4</div></td> <td nowrap="nowrap" style="width: 2%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(5.8</div></td> <td nowrap="nowrap" style="width: 2%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 60%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Decrease in valuation allowance</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(149.2</div></td> <td nowrap="nowrap" style="width: 2%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(7.9</div></td> <td nowrap="nowrap" style="width: 2%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 60%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other adjustments</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1.5</div></td> <td nowrap="nowrap" style="width: 2%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(0.6</div></td> <td nowrap="nowrap" style="width: 2%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 60%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Effective income tax rate</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(129.8</div></td> <td nowrap="nowrap" style="width: 2%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">10.7</div></td> <td nowrap="nowrap" style="width: 2%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td> </tr> </table> </div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">The following table summarizes the temporary differences and carryforwards that give rise to deferred tax assets and liabilities as of <div style="display: inline; font-style: italic; font: inherit;"> December 31 (</div>in thousands):</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 7.5%; margin-left: 7.5%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 64%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred Federal tax assets &#x2013;</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Bad debt reserves</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,570</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,459</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Stock-based compensation</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">656</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">443</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Net operating loss</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">7,337</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">7,991</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Operating lease liabilities</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,014</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,271</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Accrued compensation</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">757</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">451</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Inventories</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">214</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">27</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Goodwill and intangible assets</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">832</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,688</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Research &amp; development credits</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">533</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">533</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Other credits</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">30</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">25</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Other</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">54</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">194</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">Total deferred Federal tax assets</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">12,997</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">14,082</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Less: valuation allowance</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(9,553</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">Net deferred Federal tax assets</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">12,997</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">4,529</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred Federal tax liabilities &#x2013;</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Depreciation and asset basis differences</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(3,393</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(3,366</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Right-of-use assets</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(937</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(1,204</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">Total deferred Federal tax liabilities</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(4,330</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(4,570</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net deferred Federal tax assets (liabilities)</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">8,667</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(41</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total deferred state and local tax assets (a)</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,300</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,634</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less: valuation allowance</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(1,697</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net deferred state and local tax assets (liabilities)</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,300</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(63</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net deferred tax assets (liabilities)</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">9,967</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(104</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> </tr> </table> </div> <div style=" margin: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">&nbsp;</div> <table cellpadding="0pt" cellspacing="0pt" style="margin-right: 7.5%; margin-left: 7.5%; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <td colspan="1" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">(a) at <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> this includes state and local net operating losses of <div style="display: inline; font-style: italic; font: inherit;">$1.2</div> million and <div style="display: inline; font-style: italic; font: inherit;">$1.4</div> million, respectively.</div> </td> </tr> </table> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 25pt;">The Company's U.S. federal net operating loss carryforward for tax purposes was <div style="display: inline; font-style: italic; font: inherit;">$34.9</div> million at <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020, </div>resulting in a federal deferred tax asset of <div style="display: inline; font-style: italic; font: inherit;">$7.3</div> million. Approximately <div style="display: inline; font-style: italic; font: inherit;">$31.5</div> million of the Company's U.S. federal net operating loss carryforwards will begin to expire in various years beginning in <div style="display: inline; font-style: italic; font: inherit;">2029.</div> <div style="display: inline; font-style: italic; font: inherit;">$3.4</div> million of U.S. federal net operating loss carryforwards have an indefinite life. The Company's state net operating loss carryforward of approximately <div style="display: inline; font-style: italic; font: inherit;">$1.2</div> million is comprised of various jurisdictions. These state net operating losses can be used for a period of <div style="display: inline; font-style: italic; font: inherit;">5</div> to <div style="display: inline; font-style: italic; font: inherit;">20</div> years and vary by state, and if unused, begin to expire in <div style="display: inline; font-style: italic; font: inherit;">2021,</div> though a substantial portion expires beyond <div style="display: inline; font-style: italic; font: inherit;">2021.</div> Approximately <div style="display: inline; font-style: italic; font: inherit;">$0.1</div> million of the state net operating loss carryforwards have an indefinite life. Tax benefits of operating loss and tax credit carryforwards are evaluated on an ongoing basis, including a review of historical and projected future operating results, the eligible carryforward period, and other circumstances.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The Company continues to monitor shifts in past ownership (as defined under Section <div style="display: inline; font-style: italic; font: inherit;">382</div> of the Code). A definitive analysis necessary to quantify the effect of an ownership change was performed on the net operating loss carryforwards generated prior to <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019. </div>Based on the analysis, the Company is subject to an annual limitation of <div style="display: inline; font-style: italic; font: inherit;">$1.8</div> million on its use of remaining pre-ownership change net operating loss carryforwards of <div style="display: inline; font-style: italic; font: inherit;">$4.5</div> million (and certain other pre-change tax attributes).</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">In the <div style="display: inline; font-style: italic; font: inherit;">fourth</div> quarter of <div style="display: inline; font-style: italic; font: inherit;">2020</div> it was determined that the valuation allowance against the U.S. federal and state deferred taxes is <div style="display: inline; font-style: italic; font: inherit;">no</div> longer required and the valuation allowance of <div style="display: inline; font-style: italic; font: inherit;">$11.2</div> million that existed was released. The Company's realization of its deferred tax assets is dependent upon many factors, including, but <div style="display: inline; font-style: italic; font: inherit;">not</div> limited to, the Company's ability to generate sufficient taxable income. Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. Cumulative income in recent years and projected future taxable income is the basis for the Company's assessment that the deferred tax assets <div style="display: inline; font-style: italic; font: inherit;">no</div> longer require a full valuation allowance.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The Company had <div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">no</div></div> uncertain tax positions for the years ended <div style="display: inline; font-style: italic; font: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font: inherit;">31,</div> <div style="display: inline; font-style: italic; font: inherit;">2020</div> and <div style="display: inline; font-style: italic; font: inherit;">2019.</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The Company is subject to taxation for Federal and various state jurisdictions in the United States and Canada. The Federal income tax returns of the Company for the years <div style="display: inline; font-style: italic; font: inherit;">2017</div> through <div style="display: inline; font-style: italic; font: inherit;">2020</div> are open to examination by the Internal Revenue Service. The Company currently has an open audit with the Internal Revenue Service in relation to the Company's <div style="display: inline; font-style: italic; font: inherit;">2018</div> federal income tax return. Under examination, the Internal Revenue Service <div style="display: inline; font-style: italic; font: inherit;"> may </div>redetermine the correct taxable income for a closed year (pre-<div style="display: inline; font-style: italic; font: inherit;">2017</div>) to determine either the amount of the federal net operating loss carryforward deduction reported in the open years or the amount of a federal net operating loss deduction that is absorbed in a closed year and supports the determination of the available federal net operating loss deduction for the open years under examination. The state income tax returns and other state tax filings of the Company are subject to examination by the state taxing authorities, for various periods generally up to <div style="display: inline; font-style: italic; font: inherit;">four</div> years after they are filed. Canadian income tax returns of the Company for the years <div style="display: inline; font-style: italic; font: inherit;">2016</div> through <div style="display: inline; font-style: italic; font: inherit;">2020</div> are subject to examination by the Canada Revenue Agency.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 25pt;">On <div style="display: inline; font-style: italic; font: inherit;"> March 27, 2020, </div>the&nbsp;Coronavirus Aid, Relief, and Economic Security (CARES) Act was enacted in response to the COVID-<div style="display: inline; font-style: italic; font: inherit;">19</div> pandemic. The&nbsp;CARES Act among other things,&nbsp;allows employers to defer the deposit and payment of the employer's share of Social Security taxes. The Company, under the CARES Act, deferred paying <div style="display: inline; font-style: italic; font: inherit;">$0.7</div> million of applicable gross payroll taxes as of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020, </div>which is included in other liabilities. The <div style="display: inline; font-style: italic; font: inherit;">$0.7</div> million balance of the deferred Social Security taxes is expected to be paid in <div style="display: inline; font-style: italic; font: inherit;">two</div> equal annual installments during the years ending <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2021 </div>and <div style="display: inline; font-style: italic; font: inherit;">2022,</div> respectively. On <div style="display: inline; font-style: italic; font: inherit;"> April 15, 2020, </div>the Company received a <div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">$4.1</div></div> million loan under the Federal Paycheck Protection Program (&#x201c;PPP&#x201d;) created under the CARES Act. In response to revised eligibility guidelines announced by the U.S. Small Business Administration shortly thereafter, the Company repaid this loan in full on <div style="display: inline; font-style: italic; font: inherit;"> May 7, 2020.</div></div></div> 2018 -9789000 163000 -9789000 163000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Income Taxes </div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The Company recognizes deferred&nbsp;income tax liabilities and assets based on (i) the differences between the financial statement carrying amounts and the tax basis of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse and (ii) the tax credit carryforwards. Deferred income tax (expense) benefit results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when it is more likely than <div style="display: inline; font-style: italic; font: inherit;">not</div> that some or all of any deferred tax assets will <div style="display: inline; font-style: italic; font: inherit;">not</div> be realized.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">Provisions for federal, state and foreign taxes are calculated based on reported pre-tax earnings based on current tax law and include the cumulative effect of any changes in tax rates from those used previously in determining deferred tax assets and liabilities.&nbsp;Certain items of income and expense are recognized in different time periods for financial reporting than for income tax purposes; thus, such provisions differ from the amounts currently receivable or payable.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The Company follows a <div style="display: inline; font-style: italic; font: inherit;">two</div>-step approach for recognizing uncertain tax positions. First, it evaluates the tax position for recognition by determining if the weight of available evidence indicates it is more-likely-than-<div style="display: inline; font-style: italic; font: inherit;">not</div> that the position will be sustained upon examination. Second, for positions that are determined are more-likely-than-<div style="display: inline; font-style: italic; font: inherit;">not</div> to be sustained, it recognizes the tax benefits as the largest benefit that has a greater than <div style="display: inline; font-style: italic; font: inherit;">50%</div> likelihood of being sustained. The Company establishes a reserve for uncertain tax positions liability that is comprised of unrecognized tax benefits and related interest and penalties. The Company adjusts this liability in the period in which an uncertain tax position is effectively settled, the statute of limitations expires for the relevant taxing authority to examine the tax position, or more information becomes available.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The Company adopted ASU <div style="display: inline; font-style: italic; font: inherit;">2019</div>-<div style="display: inline; font-style: italic; font: inherit;">12,</div> Income Taxes (Topic <div style="display: inline; font-style: italic; font: inherit;">740</div>): Simplifying the Accounting for Income Taxes, in the <div style="display: inline; font-style: italic; font: inherit;">fourth</div> quarter of <div style="display: inline; font-style: italic; font: inherit;">2019.</div> This guidance simplifies various aspects related to accounting for income taxes by removing certain exceptions to the general principles in Topic <div style="display: inline; font-style: italic; font: inherit;">740</div> and also clarifies and amends existing guidance to improve consistent application. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after <div style="display: inline; font-style: italic; font: inherit;"> December 15, 2020. </div>Early adoption is permitted, including adoption in any interim period for which financial statements have <div style="display: inline; font-style: italic; font: inherit;">not</div> yet been issued. Certain amendments <div style="display: inline; font-style: italic; font: inherit;"> may </div>be applied on a retrospective, modified retrospective or prospective basis. As permitted, the Company elected to early adopt this guidance for the year ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019. </div>The adoption of this guidance did <div style="display: inline; font-style: italic; font: inherit;">not</div> have a significant impact on the Company's financial statements and primarily resulted in the reclassification of an immaterial amount from non-income tax expense to income tax expense related to the accounting for franchise taxes, with <div style="display: inline; font-style: italic; font: inherit;">no</div> impact to the Company's consolidated net income, equity or cash flows.</div></div></div></div></div></div></div></div></div></div></div></div></div></div> 102000 111000 2394000 2436000 2631000 1560000 102000 645000 740000 290000 186000 129000 1610276 1107898 2000000 2000000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">6.</div></div>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<div style="display: inline; font-weight: bold;">Intangible Assets </div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The carrying amount and accumulated amortization of intangible assets as of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019</div> were as follows (in thousands):</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; margin-left: 5%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Gross Assets</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Accumulated Amortization</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Net</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Nonamortizable intangible assets</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Trade names</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Amortizable intangible assets</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Trade names</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">23</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(23</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Physician and customer relationships</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">36,534</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(28,924</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">7,610</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Software</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">11,230</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(9,663</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,567</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total nonamortizable and amortizable intangible assets</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">49,787</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(38,610</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">11,177</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> </tr> </table> </div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; margin-left: 5%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Gross Assets</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Accumulated Amortization</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Net</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Nonamortizable intangible assets</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Trade names</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Amortizable intangible assets</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Trade names</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">23</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(23</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Physician and customer relationships</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">36,534</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(26,550</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">9,984</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Software</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">11,230</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(7,751</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">3,479</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total nonamortizable and amortizable intangible assets</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">49,787</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(34,324</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">15,463</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> </tr> </table> </div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The weighted average remaining lives of physician and customer relationships and software were <div style="display: inline; font-style: italic; font: inherit;">seven</div> years and <div style="display: inline; font-style: italic; font: inherit;">one</div> year, respectively, as of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020.</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The Company assesses impairment indicators related to its internally-developed, internal-use software, specifically looking at the effectiveness and useful lives of each project and sub-project to determine if impairment indicators are present. In <div style="display: inline; font-style: italic; font: inherit;"> December 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> respectively, the Company assessed the impairment indicators and found <div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">none</div></div> to be present.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">Amortization expense for intangible assets for the years ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019</div> was <div style="display: inline; font-style: italic; font: inherit;">$4.3</div> million and <div style="display: inline; font-style: italic; font: inherit;">$4.4</div> million, respectively, which was recorded in operating expenses. Expected annual amortization expense for the next <div style="display: inline; font-style: italic; font: inherit;">five</div> years for intangible assets recorded as of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>is as follows (in thousands):</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; margin-left: 5%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2021</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2022</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2023</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2024</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2025</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2026 and </div></div></div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">thereafter</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 16%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Amortization expense</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">3,930</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2,051</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">548</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">548</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">367</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,733</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table> </div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div></div> 49787000 49787000 11177000 15463000 1255000 1904000 1255000 1904000 1214000 1705000 3001000 2899000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Inventories</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The Company's inventories consist of disposable medical supplies, replacement parts and other supplies used in conjunction with medical equipment and are stated at the lower of cost (<div style="display: inline; font-style: italic; font: inherit;">first</div>-in, <div style="display: inline; font-style: italic; font: inherit;">first</div>-out basis) or net realizable value. The Company periodically performs an analysis of slow-moving inventory and records a reserve based on estimated obsolete inventory, which was <div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">$0.1</div></div> million as of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019.</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div> 100000 100000 1300000 600000 1200000 1000000 1932000 2239000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 7.5%; margin-left: 7.5%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 64%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating lease cost</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,617</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,948</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Variable lease cost</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">315</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">291</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total lease cost</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,932</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2,239</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash paid for amounts included in the measurement of lease liabilities and ROU assets:</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Operating cash flow from operating leases</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,603</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,610</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">ROU assets obtained in exchange for lease obligations:</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Operating leases</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">264</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">4,545</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Reductions to ROU assets resulting from reductions to lease obligations:</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Operating leases</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">22</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 7.5%; margin-left: 7.5%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Years</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Years</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 64%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average remaining lease term:</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Operating leases</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7.4</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Rate</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Rate</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average discount rate:</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Operating leases</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7.8</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7.7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Leases</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">On <div style="display: inline; font-style: italic; font: inherit;"> January 1, 2019 (</div>the &#x201c;Effective Date&#x201d;), the Company adopted Accounting Standards Update (&#x201c;ASU&#x201d;) <div style="display: inline; font-style: italic; font: inherit;">2016</div>-<div style="display: inline; font-style: italic; font: inherit;">02,</div> Leases (Topic <div style="display: inline; font-style: italic; font: inherit;">842</div>); ASU <div style="display: inline; font-style: italic; font: inherit;">2018</div>-<div style="display: inline; font-style: italic; font: inherit;">10,</div> Codification Improvements to Topic <div style="display: inline; font-style: italic; font: inherit;">842,</div> Leases; and ASU <div style="display: inline; font-style: italic; font: inherit;">2018</div>-<div style="display: inline; font-style: italic; font: inherit;">11,</div> Targeted Improvements (collectively, &#x201c;Topic <div style="display: inline; font-style: italic; font: inherit;">842&#x201d;</div>) using a modified retrospective transition approach, which requires Topic <div style="display: inline; font-style: italic; font: inherit;">842</div> to be applied to all leases existing at the date of initial application. Under Topic <div style="display: inline; font-style: italic; font: inherit;">842,</div> lessees are required to recognize a lease liability and right-of-use asset (&#x201c;ROU asset&#x201d;) for all leases and to disclose key information about leasing arrangements. Additionally, leases are classified as either financing or operating; the classification determines the pattern of expense recognition and classification within the statement of operations. The Company elected to apply its lease accounting policy only to leases with a term greater than <div style="display: inline; font-style: italic; font: inherit;">twelve</div> months.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">Topic <div style="display: inline; font-style: italic; font: inherit;">842</div> provides several optional practical expedients that we adopted at transition. The Company elected the &#x201c;package of practical expedients&#x201d;, which does <div style="display: inline; font-style: italic; font: inherit;">not</div> require it to reassess its prior conclusions regarding lease identification, lease classification and initial direct costs. The Company did <div style="display: inline; font-style: italic; font: inherit;">not</div> elect the practical expedient of hindsight to the evaluation of lease options (e.g. renewal).</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">Topic <div style="display: inline; font-style: italic; font: inherit;">842</div> also provides practical expedients for an entity's ongoing accounting. The Company elected the &#x201c;combining lease and non-lease components&#x201d; practical expedient and also elected to apply the short-term lease recognition exemption to certain leases; therefore, the Company did <div style="display: inline; font-style: italic; font: inherit;">not</div> recognize ROU assets and lease liabilities for these leases.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">In adopting Topic <div style="display: inline; font-style: italic; font: inherit;">842,</div> the Company determined and will continue to determine whether an arrangement is a lease at inception. The Company's operating leases are primarily for office space, service facility centers and equipment under operating lease arrangements that expire at various dates over the next <div style="display: inline; font-style: italic; font: inherit;">ten</div> years. The Company's leases do <div style="display: inline; font-style: italic; font: inherit;">not</div> contain any restrictive covenants. The Company's office leases generally contain renewal options for periods ranging from <div style="display: inline; font-style: italic; font: inherit;">one</div> to <div style="display: inline; font-style: italic; font: inherit;">five</div> years. Because the Company is <div style="display: inline; font-style: italic; font: inherit;">not</div> reasonably certain to exercise these renewal options, the options are <div style="display: inline; font-style: italic; font: inherit;">not</div> considered in determining the lease term, and payments associated with the option years are excluded from lease payments. The Company's office leases do <div style="display: inline; font-style: italic; font: inherit;">not</div> contain any material residual value guarantees. The Company's equipment leases generally do <div style="display: inline; font-style: italic; font: inherit;">not</div> contain renewal options. The Company is <div style="display: inline; font-style: italic; font: inherit;">not</div> reasonably certain to exercise the renewal options for those equipment leases that do contain renewal options, thus, the options are <div style="display: inline; font-style: italic; font: inherit;">not</div> considered in determining the lease term and payments associated with the option years are excluded from lease payments.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">For the Company's equipment leases, the Company used and will use the implicit rate in the lease as the discount rate, when available. Otherwise, the Company uses its incremental borrowing rate as the discount rate. For the Company's office leases, the implicit rate is typically <div style="display: inline; font-style: italic; font: inherit;">not</div> available, so the Company used and will use its incremental borrowing rate as the discount rate. The incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments. The Company's lease agreements include both lease and non-lease components. The Company elected the practical expedient that allows it to combine lease and non-lease components for all of its leases.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">Payments due under the Company's operating leases include fixed payments as well as variable payments. For the Company's office leases, variable payments include amounts for the Company's proportionate share of operating expenses, utilities, property taxes, insurance, common area maintenance and other facility-related expenses. For the Company's equipment leases, variable payments <div style="display: inline; font-style: italic; font: inherit;"> may </div>consist of sales taxes, property taxes and other fees.</div></div></div></div></div></div></div></div></div></div></div></div></div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 7.5%; margin-left: 7.5%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Operating Leases</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 82%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2021</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,108</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2022</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,045</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2023</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">941</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2024</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">949</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2025</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">914</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Thereafter</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2,253</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total undiscounted lease payments</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">7,210</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less: Imputed interest</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(2,380</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total lease liabilities</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">4,830</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div> 7210000 2253000 1108000 914000 949000 941000 1045000 2380000 P1Y P5Y <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">10.</div></div>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<div style="display: inline; font-weight: bold;">Leases</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">The Company has historically entered into a number of lease agreements under which the Company is the lessee for equipment and office leases. During the year ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020, </div>the Company entered into <div style="display: inline; font-style: italic; font: inherit;">four</div> leases for equipment.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">The components of the Company's lease costs consisted of the following as of <div style="display: inline; font-style: italic; font: inherit;"> December 31 (</div>in thousands):</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 7.5%; margin-left: 7.5%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 64%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating lease cost</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,617</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,948</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Variable lease cost</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">315</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">291</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total lease cost</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,932</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2,239</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table> </div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">Lease costs for the year ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>of approximately <div style="display: inline; font-style: italic; font: inherit;">$1.3</div> million and <div style="display: inline; font-style: italic; font: inherit;">$0.6</div> million, were recorded to G&amp;A expenses and cost of revenues, respectively. Lease costs for the year ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019 </div>of approximately <div style="display: inline; font-style: italic; font: inherit;">$1.2</div> million and <div style="display: inline; font-style: italic; font: inherit;">$1.0</div> million, were recorded to G&amp;A expenses and cost of revenues, respectively.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">Supplemental cash flow information and non-cash activity related to the Company's leases was as follows (in thousands):</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash paid for amounts included in the measurement of lease liabilities and ROU assets:</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Operating cash flow from operating leases</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,603</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,610</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">ROU assets obtained in exchange for lease obligations:</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Operating leases</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">264</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">4,545</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Reductions to ROU assets resulting from reductions to lease obligations:</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Operating leases</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">22</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table> </div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">Weighted average remaining lease terms and discount rates for the Company's leases as of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019 </div>are as follows:</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 7.5%; margin-left: 7.5%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Years</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Years</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 64%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average remaining lease term:</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Operating leases</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7.4</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Rate</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Rate</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average discount rate:</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Operating leases</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7.8</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7.7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> </tr> </table> </div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">Future maturities of lease liabilities as of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>are as follows (in thousands):</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 7.5%; margin-left: 7.5%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Operating Leases</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 82%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2021</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,108</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2022</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,045</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2023</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">941</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2024</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">949</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2025</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">914</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Thereafter</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2,253</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total undiscounted lease payments</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">7,210</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less: Imputed interest</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(2,380</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Total lease liabilities</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">4,830</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table> </div></div> 800000 1750000 56239000 56890000 96991000 79224000 22997000 21847000 800000 900000 11750000 11750000 8000000 2000000 11800000 11800000 75000000 7000000 10788000 9850000 21900000 6000000 10000000 21920000 947000 38801000 27687000 7600000 1574000 1599000 38377000 4615000 5768000 1600000 1600000 2500000 79000 725000 652000 9423000 8082000 4615000 1600000 2500000 725000 9423000 8075000 1200000 3500000 12760000 4615000 1600000 2000000 8198000 4615000 1600000 2000000 222000 8420000 17305000 21919000 4400000 6000000 7500000 1495000 222000 947000 29378000 30295000 -1117000 4097000 -12162000 -19643000 20280000 13875000 17332000 1361000 1361000 17332000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Recent Accounting Pronouncements and Developments</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">In <div style="display: inline; font-style: italic; font: inherit;"> June 2016, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font: inherit;">No.</div> <div style="display: inline; font-style: italic; font: inherit;">2016</div>-<div style="display: inline; font-style: italic; font: inherit;">13,</div> &#x201c;Financial Instruments (Topic <div style="display: inline; font-style: italic; font: inherit;">326</div>) Credit Losses&#x201d;. Topic <div style="display: inline; font-style: italic; font: inherit;">326</div> changes the impairment model for most financial assets and certain other instruments. Under the new standard, entities holding financial assets and net investment in leases that are <div style="display: inline; font-style: italic; font: inherit;">not</div> accounted for at fair value through net income are to be presented at the net amount expected to be collected. An allowance for credit losses will be a valuation account that will be deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected on the financial asset. Topic <div style="display: inline; font-style: italic; font: inherit;">326</div> was originally effective as of <div style="display: inline; font-style: italic; font: inherit;"> January 1, 2020, </div>although in <div style="display: inline; font-style: italic; font: inherit;"> November 2019, </div>the FASB delayed the effective date until fiscal years beginning after <div style="display: inline; font-style: italic; font: inherit;"> December 15, 2022 </div>for SEC filers eligible to be smaller reporting companies under the SEC's definition. The Company qualifies as a smaller reporting company under the SEC's definition. Early adoption is permitted. The Company is currently evaluating the impact of Topic <div style="display: inline; font-style: italic; font: inherit;">326</div> on its consolidated balance sheets, statements of operations, statements of cash flows and related disclosures.</div></div></div></div></div></div></div></div></div></div></div></div></div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 54pt; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">average</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">grant</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Number of</div></div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">date fair</div></div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Aggregate</div></div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">shares</div></div> </div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">value</div></div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">fair value</div></div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unvested at December 31, 2018</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">129,583</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1.42</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">26,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7.04</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Vested</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(58,314</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3.17</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">712,969</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Vested shares forgone to satisfy minimum statutory withholding</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(71,269</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3.17</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">422,779</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeitures</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unvested at December 31, 2019</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">26,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7.04</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">156,250</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">10.12</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Vested</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(28,432</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">9.28</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">367,273</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Vested shares forgone to satisfy minimum statutory withholding</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(6,818</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">9.28</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">62,479</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeitures</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(2,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">11.68</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unvested at December 31, 2020</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">145,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">9.78</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> </table></div> 1 2 2 2017 2018 2019 2020 2016 2017 2018 2019 2020 49932000 43357000 49932000 43357000 8827000 3525000 1617000 1948000 4830000 3864000 4644000 1603000 1610000 4461000 5733000 0.078 0.077 P7Y P7Y146D 1200000 1400000 34900000 2402000 1662000 105000 155000 6795000 5803000 -29000 -97000 -29000 -97000 6000 1714000 717000 1094000 2926000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;text-indent:-25pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">13.</div></div>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<div style="display: inline; font-weight: bold;">Employee Benefit Plans and Other</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The Company has a defined contribution plan in which the Company makes discretionary matching contributions for a certain percentage of employee contributions. For the years ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> the Company's matching contributions were <div style="display: inline; font-style: italic; font: inherit;">$0.8</div> million and <div style="display: inline; font-style: italic; font: inherit;">$0.7</div> million, respectively. The Company does <div style="display: inline; font-style: italic; font: inherit;">not</div> provide other post-retirement or post-employment benefits to its employees. As of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> accrued payroll liabilities included in Other current liabilities were <div style="display: inline; font-style: italic; font: inherit;">$2.8</div> million and <div style="display: inline; font-style: italic; font: inherit;">$3.5</div> million, respectively.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div></div> 0.0001 0.0001 1000000 1000000 0 0 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Reclassifications</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">Certain prior period reclassifications were made to conform with the current period presentation. These reclassifications had <div style="display: inline; font-style: italic; font: inherit;">no</div> effect on reported income (loss), overall cash flows, total assets, total liabilities or stockholders' equity as previously reported.</div></div></div></div></div></div></div></div></div></div></div></div></div></div> 4100000 30000000 37587000 9436000 4752000 2952000 190000 252000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">5.</div></div>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<div style="display: inline; font-weight: bold;">Property and Equipment</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">Property and equipment consisted of the following as of <div style="display: inline; font-style: italic; font: inherit;"> December&nbsp;</div><div style="display: inline; font-style: italic; font: inherit;">31</div> (in thousands):</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Gross Assets</div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Accumulated</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Depreciation</div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Total</div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 43%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Furniture, fixtures, and equipment</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3,742</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(2,018</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,724</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Automobiles</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">117</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(102</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">15</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Leasehold improvements</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3,416</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(859</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">2,557</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">7,275</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(2,979</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">4,296</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table> </div> <div style=" margin: 0; font-family: &quot;Times New Roman&quot;; font-size: 10pt">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Gross Assets</div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Accumulated</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Depreciation</div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Total</div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 43%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Furniture, fixtures, and equipment</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3,202</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(1,928</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,274</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Automobiles</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">117</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(90</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">27</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Leasehold improvements</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3,366</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(630</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">2,736</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">6,685</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(2,648</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">4,037</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table> </div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">Depreciation expense for property and equipment for each of the years ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019</div> was <div style="display: inline; font-style: italic; font: inherit;">$0.8</div> million and <div style="display: inline; font-style: italic; font: inherit;">$0.5</div> million, respectively. This expense was recorded in &#x201c;general and administrative expenses&#x201d; for each period.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div></div> 3742000 117000 3416000 7275000 3202000 117000 3366000 6685000 1724000 15000 2557000 4296000 1274000 27000 2736000 4037000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Property and Equipment</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">Property and equipment is stated at acquired cost and depreciated using the straight-line method over the estimated useful lives of the related assets, ranging from <div style="display: inline; font-style: italic; font: inherit;">three</div> to <div style="display: inline; font-style: italic; font: inherit;">seven</div> years. Externally purchased information technology software and hardware are depreciated over <div style="display: inline; font-style: italic; font: inherit;">three</div> and <div style="display: inline; font-style: italic; font: inherit;">five</div> years, respectively. Leasehold improvements are amortized using the straight-line method over the life of the asset or the remaining term of the lease, whichever is shorter. Maintenance and minor repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is recorded in the current period.</div></div></div></div></div></div></div></div></div></div></div></div></div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Gross Assets</div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Accumulated</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Depreciation</div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Total</div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 43%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Furniture, fixtures, and equipment</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3,742</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(2,018</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,724</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Automobiles</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">117</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(102</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">15</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Leasehold improvements</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3,416</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(859</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">2,557</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">7,275</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(2,979</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">4,296</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Gross Assets</div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Accumulated</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">Depreciation</div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Total</div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 43%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Furniture, fixtures, and equipment</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">3,202</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(1,928</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,274</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Automobiles</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">117</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(90</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">27</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Leasehold improvements</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3,366</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(630</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">2,736</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">6,685</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(2,648</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">4,037</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div> P3Y P7Y P3Y P5Y P3Y P5Y 791000 37000 4100000 37180000 4868000 8200000 1687000 190000 -44035000 -61367000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Revenue Recognition</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">Revenue is recognized at the time and in an amount that reflects the consideration expected to be received for the performance obligations that have been provided. Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic <div style="display: inline; font-style: italic; font: inherit;">606</div> &#x2013; Revenue from Contracts with Customers (&#x201c;ASC <div style="display: inline; font-style: italic; font: inherit;">606&#x201d;</div>) defines contracts as written, oral and through customary business practice. Under this definition, the Company considers contracts to be created at the time that the rental service is authorized or an order to purchase product is agreed upon regardless of whether or <div style="display: inline; font-style: italic; font: inherit;">not</div> there is a written contract.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The Company has <div style="display: inline; font-style: italic; font: inherit;">two</div> separate and distinct performance obligations offered to its customers: a rental service performance obligation or a product sale performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is defined as the unit of account for revenue recognition under ASC <div style="display: inline; font-style: italic; font: inherit;">606.</div> These performance obligations are related to separate revenue streams and at <div style="display: inline; font-style: italic; font: inherit;">no</div> point are they combined into a single transaction. Sources of net revenues include commercial insurance payers, government insurance payers, medical facilities and patients.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The Company generates the majority of its revenue from the rental of infusion pumps to its customers and a minority of its revenue from product sales. For the rental service performance obligation, revenue is based on its standalone price, determined by using reimbursement rates established by <div style="display: inline; font-style: italic; font: inherit;">third</div>-party payer or other contracts. Revenue is recognized in the period in which the related performance obligation is satisfied, which is typically at the point in time that a patient concludes a treatment, or in certain arrangements, based on the number of pumps that a facility has onsite. The Company's revenues related to product sales are recognized at the time that control of the product has been transferred to the customer; either at the time the product is shipped or the time the product has been received by the customer, depending on the delivery terms. The Company does <div style="display: inline; font-style: italic; font: inherit;">not</div> commit to long-term contracts to sell customers a certain minimum quantity of products.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The Company employs certain significant judgments to estimate the dollar amount of revenue, and related concessions, allocated to the rental service and sale of products. These judgments include, among others, the estimation of variable consideration. Variable consideration, specifically related to the Company's <div style="display: inline; font-style: italic; font: inherit;">third</div>-party payer rental revenues, is estimated as implied price concessions resulting from differences between the rates charged for services performed and the expected reimbursements for commercial payers and other implied customer concessions. The estimates for variable consideration are based on historical collections with similar payers, aged accounts receivable by payer class and payer correspondence using the portfolio approach, which provide a reasonable basis for estimating the variable portion of a transaction. The Company doesn't believe it is probable that a significant reversal of revenue will occur in future periods because (i) there is <div style="display: inline; font-style: italic; font: inherit;">no</div> significant uncertainty about the amount of considerations that are expected to be collected based on collection history and (ii) the large number of sufficiently similar contracts allows the Company to adequately estimate the component of variable consideration.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">Net revenues are adjusted when changes in estimates of variable consideration occur. Changes in estimates typically arise as a result of new information obtained, such as actual payment receipt or denial, or pricing adjustments by payers. Subsequent changes to estimates of transaction prices are recorded as adjustments to net revenue in the period of the change. Subsequent changes that are determined to be the result of an adverse change in the payer's ability to pay are recorded as an allowance for doubtful accounts.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenues and accounts receivable at their net realizable values. Inherent in these estimates is the risk that the estimates will have to be revised or updated as additional information becomes available. Specifically, the complexity of many <div style="display: inline; font-style: italic; font: inherit;">third</div>-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payers <div style="display: inline; font-style: italic; font: inherit;"> may </div>result in adjustments to amounts originally recorded. Due to continuing changes in the health care industry and <div style="display: inline; font-style: italic; font: inherit;">third</div>-party reimbursement, it is possible that management's estimates could change in the near term, which could have a material impact on the Company's results of operations and cash flows.</div></div></div></div></div></div></div></div></div></div></div></div></div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;text-indent:-25pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">3.</div></div>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<div style="display: inline; font-weight: bold;">Revenue Recognition</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The following table presents the Company's disaggregated revenue by offering type as of <div style="display: inline; font-style: italic; font: inherit;"> December 31 (</div>in thousands):</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 7.5%; margin-left: 7.5%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 64%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Third-Party Payer Rentals</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">49,266</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">40,510</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Direct Payer Rentals</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">30,765</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">26,269</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Product Sales</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">17,357</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">14,336</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total - Net revenues</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">97,388</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">81,115</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table> </div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">Third-Party Payer Rentals are entirely attributed to revenues of the ITS segment. Product Sales are entirely attributed to revenues of the DME Services segment. For the year ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020, </div><div style="display: inline; font-style: italic; font: inherit;">$11.8</div> million and <div style="display: inline; font-style: italic; font: inherit;">$19.0</div> million of Direct Payer Rentals were attributed to the ITS and DME Services segments, respectively. For the year ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019, </div><div style="display: inline; font-style: italic; font: inherit;">$11.0</div> million and <div style="display: inline; font-style: italic; font: inherit;">$15.3</div> million were attributed to the ITS and DME Services segments, respectively.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The following table presents the Company's disaggregated revenue by offering type as a percentage of total net revenues as of <div style="display: inline; font-style: italic; font: inherit;"> December 31:</div></div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 7.5%; margin-left: 7.5%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 64%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Third-Party Payer Rentals</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">50.6</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">49.9</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Direct Payer Rentals</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">31.6</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">32.4</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Product Sales</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">17.8</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">17.7</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total - Net revenues</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">100.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">100.0</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td> </tr> </table> </div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div></div> 11800000 19000000 11000000 15300000 49266000 40510000 30765000 26269000 17357000 14336000 97388000 81115000 61072000 41686000 -5370000 51540000 33363000 -3788000 264000 4545000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; margin-left: 5%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 66%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">U.S Federal income tax benefit&nbsp;(expense)</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Current</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(11</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Deferred</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">8,346</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(104</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">Total U.S. Federal income tax benefit (expense)</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">8,335</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(104</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">State and local income tax benefit&nbsp;(expense)</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Current</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(66</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(29</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Deferred</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,725</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">Total state and local income tax benefit (expense)</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,659</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(29</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Foreign income tax expense</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Current</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(205</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(30</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">Total income tax benefit (expense)</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">9,789</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(163</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0pt" cellspacing="0pt" style="margin-right: 7.5%; margin-left: 7.5%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 28%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 25%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2020</div></div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 25%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31, 2019</div></div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 28%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Current </div></div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Portion</div> </div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Long-Term </div></div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Portion</div></div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Total</div></div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Current </div></div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Portion</div></div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Long-Term </div></div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Portion</div></div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Total</div></div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 28%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Term Loan</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">4,615</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">17,305</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">21,920</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">5,768</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">21,919</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">27,687</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 28%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Equipment Line</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,600</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">4,400</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,600</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">6,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7,600</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 28%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2019 Equipment Line</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">7,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">10,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">79</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,495</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">1,574</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 28%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unamortized value of debt issuance costs</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(17</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(49</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(66</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(17</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(66</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(83</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 28%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other financing</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">725</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">222</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">947</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">652</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">947</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,599</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 28%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">9,423</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">29,378</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">38,801</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">8,082</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">30,295</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">38,377</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 7.5%; margin-left: 7.5%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 64%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred Federal tax assets &#x2013;</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Bad debt reserves</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,570</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,459</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Stock-based compensation</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">656</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">443</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Net operating loss</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">7,337</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">7,991</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Operating lease liabilities</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,014</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,271</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Accrued compensation</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">757</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">451</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Inventories</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">214</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">27</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Goodwill and intangible assets</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">832</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,688</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Research &amp; development credits</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">533</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">533</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Other credits</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">30</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">25</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Other</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">54</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">194</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">Total deferred Federal tax assets</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">12,997</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">14,082</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Less: valuation allowance</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(9,553</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">Net deferred Federal tax assets</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">12,997</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">4,529</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred Federal tax liabilities &#x2013;</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Depreciation and asset basis differences</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(3,393</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(3,366</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Right-of-use assets</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(937</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(1,204</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">Total deferred Federal tax liabilities</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(4,330</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(4,570</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net deferred Federal tax assets (liabilities)</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">8,667</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(41</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total deferred state and local tax assets (a)</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,300</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,634</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less: valuation allowance</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(1,697</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net deferred state and local tax assets (liabilities)</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,300</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(63</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net deferred tax assets (liabilities)</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">9,967</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(104</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 15%; margin-left: 72pt; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 64%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Numerator:</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Net income <div style="display: inline; font-style: italic;">(in thousands)</div></div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">17,332</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,361</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Denominator:</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Weighted average common shares outstanding:</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Basic</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">20,106,940</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">19,731,498</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Dilutive effect of restricted shares and options</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,610,276</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,107,898</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Diluted</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">21,717,216</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">20,839,396</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 60%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 2%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 2%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 60%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Income tax expense at the statutory rate</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">21.0</div></td> <td nowrap="nowrap" style="width: 2%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">21.0</div></td> <td nowrap="nowrap" style="width: 2%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 60%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">State and local income tax expense</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">5.1</div></td> <td nowrap="nowrap" style="width: 2%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2.0</div></td> <td nowrap="nowrap" style="width: 2%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 60%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Foreign income tax</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">0.2</div></td> <td nowrap="nowrap" style="width: 2%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2.0</div></td> <td nowrap="nowrap" style="width: 2%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 60%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Permanent differences</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(8.4</div></td> <td nowrap="nowrap" style="width: 2%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(5.8</div></td> <td nowrap="nowrap" style="width: 2%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 60%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Decrease in valuation allowance</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(149.2</div></td> <td nowrap="nowrap" style="width: 2%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">(7.9</div></td> <td nowrap="nowrap" style="width: 2%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 60%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other adjustments</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1.5</div></td> <td nowrap="nowrap" style="width: 2%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(0.6</div></td> <td nowrap="nowrap" style="width: 2%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 60%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Effective income tax rate</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(129.8</div></td> <td nowrap="nowrap" style="width: 2%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">10.7</div></td> <td nowrap="nowrap" style="width: 2%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">%</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Restricted share expense</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,687</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">190</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock option and SARs expense</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">923</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">807</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total stock-based compensation expense</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">2,610</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">997</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">U.S income</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">6,623</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,413</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Non-U.S. income</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">920</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">111</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Income before income taxes</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">7,543</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,524</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">December 31,</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Revolver:</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Gross availability</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">11,750</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">11,750</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Outstanding draws</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Letters of credit</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(800</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(1,750</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Landlord reserves</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(162</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(150</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Availability on Revolver</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">10,788</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">9,850</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table cellpadding="0pt" cellspacing="0pt" style="margin-right: 5%; margin-left: 5%; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 22%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2021</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2022</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2023</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2024</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2025 and </div></div></div> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">thereafter</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Total</div></div></div> </td> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 22%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Term Loan</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">4,615</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">4,615</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">4,615</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">8,075</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">21,920</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 22%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Equipment Line</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,600</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,600</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,600</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,200</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">6,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 22%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2019 Equipment Line</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">3,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">10,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 22%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unamortized value of debt issuance costs</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(17</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(17</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(17</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(15</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(66</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 22%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other financing</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">725</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">222</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">947</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 22%;"> <div style=" font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</div> </td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">9,423</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">8,420</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">8,198</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">12,760</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">38,801</div></td> <td nowrap="nowrap" style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 54pt; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted-</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Average</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Number</div></div> </div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Weighted-</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Remaining</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Aggregate</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">of Authorized</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Average Exercise</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Contractual</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Intrinsic</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 44%; border-bottom: 1px solid black;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">2014 Plan (Options)</div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Shares</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Price</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Term (in Years)</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Value</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2018</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2,224,167</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2.67</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">3.01</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">670,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">3.77</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">4.40</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(213,056</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2.33</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">624,462</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised shares forgone to satisfy minimum statutory withholding</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(51,339</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2.33</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cashless exercise</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(184,493</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2.33</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(101,946</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3.63</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2019</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2,343,333</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2.99</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1.81</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">12,989,767</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at December 31, 2019</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,501,750</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2.69</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">331,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">10.38</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">8.59</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(334,184</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2.77</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">3,135,211</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised shares forgone to satisfy minimum statutory withholding</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(125,714</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2.77</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cashless exercise</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(164,751</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2.77</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(90,336</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">3.96</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2020</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,959,348</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">4.26</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">4.42</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">28,449,362</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at December 31, 2020</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,362,932</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">3.33</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 54pt; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted-</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Average</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Number</div></div> </div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Weighted-</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Remaining</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Aggregate</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 44%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">Inducement</div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">of Authorized</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Average Exercise</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Contractual</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Intrinsic</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: center;"><div style="display: inline; font-weight: bold;">Options</div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Shares</div> <div style="display: inline; font-weight: bold;"> ( 1 )</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Price</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Term (in Years)</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Value</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2018</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">125,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2.55</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">5.42</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">111,250</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2019</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">125,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2.55</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">4.42</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">747,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(27,940</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2.55</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">242,519</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercised shares forgone to satisfy minimum statutory withholding</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(12,417</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2.55</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cashless exercise</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(14,330</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2.55</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(70,313</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">2.55</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2020</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at December 31, 2020</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 2.5%; margin-left: 2.5%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">2020</div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Corporate/</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">(in thousands)</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">ITS</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">DME Services</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Eliminations</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Total</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net revenues - external</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">61,072</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">36,316</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">97,388</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net revenues - internal</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">5,370</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(5,370</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total net revenues</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">61,072</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">41,686</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(5,370</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">97,388</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Gross profit</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">39,773</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">18,986</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">58,759</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Selling , general and administrative expenses</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">49,932</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">49,932</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Interest expense</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(1,255</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(1,255</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other expense</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(29</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(29</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Benefit from income taxes</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">9,789</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">9,789</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">17,332</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total assets</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">68,472</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">26,519</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">96,991</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Purchases of medical equipment</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">9,583</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">6,237</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">15,820</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Depreciation and amortization of intangible assets</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">10,708</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">3,317</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">14,025</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table></div><div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 2.5%; margin-left: 2.5%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">2019</div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Corporate/</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">(in thousands)</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">ITS</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">DME Services</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Eliminations</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Total</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net revenues - external</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">51,540</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">29,575</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">81,115</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net revenues - internal</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">3,788</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(3,788</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total net revenues</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">51,540</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">33,363</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(3,788</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">81,115</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Gross profit</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">33,063</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">13,819</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">46,882</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Selling, general and administrative expenses</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">43,357</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">43,357</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Interest expense</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(1,904</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(1,904</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other expense</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(97</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(97</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Provision for income taxes</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(163</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(163</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,361</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total assets</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">54,292</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">22,932</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">79,224</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Purchases of medical equipment</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">14,216</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">5,453</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">19,669</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Depreciation and amortization of intangible assets</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">9,457</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2,885</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">12,342</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Compensation expense</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">108,589</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">43,030</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Shares of stock sold to employees</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">30,012</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">33,742</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average fair value per ESPP award</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">7.43</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">3.94</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 4%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 35%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="10" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 25%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Options Outstanding</div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 13%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Options Exercisable</div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="3" rowspan="1" style="font-family: Times New Roman; font-size: 10pt; width: 4%; border-bottom: 1px solid black;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2014 Plan (Options):</div> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 9%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td colspan="3" rowspan="1" style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black; width: 4%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Range of Exercise Prices</div> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Number of Shares Outstanding</div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Weighted-Average Remaining Contractual Life</div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Weighted-Average Exercise Price</div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Number of Shares Exercisable</div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Weighted-Average Exercise Price</div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="width: 4%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 35%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 9%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 9%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 9%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 9%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 9%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 4%;">$2.01</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 35%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">$3.00</div></div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">870,011</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">3.20</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2.26</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">784,178</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2.26</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 4%;">$3.01</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 35%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">$4.00</div></div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">423,336</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2.74</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">3.23</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">301,669</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">3.21</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 4%;">$4.01</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 35%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">$5.00</div></div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">335,001</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">5.60</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">4.70</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">198,335</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">4.70</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 4%;">$6.01</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 35%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">$7.00</div></div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">50,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">4.21</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">6.82</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 4%;">$8.01</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 35%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">$9.00</div></div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">20,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">9.02</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">8.55</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 4%;">$11.01</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 35%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">$12.00</div></div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">245,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">9.38</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">11.07</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">78,750</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">11.07</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 4%;">$13.01</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td style="font-family: Times New Roman; font-size: 10pt; width: 35%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">$14.00</div></div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">16,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">9.62</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">13.30</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="width: 4%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 35%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); width: 9%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); width: 9%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); width: 9%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); width: 9%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&nbsp;</td> <td style="border-bottom: 1px solid rgb(0, 0, 0); width: 9%;">&nbsp;</td> <td style="padding-bottom: 1px; width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td colspan="3" rowspan="1" style="font-family: Times New Roman; font-size: 10pt; width: 4%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">Outstanding at December 31, 2020</div></div></div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,959,348</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">4.42</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">4.26</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,362,932</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">3.33</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; margin-left: 5%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 64%; border-bottom: 1px solid black;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock Options:</div> </td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&nbsp;</td> <td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 10%;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 64%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Expected volatility</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: Times New Roman; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;42%</div></td> <td style="width: 4%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">to</div></td> <td style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">51%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: Times New Roman; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;36%</div></td> <td style="width: 4%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">to</div></td> <td style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;38%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 64%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Risk free interest rate</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: Times New Roman; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;0.20%</div></td> <td style="width: 4%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">to</div></td> <td style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;1.56%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: Times New Roman; font-size: 10pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;1.80%</div></td> <td style="width: 4%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">to</div></td> <td style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">2.36%</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 64%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Expected lives at date of grant (in years)</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="width: 4%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">3.25</div></td> <td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="width: 4%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">4.63</div></td> <td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 64%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Weighted average fair value of options granted</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="width: 4%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">$3.87</div></td> <td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 6%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="width: 4%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><div style="display: inline; font-style: italic; font: inherit;">$1.61</div></td> <td style="width: 6%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 5%; margin-left: 5%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2021</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2022</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2023</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2024</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2025</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2026 and </div></div></div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">thereafter</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 16%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Amortization expense</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">3,930</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2,051</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">548</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">548</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">367</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 11%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,733</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;text-indent:-25pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">12.</div></div>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<div style="display: inline; font-weight: bold;">Business Segment Information</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:34pt;">During the <div style="display: inline; font-style: italic; font: inherit;">fourth</div> quarter of <div style="display: inline; font-style: italic; font: inherit;">2019,</div> the Company reorganized its segment reporting from <div style="display: inline; font-style: italic; font: inherit;">one</div> reportable segment to <div style="display: inline; font-style: italic; font: inherit;">two</div> reportable segments, ITS and DME Services, due to changes in the Company's internal reporting and the information evaluated by its chief operating decision-maker. The Company's reportable segments are organized based on service platforms, with the ITS segment reflecting higher margin rental revenues that generally include payments made by <div style="display: inline; font-style: italic; font: inherit;">third</div>-party and direct payers and the DME Services segment reflecting lower margin product sales and direct payer rental revenues. Resources are allocated and performance is assessed for these segments by the Company's Chief Executive Officer, whom the Company has determined to be its chief operating decision-maker. The Company believes that reporting performance at the gross profit level is the best indicator of segment performance.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">The financial information summarized below is presented by reportable segment:</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 2.5%; margin-left: 2.5%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">2020</div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Corporate/</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid black;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">(in thousands)</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">ITS</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">DME Services</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Eliminations</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Total</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net revenues - external</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">61,072</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">36,316</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">97,388</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net revenues - internal</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">5,370</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(5,370</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total net revenues</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">61,072</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">41,686</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(5,370</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">97,388</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Gross profit</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">39,773</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">18,986</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">58,759</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Selling , general and administrative expenses</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">49,932</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">49,932</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Interest expense</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(1,255</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(1,255</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other expense</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(29</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(29</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Benefit from income taxes</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">9,789</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">9,789</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">17,332</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total assets</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">68,472</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">26,519</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">96,991</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Purchases of medical equipment</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">9,583</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">6,237</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">15,820</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Depreciation and amortization of intangible assets</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">10,708</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">3,317</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">14,025</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table> </div> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</div> <div style=" margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 2.5%; margin-left: 2.5%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;">2019</div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Corporate/</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: thin solid rgb(0, 0, 0);"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic;">(in thousands)</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">ITS</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">DME Services</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Eliminations</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Total</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net revenues - external</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">51,540</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">29,575</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">81,115</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net revenues - internal</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">3,788</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(3,788</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total net revenues</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">51,540</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">33,363</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(3,788</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">81,115</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Gross profit</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">33,063</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">13,819</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">46,882</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Selling, general and administrative expenses</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">43,357</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">43,357</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Interest expense</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(1,904</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(1,904</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other expense</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(97</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(97</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Provision for income taxes</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(163</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">(163</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net income</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,361</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total assets</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">54,292</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">22,932</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2,000</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">79,224</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Purchases of medical equipment</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">14,216</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">5,453</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">19,669</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Depreciation and amortization of intangible assets</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">9,457</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">2,885</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">12,342</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> </table> </div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;">The presentation of gross profit above was revised from the <div style="display: inline; font-style: italic; font: inherit;">2019</div> Consolidated Financial Statements to include inter-segment revenues in the DME Services segment column from the prior presentation within the Corporate/Eliminations column. This revision is considered immaterial to the prior period based on the Company's assessment.</div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Segments</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">During the <div style="display: inline; font-style: italic; font: inherit;">fourth</div> quarter of <div style="display: inline; font-style: italic; font: inherit;">2019,</div> the Company reorganized its segment reporting from <div style="display: inline; font-style: italic; font: inherit;">one</div> reportable segment to <div style="display: inline; font-style: italic; font: inherit;">two</div> reportable segments, Integrated Therapy Services (&#x201c;ITS&#x201d;) and Durable Medical Equipment Services (&#x201c;DME Services&#x201d;), due to changes in our internal reporting and the information evaluated by our chief operating decision-maker. See Note <div style="display: inline; font-style: italic; font: inherit;">12</div> for segment disclosures.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The Company's approach is to make operational decisions and assess performance based on delivering products and services that together provide solutions to its customer base utilizing a functional management structure. Based upon this business model, the Company's Chief Executive Officer, whom the Company has determined to be its chief operating decision-maker, reviews segment financial information.</div></div></div></div></div></div></div></div></div></div></div></div></div></div> 9661000 9932000 2610000 997000 P3Y P3Y P1Y P1Y 2000 11.68 156250 100000 232500 0 26000 7.04 10.12 9.06 129583 26000 145000 232500 1.42 7.04 9.78 9.06 58314 28432 712969 367273 3.17 9.28 3.87 1.61 0.42 0.51 0.36 0.38 0.002 0.0156 0.018 0.0236 1000000 1000000 350000 2000000 400000 1501750 1362932 2.69 3.33 51339 125714 101946 90336 70313 300000 100000 700000 100000 670000 331000 12989767 28449362 111250 747500 2224167 2343333 1959348 125000 125000 2.67 2.99 4.26 2.55 2.55 2.33 2.77 2.33 2.77 3.63 3.96 3.77 10.38 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Share-Based Payments</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The Company determines the fair value of stock option awards, restricted stock awards and stock appreciation rights (collectively, &#x201c;Share-Based Awards&#x201d;) on the date of grant using option-pricing models which are affected by the Company's stock price, as well as assumptions regarding a number of other inputs using the Black-Scholes pricing model. These variables include the Company's expected stock price volatility over the expected term of the Share-Based Awards, actual and projected employee stock option exercise behaviors, risk-free interest rates and expected dividends. The expected volatility is based on the historical volatility. The Company uses historical data to estimate Share-Based Awards exercise rates. The expected term represents the period over which the Share-Based Awards are expected to be outstanding. The dividend yield is an estimate of the expected dividend yield on the Company's stock. The risk-free rate is based on U.S. Treasury yields in effect at the time of the grant for the expected term of the Share-Based Awards. All Share-Based Awards are amortized based on their graded vesting over the requisite service period of the awards. Compensation costs are recognized over the requisite service period using the accelerated method and included in general and administrative expenses.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">Additionally, the Company also determines the fair value of performance-based restricted stock units (&#x201c;PSUs&#x201d;) based upon the type of performance measure. These awards typically vest after the Company's achievement of either Company performance relative to specified performance measure goals for a specific fiscal period or when the market value of the Company's stock price reaches a target value for a minimum number of consecutive trading days. Under Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC Topic <div style="display: inline; font-style: italic; font: inherit;">718,</div> the provisions of the PSUs that vest upon achievement of a target market value are considered a market condition, and therefore the effect of that market condition is reflected in the grant date fair value for this type of award. A <div style="display: inline; font-style: italic; font: inherit;">third</div>-party valuation expert was engaged to complete a &#x201c;Monte Carlo simulation&#x201d; to account for the market condition. That simulation takes into account the beginning stock price of the Company's common stock, the expected volatilities for the Company's stock price and the expected risk-free rate of return. The single grant-date fair value computed by this valuation method is recognized by the Company in accounting for the awards regardless of the actual future outcome of the market condition. The grant date fair value of the other PSUs is calculated as the closing price of the Company's common stock on the grant date multiplied by the number of shares subject to the award. Company performance measure goals are considered a performance condition and the grant-date fair value for those PSUs corresponds with management's expectation of the probable outcome of the performance conditions as of the grant date.</div></div></div></div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 54pt; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">Weighted</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">average</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">grant</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Number of</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">date fair</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">Aggregate</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">shares</div></div> </div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">value</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">fair value</div></div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom;"> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 49%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unvested at December 31, 2019</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 1%;">&nbsp;</td> <td style="width: 14%; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td nowrap="nowrap" style="width: 1%; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">232,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">9.06</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unvested at December 31, 2020</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">232,500</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">9.06</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; font-style: italic; font: inherit;">&nbsp;</div></td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&nbsp;</td> </tr> </table></div> 2.01 3.01 4.01 6.01 8.01 11.01 13.01 784178 301669 198335 78750 1362932 870011 423336 335001 50000 20000 245000 16000 1959348 3 4 5 7 9 12 14 P5Y P10Y P3Y91D P4Y229D P3Y3D P1Y295D P4Y153D P5Y153D P4Y153D 2.26 3.21 4.70 11.07 3.33 2.26 3.23 4.70 6.82 8.55 11.07 13.30 4.26 P3Y73D P2Y270D P5Y219D P4Y76D P9Y7D P9Y138D P9Y226D P4Y153D 23096000 -3518000 23401000 -3518000 23816000 -3518000 100000 100000 122000 147000 12417 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:-27pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">2.</div></div>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<div style="display: inline; font-weight: bold;">Summary of Significant Accounting Policies</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Reclassifications</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">Certain prior period reclassifications were made to conform with the current period presentation. These reclassifications had <div style="display: inline; font-style: italic; font: inherit;">no</div> effect on reported income (loss), overall cash flows, total assets, total liabilities or stockholders' equity as previously reported.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Presentation in the Consolidated Statements</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">The Company rents and sells medical equipment. The Company purchases medical equipment directly for sale as well as medical equipment that is purchased for either rental or sale and that is unallocated at the time of purchase (&#x201c;Unallocated Assets&#x201d;). Management believes that the predominant source of revenues and cash flows from the Unallocated Assets is from rentals and most equipment purchased is likely to be rented prior to being sold. The Company concluded that (i) the assets specifically supporting its <div style="display: inline; font-style: italic; font: inherit;">two</div> primary revenue streams should be separately disclosed on the balance sheet; (ii) the purchase and sale of Unallocated Assets should be classified solely in investing cash flows based on their predominant source while medical equipment purchased specifically for sales activity should be classified in operating cash flows; and (iii) other activities ancillary to the rental process should be consistently classified.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Principles of Consolidation</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The consolidated financial statements include the accounts of the Company and all wholly owned organizations. All intercompany transactions and account balances have been eliminated in consolidation.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Segments</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">During the <div style="display: inline; font-style: italic; font: inherit;">fourth</div> quarter of <div style="display: inline; font-style: italic; font: inherit;">2019,</div> the Company reorganized its segment reporting from <div style="display: inline; font-style: italic; font: inherit;">one</div> reportable segment to <div style="display: inline; font-style: italic; font: inherit;">two</div> reportable segments, Integrated Therapy Services (&#x201c;ITS&#x201d;) and Durable Medical Equipment Services (&#x201c;DME Services&#x201d;), due to changes in our internal reporting and the information evaluated by our chief operating decision-maker. See Note <div style="display: inline; font-style: italic; font: inherit;">12</div> for segment disclosures.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The Company's approach is to make operational decisions and assess performance based on delivering products and services that together provide solutions to its customer base utilizing a functional management structure. Based upon this business model, the Company's Chief Executive Officer, whom the Company has determined to be its chief operating decision-maker, reviews segment financial information.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements, including the notes thereto. The Company considers critical accounting policies to be those that require more significant judgments and estimates in the preparation of its consolidated financial statements, including the following: revenue recognition, leases, accounts receivable and allowance for doubtful accounts, income taxes, and long-lived asset valuations. Management relies on historical experience and other assumptions believed to be reasonable in making its judgments and estimates. Actual results could differ materially from those estimates.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Business Combinations</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The Company accounts for all business combinations using the acquisition method of accounting, which allocates the fair value of the purchase consideration to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values. The excess of the purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. When determining the fair values of assets acquired and liabilities assumed, management makes significant estimates and assumptions. The Company <div style="display: inline; font-style: italic; font: inherit;"> may </div>utilize <div style="display: inline; font-style: italic; font: inherit;">third</div>-party valuation specialists to assist the Company in the allocation. Initial purchase price allocations are subject to revision within the measurement period, <div style="display: inline; font-style: italic; font: inherit;">not</div> to exceed <div style="display: inline; font-style: italic; font: inherit;">one</div> year from the date of acquisition. Acquisition-related expenses and transaction costs associated with business combinations are expensed as incurred.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Cash and Cash Equivalents</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The Company considers all highly liquid investments with original maturities of <div style="display: inline; font-style: italic; font: inherit;">three</div> months or less to be cash equivalents. The Company maintains its cash and cash equivalents primarily with <div style="display: inline; font-style: italic; font: inherit;">two</div> financial institutions that are insured with the Federal Deposit Insurance Corporation (&#x201c;FDIC&#x201d;). At times throughout the year, cash and cash equivalents balances might exceed FDIC insurance limits.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Accounts Receivable and Allowance for Doubtful Accounts</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">Amounts billed that have <div style="display: inline; font-style: italic; font: inherit;">not</div> yet been collected that also meet the conditions for unconditional right to payment are presented as accounts receivable. Accounts receivable related to rental service and delivery of products are reported at their estimated transaction prices, inclusive of adjustments for variable consideration, based on the amounts expected to be collected from payers. The Company writes off accounts receivable once collection efforts have been exhausted and an account is deemed to be uncollectible. An allowance for doubtful accounts is established as a result of an adverse change in the Company's payers' ability to pay outstanding billings. The allowance for doubtful accounts was <div style="display: inline; font-style: italic; font: inherit;">$1.0</div> million and <div style="display: inline; font-style: italic; font: inherit;">$0.4</div> million as of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> respectively.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Inventories</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The Company's inventories consist of disposable medical supplies, replacement parts and other supplies used in conjunction with medical equipment and are stated at the lower of cost (<div style="display: inline; font-style: italic; font: inherit;">first</div>-in, <div style="display: inline; font-style: italic; font: inherit;">first</div>-out basis) or net realizable value. The Company periodically performs an analysis of slow-moving inventory and records a reserve based on estimated obsolete inventory, which was <div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">$0.1</div></div> million as of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019.</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Medical Equipment</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">Medical Equipment (&#x201c;Equipment&#x201d;) consists of equipment that the Company purchases from <div style="display: inline; font-style: italic; font: inherit;">third</div>-parties and is (<div style="display: inline; font-style: italic; font: inherit;">1</div>) for sale or rent, and (<div style="display: inline; font-style: italic; font: inherit;">2</div>) used in service to generate rental revenue. Equipment, once placed into service, is depreciated using the straight-line method over the estimated useful lives of the equipment which is typically <div style="display: inline; font-style: italic; font: inherit;">seven</div> years. The Company does <div style="display: inline; font-style: italic; font: inherit;">not</div> depreciate Equipment held for sale or rent. When Equipment in rental service assets are sold, or otherwise disposed, the cost and related accumulated depreciation are removed from the accounts and a sale is recorded in the current period. The Company periodically performs an analysis of slow-moving Equipment used in service to generate rental revenue and records a reserve based on estimated obsolescence, which was <div style="display: inline; font-style: italic; font: inherit;">$0.9</div> and <div style="display: inline; font-style: italic; font: inherit;">$0.7</div> million as of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> respectively. The Company performs a similar analysis of slow-moving Equipment for sale or rent and records a reserve, which was less than <div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">$0.1</div></div> million as of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019.</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Property and Equipment</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">Property and equipment is stated at acquired cost and depreciated using the straight-line method over the estimated useful lives of the related assets, ranging from <div style="display: inline; font-style: italic; font: inherit;">three</div> to <div style="display: inline; font-style: italic; font: inherit;">seven</div> years. Externally purchased information technology software and hardware are depreciated over <div style="display: inline; font-style: italic; font: inherit;">three</div> and <div style="display: inline; font-style: italic; font: inherit;">five</div> years, respectively. Leasehold improvements are amortized using the straight-line method over the life of the asset or the remaining term of the lease, whichever is shorter. Maintenance and minor repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is recorded in the current period.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Intangible Assets</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">Intangible assets consist of trade names, physician and customer relationships and software. The physician and customer relationships arose primarily from previous acquisitions. The Company amortizes the value assigned to the physician and customer relationships on a straight-line basis over the period of expected benefit, which ranges from <div style="display: inline; font-style: italic; font: inherit;">fifteen</div> to <div style="display: inline; font-style: italic; font: inherit;">twenty</div> years. The acquired physician and customer relationship base represents a valuable asset of the Company due to the expectation of future business opportunities to be leveraged from the existing relationship with each physician and customer. The Company has long-standing relationships with numerous oncology clinics, physicians, home care and home infusion providers, skilled nursing facilities, pain centers and others. The useful lives of these relationships are based on minimal attrition experienced to date by the Company and expectations of continued minimal attrition. Acquired software is amortized on a straight-line basis over <div style="display: inline; font-style: italic; font: inherit;">three</div> years. Trade names associated with the original acquisition of InfuSystem are <div style="display: inline; font-style: italic; font: inherit;">not</div> amortized.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">Management tests indefinite life trade names for impairment annually or more frequently if deemed necessary. The impairment test for intangible assets with indefinite lives consists of a comparison of the fair value of the intangible assets with their carrying amounts. If the carrying value of the intangible assets exceeds the fair value, an impairment loss is recognized in an amount equal to that excess. The Company determines the fair value for trade names with indefinite lives through the royalty relief income valuation approach. The Company performed its annual impairment analysis as of the last day of <div style="display: inline; font-style: italic; font: inherit;"> October 2020 </div>and determined that the fair value of the trade names with indefinite lives was greater than their carrying value, resulting in <div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">no</div></div> impairment.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Software Capitalization and Depreciation</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software, including payroll and payroll-related costs for employees who are directly associated with the internal-use software project, external direct costs of materials and services and interest costs while developing the software. Capitalized software costs are included in intangible assets, net and are amortized using the straight-line method over the estimated useful life of <div style="display: inline; font-style: italic; font: inherit;">three</div> to <div style="display: inline; font-style: italic; font: inherit;">five</div> years. Capitalization of such costs ceases when the project is substantially complete and ready for its intended purpose. Costs incurred during the preliminary project and post-implementation stages, as well as software maintenance and training costs, are expensed in the period in which they are incurred. The Company did <div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">not</div></div> capitalize any internal-use software for the years ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> respectively. Amortization expense for capitalized software was <div style="display: inline; font-style: italic; font: inherit;">$1.9</div> million in <div style="display: inline; font-style: italic; font: inherit;">2020</div> and <div style="display: inline; font-style: italic; font: inherit;">$2.0</div> million in <div style="display: inline; font-style: italic; font: inherit;">2019.</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Impairment of Long-Lived Assets</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">Long-lived assets held for use, which includes medical equipment in rental service, property and equipment and amortizable intangible assets, are reviewed for impairment when events or changes in circumstances indicate that their carrying value <div style="display: inline; font-style: italic; font: inherit;"> may </div><div style="display: inline; font-style: italic; font: inherit;">not</div> be recoverable. If an impairment indicator exists, the Company assesses the asset or asset group for recoverability. Recoverability of these assets is determined based upon the expected undiscounted future net cash flows from the operations to which the assets relate, utilizing management's best estimates, appropriate assumptions and projections at the time. If the carrying value is determined <div style="display: inline; font-style: italic; font: inherit;">not</div> to be recoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair market value of the asset or asset group.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The Company assesses impairment indicators related to its internally-developed, internal-use software, specifically looking at the effectiveness and useful lives of each project and sub-project to determine if impairment indicators are present. In <div style="display: inline; font-style: italic; font: inherit;"> December 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> respectively, the Company assessed the impairment indicators and found <div style="display: inline; font-style: italic; font: inherit;">none</div> to be present.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Leases</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">On <div style="display: inline; font-style: italic; font: inherit;"> January 1, 2019 (</div>the &#x201c;Effective Date&#x201d;), the Company adopted Accounting Standards Update (&#x201c;ASU&#x201d;) <div style="display: inline; font-style: italic; font: inherit;">2016</div>-<div style="display: inline; font-style: italic; font: inherit;">02,</div> Leases (Topic <div style="display: inline; font-style: italic; font: inherit;">842</div>); ASU <div style="display: inline; font-style: italic; font: inherit;">2018</div>-<div style="display: inline; font-style: italic; font: inherit;">10,</div> Codification Improvements to Topic <div style="display: inline; font-style: italic; font: inherit;">842,</div> Leases; and ASU <div style="display: inline; font-style: italic; font: inherit;">2018</div>-<div style="display: inline; font-style: italic; font: inherit;">11,</div> Targeted Improvements (collectively, &#x201c;Topic <div style="display: inline; font-style: italic; font: inherit;">842&#x201d;</div>) using a modified retrospective transition approach, which requires Topic <div style="display: inline; font-style: italic; font: inherit;">842</div> to be applied to all leases existing at the date of initial application. Under Topic <div style="display: inline; font-style: italic; font: inherit;">842,</div> lessees are required to recognize a lease liability and right-of-use asset (&#x201c;ROU asset&#x201d;) for all leases and to disclose key information about leasing arrangements. Additionally, leases are classified as either financing or operating; the classification determines the pattern of expense recognition and classification within the statement of operations. The Company elected to apply its lease accounting policy only to leases with a term greater than <div style="display: inline; font-style: italic; font: inherit;">twelve</div> months.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">Topic <div style="display: inline; font-style: italic; font: inherit;">842</div> provides several optional practical expedients that we adopted at transition. The Company elected the &#x201c;package of practical expedients&#x201d;, which does <div style="display: inline; font-style: italic; font: inherit;">not</div> require it to reassess its prior conclusions regarding lease identification, lease classification and initial direct costs. The Company did <div style="display: inline; font-style: italic; font: inherit;">not</div> elect the practical expedient of hindsight to the evaluation of lease options (e.g. renewal).</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">Topic <div style="display: inline; font-style: italic; font: inherit;">842</div> also provides practical expedients for an entity's ongoing accounting. The Company elected the &#x201c;combining lease and non-lease components&#x201d; practical expedient and also elected to apply the short-term lease recognition exemption to certain leases; therefore, the Company did <div style="display: inline; font-style: italic; font: inherit;">not</div> recognize ROU assets and lease liabilities for these leases.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">In adopting Topic <div style="display: inline; font-style: italic; font: inherit;">842,</div> the Company determined and will continue to determine whether an arrangement is a lease at inception. The Company's operating leases are primarily for office space, service facility centers and equipment under operating lease arrangements that expire at various dates over the next <div style="display: inline; font-style: italic; font: inherit;">ten</div> years. The Company's leases do <div style="display: inline; font-style: italic; font: inherit;">not</div> contain any restrictive covenants. The Company's office leases generally contain renewal options for periods ranging from <div style="display: inline; font-style: italic; font: inherit;">one</div> to <div style="display: inline; font-style: italic; font: inherit;">five</div> years. Because the Company is <div style="display: inline; font-style: italic; font: inherit;">not</div> reasonably certain to exercise these renewal options, the options are <div style="display: inline; font-style: italic; font: inherit;">not</div> considered in determining the lease term, and payments associated with the option years are excluded from lease payments. The Company's office leases do <div style="display: inline; font-style: italic; font: inherit;">not</div> contain any material residual value guarantees. The Company's equipment leases generally do <div style="display: inline; font-style: italic; font: inherit;">not</div> contain renewal options. The Company is <div style="display: inline; font-style: italic; font: inherit;">not</div> reasonably certain to exercise the renewal options for those equipment leases that do contain renewal options, thus, the options are <div style="display: inline; font-style: italic; font: inherit;">not</div> considered in determining the lease term and payments associated with the option years are excluded from lease payments.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">For the Company's equipment leases, the Company used and will use the implicit rate in the lease as the discount rate, when available. Otherwise, the Company uses its incremental borrowing rate as the discount rate. For the Company's office leases, the implicit rate is typically <div style="display: inline; font-style: italic; font: inherit;">not</div> available, so the Company used and will use its incremental borrowing rate as the discount rate. The incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments. The Company's lease agreements include both lease and non-lease components. The Company elected the practical expedient that allows it to combine lease and non-lease components for all of its leases.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">Payments due under the Company's operating leases include fixed payments as well as variable payments. For the Company's office leases, variable payments include amounts for the Company's proportionate share of operating expenses, utilities, property taxes, insurance, common area maintenance and other facility-related expenses. For the Company's equipment leases, variable payments <div style="display: inline; font-style: italic; font: inherit;"> may </div>consist of sales taxes, property taxes and other fees.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Revenue Recognition</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">Revenue is recognized at the time and in an amount that reflects the consideration expected to be received for the performance obligations that have been provided. Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic <div style="display: inline; font-style: italic; font: inherit;">606</div> &#x2013; Revenue from Contracts with Customers (&#x201c;ASC <div style="display: inline; font-style: italic; font: inherit;">606&#x201d;</div>) defines contracts as written, oral and through customary business practice. Under this definition, the Company considers contracts to be created at the time that the rental service is authorized or an order to purchase product is agreed upon regardless of whether or <div style="display: inline; font-style: italic; font: inherit;">not</div> there is a written contract.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The Company has <div style="display: inline; font-style: italic; font: inherit;">two</div> separate and distinct performance obligations offered to its customers: a rental service performance obligation or a product sale performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is defined as the unit of account for revenue recognition under ASC <div style="display: inline; font-style: italic; font: inherit;">606.</div> These performance obligations are related to separate revenue streams and at <div style="display: inline; font-style: italic; font: inherit;">no</div> point are they combined into a single transaction. Sources of net revenues include commercial insurance payers, government insurance payers, medical facilities and patients.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The Company generates the majority of its revenue from the rental of infusion pumps to its customers and a minority of its revenue from product sales. For the rental service performance obligation, revenue is based on its standalone price, determined by using reimbursement rates established by <div style="display: inline; font-style: italic; font: inherit;">third</div>-party payer or other contracts. Revenue is recognized in the period in which the related performance obligation is satisfied, which is typically at the point in time that a patient concludes a treatment, or in certain arrangements, based on the number of pumps that a facility has onsite. The Company's revenues related to product sales are recognized at the time that control of the product has been transferred to the customer; either at the time the product is shipped or the time the product has been received by the customer, depending on the delivery terms. The Company does <div style="display: inline; font-style: italic; font: inherit;">not</div> commit to long-term contracts to sell customers a certain minimum quantity of products.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The Company employs certain significant judgments to estimate the dollar amount of revenue, and related concessions, allocated to the rental service and sale of products. These judgments include, among others, the estimation of variable consideration. Variable consideration, specifically related to the Company's <div style="display: inline; font-style: italic; font: inherit;">third</div>-party payer rental revenues, is estimated as implied price concessions resulting from differences between the rates charged for services performed and the expected reimbursements for commercial payers and other implied customer concessions. The estimates for variable consideration are based on historical collections with similar payers, aged accounts receivable by payer class and payer correspondence using the portfolio approach, which provide a reasonable basis for estimating the variable portion of a transaction. The Company doesn't believe it is probable that a significant reversal of revenue will occur in future periods because (i) there is <div style="display: inline; font-style: italic; font: inherit;">no</div> significant uncertainty about the amount of considerations that are expected to be collected based on collection history and (ii) the large number of sufficiently similar contracts allows the Company to adequately estimate the component of variable consideration.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">Net revenues are adjusted when changes in estimates of variable consideration occur. Changes in estimates typically arise as a result of new information obtained, such as actual payment receipt or denial, or pricing adjustments by payers. Subsequent changes to estimates of transaction prices are recorded as adjustments to net revenue in the period of the change. Subsequent changes that are determined to be the result of an adverse change in the payer's ability to pay are recorded as an allowance for doubtful accounts.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenues and accounts receivable at their net realizable values. Inherent in these estimates is the risk that the estimates will have to be revised or updated as additional information becomes available. Specifically, the complexity of many <div style="display: inline; font-style: italic; font: inherit;">third</div>-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payers <div style="display: inline; font-style: italic; font: inherit;"> may </div>result in adjustments to amounts originally recorded. Due to continuing changes in the health care industry and <div style="display: inline; font-style: italic; font: inherit;">third</div>-party reimbursement, it is possible that management's estimates could change in the near term, which could have a material impact on the Company's results of operations and cash flows.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Cost of Revenues</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">Cost of revenues include the costs of servicing and maintaining pumps, products sold, shipping and other direct and indirect costs related to net revenues. Shipping and handling costs incurred after control over a product has transferred to a customer are accounted for as a fulfillment cost.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Customer Concentration</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">For <div style="display: inline; font-style: italic; font: inherit;">2020</div> and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> the Company's largest contracted payer was a national payer which accounted for approximately <div style="display: inline; font-style: italic; font: inherit;">14%</div> and <div style="display: inline; font-style: italic; font: inherit;">8%</div> of ITS net revenues for <div style="display: inline; font-style: italic; font: inherit;">2020</div> and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> respectively, and approximately <div style="display: inline; font-style: italic; font: inherit;">9%</div> and <div style="display: inline; font-style: italic; font: inherit;">5%</div> of total consolidated net revenues for <div style="display: inline; font-style: italic; font: inherit;">2020</div> and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> respectively.</div> <div style=" font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The Company also contracts with various other <div style="display: inline; font-style: italic; font: inherit;">third</div>-party payer organizations, Medicaid, commercial Medicare replacement plans, self-insured plans, facilities of our Medicare patients and numerous other insurance carriers. Other than the payer noted above, <div style="display: inline; font-style: italic; font: inherit;">no</div> other single payer represented more than <div style="display: inline; font-style: italic; font: inherit;">7%</div> of the Company's ITS net revenue.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Income Taxes </div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The Company recognizes deferred&nbsp;income tax liabilities and assets based on (i) the differences between the financial statement carrying amounts and the tax basis of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse and (ii) the tax credit carryforwards. Deferred income tax (expense) benefit results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when it is more likely than <div style="display: inline; font-style: italic; font: inherit;">not</div> that some or all of any deferred tax assets will <div style="display: inline; font-style: italic; font: inherit;">not</div> be realized.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">Provisions for federal, state and foreign taxes are calculated based on reported pre-tax earnings based on current tax law and include the cumulative effect of any changes in tax rates from those used previously in determining deferred tax assets and liabilities.&nbsp;Certain items of income and expense are recognized in different time periods for financial reporting than for income tax purposes; thus, such provisions differ from the amounts currently receivable or payable.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The Company follows a <div style="display: inline; font-style: italic; font: inherit;">two</div>-step approach for recognizing uncertain tax positions. First, it evaluates the tax position for recognition by determining if the weight of available evidence indicates it is more-likely-than-<div style="display: inline; font-style: italic; font: inherit;">not</div> that the position will be sustained upon examination. Second, for positions that are determined are more-likely-than-<div style="display: inline; font-style: italic; font: inherit;">not</div> to be sustained, it recognizes the tax benefits as the largest benefit that has a greater than <div style="display: inline; font-style: italic; font: inherit;">50%</div> likelihood of being sustained. The Company establishes a reserve for uncertain tax positions liability that is comprised of unrecognized tax benefits and related interest and penalties. The Company adjusts this liability in the period in which an uncertain tax position is effectively settled, the statute of limitations expires for the relevant taxing authority to examine the tax position, or more information becomes available.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The Company adopted ASU <div style="display: inline; font-style: italic; font: inherit;">2019</div>-<div style="display: inline; font-style: italic; font: inherit;">12,</div> Income Taxes (Topic <div style="display: inline; font-style: italic; font: inherit;">740</div>): Simplifying the Accounting for Income Taxes, in the <div style="display: inline; font-style: italic; font: inherit;">fourth</div> quarter of <div style="display: inline; font-style: italic; font: inherit;">2019.</div> This guidance simplifies various aspects related to accounting for income taxes by removing certain exceptions to the general principles in Topic <div style="display: inline; font-style: italic; font: inherit;">740</div> and also clarifies and amends existing guidance to improve consistent application. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after <div style="display: inline; font-style: italic; font: inherit;"> December 15, 2020. </div>Early adoption is permitted, including adoption in any interim period for which financial statements have <div style="display: inline; font-style: italic; font: inherit;">not</div> yet been issued. Certain amendments <div style="display: inline; font-style: italic; font: inherit;"> may </div>be applied on a retrospective, modified retrospective or prospective basis. As permitted, the Company elected to early adopt this guidance for the year ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2019. </div>The adoption of this guidance did <div style="display: inline; font-style: italic; font: inherit;">not</div> have a significant impact on the Company's financial statements and primarily resulted in the reclassification of an immaterial amount from non-income tax expense to income tax expense related to the accounting for franchise taxes, with <div style="display: inline; font-style: italic; font: inherit;">no</div> impact to the Company's consolidated net income, equity or cash flows.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Treasury Stock</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The Company periodically repurchases shares of its common stock. These repurchases take place either as part of a board-authorized program, which <div style="display: inline; font-style: italic; font: inherit;"> may </div>include open market transactions or privately negotiated transactions and <div style="display: inline; font-style: italic; font: inherit;"> may </div>be made under a Rule <div style="display: inline; font-style: italic; font: inherit;">10b5</div>-<div style="display: inline; font-style: italic; font: inherit;">1</div> plan, or in targeted stock purchase agreements approved by the board. Treasury stock is accounted for using the par value method.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;"></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Share-Based Payments</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The Company determines the fair value of stock option awards, restricted stock awards and stock appreciation rights (collectively, &#x201c;Share-Based Awards&#x201d;) on the date of grant using option-pricing models which are affected by the Company's stock price, as well as assumptions regarding a number of other inputs using the Black-Scholes pricing model. These variables include the Company's expected stock price volatility over the expected term of the Share-Based Awards, actual and projected employee stock option exercise behaviors, risk-free interest rates and expected dividends. The expected volatility is based on the historical volatility. The Company uses historical data to estimate Share-Based Awards exercise rates. The expected term represents the period over which the Share-Based Awards are expected to be outstanding. The dividend yield is an estimate of the expected dividend yield on the Company's stock. The risk-free rate is based on U.S. Treasury yields in effect at the time of the grant for the expected term of the Share-Based Awards. All Share-Based Awards are amortized based on their graded vesting over the requisite service period of the awards. Compensation costs are recognized over the requisite service period using the accelerated method and included in general and administrative expenses.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">Additionally, the Company also determines the fair value of performance-based restricted stock units (&#x201c;PSUs&#x201d;) based upon the type of performance measure. These awards typically vest after the Company's achievement of either Company performance relative to specified performance measure goals for a specific fiscal period or when the market value of the Company's stock price reaches a target value for a minimum number of consecutive trading days. Under Financial Accounting Standards Board (&#x201c;FASB&#x201d;) ASC Topic <div style="display: inline; font-style: italic; font: inherit;">718,</div> the provisions of the PSUs that vest upon achievement of a target market value are considered a market condition, and therefore the effect of that market condition is reflected in the grant date fair value for this type of award. A <div style="display: inline; font-style: italic; font: inherit;">third</div>-party valuation expert was engaged to complete a &#x201c;Monte Carlo simulation&#x201d; to account for the market condition. That simulation takes into account the beginning stock price of the Company's common stock, the expected volatilities for the Company's stock price and the expected risk-free rate of return. The single grant-date fair value computed by this valuation method is recognized by the Company in accounting for the awards regardless of the actual future outcome of the market condition. The grant date fair value of the other PSUs is calculated as the closing price of the Company's common stock on the grant date multiplied by the number of shares subject to the award. Company performance measure goals are considered a performance condition and the grant-date fair value for those PSUs corresponds with management's expectation of the probable outcome of the performance conditions as of the grant date.</div></div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;"></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Deferred Debt Issuance Costs</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">Capitalized debt issuance costs as of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019</div> relate to the Company's credit facility. The costs related to the agreement are netted against current and non-current debt. The Company amortizes these costs using the interest method through the maturity date of the underlying debt.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;"></div></div> <div style="display: inline; font-style: italic; font: inherit;"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Earnings Per Share</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The Company reports its earnings per share in accordance with ASU <div style="display: inline; font-style: italic; font: inherit;">2017</div>-<div style="display: inline; font-style: italic; font: inherit;">11,</div> Earnings Per Share (Topic <div style="display: inline; font-style: italic; font: inherit;">260</div>), which requires the presentation of both basic and diluted earnings per share on the statements of operations. The diluted weighted average common shares include adjustments for the potential effects of outstanding stock options but only in the periods in which such effect is dilutive under the treasury stock method. Included in our basic and diluted weighted average common shares are those stock options and restricted stock awards due to participants granted from the <div style="display: inline; font-style: italic; font: inherit;">2014</div> stock incentive plan. Anti-dilutive stock awards are comprised of stock options and unvested restricted stock awards, which would have been anti-dilutive in the application of the treasury stock method in accordance with ASU <div style="display: inline; font-style: italic; font: inherit;">2017</div>-<div style="display: inline; font-style: italic; font: inherit;">11,</div> Earnings Per Share (Topic <div style="display: inline; font-style: italic; font: inherit;">260</div>). In periods where the Company records a net loss, the diluted per share amount is the same as the basic per share amount.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">In accordance with this topic, the following table reconciles income and share amounts utilized to calculate basic and diluted net income per common share as of <div style="display: inline; font-style: italic; font: inherit;"> December 31 (</div>in thousands, except shares):</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div> <table border="0" cellpadding="0" cellspacing="0" style="margin-right: 15%; margin-left: 72pt; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 64%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Numerator:</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Net income <div style="display: inline; font-style: italic;">(in thousands)</div></div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">17,332</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">1,361</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Denominator:</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Weighted average common shares outstanding:</div> </td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Basic</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">20,106,940</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><div style="display: inline; font-style: italic; font: inherit;">19,731,498</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Dilutive effect of restricted shares and options</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,610,276</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">1,107,898</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Diluted</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">21,717,216</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&nbsp;</td> <td style="width: 15%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><div style="display: inline; font-style: italic; font: inherit;">20,839,396</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> </tr> </table> </div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">Stock options of less than <div style="display: inline; font-style: italic; font: inherit;"><div style="display: inline; font-style: italic; font: inherit;">0.1</div></div> million shares were <div style="display: inline; font-style: italic; font: inherit;">not</div> included in the calculations for both the years ended <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019</div> because they would have an anti-dilutive effect.</div></div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;"></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Fair Value of Financial Instruments</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">The carrying amounts reported in the consolidated balance sheets as of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019</div> for cash, accounts receivable, accounts payable and other current liabilities approximate fair value because of the short-term nature of these instruments (Level I). The carrying value of the Company's long-term debt with variable interest rates approximates fair value based on instruments with similar terms (Level II).</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">The Company has adopted ASC <div style="display: inline; font-style: italic; font: inherit;">820,</div> Fair Value Measurements, which defines fair value, establishes a framework for assets and liabilities being measured and reported at fair value and appends disclosures about fair value measurements.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:27pt;">For financial assets and liabilities measured at fair value on a recurring basis, fair value is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date. A <div style="display: inline; font-style: italic; font: inherit;">three</div>-level fair value hierarchy prioritizes the inputs used to measure fair value as follows:</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 54pt;">&nbsp;</td> <td style="width: 54pt;"> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; text-decoration: underline;">Level I</div>:</div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">quoted prices in active markets for identical instruments;</div> </td> </tr> </table> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 27pt;text-indent:27pt;">&nbsp;</div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 54pt;">&nbsp;</td> <td style="width: 54pt;"> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; text-decoration: underline;">Level II</div>:</div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">quoted prices in active markets for similar instruments, quoted prices for identical instruments in markets that are <div style="display: inline; font-style: italic; font: inherit;">not</div> active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the instrument; and</div> </td> </tr> </table> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <table border="0" cellpadding="0" cellspacing="0" style="; text-indent: 0px; min-width: 700px;"> <tr style="vertical-align: top;"> <td style="width: 54pt;">&nbsp;</td> <td style="width: 54pt;"> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><div style="display: inline; text-decoration: underline;">Level III</div>:</div> </td> <td> <div style=" margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">significant inputs to the valuation model are unobservable.</div> </td> </tr> </table> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Recent Accounting Pronouncements and Developments</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">In <div style="display: inline; font-style: italic; font: inherit;"> June 2016, </div>the FASB issued ASU <div style="display: inline; font-style: italic; font: inherit;">No.</div> <div style="display: inline; font-style: italic; font: inherit;">2016</div>-<div style="display: inline; font-style: italic; font: inherit;">13,</div> &#x201c;Financial Instruments (Topic <div style="display: inline; font-style: italic; font: inherit;">326</div>) Credit Losses&#x201d;. Topic <div style="display: inline; font-style: italic; font: inherit;">326</div> changes the impairment model for most financial assets and certain other instruments. Under the new standard, entities holding financial assets and net investment in leases that are <div style="display: inline; font-style: italic; font: inherit;">not</div> accounted for at fair value through net income are to be presented at the net amount expected to be collected. An allowance for credit losses will be a valuation account that will be deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected on the financial asset. Topic <div style="display: inline; font-style: italic; font: inherit;">326</div> was originally effective as of <div style="display: inline; font-style: italic; font: inherit;"> January 1, 2020, </div>although in <div style="display: inline; font-style: italic; font: inherit;"> November 2019, </div>the FASB delayed the effective date until fiscal years beginning after <div style="display: inline; font-style: italic; font: inherit;"> December 15, 2022 </div>for SEC filers eligible to be smaller reporting companies under the SEC's definition. The Company qualifies as a smaller reporting company under the SEC's definition. Early adoption is permitted. The Company is currently evaluating the impact of Topic <div style="display: inline; font-style: italic; font: inherit;">326</div> on its consolidated balance sheets, statements of operations, statements of cash flows and related disclosures.</div></div> -1659000 29000 30012 33742 33000 29000 28000 394000 505000 213056 334184 27940 139000 139000 923000 807000 5000000 2000 83167000 -62728000 20441000 2000 83699000 -61367000 22334000 2000 84785000 -44035000 40752000 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;text-indent:-25pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-style: italic; font: inherit;">15.</div></div>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<div style="display: inline; font-weight: bold;">Subsequent Events</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Acquisition</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On <div style="display: inline; font-style: italic; font: inherit;"> February 3, 2021, </div>the Company announced that it had acquired FilAMed, a privately held biomedical services company based in Bakersfield, California, for an approximate purchase price of <div style="display: inline; font-style: italic; font: inherit;">$1.4</div> million.&nbsp; The initial accounting for the business combination, including the estimated fair value of the assets and liabilities acquired, is incomplete as a result of the timing of the acquisition. This acquisition will supplement the Company's existing biomedical recertification, maintenance and repair services for acute care facilities and other alternate site settings including home care and home infusion providers, skilled nursing facilities, pain centers and others.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><div style="display: inline; font-style: italic;">Credit Agreement</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <div style="display: inline; font-style: italic; font: inherit;"> February 5, 2021, </div>the Company entered into a Credit Agreement (the <div style="display: inline; font-style: italic; font: inherit;">&#x201c;2021</div> Credit Agreement&#x201d;) with JPMorgan Chase Bank, N.A., as administrative agent (the &#x201c;Agent&#x201d;), sole bookrunner and sole lead arranger, and the lenders party thereto. The borrowers under the <div style="display: inline; font-style: italic; font: inherit;">2021</div> Credit Agreement are the Company, InfuSystem Holdings USA, Inc. (&#x201c;Holdings&#x201d;), ISI, First Biomedical, , and IFC LLC (&#x201c;IFC&#x201d; and, collectively with the Company, Holdings, ISI and First Biomedical, the &#x201c;Borrowers&#x201d;).</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The <div style="display: inline; font-style: italic; font: inherit;">2021</div> Credit Agreement provides for a revolving credit facility (the &#x201c;Revolving Facility&#x201d;) of <div style="display: inline; font-style: italic; font: inherit;">$75</div> million, maturing on <div style="display: inline; font-style: italic; font: inherit;"> February 5, 2026. </div>The Revolving Facility <div style="display: inline; font-style: italic; font: inherit;"> may </div>be increased by <div style="display: inline; font-style: italic; font: inherit;">$25</div> million, subject to certain conditions, including the consent of the Agent and obtaining necessary commitments. The lenders under the <div style="display: inline; font-style: italic; font: inherit;">2021</div> Credit Agreement <div style="display: inline; font-style: italic; font: inherit;"> may </div>issue up to <div style="display: inline; font-style: italic; font: inherit;">$7</div> million in letters of credit subject to the satisfaction of certain conditions. On <div style="display: inline; font-style: italic; font: inherit;"> February 5, 2021, </div>the Borrowers made an initial borrowing of <div style="display: inline; font-style: italic; font: inherit;">$30</div> million under the Revolving Facility. Proceeds from the loan, along with approximately <div style="display: inline; font-style: italic; font: inherit;">$8.2</div> million in cash, were used to repay all amounts due under the Company's existing credit facility dated <div style="display: inline; font-style: italic; font: inherit;"> March 23, 2015 (</div>the <div style="display: inline; font-style: italic; font: inherit;">&#x201c;2015</div> Credit Agreement&#x201d;).</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Amounts outstanding under the Revolving Facility bear interest at a variable rate equal to, at the Company's election, a LIBO Rate for Eurodollar loans or an Alternate Base Rate for ABR loans, as defined by the <div style="display: inline; font-style: italic; font: inherit;">2021</div> Credit Agreement, plus a spread that will vary depending upon the Company's leverage ratio. The spread ranges from <div style="display: inline; font-style: italic; font: inherit;">2.00%</div> to <div style="display: inline; font-style: italic; font: inherit;">3.00%</div> for Eurodollar Loans and <div style="display: inline; font-style: italic; font: inherit;">1.00%</div> to <div style="display: inline; font-style: italic; font: inherit;">2.00%</div> for base rate loans. The initial spread under the <div style="display: inline; font-style: italic; font: inherit;">2021</div> Credit Agreement is <div style="display: inline; font-style: italic; font: inherit;">2.00%</div> for Eurodollar loans and <div style="display: inline; font-style: italic; font: inherit;">1.00%</div> for ABR loans.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The <div style="display: inline; font-style: italic; font: inherit;">2021</div> Credit Agreement has customary representations and warranties, and the ability to borrow under the facility is subject to ongoing compliance with a number of customary affirmative and negative covenants, including limitations on indebtedness, liens, mergers, acquisitions, investments, asset sales, affiliate transactions and restricted payments, as well as financial covenants, including the following:</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <table border="0" cellpadding="0" cellspacing="0" style=";font-family:Times New Roman;font-size:10pt; min-width: 700px;"> <tr> <td style="width:18pt;">&nbsp;</td> <td style="vertical-align:top;width:18pt;"> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</div> </td> <td style="vertical-align:top;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a minimum fixed charge coverage ratio (defined as the ratio of consolidated EBITDA (as defined in the <div style="display: inline; font-style: italic; font: inherit;">2021</div> Credit Agreement) less <div style="display: inline; font-style: italic; font: inherit;">50%</div> of depreciation expense), to consolidated fixed charges (as defined in the <div style="display: inline; font-style: italic; font: inherit;">2021</div> Credit Agreement)) for the prior <div style="display: inline; font-style: italic; font: inherit;">four</div> most recently ended calendar quarters of <div style="display: inline; font-style: italic; font: inherit;">1.20</div> to <div style="display: inline; font-style: italic; font: inherit;">1.00;</div> and</div> </td> </tr> </table> <table border="0" cellpadding="0" cellspacing="0" style=";font-family:Times New Roman;font-size:10pt; min-width: 700px;"> <tr> <td style="width:18pt;">&nbsp;</td> <td style="vertical-align:top;width:18pt;"> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</div> </td> <td style="vertical-align:top;"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a maximum leverage ratio (defined as total indebtedness to EBITDA for the prior <div style="display: inline; font-style: italic; font: inherit;">four</div> most recently ended calendar quarters) of <div style="display: inline; font-style: italic; font: inherit;">3.50</div> to <div style="display: inline; font-style: italic; font: inherit;">1.00.</div></div> </td> </tr> </table> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The <div style="display: inline; font-style: italic; font: inherit;">2021</div> Credit Agreement includes customary events of default, and the occurrence of an event of default will permit the lenders to terminate commitments to lend under the Revolving Facility and accelerate payment of all amounts outstanding thereunder.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Pledge and Security Agreement</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Simultaneous with the execution of the <div style="display: inline; font-style: italic; font: inherit;">2021</div> Credit Agreement, the Company entered into a Pledge and Security Agreement to secure repayment of the obligations of the Borrowers. Under the Pledge and Security Agreement, each Borrower has granted to the Agent, for the benefit of various secured parties, a <div style="display: inline; font-style: italic; font: inherit;">first</div> priority security interest in substantially all of the personal property assets of each of the Borrowers, including the shares of each of Holdings, ISI and First Biomedical and the equity interests of IFC.</div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;"><div style="display: inline; font-style: italic; font: inherit;">2015</div> Credit Agreement</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <div style="display: inline; font-style: italic; font: inherit;"> February 5, 2020, </div>in connection with the execution and closing of the <div style="display: inline; font-style: italic; font: inherit;">2021</div> Credit Agreement, the Company, along with its wholly owned subsidiaries as borrowers, terminated the <div style="display: inline; font-style: italic; font: inherit;">2015</div> Credit Agreement. All outstanding loans under the <div style="display: inline; font-style: italic; font: inherit;">2015</div> Credit Agreement have been repaid and all liens under the <div style="display: inline; font-style: italic; font: inherit;">2015</div> Credit Agreement have been released, except that a letter of credit originally issued under the <div style="display: inline; font-style: italic; font: inherit;">2015</div> Credit Agreement in the amount of approximately <div style="display: inline; font-style: italic; font: inherit;">$0.8</div> million was transferred to the <div style="display: inline; font-style: italic; font: inherit;">2021</div> Credit Agreement.</div></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><table border="0" cellpadding="0" cellspacing="0" style="margin-right: 10%; margin-left: 10%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; min-; min-width: 700px;"> <tr style="vertical-align: bottom;"> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2020</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> <td style="font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">2019</div></div></div> </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Valuation allowance at the Beginning of Period</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(11,250</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(11,370</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Income tax expense</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Release of valuation allowance</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">11,250</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&nbsp;</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">120</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&nbsp;</td> </tr> <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"> <td style="font-family: Times New Roman; font-size: 10pt;"> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Valuation allowance at the End of Period</div> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">-</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&nbsp;</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0); text-align: right;"><div style="display: inline; font-style: italic; font: inherit;">(11,250</div></td> <td nowrap="nowrap" style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td> </tr> </table></div> <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Accounts Receivable and Allowance for Doubtful Accounts</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">Amounts billed that have <div style="display: inline; font-style: italic; font: inherit;">not</div> yet been collected that also meet the conditions for unconditional right to payment are presented as accounts receivable. Accounts receivable related to rental service and delivery of products are reported at their estimated transaction prices, inclusive of adjustments for variable consideration, based on the amounts expected to be collected from payers. The Company writes off accounts receivable once collection efforts have been exhausted and an account is deemed to be uncollectible. An allowance for doubtful accounts is established as a result of an adverse change in the Company's payers' ability to pay outstanding billings. The allowance for doubtful accounts was <div style="display: inline; font-style: italic; font: inherit;">$1.0</div> million and <div style="display: inline; font-style: italic; font: inherit;">$0.4</div> million as of <div style="display: inline; font-style: italic; font: inherit;"> December 31, 2020 </div>and <div style="display: inline; font-style: italic; font: inherit;">2019,</div> respectively.</div></div></div></div></div></div></div></div></div></div></div></div></div></div> 66000 83000 0 0 <div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><div style="display: inline; font-style: italic;">Use of Estimates</div></div> <div style=" font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</div> <div style=" font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements, including the notes thereto. The Company considers critical accounting policies to be those that require more significant judgments and estimates in the preparation of its consolidated financial statements, including the following: revenue recognition, leases, accounts receivable and allowance for doubtful accounts, income taxes, and long-lived asset valuations. Management relies on historical experience and other assumptions believed to be reasonable in making its judgments and estimates. Actual results could differ materially from those estimates.</div></div></div></div></div></div></div></div></div></div></div></div></div></div> -11200000 315000 291000 21717216 20839396 20106940 19731498 at December 31, 2019, this includes state and local net operating losses of $1.4 million Amounts consist of current liabilities for medical equipment that have not been included in investing activities. These amounts have not been paid for as of December 31, 2020 and 2019, respectively, but will be included as a cash outflow from investing activities for purchases of medical equipment and property when paid. Represents inducement stock options to purchase shares of the Company's Common Stock to executive level managers. xbrli:shares xbrli:pure iso4217:USD iso4217:USD xbrli:shares 0001337013 2014-05-01 2014-05-31 0001337013 2016-09-07 2016-09-07 0001337013 infu:InducementStockOptionsMember 2018-01-01 2018-12-31 0001337013 infu:AmendedAndRestatedStockIncentivePlan2014Member 2018-01-01 2018-12-31 0001337013 infu:AmendedAndRestatedStockIncentivePlan2014Member 2018-07-19 2018-07-19 0001337013 2019-01-01 2019-09-30 0001337013 2019-01-01 2019-12-31 0001337013 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001337013 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001337013 us-gaap:EmployeeStockOptionMember srt:ChiefExecutiveOfficerMember 2019-01-01 2019-12-31 0001337013 infu:InducementStockOptionsMember 2019-01-01 2019-12-31 0001337013 us-gaap:PerformanceSharesMember 2019-01-01 2019-12-31 0001337013 us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0001337013 us-gaap:RestrictedStockMember srt:MaximumMember 2019-01-01 2019-12-31 0001337013 infu:DirectPayerRentalsMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001337013 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001337013 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember infu:NationalAssociation2Member 2019-01-01 2019-12-31 0001337013 us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001337013 us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember infu:NationalAssociation2Member infu:OncologyBusinessMember 2019-01-01 2019-12-31 0001337013 infu:ThirdpartyPayorRentalRevenueMember us-gaap:CustomerConcentrationRiskMember 2019-01-01 2019-12-31 0001337013 infu:CorporateAndEliminationsMember 2019-01-01 2019-12-31 0001337013 us-gaap:OperatingSegmentsMember infu:DMEServicesSegmentMember 2019-01-01 2019-12-31 0001337013 us-gaap:OperatingSegmentsMember infu:ITSSegmentMember 2019-01-01 2019-12-31 0001337013 infu:DirectPayerRentalsMember 2019-01-01 2019-12-31 0001337013 infu:DirectPayerRentalsMember infu:DMEServicesSegmentMember 2019-01-01 2019-12-31 0001337013 infu:DirectPayerRentalsMember infu:ITSSegmentMember 2019-01-01 2019-12-31 0001337013 infu:ProductSalesMember 2019-01-01 2019-12-31 0001337013 infu:ThirdpartyPayorRentalRevenueMember 2019-01-01 2019-12-31 0001337013 infu:EquipmentLineMember infu:CreditFacilityMember srt:MaximumMember 2019-01-01 2019-12-31 0001337013 us-gaap:CostOfSalesMember 2019-01-01 2019-12-31 0001337013 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-12-31 0001337013 infu:AmendedAndRestatedStockIncentivePlan2014Member 2019-01-01 2019-12-31 0001337013 srt:MaximumMember 2019-01-01 2019-12-31 0001337013 srt:MinimumMember 2019-01-01 2019-12-31 0001337013 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001337013 us-gaap:CommonStockMember 2019-01-01 2019-12-31 0001337013 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001337013 us-gaap:TreasuryStockMember 2019-01-01 2019-12-31 0001337013 infu:MedicalEquipmentMember infu:FinancingAgreementMember 2019-04-15 2019-04-15 0001337013 infu:AmendedAndRestatedStockIncentivePlan2014Member 2019-05-15 2019-05-15 0001337013 2019-10-01 2019-12-31 0001337013 infu:EquipmentLineMember infu:CreditFacilityMember 2019-11-07 2019-11-07 0001337013 2020-01-01 2020-12-31 0001337013 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001337013 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001337013 us-gaap:EmployeeStockOptionMember srt:MaximumMember 2020-01-01 2020-12-31 0001337013 us-gaap:EmployeeStockOptionMember srt:MinimumMember 2020-01-01 2020-12-31 0001337013 us-gaap:EmployeeStockOptionMember srt:ChiefExecutiveOfficerMember 2020-01-01 2020-12-31 0001337013 infu:InducementStockOptionsMember 2020-01-01 2020-12-31 0001337013 us-gaap:PerformanceSharesMember 2020-01-01 2020-12-31 0001337013 us-gaap:PerformanceSharesMember srt:MaximumMember 2020-01-01 2020-12-31 0001337013 us-gaap:PerformanceSharesMember infu:SharebasedPaymentArrangementAchievingMinimumThresholdMember 2020-01-01 2020-12-31 0001337013 us-gaap:PerformanceSharesMember infu:SharebasedPaymentArrangementExceedingMinimumThresholdMember 2020-01-01 2020-12-31 0001337013 us-gaap:RestrictedStockMember 2020-01-01 2020-12-31 0001337013 us-gaap:RestrictedStockUnitsRSUMember srt:MaximumMember 2020-01-01 2020-12-31 0001337013 us-gaap:CostOfGoodsProductLineMember us-gaap:SupplierConcentrationRiskMember infu:AmbulatoryPumpsMember srt:MinimumMember infu:MoogMedicalDevicesGroupMember 2020-01-01 2020-12-31 0001337013 us-gaap:CostOfGoodsProductLineMember us-gaap:SupplierConcentrationRiskMember infu:AmbulatoryPumpsMember srt:MinimumMember infu:SmithsMedicalIncMember 2020-01-01 2020-12-31 0001337013 us-gaap:CostOfGoodsProductLineMember us-gaap:SupplierConcentrationRiskMember infu:NPWTMedicalEquipmentMember srt:MinimumMember infu:CardinalHealthIncMember 2020-01-01 2020-12-31 0001337013 infu:DirectPayerRentalsMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001337013 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001337013 us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember infu:NationalAssociation2Member 2020-01-01 2020-12-31 0001337013 us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001337013 us-gaap:SalesRevenueProductLineMember us-gaap:CustomerConcentrationRiskMember infu:NationalAssociation2Member infu:OncologyBusinessMember 2020-01-01 2020-12-31 0001337013 infu:ThirdpartyPayorRentalRevenueMember us-gaap:CustomerConcentrationRiskMember 2020-01-01 2020-12-31 0001337013 infu:CorporateAndEliminationsMember 2020-01-01 2020-12-31 0001337013 us-gaap:OperatingSegmentsMember infu:DMEServicesSegmentMember 2020-01-01 2020-12-31 0001337013 us-gaap:OperatingSegmentsMember infu:ITSSegmentMember 2020-01-01 2020-12-31 0001337013 infu:DirectPayerRentalsMember 2020-01-01 2020-12-31 0001337013 infu:DirectPayerRentalsMember infu:DMEServicesSegmentMember 2020-01-01 2020-12-31 0001337013 infu:DirectPayerRentalsMember infu:ITSSegmentMember 2020-01-01 2020-12-31 0001337013 infu:ProductSalesMember 2020-01-01 2020-12-31 0001337013 infu:ThirdpartyPayorRentalRevenueMember 2020-01-01 2020-12-31 0001337013 infu:CreditFacilityMember infu:CBFloatingRateLoanMember srt:MaximumMember infu:GreaterOfPrimeRateOrLIBORPlus25Member 2020-01-01 2020-12-31 0001337013 infu:CreditFacilityMember infu:CBFloatingRateLoanMember srt:MinimumMember infu:GreaterOfPrimeRateOrLIBORPlus25Member 2020-01-01 2020-12-31 0001337013 infu:CreditFacilityMember infu:CBFloatingRateLoanMember infu:CBFloatingRateMember 2020-01-01 2020-12-31 0001337013 infu:CreditFacilityMember infu:CBFloatingRateLoanMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-01-01 2020-12-31 0001337013 infu:CreditFacilityMember infu:EurodollarLoanMember srt:MaximumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-01-01 2020-12-31 0001337013 infu:CreditFacilityMember infu:EurodollarLoanMember srt:MinimumMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-01-01 2020-12-31 0001337013 infu:CreditFacilityMember infu:EurodollarLoanMember us-gaap:LondonInterbankOfferedRateLIBORMember 2020-01-01 2020-12-31 0001337013 us-gaap:ComputerSoftwareIntangibleAssetMember 2020-01-01 2020-12-31 0001337013 infu:PhysicianAndCustomerRelationshipsMember 2020-01-01 2020-12-31 0001337013 infu:PhysicianAndCustomerRelationshipsMember srt:MaximumMember 2020-01-01 2020-12-31 0001337013 infu:PhysicianAndCustomerRelationshipsMember srt:MinimumMember 2020-01-01 2020-12-31 0001337013 us-gaap:CostOfSalesMember 2020-01-01 2020-12-31 0001337013 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0001337013 us-gaap:DomesticCountryMember us-gaap:InternalRevenueServiceIRSMember 2020-01-01 2020-12-31 0001337013 us-gaap:ForeignCountryMember us-gaap:CanadaRevenueAgencyMember 2020-01-01 2020-12-31 0001337013 us-gaap:StateAndLocalJurisdictionMember srt:MaximumMember 2020-01-01 2020-12-31 0001337013 us-gaap:StateAndLocalJurisdictionMember srt:MinimumMember 2020-01-01 2020-12-31 0001337013 infu:AmendedAndRestatedStockIncentivePlan2014Member 2020-01-01 2020-12-31 0001337013 infu:AmendedAndRestatedStockIncentivePlan2014Member infu:Range1Member 2020-01-01 2020-12-31 0001337013 infu:AmendedAndRestatedStockIncentivePlan2014Member infu:Range2Member 2020-01-01 2020-12-31 0001337013 infu:AmendedAndRestatedStockIncentivePlan2014Member infu:Range3Member 2020-01-01 2020-12-31 0001337013 infu:AmendedAndRestatedStockIncentivePlan2014Member infu:Range4Member 2020-01-01 2020-12-31 0001337013 infu:AmendedAndRestatedStockIncentivePlan2014Member infu:Range5Member 2020-01-01 2020-12-31 0001337013 infu:AmendedAndRestatedStockIncentivePlan2014Member infu:Range6Member 2020-01-01 2020-12-31 0001337013 infu:AmendedAndRestatedStockIncentivePlan2014Member infu:Range7Member 2020-01-01 2020-12-31 0001337013 us-gaap:ComputerEquipmentMember 2020-01-01 2020-12-31 0001337013 infu:InformationTechnologySoftwareMember 2020-01-01 2020-12-31 0001337013 us-gaap:SoftwareDevelopmentMember srt:MaximumMember 2020-01-01 2020-12-31 0001337013 us-gaap:SoftwareDevelopmentMember srt:MinimumMember 2020-01-01 2020-12-31 0001337013 srt:MaximumMember 2020-01-01 2020-12-31 0001337013 srt:MinimumMember 2020-01-01 2020-12-31 0001337013 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001337013 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001337013 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001337013 us-gaap:TreasuryStockMember 2020-01-01 2020-12-31 0001337013 infu:PaycheckProtectionProgramCaresActMember 2020-04-15 2020-04-15 0001337013 infu:PaycheckProtectionProgramCaresActMember 2020-05-07 2020-05-07 0001337013 2020-10-01 2020-10-31 0001337013 2020-10-01 2020-12-31 0001337013 infu:FilAMedMember us-gaap:SubsequentEventMember 2021-02-03 2021-02-03 0001337013 us-gaap:RevolvingCreditFacilityMember infu:The2015CreditAgreementMember us-gaap:SubsequentEventMember 2021-02-05 2021-02-05 0001337013 us-gaap:RevolvingCreditFacilityMember infu:The2021CreditAgreementMember us-gaap:SubsequentEventMember 2021-02-05 2021-02-05 0001337013 infu:The2021CreditAgreementMember infu:ABRLoansMember srt:MaximumMember us-gaap:SubsequentEventMember us-gaap:BaseRateMember 2021-02-05 2021-02-05 0001337013 infu:The2021CreditAgreementMember infu:ABRLoansMember srt:MinimumMember us-gaap:SubsequentEventMember us-gaap:BaseRateMember 2021-02-05 2021-02-05 0001337013 infu:The2021CreditAgreementMember infu:ABRLoansMember us-gaap:SubsequentEventMember us-gaap:BaseRateMember 2021-02-05 2021-02-05 0001337013 infu:The2021CreditAgreementMember infu:EurodollarLoanMember srt:MaximumMember us-gaap:SubsequentEventMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-02-05 2021-02-05 0001337013 infu:The2021CreditAgreementMember infu:EurodollarLoanMember srt:MinimumMember us-gaap:SubsequentEventMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-02-05 2021-02-05 0001337013 infu:The2021CreditAgreementMember infu:EurodollarLoanMember us-gaap:SubsequentEventMember us-gaap:LondonInterbankOfferedRateLIBORMember 2021-02-05 2021-02-05 0001337013 infu:The2021CreditAgreementMember us-gaap:SubsequentEventMember 2021-02-05 2021-02-05 0001337013 infu:AmendedAndRestatedStockIncentivePlan2014Member 2014-04-23 0001337013 2014-05-31 0001337013 2018-12-31 0001337013 infu:InducementStockOptionsMember 2018-12-31 0001337013 us-gaap:RestrictedStockMember 2018-12-31 0001337013 infu:EquipmentLineMember infu:CreditFacilityMember 2018-12-31 0001337013 infu:AmendedAndRestatedStockIncentivePlan2014Member 2018-12-31 0001337013 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001337013 us-gaap:CommonStockMember 2018-12-31 0001337013 us-gaap:RetainedEarningsMember 2018-12-31 0001337013 us-gaap:TreasuryStockMember 2018-12-31 0001337013 infu:EquipmentLineMember infu:CreditFacilityMember 2019-02-05 0001337013 infu:EquipmentLineMember infu:CreditFacilityMember 2019-03-31 0001337013 infu:MedicalEquipmentMember infu:FinancingAgreementMember 2019-04-15 0001337013 infu:ShareRepurchaseProgram2020RepurchasesMember 2019-09-30 0001337013 infu:EquipmentLineMember infu:CreditFacilityMember 2019-11-07 0001337013 us-gaap:RevolvingCreditFacilityMember infu:CreditFacilityMember 2019-11-07 0001337013 2019-12-31 0001337013 infu:InducementStockOptionsMember 2019-12-31 0001337013 us-gaap:PerformanceSharesMember 2019-12-31 0001337013 us-gaap:RestrictedStockMember 2019-12-31 0001337013 us-gaap:OtherCurrentLiabilitiesMember 2019-12-31 0001337013 infu:CorporateAndEliminationsMember 2019-12-31 0001337013 us-gaap:OperatingSegmentsMember infu:DMEServicesSegmentMember 2019-12-31 0001337013 us-gaap:OperatingSegmentsMember infu:ITSSegmentMember 2019-12-31 0001337013 infu:EquipmentLineMember 2019-12-31 0001337013 us-gaap:RevolvingCreditFacilityMember 2019-12-31 0001337013 infu:The2019EquipmentLineMember 2019-12-31 0001337013 infu:FinancingAgreementMember 2019-12-31 0001337013 us-gaap:ComputerSoftwareIntangibleAssetMember 2019-12-31 0001337013 infu:PhysicianAndCustomerRelationshipsMember 2019-12-31 0001337013 us-gaap:TradeNamesMember 2019-12-31 0001337013 us-gaap:DomesticCountryMember 2019-12-31 0001337013 us-gaap:StateAndLocalJurisdictionMember 2019-12-31 0001337013 infu:TradeNames1Member 2019-12-31 0001337013 infu:TermLoanMember 2019-12-31 0001337013 infu:AmendedAndRestatedStockIncentivePlan2014Member 2019-12-31 0001337013 us-gaap:AutomobilesMember 2019-12-31 0001337013 us-gaap:FurnitureAndFixturesMember 2019-12-31 0001337013 us-gaap:LeaseholdImprovementsMember 2019-12-31 0001337013 srt:MaximumMember 2019-12-31 0001337013 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001337013 us-gaap:CommonStockMember 2019-12-31 0001337013 us-gaap:RetainedEarningsMember 2019-12-31 0001337013 us-gaap:TreasuryStockMember 2019-12-31 0001337013 us-gaap:LetterOfCreditMember infu:The2015CreditAgreementMember 2020-02-04 0001337013 2020-06-30 0001337013 2020-12-31 0001337013 infu:InducementStockOptionsMember 2020-12-31 0001337013 us-gaap:PerformanceSharesMember 2020-12-31 0001337013 us-gaap:RestrictedStockMember 2020-12-31 0001337013 us-gaap:OtherCurrentLiabilitiesMember 2020-12-31 0001337013 us-gaap:OtherLiabilitiesMember 2020-12-31 0001337013 infu:MedicalEquipmentMember infu:FinancingAgreementMember 2020-12-31 0001337013 infu:CorporateAndEliminationsMember 2020-12-31 0001337013 us-gaap:OperatingSegmentsMember infu:DMEServicesSegmentMember 2020-12-31 0001337013 us-gaap:OperatingSegmentsMember infu:ITSSegmentMember 2020-12-31 0001337013 infu:EquipmentLineMember 2020-12-31 0001337013 infu:EquipmentLineMember infu:CreditFacilityMember 2020-12-31 0001337013 us-gaap:RevolvingCreditFacilityMember 2020-12-31 0001337013 us-gaap:RevolvingCreditFacilityMember infu:CreditFacilityMember 2020-12-31 0001337013 infu:The2019EquipmentLineMember 2020-12-31 0001337013 infu:CreditFacilityMember infu:CBFloatingRateLoanMember 2020-12-31 0001337013 infu:CreditFacilityMember infu:CBFloatingRateLoanMember infu:CBFloatingRateMember 2020-12-31 0001337013 infu:CreditFacilityMember infu:EurodollarLoanMember 2020-12-31 0001337013 infu:CreditFacilityMember infu:TermLoanMember 2020-12-31 0001337013 infu:FinancingAgreementMember 2020-12-31 0001337013 us-gaap:ComputerSoftwareIntangibleAssetMember 2020-12-31 0001337013 infu:PhysicianAndCustomerRelationshipsMember 2020-12-31 0001337013 us-gaap:TradeNamesMember 2020-12-31 0001337013 us-gaap:DomesticCountryMember 2020-12-31 0001337013 us-gaap:StateAndLocalJurisdictionMember 2020-12-31 0001337013 infu:TradeNames1Member 2020-12-31 0001337013 infu:TermLoanMember 2020-12-31 0001337013 infu:AmendedAndRestatedStockIncentivePlan2014Member 2020-12-31 0001337013 infu:AmendedAndRestatedStockIncentivePlan2014Member infu:Range1Member 2020-12-31 0001337013 infu:AmendedAndRestatedStockIncentivePlan2014Member infu:Range2Member 2020-12-31 0001337013 infu:AmendedAndRestatedStockIncentivePlan2014Member infu:Range3Member 2020-12-31 0001337013 infu:AmendedAndRestatedStockIncentivePlan2014Member infu:Range4Member 2020-12-31 0001337013 infu:AmendedAndRestatedStockIncentivePlan2014Member infu:Range5Member 2020-12-31 0001337013 infu:AmendedAndRestatedStockIncentivePlan2014Member infu:Range6Member 2020-12-31 0001337013 infu:AmendedAndRestatedStockIncentivePlan2014Member infu:Range7Member 2020-12-31 0001337013 us-gaap:AutomobilesMember 2020-12-31 0001337013 us-gaap:FurnitureAndFixturesMember 2020-12-31 0001337013 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001337013 srt:MaximumMember 2020-12-31 0001337013 srt:MinimumMember 2020-12-31 0001337013 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001337013 us-gaap:CommonStockMember 2020-12-31 0001337013 us-gaap:RetainedEarningsMember 2020-12-31 0001337013 us-gaap:TreasuryStockMember 2020-12-31 0001337013 us-gaap:LetterOfCreditMember infu:The2021CreditAgreementMember us-gaap:SubsequentEventMember 2021-02-05 0001337013 us-gaap:RevolvingCreditFacilityMember infu:The2021CreditAgreementMember us-gaap:SubsequentEventMember 2021-02-05 0001337013 infu:The2021CreditAgreementMember us-gaap:SubsequentEventMember 2021-02-05 0001337013 2021-03-16 EX-101.SCH 9 infu-20201231.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Consolidated Balance Sheets link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Consolidated Balance Sheets (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Consolidated Statements of Operations link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Consolidated Statements of Stockholders' Equity link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Consolidated Statements of Cash Flows link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 1 - Basis of Presentation and Nature of Operations link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 2 - Summary of Significant Accounting Policies link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 3 - Revenue Recognition link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 4 - Medical Equipment link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 5 - Property and Equipment link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 6 - Intangible Assets link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 7 - Debt link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Note 8 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 9 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 10 - Leases link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 11 - Share-based Compensation link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 12 - Business Segment Information link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 13 - Employee Benefit Plans and Other link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 14 - COVID-19 link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 15 - Subsequent Events link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 3 - Revenue Recognition (Tables) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 4 - Medical Equipment (Tables) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 5 - Property and Equipment (Tables) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 6 - Intangible Assets (Tables) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 7 - Debt (Tables) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 8 - Income Taxes (Tables) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 10 - Leases (Tables) link:calculationLink link:definitionLink link:presentationLink 030 - Disclosure - Note 11 - Share-based Compensation (Tables) link:calculationLink link:definitionLink link:presentationLink 031 - Disclosure - Note 12 - Business Segment Information (Tables) link:calculationLink link:definitionLink link:presentationLink 032 - Disclosure - Note 1 - Basis of Presentation and Nature of Operations (Details Textual) link:calculationLink link:definitionLink link:presentationLink 033 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 034 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Summary of Income and Share Amounts Utilized to Calculate Basic and Diluted Net Income Per Common Share (Details) link:calculationLink link:definitionLink link:presentationLink 035 - Disclosure - Note 3 - Revenue Recognition (Details Textual) link:calculationLink link:definitionLink link:presentationLink 036 - Disclosure - Note 3 - Revenue Recognition - Disaggregated Revenue by Revenue Stream (Details) link:calculationLink link:definitionLink link:presentationLink 037 - Disclosure - Note 4 - Medical Equipment (Details Textual) link:calculationLink link:definitionLink link:presentationLink 038 - Disclosure - Note 4 - Medical Equipment - Summary of Medical Equipment (Details) link:calculationLink link:definitionLink link:presentationLink 039 - Disclosure - Note 5 - Property and Equipment (Details Textual) link:calculationLink link:definitionLink link:presentationLink 040 - Disclosure - Note 5 - Property and Equipment - Property and Equipment (Details) link:calculationLink link:definitionLink link:presentationLink 041 - Disclosure - Note 6 - Intangible Assets (Details Textual) link:calculationLink link:definitionLink link:presentationLink 042 - Disclosure - Note 6 - Intangible Assets - Summary of Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 043 - Disclosure - Note 6 - Intangible Assets - Expected Annual Amortization Expense for Intangible Assets (Details) link:calculationLink link:definitionLink link:presentationLink 044 - Disclosure - Note 7 - Debt (Details Textual) link:calculationLink link:definitionLink link:presentationLink 045 - Disclosure - Note 7 - Debt - Summary of Revolver Based Upon Borrowers' Eligible Accounts Receivable and Inventory (Details) link:calculationLink link:definitionLink link:presentationLink 046 - Disclosure - Note 7 - Debt - Summary of Future Maturities of Loans (Details) link:calculationLink link:definitionLink link:presentationLink 047 - Disclosure - Note 7 - Debt - Summary of Company's Current and Long-term Debt (Details) link:calculationLink link:definitionLink link:presentationLink 048 - Disclosure - Note 8 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 049 - Disclosure - Note 8 - Income Taxes - Summary of (Loss) Income Before Income Taxes (Details) link:calculationLink link:definitionLink link:presentationLink 050 - Disclosure - Note 8 - Income Taxes - Summary of Components of Consolidated Provision for Income Taxes (Details) link:calculationLink link:definitionLink link:presentationLink 051 - Disclosure - Note 8 - Income Taxes - Changes in Valuation Allowance (Details) link:calculationLink link:definitionLink link:presentationLink 052 - Disclosure - Note 8 - Income Taxes - Reconciliations of Effective Income Tax Rate to Federal Statutory Rate (Details) link:calculationLink link:definitionLink link:presentationLink 053 - Disclosure - Note 8 - Income Taxes - Summary of Temporary Differences and Carryforwards That Give Rise to Deferred Tax Assets and Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 054 - Disclosure - Note 10 - Leases (Details Textual) link:calculationLink link:definitionLink link:presentationLink 055 - Disclosure - Note 10 - Leases - Lease Cost (Details) link:calculationLink link:definitionLink link:presentationLink 056 - Disclosure - Note 10 - Leases - Maturities of Lease Liabilities (Details) link:calculationLink link:definitionLink link:presentationLink 057 - Disclosure - Note 11 - Share-based Compensation (Details Textual) link:calculationLink link:definitionLink link:presentationLink 058 - Disclosure - Note 11 - Share-based Compensation - Summary of Restricted Share Activity, Excluding Company's Employee Stock Purchase Plan (Details) link:calculationLink link:definitionLink link:presentationLink 059 - Disclosure - Note 11 - Share-based Compensation - PSU Activity (Details) link:calculationLink link:definitionLink link:presentationLink 060 - Disclosure - Note 11 - Share-based Compensation - Summary of Activity Relating to Company's ESPP Program (Details) link:calculationLink link:definitionLink link:presentationLink 061 - Disclosure - Note 11 - Share-based Compensation - Summary of Stock Option and Inducement Stock Option Activity (Details) link:calculationLink link:definitionLink link:presentationLink 062 - Disclosure - Note 11 - Share-based Compensation - Schedule of Stock Options Outstanding (Details) link:calculationLink link:definitionLink link:presentationLink 063 - Disclosure - Note 11 - Share-based Compensation - Schedule of Share-based Compensation Expense Based on Fair Value of Options (Details) link:calculationLink link:definitionLink link:presentationLink 064 - Disclosure - Note 11 - Share-based Compensation - Stock-based Compensation (Details) link:calculationLink link:definitionLink link:presentationLink 065 - Disclosure - Note 12 - Business Segment Information (Details Textual) link:calculationLink link:definitionLink link:presentationLink 066 - Disclosure - Note 12 - Business Segment Information - Summary of Financial Information By Reportable Segment (Details) link:calculationLink link:definitionLink link:presentationLink 067 - Disclosure - Note 13 - Employee Benefit Plans and Other (Details Textual) link:calculationLink link:definitionLink link:presentationLink 068 - Disclosure - Note 15 - Subsequent Events (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 10 infu-20201231_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 11 infu-20201231_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 12 infu-20201231_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Note To Financial Statement Details Textual Weighted average fair value of options granted (in dollars per share) Significant Accounting Policies Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block] Note 2 - Summary of Significant Accounting Policies Note 3 - Revenue Recognition Risk free interest rate Note 4 - Medical Equipment Note 5 - Property and Equipment Note 6 - Intangible Assets Note 7 - Debt Note 8 - Income Taxes Note 10 - Leases Income Tax Disclosure [Text Block] Note 11 - Share-based Compensation Note 12 - Business Segment Information Note 2 - Summary of Significant Accounting Policies - Summary of Income and Share Amounts Utilized to Calculate Basic and Diluted Net Income Per Common Share (Details) Expected volatility Note 3 - Revenue Recognition - Disaggregated Revenue by Revenue Stream (Details) Note 4 - Medical Equipment - Summary of Medical Equipment (Details) us-gaap_LiabilitiesCurrent Total current liabilities Schedule of Maturities of Long-term Debt [Table Text Block] Note 5 - Property and Equipment - Property and Equipment (Details) Schedule of Debt [Table Text Block] Note 6 - Intangible Assets - Summary of Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets (Details) Note 6 - Intangible Assets - Expected Annual Amortization Expense for Intangible Assets (Details) Expected lives at date of grant (in years) (Year) Note 7 - Debt - Summary of Revolver Based Upon Borrowers' Eligible Accounts Receivable and Inventory (Details) Other current liabilities Note 7 - Debt - Summary of Future Maturities of Loans (Details) Note 7 - Debt - Summary of Company's Current and Long-term Debt (Details) us-gaap_BusinessCombinationConsiderationTransferred1 Business Combination, Consideration Transferred, Total Note 8 - Income Taxes - Summary of (Loss) Income Before Income Taxes (Details) Note 8 - Income Taxes - Summary of Components of Consolidated Provision for Income Taxes (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue Vested, aggregate fair value Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Note 8 - Income Taxes - Changes in Valuation Allowance (Details) Note 8 - Income Taxes - Reconciliations of Effective Income Tax Rate to Federal Statutory Rate (Details) Note 8 - Income Taxes - Summary of Temporary Differences and Carryforwards That Give Rise to Deferred Tax Assets and Liabilities (Details) Note 10 - Leases - Lease Cost (Details) Note 10 - Leases - Maturities of Lease Liabilities (Details) Note 11 - Share-based Compensation - Summary of Restricted Share Activity, Excluding Company's Employee Stock Purchase Plan (Details) Note 11 - Share-based Compensation - PSU Activity (Details) Note 11 - Share-based Compensation - Summary of Activity Relating to Company's ESPP Program (Details) Note 11 - Share-based Compensation - Summary of Stock Option and Inducement Stock Option Activity (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Granted, weighted average grant date fair value (in dollars per share) Share-based Payment Arrangement, Performance Shares, Activity [Table Text Block] Note 11 - Share-based Compensation - Schedule of Stock Options Outstanding (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Vested, weighted average grant date fair value (in dollars per share) Note 11 - Share-based Compensation - Schedule of Share-based Compensation Expense Based on Fair Value of Options (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Forfeitures, weighted average grant date fair value (in dollars per share) Note 11 - Share-based Compensation - Stock-based Compensation (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Unvested, weighted average grant date fair value (in dollars per share) Unvested, weighted average grant date fair value (in dollars per share) Note 12 - Business Segment Information - Summary of Financial Information By Reportable Segment (Details) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Forfeitures, number of shares (in shares) Notes To Financial Statements Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Unvested, number of shares (in shares) Unvested, number of shares (in shares) Notes To Financial Statements [Abstract] Schedule of Nonvested Share Activity [Table Text Block] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Vested, number of shares (in shares) Nonvested Restricted Stock Shares Activity [Table Text Block] Current portion of long-term debt Current portion of long-term debt Exercisable, weighted average exercise price (in dollars per share) Exercisable, number of authorized shares (in shares) Outstanding, weighted average remaining contractual term (Year) Outstanding, aggregate intrinsic value us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Outstanding, weighted average exercise price (in dollars per share) Outstanding, weighted average exercise price (in dollars per share) FilAMed [Member] Represents information pertaining to FilAMed. Forfeited, weighted average exercise price (in dollars per share) Exercised shares forgone to satisfy minimum statutory withholding, weighted average exercise price (in dollars per share) Granted, weighted average exercise price (in dollars per share) Exercised, weighted average exercise price (in dollars per share) us-gaap_EmployeeRelatedLiabilitiesCurrent Employee-related Liabilities, Current, Total Lessee, Operating Leases [Text Block] Accounts payable Revolving Credit Facility [Member] Proceeds from sale of medical equipment, property and equipment us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Outstanding, number of authorized shares (in shares) Outstanding, number of authorized shares (in shares) Revenue Recognition, Cost of Revenue [Policy Text Block] Disclosure of accounting policy for the cost of revenue for servicing and maintaining products sold including shipping and handling costs. us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod Exercised shares forgone to satisfy minimum statutory withholding, number of authorized shares (in shares) Additions to medical equipment and property Capital Expenditures Incurred but Not yet Paid Paycheck Protection Program CARES Act [Member] Represents loan designed to provide funds for small businesses to keep their employees on the payroll. Credit Facility [Axis] Credit Facility [Domain] Treasury Stock, Policy [Policy Text Block] Disclosure of accounting policy for policy of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock. us-gaap_PolicyTextBlockAbstract Accounting Policies Medical equipment for sale or rental Medical Equipment for sale or rental - net Represents medical equipment held for sale or rental as of the balance sheet date. Medical equipment in rental service, net of accumulated depreciation Medical Equipment in rental service - net Represents medical equipment in rental service, net of accumulated depreciation, as of the balance sheet date. Trade Names [Member] us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares) Indefinite-lived Intangible Assets [Axis] Indefinite-lived Intangible Assets, Major Class Name [Domain] Dilutive effect of restricted shares and options (in shares) us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchase of property and equipment us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares) us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year) Weighted average common shares outstanding: infu_LongtermDebtMaturitiesRepaymentsOfPrincipalYearFourAndThereafter 2025 and thereafter Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year and after fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). Current liabilities: Vesting [Axis] Vesting [Domain] SUPPLEMENTAL DISCLOSURES us-gaap_Assets Total assets Total assets Plan Name [Axis] Plan Name [Domain] us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Computer Software, Intangible Asset [Member] us-gaap_DeferredIncomeTaxAssetsNet Deferred income taxes Finite-Lived Intangible Assets by Major Class [Axis] Share-based Payment Arrangement [Text Block] Finite-Lived Intangible Assets, Major Class Name [Domain] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation Award Type [Domain] Numerator: Award Type [Axis] Net income (in thousands) Net income Net income Net income us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization Amortizable intangible assets, accumulated amortization Amortizable intangible assets, net us-gaap_FiniteLivedIntangibleAssetsNet Total nonamortizable and amortizable intangible assets, net Intangible assets, net Restricted Stock Units (RSUs) [Member] Amortizable intangible assets, gross assets us-gaap_FiniteLivedIntangibleAssetsGross infu_LineOfCreditFacilityMaximumOnetimeCharges Line of Credit Facility, Maximum One-time Charges The maximum one-time charges of the line of credit facility. Restricted Stock [Member] infu_LineOfCreditFacilityInvoicedHardCostMaximumPercent Line of Credit Facility, Invoiced Hard Cost Maximum Percent The invoiced hard cost maximum percent of the line of credit facility. Performance Shares [Member] Share-based Payment Arrangement, Option [Member] infu_LineOfCreditFacilityMaximumLeaseBuyoutExpenses Line of Credit Facility, Maximum Lease Buyout Expenses The maximum lease buyout expenses of the line of credit facility. Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Nonamortizable intangible assets us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill Commitments and Contingencies Disclosure [Text Block] us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Accumulated Depreciation Total us-gaap_PropertyPlantAndEquipmentNet Property & equipment, net of accumulated depreciation Gross Assets us-gaap_PropertyPlantAndEquipmentGross Canada Revenue Agency [Member] Long-term Debt, Type [Axis] Long-term Debt, Type [Domain] infu_LineOfCreditFacilityAdditionalMaximumBorrowingCapacity Line of Credit Facility Additional Maximum Borrowing Capacity The amount of additional maximum borrowing capacity for a line of credit. INVESTING ACTIVITIES infu_NumberOfOperatingLocations Number of Operating Locations Represents the entity's number of operating locations as of the balance sheet date. infu_NumberOfFinancialInstitutions Number of Financial Institutions Represents the number of financial institutions where the entity maintains its cash and cash equivalents. Physician and Customer Relationships [Member] Represents information pertaining to physician and customer relationships. infu_MedicalEquipmentInRentalServicesUsefulLife Medical Equipment in Rental Services, Useful Life (Year) Represents the useful life of medical equipment in rental services. Letter of Credit [Member] us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments Income before income taxes us-gaap_IncomeTaxExpenseBenefit Benefit from (provision for) income taxes Total income tax benefit (expense) Benefit from income taxes Medical Equipment [Policy Text Block] Disclosure of accounting policy for medical equipment. Presentation in Consolidated Statements [Policy Text Block] Disclosure of accounting policy for presentation in consolidated statements. us-gaap_OperatingExpenses Total selling, general and administrative Selling , general and administrative expenses us-gaap_DebtInstrumentTerm Debt Instrument, Term (Month) 2014 Amended and Restated Stock Incentive Plan [Member] Related to the 2014 amended and restated stock incentive plan. General and administrative Cash and cash equivalents Medical Equipment and Property Disclosure [Text Block] The entire disclosure for medical equipment and property. Schedule of Medical Equipment [Table Text Block] Tabular disclosure of medical equipment. infu_DepreciationExpenseRelatedToMedicalEquipment Depreciation Expense Related to Medical Equipment Represents the amount of depreciation expense related to medical equipment recorded during the period. infu_MedicalEquipmentInRentalServicesAccumulatedDepreciation Accumulated depreciation Represents the amount of accumulated depreciation related to medical equipment in rental services. infu_MedicalEquipmentNet Total Represents the net amount of medical equipment, as of the balance sheet date. Medical Equipment in rental service infu_MedicalEquipmentInRentalServicesGross Represents the gross amount of medical equipment in rental services. infu_MedicalEquipmentInRentalServicesReserve Medical Equipment in Rental Services Reserve Medical Equipment in rental service - pump reserve Represents the amount of medical equipment in rental services reserve, as of the balance sheet date. us-gaap_DefinedBenefitPlanContributionsByEmployer Defined Benefit Plan, Plan Assets, Contributions by Employer Amendment Flag Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets [Table Text Block] Tabular disclosure of the carrying amount and accumulated amortization of identifiable intangible assets. Use of Estimates, Policy [Policy Text Block] infu_EmployeeStockOwnershipPlanESOPPurchasePerEmployeeMaximum Employee Stock Ownership Plan ESOP Purchase Per Employee Maximum The maximum threshold, per employee, of purchases made in the employee stock ownership plan. New Accounting Pronouncements, Policy [Policy Text Block] infu_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlanNumberOfRemainingSharesAvailableForFutureIssuance Stock Issued During Period Shares Employee Stock Ownership Plan Number of Remaining Shares Available for Future Issuance (in shares) Stock issued during period shares employee stock ownership plan number of remaining shares available for future issuance. infu_EmployeeStockPurchasePlanDiscountRate Employee Stock Purchase Plan Discount Rate The discount rate applied to an employee stock purchase plan. Accounts payable and other liabilities infu_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationInPeriodFairValue Vested shares forgone to satisfy minimum statutory withholding, aggregate fair value Fair value of share-based awards expired during the period, to receive or retain shares or units, other instruments, or cash. Weighted average fair value per ESPP award (in dollars per share) The weighted average purchase price of shares purchased under the employee stock purchase plan. Reclassification, Comparability Adjustment [Policy Text Block] infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsInPeriod Vested shares forgone to satisfy minimum statutory withholding, number of shares (in shares) The number of equity-based payment instruments, excluding stock (or unit) options, that expired during the reporting period. us-gaap_DebtInstrumentPeriodicPaymentPrincipal Debt Instrument, Periodic Payment, Principal infu_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsExpirationsWeightedAverageGrantDateFairValue Vested shares forgone to satisfy minimum statutory withholding, weighted average grant date fair value (in dollars per share) The weighted average fair value at grant date for nonvested equity-based awards expired during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). us-gaap_SharesOutstanding Balances (in shares) Balances (in shares) infu_CashlessExerciseOfStockOptionsShares Cashless exercise, number of authorized shares (in shares) The number of shares exercised in a cashless transaction. Common stock, shares outstanding (in shares) Cashless exercise, weighted average exercise price (in dollars per share) The weighted average exercise price of awarded shares exercised in the period in a cashless transaction. Current Fiscal Year End Date us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Debt Instrument, Basis Spread on Variable Rate Changes in Liabilities - Increase: Variable lease cost us-gaap_LeaseCost Lease, Cost, Total Total lease cost Inducement Stock Options [Member] Related to the inducement stock option awards. Exercised, aggregate intrinsic value Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding for the shares exercised during the period. us-gaap_DebtInstrumentInterestRateEffectivePercentage Debt Instrument, Interest Rate, Effective Percentage Granted, weighted average remaining contractual term (Year) Weighted average remaining contractual term for option awards granted, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Basis of Accounting [Text Block] Operating leases Range 3 [Member] Related to the third exercise price range. Document Fiscal Period Focus Operating lease cost Range 1 [Member] Related to the exercise price range. Document Fiscal Year Focus Consolidation, Policy [Policy Text Block] Range 2 [Member] Related to the second exercise price range. Lease, Cost [Table Text Block] Document Period End Date ROU assets obtained in exchange for lease obligations: Operating leases Weighted average remaining lease term: Operating leases (Year) Entity Emerging Growth Company Document Type Entity Small Business Entity Shell Company Document Information [Line Items] Document Information [Table] infu_DebtInstrumentBasisSpreadOnVariableRateBeforeMarginRate Debt Instrument, Basis Spread on Variable Rate, Before Margin Rate Percentage points, excluding the margin rate, added to the reference rate to compute the variable rate on the debt instrument. Entity Public Float infu_NetOperatingLossCarryforwardsLimitationOnUse Net Operating Loss Carryforwards Limitation on Use The annual limitations on use applicable to net operating loss carryforwards. Entity Filer Category Debt Instrument [Axis] Entity Current Reporting Status Debt Instrument, Name [Domain] Entity Voluntary Filers infu_OperatingLossCarryforwardsExpirationPeriods Operating Loss Carryforwards Expiration Periods (Year) The duration of operating loss carryforwards before expiration begins. Entity Well-known Seasoned Issuer us-gaap_ImpairmentOfIntangibleAssetsFinitelived Impairment of Intangible Assets, Finite-lived London Interbank Offered Rate (LIBOR) [Member] infu_RemainingPreownershipNetOperatingLossCarryforwards Remaining Preownership Net Operating Loss Carryforwards Amount of remaining preownership net operating loss carryforwards. us-gaap_CapitalizedComputerSoftwareNet Capitalized Computer Software, Net, Ending Balance Variable Rate [Domain] Permanent differences Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the permanent differences. us-gaap_CapitalizedComputerSoftwareAmortization1 Capitalized Computer Software, Amortization Term Loan [Member] Represents information pertaining to the Term Loan. us-gaap_ImpairmentOfLongLivedAssetsHeldForUse Impairment of Long-Lived Assets Held-for-use us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) Variable Rate [Axis] us-gaap_ConcentrationRiskPercentage1 Concentration Risk, Percentage us-gaap_IncreaseDecreaseInAccountsReceivable Accounts receivable Stock-based compensation expense us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Loss on disposal of medical equipment and other assets Entity Central Index Key infu_LandlordReserves Landlord reserves Amount of landlord reserves. Depreciation and amortization of intangible assets Entity Registrant Name infu_UnamortizedValueOfDebtIssuanceCostsPrincipalCurrent Unamortized value of the debt issuance costs, 2021 Unamortized value of debt issuance costs principal during the next 12 months (for annual periods) remainder of fiscal year (for interim periods). Employee stock purchase plan Entity [Domain] Customer Concentration Risk [Member] infu_UnamortizedValueOfDebtIssuanceCostsPrincipalInYearFour Unamortized value of the debt issuance costs, 2024 Unamortized value of debt issuance costs principal in year four. Legal Entity [Axis] infu_UnamortizedValueOfDebtIssuanceCostsPrincipalInYearTwo Unamortized value of the debt issuance costs, 2022 Unamortized value of debt issuance costs principal in year two. Supplier Concentration Risk [Member] infu_UnamortizedValueOfDebtIssuanceCostsPrincipalInYearThree Unamortized value of the debt issuance costs, 2023 Unamortized value of debt issuance costs principal in year three. Amortization of intangible assets Amortization of intangibles Amortization of Intangible Assets, Total infu_UnamortizedDebtIssuanceExpenseCurrent Unamortized value of the debt issuance costs, current portion of long-term debt The current portion of unamortized debt issuance expense. infu_UnamortizedDebtIssuanceExpenseNoncurrent Unamortized value of the debt issuance costs, long-term debt The noncurrent portion of unamortized debt issuance expense. Concentration Risk Type [Axis] Concentration Risk Type [Domain] Cost of Goods and Service, Product and Service Benchmark [Member] Trade Names 1 [Member] Rights acquired through registration of a business name to gain or protect exclusive use thereof. Entity Common Stock, Shares Outstanding (in shares) us-gaap_DepreciationNonproduction Depreciation, Nonproduction Revenue Benchmark [Member] Revenue, Product and Service Benchmark [Member] us-gaap_IncreaseDecreaseInOtherCurrentAssets Other current assets us-gaap_IncreaseDecreaseInOtherNoncurrentAssets Other assets Revenue from Contract with Customer Benchmark [Member] us-gaap_IncreaseDecreaseInInventories Inventories Trading Symbol Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Domain] Employee stock purchase plan (in shares) Shares of stock sold to employees (in shares) us-gaap_GainLossOnDispositionOfAssets Gain on sale of medical equipment Availability on Revolver us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised Exercised, number of authorized shares (in shares) us-gaap_TableTextBlock Notes Tables us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Line of Credit Facility, Maximum Borrowing Capacity us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity Line of Credit Facility, Current Borrowing Capacity Gross availability Stock-based shares issued upon vesting - gross (in shares) Stock-based shares issued upon vesting - gross Provision for doubtful accounts Granted, number of authorized shares (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod Forfeited, number of authorized shares (in shares) Selling and marketing Common stock - issued (in shares) Schedule of Line of Credit Facilities [Table Text Block] Selling, general and administrative expenses: us-gaap_LiabilitiesAndStockholdersEquity Total liabilities and stockholders’ equity Common stock - issued infu_LenderPrimeRate Lender Prime Rate Represents the lender's prime rate. Changes in Assets - Increase: Retained deficit infu_UnamortizedValueOfDebtIssuanceCostsPrincipalInYearFourAndThereafter Unamortized value of the debt issuance costs, 2025 and thereafter Unamortized value of debt issuance costs principal in year four and thereafter. Debt Disclosure [Text Block] us-gaap_InterestExpense Interest expense Interest expense Amortization of deferred debt issuance costs us-gaap_DisclosureTextBlockAbstract Notes to Financial Statements Subsequent Event [Member] Operating lease liabilities, net of current portion Total lease liabilities Subsequent Event Type [Axis] Subsequent Event Type [Domain] Retirement Benefits [Text Block] Total nonamortizable and amortizable intangible assets, gross assets us-gaap_IntangibleAssetsGrossExcludingGoodwill Subsequent Events [Text Block] Operating lease right of use assets us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Total undiscounted lease payments us-gaap_UnamortizedDebtIssuanceExpense Unamortized value of the debt issuance costs, Total Capitalization of Internal Costs, Policy [Policy Text Block] us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount Less: Imputed interest us-gaap_DeferredIncomeTaxExpenseBenefit Deferred income taxes Amortization expense, 2026 and thereafter us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree 2023 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour 2024 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive 2025 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive Thereafter Information Technology Software [Member] Represents the external information technology software used. Amortization expense, 2022 Fair Value of Financial Instruments, Policy [Policy Text Block] Amortization expense, 2023 Amortization expense, 2024 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths 2021 Amortization expense, 2025 us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo 2022 Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Segment Reporting, Policy [Policy Text Block] Amortization expense, 2021 Stock option and SARs expense Restricted share expense Lessee, Operating Lease, Liability, Maturity [Table Text Block] us-gaap_ShareBasedCompensation Total stock-based compensation expense Stock-based compensation Other assets Lessee, Leases [Policy Text Block] us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 Finite-Lived Intangible Assets, Remaining Amortization Period (Year) Business Combinations Policy [Policy Text Block] us-gaap_FiniteLivedIntangibleAssetUsefulLife Finite-Lived Intangible Asset, Useful Life (Year) Earnings Per Share, Policy [Policy Text Block] Net revenues Revenues, Total Total net revenues Income Tax, Policy [Policy Text Block] us-gaap_LesseeOperatingLeaseRenewalTerm Lessee, Operating Lease, Renewal Term (Year) Cardinal Health, Inc. [Member] Information related to Cardinal Health, Inc. Depreciation Ambulatory Pumps [Member] Information related to the ambulatory pumps. Smiths Medical, Inc. [Member] Information related to Smiths Medical, Inc. us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation (in shares) Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation (in shares) Intangible Assets Disclosure [Text Block] NPWT Medical Equipment [Member] Information related to the NPWT medical equipment. Oncology Business [Member] Represents the information pertaining to the Oncology Business. Moog Medical Devices Group [Member] Information related to Moog Medical Devices Group. us-gaap_AssetsCurrent Total current assets Share-based Payment Arrangement [Policy Text Block] Range 7 [Member] Related to the seventh exercise price range. Share-based Payment Arrangement, Achieving Minimum Threshold [Member] Represents information related to the achievement of minimum threshold under the share-based payment arrangement. Range 4 [Member] Related to the fourth exercise price range. Range 5 [Member] Related to the fifth exercise price range. Range 6 [Member] Related to the sixth exercise price range. infu_LineOfCreditFacilityAdditionalBorrowingCapacitySubjectToCertainConditions Line of Credit Facility, Additional Borrowing Capacity Subject to Certain Conditions Additional borrowing capacity under the credit facility subject to certain conditions. Share-based Payment Arrangement, Exceeding Minimum Threshold [Member] Represents information related to exceeding the minimum threshold under the share-based payment arrangement. Common stock, $.0001 par value: authorized 200,000,000 shares; issued and outstanding 23,816,193 and 20,297,704, as of December 31, 2020, respectively, and issued and outstanding 23,400,625 and 19,882,136, as of December 31, 2019, respectively. The 2021 Credit Agreement [Member] Information related to the "2021 Credit Agreement". ABR Loans [Member] Information related to the ABR loans. Adjustments to reconcile net income to net cash provided by operating activities: infu_DebtInstrumentCovenantMinimumFixedCoverageRatio Debt Instrument, Covenant, Minimum Fixed Coverage Ratio The minimum fixed coverage ratio required by the debt agreement. Common stock, shares authorized (in shares) infu_DeferredTaxAssetsValuationAllowanceExpense Income tax expense Amount of increase in the valuation allowance for deferred tax assets charged to income tax expense. Release of valuation allowance Amount of decrease in the valuation allowance for deferred tax assets due to the release of valuation allowance. Common stock, shares issued (in shares) The 2015 Credit Agreement [Member] Information related to the "2015 Credit Agreement". Common stock, par value (in dollars per share) Equipment Line [Member] Information related to the equipment line. infu_DebtInstrumentCovenantMaximumLeverageRatio Debt Instrument, Covenant, Maximum Leverage Ratio The maximum leverage ratio required by the debt agreement. us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount Revenue from Contract with Customer [Policy Text Block] infu_PercentageOfTotalDepreciationExpense Percentage of Total Depreciation Expense The percentage of total depreciation expense. Valuation allowance at the Beginning of Period Valuation allowance at the End of Period us-gaap_DeferredTaxAssetsValuationAllowance Less: valuation allowance Statistical Measurement [Domain] Operating cash flow from operating leases Maximum [Member] Summary of Valuation Allowance [Table Text Block] NON-CASH TRANSACTIONS Minimum [Member] Product and Service [Axis] Other current assets Product and Service [Domain] us-gaap_DeferredTaxAssetsNet Net deferred Federal tax assets Statistical Measurement [Axis] Deferred Charges, Policy [Policy Text Block] Preferred stock, $.0001 par value: authorized 1,000,000 shares; none issued Net deferred tax assets us-gaap_DeferredTaxAssetsLiabilitiesNet Net deferred tax assets Preferred stock, shares issued (in shares) Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Cash paid for interest Cash paid for income taxes Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block] Eurodollar Loan [Member] Represents the information pertaining to the Eurodollar Loan. Other Property, Plant and Equipment Disclosure [Text Block] Property, Plant and Equipment [Table Text Block] us-gaap_DeferredTaxAssetsGross Total deferred tax assets Total deferred tax assets Preferred stock, shares authorized (in shares) us-gaap_DeferredIncomeTaxLiabilities Total deferred Federal tax liabilities Inventories us-gaap_InventoryNet Greater of Prime Rate or LIBOR Plus 2.5% [Member] Represents the information pertaining to the greater of prime rate or LIBOR plus 2.5%. Preferred stock, par value (in dollars per share) CB Floating Rate Loan [Member] Represents the information pertaining to the CB Floating Rate Loan. us-gaap_InventoryValuationReserves Inventory Valuation Reserves, Ending Balance infu_ShareBasedCompensationArrangementByShareBasedpaymentawardpercentageoftargetnumberofsharestobeearned Share-based Compensation Arrangement By Share-based Payment Award Percentage of Target Number of Shares to be Earned The percentage of target number of shares to be earned under share based payment arrangement. Exercised shares forgone to satisfy minimum statutory withholding (in dollars per share) Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that were forgone to satisfy minimum statutory tax withholding. Customer [Axis] Inventories Customer [Domain] Goodwill and intangible assets us-gaap_PropertyPlantAndEquipmentUsefulLife Property, Plant and Equipment, Useful Life (Year) OPERATING ACTIVITIES National Association 2 [Member] Represents the information pertaining to the second national association comprised of multiple members. Schedule of Segment Reporting Information, by Segment [Table Text Block] Bad debt reserves Statement [Line Items] us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent Accounts Receivable, Allowance for Credit Loss, Current Furniture and Fixtures [Member] Accounts receivable, net us-gaap_NumberOfReportableSegments Number of Reportable Segments Stock-based compensation Additional paid-in capital Accrued compensation Stockholders’ equity: Leasehold Improvements [Member] Property, Plant and Equipment, Policy [Policy Text Block] Other expense Other expense Long-Lived Tangible Asset [Axis] Other credits Long-Lived Tangible Asset [Domain] Segment Reporting Disclosure [Text Block] Net operating loss Deferred Tax Assets, Operating Loss Carryforwards, Total Chief Executive Officer [Member] Research & development credits Current assets: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations Cash and cash equivalents, beginning of year Cash and cash equivalents, end of year Inventory, Policy [Policy Text Block] us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net change in cash and cash equivalents infu_OperatingLossCarryforwardsWithIndefiniteLife Operating Loss Carryforwards with Indefinite Life Represents the amount of operating loss carryforwards that have an indefinite life. us-gaap_NetCashProvidedByUsedInFinancingActivities NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES us-gaap_Liabilities Total liabilities us-gaap_OperatingIncomeLoss Operating income us-gaap_NetCashProvidedByUsedInOperatingActivities NET CASH PROVIDED BY OPERATING ACTIVITIES Other expense: Net deferred tax liabilities us-gaap_DeferredTaxLiabilities Net deferred tax liabilities us-gaap_NetCashProvidedByUsedInInvestingActivities NET CASH USED IN INVESTING ACTIVITIES DME Services Segment [Member] Represents information regarding the DME Services segment. ITS Segment [Member] Represents information regarding the ITS segment. us-gaap_GrossProfit Gross profit Gross profit Base Rate [Member] Cost of revenues infu_MedicalEquipmentForSaleOrRentalReserve Medical Equipment for Sale or Rental, Reserve Medical Equipment for sale or rental - pump reserve Represents the amount of reserve associated with medical equipment for sale or rental, as of the balance sheet date. infu_MedicalEquipmentHeldForSaleOrRentalGross Medical Equipment for sale or rental Represents medical equipment held for sale or rental as of the balance sheet date, before reserves. infu_OperatingLossCarryforwardsWithADefiniteLife Operating Loss Carryforwards with a Definite Life Represents the amount of operating loss carryforwards that have an indefinite life. Deferred income taxes Consolidation Items [Domain] The 2019 Equipment Line [Member] Represents information regarding the 2019 Equipment Line. CB Floating Rate [Member] Represents information regarding the CB Floating Rate. Consolidation Items [Axis] Cash proceeds from 2019 equipment line, equipment line, revolving credit facility and other financing infu_DeferredTaxLiabilitiesRightOfUseAssets Right-of-use assets Amount of deferred tax liability attributable to right-of-use assets. Third-Party Payor Rental Revenue [Member] Represents third-party payor rental revenue. Operating lease liabilities Amount before allocation of valuation allowances of deferred tax asset attributable to operating lease liabilities. Concentration Risk, Credit Risk, Policy [Policy Text Block] infu_NumberOfLeasesEnteredIntoDuringThePeriodForEquipment Number of Leases Entered Into During the Period for Equipment Represents the number of leases entered into during the period for equipment. us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Common stock repurchased to satisfy statutory withholding on employee stock-based compensation plans us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment Depreciation and asset basis differences Share Repurchase Program, 2020 Repurchases [Member] Represents information pertaining to 2020 Repurchases under the Share Repurchase Program. us-gaap_LettersOfCreditOutstandingAmount Letters of credit Reductions to ROU assets resulting from reductions to lease obligations: Operating leases Represents the amount of reductions to right-of-use assets resulting from reductions to lease obligations. us-gaap_AccruedPayrollTaxesCurrentAndNoncurrent Accrued Payroll Taxes Net revenues - internal Represents the amount of internal net revenues recognized during the period. Net revenues - external Represents the amount of external net revenues recognized during the period. Cash proceeds from stock plans infu_PaymentsToAcquireMedicalEquipment Purchase of medical equipment Purchases of medical equipment Represents the amount of cash paid during the period to acquire medical equipment. Retained Earnings [Member] Title of Individual [Domain] us-gaap_CurrentStateAndLocalTaxExpenseBenefit Current, state and local Title of Individual [Axis] us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit Deferred, state and local Treasury Stock [Member] us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations Total state and local income tax benefit (expense) us-gaap_CurrentForeignTaxExpenseBenefit Current Additional Paid-in Capital [Member] Share Repurchase Program [Domain] U.S Federal income tax benefit (expense) us-gaap_CurrentFederalTaxExpenseBenefit Current, federal Common Stock [Member] Corporate and Eliminations [Member] Represents information regarding corporate and eliminations. us-gaap_StockRepurchaseProgramAuthorizedAmount1 Stock Repurchase Program, Authorized Amount us-gaap_DeferredFederalIncomeTaxExpenseBenefit Deferred, federal us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations Total U.S. Federal income tax benefit (expense) Collateral Held [Domain] Equity Components [Axis] Share Repurchase Program [Axis] Equity Component [Domain] Total us-gaap_LongTermDebt Long-term Debt, Total Collateral Held [Axis] Other Liabilities [Member] Other Current Liabilities [Member] Non-U.S. income us-gaap_IncomeTaxExaminationYearUnderExamination Income Tax Examination, Year under Examination us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Income before income taxes U.S income us-gaap_LineOfCredit Long-term Line of Credit, Total Outstanding draws us-gaap_PaymentsOfDebtIssuanceCosts Debt issuance costs State and Local Jurisdiction [Member] Income Tax Authority, Name [Axis] us-gaap_DeferredFinanceCostsNet Unamortized value of debt issuance costs Income Tax Authority, Name [Domain] Internal Revenue Service (IRS) [Member] Automobiles [Member] Income Tax Authority [Axis] Income Tax Authority [Domain] Disaggregation of Revenue [Table Text Block] Domestic Tax Authority [Member] Foreign Tax Authority [Member] us-gaap_RepaymentsOfLongTermDebt Repayments of Long-term Debt, Total Granted, aggregate intrinsic value The aggregate intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. Revenue from Contract with Customer [Text Block] us-gaap_RepaymentsOfLongTermDebtAndCapitalSecurities Principal payments on term loans, equipment line, revolving credit facility and other financing Accounts Receivable [Policy Text Block] Computer Equipment [Member] Cash and Cash Equivalents, Policy [Policy Text Block] Balance Sheet Location [Axis] Balance Sheet Location [Domain] Software Development [Member] us-gaap_UnrecognizedTaxBenefits Unrecognized Tax Benefits, Ending Balance General and Administrative Expense [Member] Accounting Policies [Abstract] Significant Accounting Policies [Text Block] us-gaap_OpenTaxYear Open Tax Year us-gaap_RepaymentsOfLongTermLinesOfCredit Repayments of Long-term Lines of Credit Entity Interactive Data Current Direct Payer Rentals [Member] Represents direct payer rental revenue. Title of 12(b) Security Credit Facility [Member] Represents information about credit facility. us-gaap_ProceedsFromIssuanceOfLongTermDebt Proceeds from Issuance of Long-term Debt, Total Cost of Sales [Member] us-gaap_ProceedsFromLongTermLinesOfCredit Proceeds from Long-term Lines of Credit Income Statement Location [Axis] Income Statement Location [Domain] infu_LIBORRate LIBOR Rate Represents the LIBOR rate. Product Sales [Member] Represents information about product sales. infu_LineOfCreditFacilityBorrowingBase Line of Credit Facility, Borrowing Base The amount of money that a lender is willing to loan a company calculated as the sum of the company's eligible accounts receivable and eligible inventory as define by the credit agreement. Effect of Covid-19 Pandemic [Text Block] The entire disclosure for effects of COVID-19 pandemic. Segments [Axis] Segments [Domain] us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) Diluted (in shares) Diluted (in shares) us-gaap_OperatingLossCarryforwards Operating Loss Carryforwards, Total Net income per share: Statement [Table] Statement of Financial Position [Abstract] Diluted (in dollars per share) Basic (in shares) Other adjustments us-gaap_EffectiveIncomeTaxRateContinuingOperations Effective income tax rate Business Acquisition [Axis] Basic (in dollars per share) Business Acquisition, Acquiree [Domain] Decrease in valuation allowance Statement of Cash Flows [Abstract] Statement of Stockholders' Equity [Abstract] Income Statement [Abstract] us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree 2023 us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour 2024 us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths 2021 us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo 2022 Contract with Customer, Sales Channel [Axis] Contract with Customer, Sales Channel [Domain] Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block] Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Schedule of Deferred Tax Assets and Liabilities [Table Text Block] Schedule of Effective Income Tax Rate Reconciliation [Table Text Block] us-gaap_EmployeeStockOwnershipPlanESOPSharesContributedToESOP Employee Stock Ownership Plan (ESOP), Shares Contributed to ESOP (in shares) State and local income tax expense Foreign income tax FINANCING ACTIVITIES Income tax expense at the statutory rate Medical Equipment [Member] Represents medical equipment. Financing Agreement [Member] Information pertaining to the financing agreement (the "Financing Agreement"). Compensation expense us-gaap_StockholdersEquity Total stockholders’ equity Balances Balances Supplier [Axis] Class of Stock [Axis] Supplier [Domain] Long-term debt Long-term debt, net of current portion Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Options outstanding, weighted-average exercise price (in dollars per share) Options outstanding, weighted-average remaining contractual life (Year) Options exercisable, number of shares exercisable (in shares) Options exercisable, weighted-average exercise price (in dollars per share) Operating Segments [Member] Exercise price, upper range (in dollars per share) Options outstanding, number of shares outstanding (in shares) Exercise Price Range [Axis] Exercise Price Range [Domain] Exercise price, lower range (in dollars per share) EX-101.PRE 13 infu-20201231_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 14 infulogo.jpg begin 644 infulogo.jpg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end XML 15 R1.htm IDEA: XBRL DOCUMENT v3.21.1
Document And Entity Information - USD ($)
12 Months Ended
Dec. 31, 2020
Mar. 16, 2021
Jun. 30, 2020
Document Information [Line Items]      
Entity Registrant Name InfuSystem Holdings, Inc    
Entity Central Index Key 0001337013    
Trading Symbol infu    
Current Fiscal Year End Date --12-31    
Entity Filer Category Non-accelerated Filer    
Entity Current Reporting Status Yes    
Entity Voluntary Filers No    
Entity Well-known Seasoned Issuer No    
Entity Emerging Growth Company false    
Entity Small Business true    
Entity Interactive Data Current Yes    
Entity Common Stock, Shares Outstanding (in shares)   20,336,671  
Entity Public Float     $ 150,739,346
Entity Shell Company false    
Document Type 10-K    
Document Period End Date Dec. 31, 2020    
Document Fiscal Year Focus 2020    
Document Fiscal Period Focus FY    
Amendment Flag false    
Title of 12(b) Security Common Stock, par value $0.0001 per share    
XML 16 R2.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Balance Sheets - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 9,648 $ 2,647
Accounts receivable, net 14,720 12,097
Inventories 3,001 2,899
Other current assets 2,402 1,662
Total current assets 29,771 19,305
Medical equipment for sale or rental 1,603 1,306
Medical equipment in rental service, net of accumulated depreciation 35,611 33,225
Property & equipment, net of accumulated depreciation 4,296 4,037
Intangible assets, net 11,177 15,463
Operating lease right of use assets 4,461 5,733
Deferred income taxes 9,967
Other assets 105 155
Total assets 96,991 79,224
Current liabilities:    
Accounts payable 6,779 7,962
Current portion of long-term debt 9,423 8,082
Other current liabilities 6,795 5,803
Total current liabilities 22,997 21,847
Long-term debt, net of current portion 29,378 30,295
Deferred income taxes 104
Operating lease liabilities, net of current portion 3,864 4,644
Total liabilities 56,239 56,890
Stockholders’ equity:    
Preferred stock, $.0001 par value: authorized 1,000,000 shares; none issued
Common stock, $.0001 par value: authorized 200,000,000 shares; issued and outstanding 23,816,193 and 20,297,704, as of December 31, 2020, respectively, and issued and outstanding 23,400,625 and 19,882,136, as of December 31, 2019, respectively. 2 2
Additional paid-in capital 84,785 83,699
Retained deficit (44,035) (61,367)
Total stockholders’ equity 40,752 22,334
Total liabilities and stockholders’ equity $ 96,991 $ 79,224
XML 17 R3.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Balance Sheets (Parentheticals) - $ / shares
Dec. 31, 2020
Dec. 31, 2019
Preferred stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized (in shares) 1,000,000 1,000,000
Preferred stock, shares issued (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized (in shares) 200,000,000 200,000,000
Common stock, shares issued (in shares) 23,816,193 23,400,625
Common stock, shares outstanding (in shares) 20,297,704 19,882,136
XML 18 R4.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Statements of Operations - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Net revenues $ 97,388 $ 81,115
Cost of revenues 38,629 34,233
Gross profit 58,759 46,882
Selling, general and administrative expenses:    
Provision for doubtful accounts 791 37
Amortization of intangibles 4,285 4,402
Selling and marketing 9,661 9,932
General and administrative 35,195 28,986
Total selling, general and administrative 49,932 43,357
Operating income 8,827 3,525
Other expense:    
Interest expense (1,255) (1,904)
Other expense (29) (97)
Income before income taxes 7,543 1,524
Benefit from (provision for) income taxes 9,789 (163)
Net income $ 17,332 $ 1,361
Net income per share:    
Basic (in dollars per share) $ 0.86 $ 0.07
Diluted (in dollars per share) $ 0.80 $ 0.07
Weighted average common shares outstanding:    
Basic (in shares) 20,106,940 19,731,498
Diluted (in shares) 21,717,216 20,839,396
XML 19 R5.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Statements of Stockholders' Equity - USD ($)
$ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Treasury Stock [Member]
Total
Balances (in shares) at Dec. 31, 2018 23,096,000     (3,518,000)  
Balances at Dec. 31, 2018 $ 2 $ 83,167 $ (62,728) $ 20,441
Stock-based shares issued upon vesting - gross (in shares) 394,000      
Stock-based shares issued upon vesting - gross   139     139
Stock-based compensation expense   997     $ 997
Employee stock purchase plan (in shares) 33,000     33,742
Employee stock purchase plan   113     $ 113
Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation (in shares) (122,000)     (100,000)
Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation   (717)     $ (717)
Net income 1,361 1,361
Balances (in shares) at Dec. 31, 2019 23,401,000     (3,518,000)  
Balances at Dec. 31, 2019 $ 2 83,699 (61,367) 22,334
Stock-based shares issued upon vesting - gross (in shares) 505,000      
Stock-based shares issued upon vesting - gross      
Stock-based compensation expense   2,610     $ 2,610
Employee stock purchase plan (in shares) 29,000     30,012
Employee stock purchase plan   190     $ 190
Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation (in shares) (147,000)     (100,000)
Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation   (1,714)     $ (1,714)
Net income 17,332 17,332
Common stock - issued (in shares) 28,000      
Common stock - issued
Balances (in shares) at Dec. 31, 2020 23,816,000     (3,518,000)  
Balances at Dec. 31, 2020 $ 2 $ 84,785 $ (44,035) $ 40,752
XML 20 R6.htm IDEA: XBRL DOCUMENT v3.21.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
OPERATING ACTIVITIES    
Net income $ 17,332 $ 1,361
Adjustments to reconcile net income to net cash provided by operating activities:    
Provision for doubtful accounts 791 37
Depreciation 9,740 7,940
Loss on disposal of medical equipment and other assets 418 638
Gain on sale of medical equipment (3,577) (1,453)
Amortization of intangible assets 4,285 4,402
Amortization of deferred debt issuance costs 17 37
Stock-based compensation 2,610 997
Deferred income taxes (10,071) 104
Changes in Assets - Increase:    
Accounts receivable (2,631) (1,560)
Inventories (102) (645)
Other current assets (740) (290)
Other assets (186) (129)
Changes in Liabilities - Increase:    
Accounts payable and other liabilities 2,394 2,436
NET CASH PROVIDED BY OPERATING ACTIVITIES 20,280 13,875
INVESTING ACTIVITIES    
Purchase of medical equipment (15,820) (19,669)
Purchase of property and equipment (1,094) (2,926)
Proceeds from sale of medical equipment, property and equipment 4,752 2,952
NET CASH USED IN INVESTING ACTIVITIES (12,162) (19,643)
FINANCING ACTIVITIES    
Principal payments on term loans, equipment line, revolving credit facility and other financing (37,180) (4,868)
Cash proceeds from 2019 equipment line, equipment line, revolving credit facility and other financing 37,587 9,436
Debt issuance costs (6)
Common stock repurchased to satisfy statutory withholding on employee stock-based compensation plans (1,714) (717)
Cash proceeds from stock plans 190 252
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES (1,117) 4,097
Net change in cash and cash equivalents 7,001 (1,671)
Cash and cash equivalents, beginning of year 2,647 4,318
Cash and cash equivalents, end of year 9,648 2,647
SUPPLEMENTAL DISCLOSURES    
Cash paid for interest 1,214 1,705
Cash paid for income taxes 102 111
NON-CASH TRANSACTIONS    
Additions to medical equipment and property [1] $ 793 $ 2,773
[1] Amounts consist of current liabilities for medical equipment that have not been included in investing activities. These amounts have not been paid for as of December 31, 2020 and 2019, respectively, but will be included as a cash outflow from investing activities for purchases of medical equipment and property when paid.
XML 21 R7.htm IDEA: XBRL DOCUMENT v3.21.1
Note 1 - Basis of Presentation and Nature of Operations
12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Basis of Accounting [Text Block]
1.
         
Basis of Presentation and Nature of Operations
 
InfuSystem Holdings, Inc. and its consolidated subsidiaries (the “Company”) are a leading provider of infusion pumps and related products and services for patients in the home, oncology clinics, ambulatory surgery centers, and other sites of care from
five
locations in the United States and Canada. The Company provides products and services to hospitals, oncology practices and facilities and other alternate site health care providers. Headquartered in Rochester Hills, Michigan, the Company delivers local, field-based customer support, and also operates pump service and repair Centers of Excellence in Michigan, Kansas, California, Massachusetts and Ontario, Canada. InfuSystem Inc. (“ISI”), which is an operating subsidiary of the Company, is accredited by the Community Health Accreditation Program while First Biomedical, Inc. (First Biomedical), which is an operating subsidiary of the Company, is ISO certified.
 
The Company's core service is to supply electronic ambulatory infusion pumps and associated disposable supply kits to oncology clinics, infusion clinics and hospital outpatient chemotherapy clinics to be utilized in the treatment of a variety of cancers including colorectal cancer, pain management and other disease states. The majority of the Company's pumps are electronic infusion pumps. Smiths Medical, Inc. and Moog Medical Devices Group each supplied more than
10%
of the ambulatory pumps purchased by the Company in
2020.
The Company has a supply agreement in place with each of these suppliers. Certain “spot” purchases are made on the open market subject to individual negotiation. The Company also supplies Negative Pressure Wound Therapy (“NPWT”) medical equipment, as well as related disposables and ancillary supplies. Cardinal Health, Inc. supplied more than
10%
of the NPWT medical equipment purchased by the Company in
2020.
The Company has a supply agreement in place with Cardinal Health, Inc.
 
In addition, the Company sells or rents new and pre-owned pole-mounted and ambulatory infusion pumps to, and provides biomedical recertification, maintenance and repair services for oncology practices, as well as other alternate site settings including home care and home infusion providers, skilled nursing facilities, pain centers and others. The Company also provides these products and services to customers in the hospital market.
 
The Company purchases new and pre-owned pole-mounted and ambulatory infusion pumps from a variety of sources on a non-exclusive basis. The Company repairs, refurbishes and provides biomedical certification for the devices as needed. The pumps are then available for sale, rental or to be used within the Company's ambulatory infusion pump management service.
 
The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”).
XML 22 R8.htm IDEA: XBRL DOCUMENT v3.21.1
Note 2 - Summary of Significant Accounting Policies
12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Significant Accounting Policies [Text Block]
2.
         
Summary of Significant Accounting Policies
 
Reclassifications
 
Certain prior period reclassifications were made to conform with the current period presentation. These reclassifications had
no
effect on reported income (loss), overall cash flows, total assets, total liabilities or stockholders' equity as previously reported.
 
Presentation in the Consolidated Statements
 
The Company rents and sells medical equipment. The Company purchases medical equipment directly for sale as well as medical equipment that is purchased for either rental or sale and that is unallocated at the time of purchase (“Unallocated Assets”). Management believes that the predominant source of revenues and cash flows from the Unallocated Assets is from rentals and most equipment purchased is likely to be rented prior to being sold. The Company concluded that (i) the assets specifically supporting its
two
primary revenue streams should be separately disclosed on the balance sheet; (ii) the purchase and sale of Unallocated Assets should be classified solely in investing cash flows based on their predominant source while medical equipment purchased specifically for sales activity should be classified in operating cash flows; and (iii) other activities ancillary to the rental process should be consistently classified.
 
Principles of Consolidation
 
The consolidated financial statements include the accounts of the Company and all wholly owned organizations. All intercompany transactions and account balances have been eliminated in consolidation.
 
Segments
 
During the
fourth
quarter of
2019,
the Company reorganized its segment reporting from
one
reportable segment to
two
reportable segments, Integrated Therapy Services (“ITS”) and Durable Medical Equipment Services (“DME Services”), due to changes in our internal reporting and the information evaluated by our chief operating decision-maker. See Note
12
for segment disclosures.
 
The Company's approach is to make operational decisions and assess performance based on delivering products and services that together provide solutions to its customer base utilizing a functional management structure. Based upon this business model, the Company's Chief Executive Officer, whom the Company has determined to be its chief operating decision-maker, reviews segment financial information.
 
Use of Estimates
 
The preparation of financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements, including the notes thereto. The Company considers critical accounting policies to be those that require more significant judgments and estimates in the preparation of its consolidated financial statements, including the following: revenue recognition, leases, accounts receivable and allowance for doubtful accounts, income taxes, and long-lived asset valuations. Management relies on historical experience and other assumptions believed to be reasonable in making its judgments and estimates. Actual results could differ materially from those estimates.
 
Business Combinations
 
The Company accounts for all business combinations using the acquisition method of accounting, which allocates the fair value of the purchase consideration to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values. The excess of the purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. When determining the fair values of assets acquired and liabilities assumed, management makes significant estimates and assumptions. The Company
may
utilize
third
-party valuation specialists to assist the Company in the allocation. Initial purchase price allocations are subject to revision within the measurement period,
not
to exceed
one
year from the date of acquisition. Acquisition-related expenses and transaction costs associated with business combinations are expensed as incurred.
 
Cash and Cash Equivalents
 
The Company considers all highly liquid investments with original maturities of
three
months or less to be cash equivalents. The Company maintains its cash and cash equivalents primarily with
two
financial institutions that are insured with the Federal Deposit Insurance Corporation (“FDIC”). At times throughout the year, cash and cash equivalents balances might exceed FDIC insurance limits.
 
Accounts Receivable and Allowance for Doubtful Accounts
 
Amounts billed that have
not
yet been collected that also meet the conditions for unconditional right to payment are presented as accounts receivable. Accounts receivable related to rental service and delivery of products are reported at their estimated transaction prices, inclusive of adjustments for variable consideration, based on the amounts expected to be collected from payers. The Company writes off accounts receivable once collection efforts have been exhausted and an account is deemed to be uncollectible. An allowance for doubtful accounts is established as a result of an adverse change in the Company's payers' ability to pay outstanding billings. The allowance for doubtful accounts was
$1.0
million and
$0.4
million as of
December 31, 2020
and
2019,
respectively.
 
Inventories
 
The Company's inventories consist of disposable medical supplies, replacement parts and other supplies used in conjunction with medical equipment and are stated at the lower of cost (
first
-in,
first
-out basis) or net realizable value. The Company periodically performs an analysis of slow-moving inventory and records a reserve based on estimated obsolete inventory, which was
$0.1
million as of
December 31, 2020
and
2019.
 
Medical Equipment
 
Medical Equipment (“Equipment”) consists of equipment that the Company purchases from
third
-parties and is (
1
) for sale or rent, and (
2
) used in service to generate rental revenue. Equipment, once placed into service, is depreciated using the straight-line method over the estimated useful lives of the equipment which is typically
seven
years. The Company does
not
depreciate Equipment held for sale or rent. When Equipment in rental service assets are sold, or otherwise disposed, the cost and related accumulated depreciation are removed from the accounts and a sale is recorded in the current period. The Company periodically performs an analysis of slow-moving Equipment used in service to generate rental revenue and records a reserve based on estimated obsolescence, which was
$0.9
and
$0.7
million as of
December 31, 2020
and
2019,
respectively. The Company performs a similar analysis of slow-moving Equipment for sale or rent and records a reserve, which was less than
$0.1
million as of
December 31, 2020
and
2019.
 
Property and Equipment
 
Property and equipment is stated at acquired cost and depreciated using the straight-line method over the estimated useful lives of the related assets, ranging from
three
to
seven
years. Externally purchased information technology software and hardware are depreciated over
three
and
five
years, respectively. Leasehold improvements are amortized using the straight-line method over the life of the asset or the remaining term of the lease, whichever is shorter. Maintenance and minor repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is recorded in the current period.
 
Intangible Assets
 
Intangible assets consist of trade names, physician and customer relationships and software. The physician and customer relationships arose primarily from previous acquisitions. The Company amortizes the value assigned to the physician and customer relationships on a straight-line basis over the period of expected benefit, which ranges from
fifteen
to
twenty
years. The acquired physician and customer relationship base represents a valuable asset of the Company due to the expectation of future business opportunities to be leveraged from the existing relationship with each physician and customer. The Company has long-standing relationships with numerous oncology clinics, physicians, home care and home infusion providers, skilled nursing facilities, pain centers and others. The useful lives of these relationships are based on minimal attrition experienced to date by the Company and expectations of continued minimal attrition. Acquired software is amortized on a straight-line basis over
three
years. Trade names associated with the original acquisition of InfuSystem are
not
amortized.
 
Management tests indefinite life trade names for impairment annually or more frequently if deemed necessary. The impairment test for intangible assets with indefinite lives consists of a comparison of the fair value of the intangible assets with their carrying amounts. If the carrying value of the intangible assets exceeds the fair value, an impairment loss is recognized in an amount equal to that excess. The Company determines the fair value for trade names with indefinite lives through the royalty relief income valuation approach. The Company performed its annual impairment analysis as of the last day of
October 2020
and determined that the fair value of the trade names with indefinite lives was greater than their carrying value, resulting in
no
impairment.
 
Software Capitalization and Depreciation
 
The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software, including payroll and payroll-related costs for employees who are directly associated with the internal-use software project, external direct costs of materials and services and interest costs while developing the software. Capitalized software costs are included in intangible assets, net and are amortized using the straight-line method over the estimated useful life of
three
to
five
years. Capitalization of such costs ceases when the project is substantially complete and ready for its intended purpose. Costs incurred during the preliminary project and post-implementation stages, as well as software maintenance and training costs, are expensed in the period in which they are incurred. The Company did
not
capitalize any internal-use software for the years ended
December 31, 2020
and
2019,
respectively. Amortization expense for capitalized software was
$1.9
million in
2020
and
$2.0
million in
2019.
 
Impairment of Long-Lived Assets
 
Long-lived assets held for use, which includes medical equipment in rental service, property and equipment and amortizable intangible assets, are reviewed for impairment when events or changes in circumstances indicate that their carrying value
may
not
be recoverable. If an impairment indicator exists, the Company assesses the asset or asset group for recoverability. Recoverability of these assets is determined based upon the expected undiscounted future net cash flows from the operations to which the assets relate, utilizing management's best estimates, appropriate assumptions and projections at the time. If the carrying value is determined
not
to be recoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair market value of the asset or asset group.
 
The Company assesses impairment indicators related to its internally-developed, internal-use software, specifically looking at the effectiveness and useful lives of each project and sub-project to determine if impairment indicators are present. In
December 2020
and
2019,
respectively, the Company assessed the impairment indicators and found
none
to be present.
 
Leases
 
On
January 1, 2019 (
the “Effective Date”), the Company adopted Accounting Standards Update (“ASU”)
2016
-
02,
Leases (Topic
842
); ASU
2018
-
10,
Codification Improvements to Topic
842,
Leases; and ASU
2018
-
11,
Targeted Improvements (collectively, “Topic
842”
) using a modified retrospective transition approach, which requires Topic
842
to be applied to all leases existing at the date of initial application. Under Topic
842,
lessees are required to recognize a lease liability and right-of-use asset (“ROU asset”) for all leases and to disclose key information about leasing arrangements. Additionally, leases are classified as either financing or operating; the classification determines the pattern of expense recognition and classification within the statement of operations. The Company elected to apply its lease accounting policy only to leases with a term greater than
twelve
months.
 
Topic
842
provides several optional practical expedients that we adopted at transition. The Company elected the “package of practical expedients”, which does
not
require it to reassess its prior conclusions regarding lease identification, lease classification and initial direct costs. The Company did
not
elect the practical expedient of hindsight to the evaluation of lease options (e.g. renewal).
 
Topic
842
also provides practical expedients for an entity's ongoing accounting. The Company elected the “combining lease and non-lease components” practical expedient and also elected to apply the short-term lease recognition exemption to certain leases; therefore, the Company did
not
recognize ROU assets and lease liabilities for these leases.
 
In adopting Topic
842,
the Company determined and will continue to determine whether an arrangement is a lease at inception. The Company's operating leases are primarily for office space, service facility centers and equipment under operating lease arrangements that expire at various dates over the next
ten
years. The Company's leases do
not
contain any restrictive covenants. The Company's office leases generally contain renewal options for periods ranging from
one
to
five
years. Because the Company is
not
reasonably certain to exercise these renewal options, the options are
not
considered in determining the lease term, and payments associated with the option years are excluded from lease payments. The Company's office leases do
not
contain any material residual value guarantees. The Company's equipment leases generally do
not
contain renewal options. The Company is
not
reasonably certain to exercise the renewal options for those equipment leases that do contain renewal options, thus, the options are
not
considered in determining the lease term and payments associated with the option years are excluded from lease payments.
 
For the Company's equipment leases, the Company used and will use the implicit rate in the lease as the discount rate, when available. Otherwise, the Company uses its incremental borrowing rate as the discount rate. For the Company's office leases, the implicit rate is typically
not
available, so the Company used and will use its incremental borrowing rate as the discount rate. The incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments. The Company's lease agreements include both lease and non-lease components. The Company elected the practical expedient that allows it to combine lease and non-lease components for all of its leases.
 
Payments due under the Company's operating leases include fixed payments as well as variable payments. For the Company's office leases, variable payments include amounts for the Company's proportionate share of operating expenses, utilities, property taxes, insurance, common area maintenance and other facility-related expenses. For the Company's equipment leases, variable payments
may
consist of sales taxes, property taxes and other fees.
 
Revenue Recognition
 
Revenue is recognized at the time and in an amount that reflects the consideration expected to be received for the performance obligations that have been provided. Accounting Standards Codification (“ASC”) Topic
606
– Revenue from Contracts with Customers (“ASC
606”
) defines contracts as written, oral and through customary business practice. Under this definition, the Company considers contracts to be created at the time that the rental service is authorized or an order to purchase product is agreed upon regardless of whether or
not
there is a written contract.
 
The Company has
two
separate and distinct performance obligations offered to its customers: a rental service performance obligation or a product sale performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is defined as the unit of account for revenue recognition under ASC
606.
These performance obligations are related to separate revenue streams and at
no
point are they combined into a single transaction. Sources of net revenues include commercial insurance payers, government insurance payers, medical facilities and patients.
 
The Company generates the majority of its revenue from the rental of infusion pumps to its customers and a minority of its revenue from product sales. For the rental service performance obligation, revenue is based on its standalone price, determined by using reimbursement rates established by
third
-party payer or other contracts. Revenue is recognized in the period in which the related performance obligation is satisfied, which is typically at the point in time that a patient concludes a treatment, or in certain arrangements, based on the number of pumps that a facility has onsite. The Company's revenues related to product sales are recognized at the time that control of the product has been transferred to the customer; either at the time the product is shipped or the time the product has been received by the customer, depending on the delivery terms. The Company does
not
commit to long-term contracts to sell customers a certain minimum quantity of products.
 
The Company employs certain significant judgments to estimate the dollar amount of revenue, and related concessions, allocated to the rental service and sale of products. These judgments include, among others, the estimation of variable consideration. Variable consideration, specifically related to the Company's
third
-party payer rental revenues, is estimated as implied price concessions resulting from differences between the rates charged for services performed and the expected reimbursements for commercial payers and other implied customer concessions. The estimates for variable consideration are based on historical collections with similar payers, aged accounts receivable by payer class and payer correspondence using the portfolio approach, which provide a reasonable basis for estimating the variable portion of a transaction. The Company doesn't believe it is probable that a significant reversal of revenue will occur in future periods because (i) there is
no
significant uncertainty about the amount of considerations that are expected to be collected based on collection history and (ii) the large number of sufficiently similar contracts allows the Company to adequately estimate the component of variable consideration.
 
Net revenues are adjusted when changes in estimates of variable consideration occur. Changes in estimates typically arise as a result of new information obtained, such as actual payment receipt or denial, or pricing adjustments by payers. Subsequent changes to estimates of transaction prices are recorded as adjustments to net revenue in the period of the change. Subsequent changes that are determined to be the result of an adverse change in the payer's ability to pay are recorded as an allowance for doubtful accounts.
 
Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenues and accounts receivable at their net realizable values. Inherent in these estimates is the risk that the estimates will have to be revised or updated as additional information becomes available. Specifically, the complexity of many
third
-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payers
may
result in adjustments to amounts originally recorded. Due to continuing changes in the health care industry and
third
-party reimbursement, it is possible that management's estimates could change in the near term, which could have a material impact on the Company's results of operations and cash flows.
 
Cost of Revenues
 
Cost of revenues include the costs of servicing and maintaining pumps, products sold, shipping and other direct and indirect costs related to net revenues. Shipping and handling costs incurred after control over a product has transferred to a customer are accounted for as a fulfillment cost.
 
Customer Concentration
 
For
2020
and
2019,
the Company's largest contracted payer was a national payer which accounted for approximately
14%
and
8%
of ITS net revenues for
2020
and
2019,
respectively, and approximately
9%
and
5%
of total consolidated net revenues for
2020
and
2019,
respectively.
 
The Company also contracts with various other
third
-party payer organizations, Medicaid, commercial Medicare replacement plans, self-insured plans, facilities of our Medicare patients and numerous other insurance carriers. Other than the payer noted above,
no
other single payer represented more than
7%
of the Company's ITS net revenue.
 
Income Taxes
 
The Company recognizes deferred income tax liabilities and assets based on (i) the differences between the financial statement carrying amounts and the tax basis of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse and (ii) the tax credit carryforwards. Deferred income tax (expense) benefit results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when it is more likely than
not
that some or all of any deferred tax assets will
not
be realized.
 
Provisions for federal, state and foreign taxes are calculated based on reported pre-tax earnings based on current tax law and include the cumulative effect of any changes in tax rates from those used previously in determining deferred tax assets and liabilities. Certain items of income and expense are recognized in different time periods for financial reporting than for income tax purposes; thus, such provisions differ from the amounts currently receivable or payable.
 
The Company follows a
two
-step approach for recognizing uncertain tax positions. First, it evaluates the tax position for recognition by determining if the weight of available evidence indicates it is more-likely-than-
not
that the position will be sustained upon examination. Second, for positions that are determined are more-likely-than-
not
to be sustained, it recognizes the tax benefits as the largest benefit that has a greater than
50%
likelihood of being sustained. The Company establishes a reserve for uncertain tax positions liability that is comprised of unrecognized tax benefits and related interest and penalties. The Company adjusts this liability in the period in which an uncertain tax position is effectively settled, the statute of limitations expires for the relevant taxing authority to examine the tax position, or more information becomes available.
 
The Company adopted ASU
2019
-
12,
Income Taxes (Topic
740
): Simplifying the Accounting for Income Taxes, in the
fourth
quarter of
2019.
This guidance simplifies various aspects related to accounting for income taxes by removing certain exceptions to the general principles in Topic
740
and also clarifies and amends existing guidance to improve consistent application. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after
December 15, 2020.
Early adoption is permitted, including adoption in any interim period for which financial statements have
not
yet been issued. Certain amendments
may
be applied on a retrospective, modified retrospective or prospective basis. As permitted, the Company elected to early adopt this guidance for the year ended
December 31, 2019.
The adoption of this guidance did
not
have a significant impact on the Company's financial statements and primarily resulted in the reclassification of an immaterial amount from non-income tax expense to income tax expense related to the accounting for franchise taxes, with
no
impact to the Company's consolidated net income, equity or cash flows.
 
Treasury Stock
 
The Company periodically repurchases shares of its common stock. These repurchases take place either as part of a board-authorized program, which
may
include open market transactions or privately negotiated transactions and
may
be made under a Rule
10b5
-
1
plan, or in targeted stock purchase agreements approved by the board. Treasury stock is accounted for using the par value method.
 
Share-Based Payments
 
The Company determines the fair value of stock option awards, restricted stock awards and stock appreciation rights (collectively, “Share-Based Awards”) on the date of grant using option-pricing models which are affected by the Company's stock price, as well as assumptions regarding a number of other inputs using the Black-Scholes pricing model. These variables include the Company's expected stock price volatility over the expected term of the Share-Based Awards, actual and projected employee stock option exercise behaviors, risk-free interest rates and expected dividends. The expected volatility is based on the historical volatility. The Company uses historical data to estimate Share-Based Awards exercise rates. The expected term represents the period over which the Share-Based Awards are expected to be outstanding. The dividend yield is an estimate of the expected dividend yield on the Company's stock. The risk-free rate is based on U.S. Treasury yields in effect at the time of the grant for the expected term of the Share-Based Awards. All Share-Based Awards are amortized based on their graded vesting over the requisite service period of the awards. Compensation costs are recognized over the requisite service period using the accelerated method and included in general and administrative expenses.
 
Additionally, the Company also determines the fair value of performance-based restricted stock units (“PSUs”) based upon the type of performance measure. These awards typically vest after the Company's achievement of either Company performance relative to specified performance measure goals for a specific fiscal period or when the market value of the Company's stock price reaches a target value for a minimum number of consecutive trading days. Under Financial Accounting Standards Board (“FASB”) ASC Topic
718,
the provisions of the PSUs that vest upon achievement of a target market value are considered a market condition, and therefore the effect of that market condition is reflected in the grant date fair value for this type of award. A
third
-party valuation expert was engaged to complete a “Monte Carlo simulation” to account for the market condition. That simulation takes into account the beginning stock price of the Company's common stock, the expected volatilities for the Company's stock price and the expected risk-free rate of return. The single grant-date fair value computed by this valuation method is recognized by the Company in accounting for the awards regardless of the actual future outcome of the market condition. The grant date fair value of the other PSUs is calculated as the closing price of the Company's common stock on the grant date multiplied by the number of shares subject to the award. Company performance measure goals are considered a performance condition and the grant-date fair value for those PSUs corresponds with management's expectation of the probable outcome of the performance conditions as of the grant date.
 
Deferred Debt Issuance Costs
 
Capitalized debt issuance costs as of
December 31, 2020
and
2019
relate to the Company's credit facility. The costs related to the agreement are netted against current and non-current debt. The Company amortizes these costs using the interest method through the maturity date of the underlying debt.
 
Earnings Per Share
 
The Company reports its earnings per share in accordance with ASU
2017
-
11,
Earnings Per Share (Topic
260
), which requires the presentation of both basic and diluted earnings per share on the statements of operations. The diluted weighted average common shares include adjustments for the potential effects of outstanding stock options but only in the periods in which such effect is dilutive under the treasury stock method. Included in our basic and diluted weighted average common shares are those stock options and restricted stock awards due to participants granted from the
2014
stock incentive plan. Anti-dilutive stock awards are comprised of stock options and unvested restricted stock awards, which would have been anti-dilutive in the application of the treasury stock method in accordance with ASU
2017
-
11,
Earnings Per Share (Topic
260
). In periods where the Company records a net loss, the diluted per share amount is the same as the basic per share amount.
 
In accordance with this topic, the following table reconciles income and share amounts utilized to calculate basic and diluted net income per common share as of
December 31 (
in thousands, except shares):
 
   
2020
   
2019
 
Numerator:
               
Net income
(in thousands)
  $
17,332
    $
1,361
 
Denominator:
               
Weighted average common shares outstanding:
               
Basic
   
20,106,940
     
19,731,498
 
Dilutive effect of restricted shares and options
   
1,610,276
     
1,107,898
 
Diluted
   
21,717,216
     
20,839,396
 
 
Stock options of less than
0.1
million shares were
not
included in the calculations for both the years ended
December 31, 2020
and
2019
because they would have an anti-dilutive effect.
 
Fair Value of Financial Instruments
 
The carrying amounts reported in the consolidated balance sheets as of
December 31, 2020
and
2019
for cash, accounts receivable, accounts payable and other current liabilities approximate fair value because of the short-term nature of these instruments (Level I). The carrying value of the Company's long-term debt with variable interest rates approximates fair value based on instruments with similar terms (Level II).
 
The Company has adopted ASC
820,
Fair Value Measurements, which defines fair value, establishes a framework for assets and liabilities being measured and reported at fair value and appends disclosures about fair value measurements.
 
For financial assets and liabilities measured at fair value on a recurring basis, fair value is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date. A
three
-level fair value hierarchy prioritizes the inputs used to measure fair value as follows:
 
 
Level I
:
quoted prices in active markets for identical instruments;
 
 
Level II
:
quoted prices in active markets for similar instruments, quoted prices for identical instruments in markets that are
not
active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the instrument; and
 
 
Level III
:
significant inputs to the valuation model are unobservable.
 
Recent Accounting Pronouncements and Developments
 
In
June 2016,
the FASB issued ASU
No.
2016
-
13,
“Financial Instruments (Topic
326
) Credit Losses”. Topic
326
changes the impairment model for most financial assets and certain other instruments. Under the new standard, entities holding financial assets and net investment in leases that are
not
accounted for at fair value through net income are to be presented at the net amount expected to be collected. An allowance for credit losses will be a valuation account that will be deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected on the financial asset. Topic
326
was originally effective as of
January 1, 2020,
although in
November 2019,
the FASB delayed the effective date until fiscal years beginning after
December 15, 2022
for SEC filers eligible to be smaller reporting companies under the SEC's definition. The Company qualifies as a smaller reporting company under the SEC's definition. Early adoption is permitted. The Company is currently evaluating the impact of Topic
326
on its consolidated balance sheets, statements of operations, statements of cash flows and related disclosures.
XML 23 R9.htm IDEA: XBRL DOCUMENT v3.21.1
Note 3 - Revenue Recognition
12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Revenue from Contract with Customer [Text Block]
3.
         
Revenue Recognition
 
The following table presents the Company's disaggregated revenue by offering type as of
December 31 (
in thousands):
 
   
2020
   
2019
 
                 
Third-Party Payer Rentals
  $
49,266
    $
40,510
 
Direct Payer Rentals
  $
30,765
    $
26,269
 
Product Sales
  $
17,357
    $
14,336
 
                 
Total - Net revenues
  $
97,388
    $
81,115
 
 
Third-Party Payer Rentals are entirely attributed to revenues of the ITS segment. Product Sales are entirely attributed to revenues of the DME Services segment. For the year ended
December 31, 2020,
$11.8
million and
$19.0
million of Direct Payer Rentals were attributed to the ITS and DME Services segments, respectively. For the year ended
December 31, 2019,
$11.0
million and
$15.3
million were attributed to the ITS and DME Services segments, respectively.
 
The following table presents the Company's disaggregated revenue by offering type as a percentage of total net revenues as of
December 31:
 
   
2020
   
2019
 
                 
Third-Party Payer Rentals
   
50.6
%    
49.9
%
Direct Payer Rentals
   
31.6
%    
32.4
%
Product Sales
   
17.8
%    
17.7
%
                 
Total - Net revenues
   
100.0
%    
100.0
%
 
XML 24 R10.htm IDEA: XBRL DOCUMENT v3.21.1
Note 4 - Medical Equipment
12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Medical Equipment and Property Disclosure [Text Block]
4.
         
Medical Equipment
 
Medical equipment consisted of the following as of
December 
31
(in thousands):
 
   
2020
   
2019
 
Medical Equipment for sale or rental
  $
1,636
    $
1,334
 
Medical Equipment for sale or rental - pump reserve
   
(33
)    
(28
)
Medical Equipment for sale or rental - net
   
1,603
     
1,306
 
                 
Medical Equipment in rental service
   
83,411
     
75,853
 
Medical Equipment in rental service - pump reserve
   
(893
)    
(720
)
Accumulated depreciation
   
(46,907
)    
(41,908
)
Medical Equipment in rental service - net
   
35,611
     
33,225
 
                 
Total
  $
37,214
    $
34,531
 
 
Depreciation expense for medical equipment for the years ended
December 31, 2020
and
2019
was
$8.9
million and
$7.5
million, respectively, which were recorded in “cost of revenues” for each period.
XML 25 R11.htm IDEA: XBRL DOCUMENT v3.21.1
Note 5 - Property and Equipment
12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Property, Plant and Equipment Disclosure [Text Block]
5.
         
Property and Equipment
 
Property and equipment consisted of the following as of
December 
31
(in thousands):
 
   
2020
 
   
Gross Assets
   
Accumulated
Depreciation
   
Total
 
Furniture, fixtures, and equipment
  $
3,742
    $
(2,018
)   $
1,724
 
Automobiles
   
117
     
(102
)    
15
 
Leasehold improvements
   
3,416
     
(859
)    
2,557
 
                         
Total
  $
7,275
    $
(2,979
)   $
4,296
 
 
   
2019
 
   
Gross Assets
   
Accumulated
Depreciation
   
Total
 
Furniture, fixtures, and equipment
  $
3,202
    $
(1,928
)   $
1,274
 
Automobiles
   
117
     
(90
)    
27
 
Leasehold improvements
   
3,366
     
(630
)    
2,736
 
                         
Total
  $
6,685
    $
(2,648
)   $
4,037
 
 
Depreciation expense for property and equipment for each of the years ended
December 31, 2020
and
2019
was
$0.8
million and
$0.5
million, respectively. This expense was recorded in “general and administrative expenses” for each period.
 
XML 26 R12.htm IDEA: XBRL DOCUMENT v3.21.1
Note 6 - Intangible Assets
12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Intangible Assets Disclosure [Text Block]
6.
         
Intangible Assets
 
The carrying amount and accumulated amortization of intangible assets as of
December 31, 2020
and
2019
were as follows (in thousands):
 
   
2020
 
   
Gross Assets
   
Accumulated Amortization
   
Net
 
Nonamortizable intangible assets
                       
Trade names
  $
2,000
    $
-
    $
2,000
 
Amortizable intangible assets
                       
Trade names
   
23
     
(23
)    
-
 
Physician and customer relationships
   
36,534
     
(28,924
)    
7,610
 
Software
   
11,230
     
(9,663
)    
1,567
 
                         
Total nonamortizable and amortizable intangible assets
  $
49,787
    $
(38,610
)   $
11,177
 
 
 
   
2019
 
   
Gross Assets
   
Accumulated Amortization
   
Net
 
Nonamortizable intangible assets
                       
Trade names
  $
2,000
    $
-
    $
2,000
 
Amortizable intangible assets
                       
Trade names
   
23
     
(23
)    
-
 
Physician and customer relationships
   
36,534
     
(26,550
)    
9,984
 
Software
   
11,230
     
(7,751
)    
3,479
 
                         
Total nonamortizable and amortizable intangible assets
  $
49,787
    $
(34,324
)   $
15,463
 
 
The weighted average remaining lives of physician and customer relationships and software were
seven
years and
one
year, respectively, as of
December 31, 2020.
 
The Company assesses impairment indicators related to its internally-developed, internal-use software, specifically looking at the effectiveness and useful lives of each project and sub-project to determine if impairment indicators are present. In
December 2020
and
2019,
respectively, the Company assessed the impairment indicators and found
none
to be present.
 
Amortization expense for intangible assets for the years ended
December 31, 2020
and
2019
was
$4.3
million and
$4.4
million, respectively, which was recorded in operating expenses. Expected annual amortization expense for the next
five
years for intangible assets recorded as of
December 31, 2020
is as follows (in thousands):
 
   
2021
   
2022
   
2023
   
2024
   
2025
   
2026 and
thereafter
 
Amortization expense
  $
3,930
    $
2,051
    $
548
    $
548
    $
367
    $
1,733
 
 
XML 27 R13.htm IDEA: XBRL DOCUMENT v3.21.1
Note 7 - Debt
12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Debt Disclosure [Text Block]
7.
         
Debt
 
On
February 5, 2019,
the Company and its primary lender entered into the
fifth
amendment (the “Fifth Amendment”) to its Credit Agreement entered into on
March 23, 2015 (
as amended, the
“2015
Credit Agreement”). The Fifth Amendment amended the
2015
Credit Agreement to, among other things:
 
 
increase our borrowing capacity under the equipment line to
$8.0
million, which allows for capital expenditure financing to the Company for the sole purpose of purchasing medical equipment (the “Equipment Line”);
 
revise the definition of earnings before interest, taxes, depreciation and amortization (“EBITDA”), a non-GAAP financial measure, to include additional add-back adjustments for the years ended
December 31, 2018
and
2019;
 
revise the definition of fixed charge coverage ratio for the year ended
December 31, 2019
to include an unfinanced portion of capital expenditures of up to
$7.0
million for the year ended
December 31, 2019;
 
revise the
2015
Credit Agreement's maximum permitted indebtedness to finance the acquisition, construction or improvement of any fixed or capital assets; and
 
revise the maximum leverage ratio for each of the quarters during
December 31, 2018
and
December 31, 2019.
 
On
April 15, 2019,
the Company sold for
$2.0
million and immediately leased back certain medical equipment in rental service to a
third
party specializing in such transactions. The leaseback term is
36
months. Because the arrangement contains a purchase option that the Company is reasonably certain to exercise, this transaction did
not
qualify for the sale-leaseback accounting under ASC
842.
The medical equipment remains recorded on the accompanying consolidated balance sheet and the proceeds received have been classified as an Other Financing liability, which is being paid off monthly over the term of the lease. The balance of Other Financing as of
December 31, 2020
was
$0.9
million.
 
On
November 7, 2019,
the Company and its primary lender entered into the
sixth
amendment (the “Sixth Amendment”) to its
2015
Credit Agreement. The Sixth Amendment amended the
2015
Credit Agreement to, among other things:
 
 
provide for a
2019
capital expenditure loan (the
“2019
Equipment Line”) commitment of
$10.0
million (in addition to the existing Equipment Line of
$8.0
million), which
may
be drawn upon until the earlier of the full commitment being advanced or
December 31, 2020,
to be used solely to purchase eligible equipment to be used in the Company's business and in amounts
not
to exceed
90.0%
of the invoiced hard costs of such acquired equipment;
 
increase the commitment for the revolving credit facility (the “Revolver”) under the
2015
Credit Agreement to
$11.8
million;
 
revise the definition of EBITDA to include the following additional or revised add-back adjustments: (i)
one
-time charges in an aggregate amount
not
to exceed
$0.3
million and incurred prior to
December 31, 2019
relating to the Company's integration of business previously served by another major provider of electronic oncology pumps; (ii)
one
-time charges in an aggregate amount
not
to exceed
$0.3
million and incurred prior to
December 31, 2019
relating to the Company's facility move; (iii) lease buyout expenses
not
to exceed: (
x
)
$0.1
million incurred on or prior to
December 31, 2018; (
y)
$0.2
million incurred after
December 31, 2018
but on or prior to
March 31, 2019;
and (z)
$0.2
million incurred after
September 30, 2019
but on or prior to
December 31, 2020;
and (iv) any other non-cash charges for such period (but excluding certain non-cash charges);
 
revise the definition of Fixed Charge Coverage Ratio to mean, for any period, the ratio of (a) EBITDA minus Maintenance Capital Expenditures (defined to mean, for any period,
50.0%
of depreciation expense) to (b) Fixed Charges, all calculated for the Company and its subsidiaries on a consolidated basis in accordance with GAAP;
 
revise the definitions of Revolving Credit Maturity Date and Term Maturity Date to mean the date
five
years after the Sixth Amendment Effective Date and add a definition for the
2019
Equipment Line Maturity Date to provide for the same maturity date;
 
reflect the refinancing of the Term A Loans, Term B Loans and Term C Loan as a single term loan (the “Term Loan”) on the Sixth Amendment Effective Date and, commencing on the last Business Day of
December 2019,
the consecutive quarterly principal installment payments changed to approximately
$1.2
million; and
 
revise Section
5.01
(e) of the
2015
Credit Agreement, which governs the Company's obligation to deliver financial statements to the lender, to require the Company to provide financial statements (
x
) as soon as possible but in any event within
30
days of the end of each fiscal quarter, or within
30
days of the end of each calendar month if any revolving loans were outstanding in month, (y) in connection with, and prior to, requesting any letter of credit and (z) at such other times as
may
be requested by the lender.
 
These debt amendments were accounted for as debt modifications. As of
December 31, 2020,
the Company was in compliance with all financial covenants under the
2015
Credit Agreement.
 
As of
December 31, 2020,
the Company's Term Loan, Equipment Line and
2019
Equipment line under the
2015
Credit Agreement had balances of
$21.9
million,
$6.0
million and
$10.0
million, respectively. The availability under the Revolver is subject to a borrowing base, which is calculated as the sum of the Company's eligible accounts receivable and eligible inventory as defined by the
2015
Credit Agreement. As of
December 31, 2020,
the borrowing base was approximately
$15.6
million, which exceeded the gross available borrowing amount of
$11.8
million. The following table illustrates the net availability under the Revolver as of the applicable balance sheet date (in thousands):
 
   
December 31,
   
December 31,
 
   
2020
   
2019
 
Revolver:
               
Gross availability
  $
11,750
    $
11,750
 
Outstanding draws
   
-
     
-
 
Letters of credit
   
(800
)    
(1,750
)
Landlord reserves
   
(162
)    
(150
)
Availability on Revolver
  $
10,788
    $
9,850
 
 
The Company had future maturities of loans as of
December 31, 2020
as follows (in thousands):
 
   
2021
   
2022
   
2023
   
2024
   
2025 and
thereafter
   
Total
 
Term Loan
  $
4,615
    $
4,615
    $
4,615
    $
8,075
    $
-
    $
21,920
 
Equipment Line
   
1,600
     
1,600
     
1,600
     
1,200
     
-
     
6,000
 
2019 Equipment Line
   
2,500
     
2,000
     
2,000
     
3,500
     
-
     
10,000
 
Unamortized value of debt issuance costs
   
(17
)    
(17
)    
(17
)    
(15
)    
-
     
(66
)
Other financing
   
725
     
222
     
-
     
-
     
-
     
947
 
Total
  $
9,423
    $
8,420
    $
8,198
    $
12,760
    $
-
    $
38,801
 
 
The following is a breakdown of the Company's current and long-term debt as of
December 31, 2020
and
December 31, 2019 (
in thousands):
 
   
December 31, 2020
   
December 31, 2019
 
   
Current
Portion
   
Long-Term
Portion
   
Total
   
Current
Portion
   
Long-Term
Portion
   
Total
 
Term Loan
  $
4,615
    $
17,305
    $
21,920
    $
5,768
    $
21,919
    $
27,687
 
Equipment Line
   
1,600
     
4,400
     
6,000
     
1,600
     
6,000
     
7,600
 
2019 Equipment Line
   
2,500
     
7,500
     
10,000
     
79
     
1,495
     
1,574
 
Unamortized value of debt issuance costs
   
(17
)    
(49
)    
(66
)    
(17
)    
(66
)    
(83
)
Other financing
   
725
     
222
     
947
     
652
     
947
     
1,599
 
Total
  $
9,423
    $
29,378
    $
38,801
    $
8,082
    $
30,295
    $
38,377
 
 
As of
December 31, 2020,
interest on the credit facility is payable at our option as a (i) Eurodollar Loan, which bears interest at a per annum rate equal to the applicable
30
-day London Interbank Offered Rate (“LIBOR”) plus an applicable margin ranging from
2.00%
to
3.00%
or (ii) CB Floating Rate (“CBFR”) Loan, which bears interest at a per annum rate equal to the greater of (a) the lender's prime rate or (b) LIBOR plus
2.50%,
in each case, plus a margin ranging from -
1.00%
to
0.25%
based on our leverage ratio as defined in the
2015
Credit Agreement. The actual Eurodollar Loan rate at
December 31, 2020
was
2.19%
(LIBOR of
0.19%
plus
2.00%
). The actual CBFR Loan rate at
December 31, 2020
was
2.25%
(lender's prime rate of
3.25%
minus
1.00%
).
 
Subsequent to
December 31, 2020,
the Company entered into the
2021
Credit Agreement, which replaced the
2015
Credit Agreement. For more information regarding the
2021
Credit Agreement, refer to the “Subsequent Events” discussion included in Note
15
in the Notes to the Consolidated Financial Statements included in this Form
10
-K.
 
XML 28 R14.htm IDEA: XBRL DOCUMENT v3.21.1
Note 8 - Income Taxes
12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Income Tax Disclosure [Text Block]
8.
         
Income Taxes
 
The following table summarizes the Company's income before income taxes for the years ended
December 31 (
in thousands):
 
   
2020
   
2019
 
U.S income
  $
6,623
    $
1,413
 
Non-U.S. income
   
920
     
111
 
Income before income taxes
  $
7,543
    $
1,524
 
 
The following table summarizes the Company's components of the consolidated benefit from (provision for) income taxes for the years ended
December 
31
(in thousands):
 
   
2020
   
2019
 
U.S Federal income tax benefit (expense)
               
Current
  $
(11
)   $
-
 
Deferred
   
8,346
     
(104
)
Total U.S. Federal income tax benefit (expense)
   
8,335
     
(104
)
State and local income tax benefit (expense)
               
Current
   
(66
)    
(29
)
Deferred
   
1,725
     
-
 
Total state and local income tax benefit (expense)
   
1,659
     
(29
)
Foreign income tax expense
               
Current
   
(205
)    
(30
)
Total income tax benefit (expense)
  $
9,789
    $
(163
)
 
The following table summarizes activity related to the Company's valuation allowance for the years ended
December 31 (
in thousands):
 
   
2020
   
2019
 
Valuation allowance at the Beginning of Period
  $
(11,250
)   $
(11,370
)
Income tax expense
   
-
     
-
 
Release of valuation allowance
   
11,250
     
120
 
Valuation allowance at the End of Period
  $
-
    $
(11,250
)
 
The following table summarizes a reconciliation of the Company's effective income tax rate to the U.S. federal statutory rate for the years ended
December 31:
 
   
2020
   
2019
 
Income tax expense at the statutory rate
   
21.0
%    
21.0
%
State and local income tax expense
   
5.1
%    
2.0
%
Foreign income tax
   
0.2
%    
2.0
%
Permanent differences
   
(8.4
%)    
(5.8
%)
Decrease in valuation allowance
   
(149.2
%)    
(7.9
%)
Other adjustments
   
1.5
%    
(0.6
%)
Effective income tax rate
   
(129.8
%)    
10.7
%
 
The following table summarizes the temporary differences and carryforwards that give rise to deferred tax assets and liabilities as of
December 31 (
in thousands):
 
   
2020
   
2019
 
Deferred Federal tax assets –
               
Bad debt reserves
  $
1,570
    $
1,459
 
Stock-based compensation
   
656
     
443
 
Net operating loss
   
7,337
     
7,991
 
Operating lease liabilities
   
1,014
     
1,271
 
Accrued compensation
   
757
     
451
 
Inventories
   
214
     
27
 
Goodwill and intangible assets
   
832
     
1,688
 
Research & development credits
   
533
     
533
 
Other credits
   
30
     
25
 
Other
   
54
     
194
 
Total deferred Federal tax assets
   
12,997
     
14,082
 
Less: valuation allowance
   
-
     
(9,553
)
Net deferred Federal tax assets
   
12,997
     
4,529
 
Deferred Federal tax liabilities –
               
Depreciation and asset basis differences
   
(3,393
)    
(3,366
)
Right-of-use assets
   
(937
)    
(1,204
)
Total deferred Federal tax liabilities
   
(4,330
)    
(4,570
)
Net deferred Federal tax assets (liabilities)
   
8,667
     
(41
)
Total deferred state and local tax assets (a)
   
1,300
     
1,634
 
Less: valuation allowance
   
-
     
(1,697
)
Net deferred state and local tax assets (liabilities)
   
1,300
     
(63
)
Net deferred tax assets (liabilities)
  $
9,967
    $
(104
)
 
(a) at
December 31, 2020
and
2019,
this includes state and local net operating losses of
$1.2
million and
$1.4
million, respectively.
 
The Company's U.S. federal net operating loss carryforward for tax purposes was
$34.9
million at
December 31, 2020,
resulting in a federal deferred tax asset of
$7.3
million. Approximately
$31.5
million of the Company's U.S. federal net operating loss carryforwards will begin to expire in various years beginning in
2029.
$3.4
million of U.S. federal net operating loss carryforwards have an indefinite life. The Company's state net operating loss carryforward of approximately
$1.2
million is comprised of various jurisdictions. These state net operating losses can be used for a period of
5
to
20
years and vary by state, and if unused, begin to expire in
2021,
though a substantial portion expires beyond
2021.
Approximately
$0.1
million of the state net operating loss carryforwards have an indefinite life. Tax benefits of operating loss and tax credit carryforwards are evaluated on an ongoing basis, including a review of historical and projected future operating results, the eligible carryforward period, and other circumstances.
 
The Company continues to monitor shifts in past ownership (as defined under Section
382
of the Code). A definitive analysis necessary to quantify the effect of an ownership change was performed on the net operating loss carryforwards generated prior to
December 31, 2019.
Based on the analysis, the Company is subject to an annual limitation of
$1.8
million on its use of remaining pre-ownership change net operating loss carryforwards of
$4.5
million (and certain other pre-change tax attributes).
 
In the
fourth
quarter of
2020
it was determined that the valuation allowance against the U.S. federal and state deferred taxes is
no
longer required and the valuation allowance of
$11.2
million that existed was released. The Company's realization of its deferred tax assets is dependent upon many factors, including, but
not
limited to, the Company's ability to generate sufficient taxable income. Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax assets. Cumulative income in recent years and projected future taxable income is the basis for the Company's assessment that the deferred tax assets
no
longer require a full valuation allowance.
 
The Company had
no
uncertain tax positions for the years ended
December 
31,
2020
and
2019.
 
The Company is subject to taxation for Federal and various state jurisdictions in the United States and Canada. The Federal income tax returns of the Company for the years
2017
through
2020
are open to examination by the Internal Revenue Service. The Company currently has an open audit with the Internal Revenue Service in relation to the Company's
2018
federal income tax return. Under examination, the Internal Revenue Service
may
redetermine the correct taxable income for a closed year (pre-
2017
) to determine either the amount of the federal net operating loss carryforward deduction reported in the open years or the amount of a federal net operating loss deduction that is absorbed in a closed year and supports the determination of the available federal net operating loss deduction for the open years under examination. The state income tax returns and other state tax filings of the Company are subject to examination by the state taxing authorities, for various periods generally up to
four
years after they are filed. Canadian income tax returns of the Company for the years
2016
through
2020
are subject to examination by the Canada Revenue Agency.
 
On
March 27, 2020,
the Coronavirus Aid, Relief, and Economic Security (CARES) Act was enacted in response to the COVID-
19
pandemic. The CARES Act among other things, allows employers to defer the deposit and payment of the employer's share of Social Security taxes. The Company, under the CARES Act, deferred paying
$0.7
million of applicable gross payroll taxes as of
December 31, 2020,
which is included in other liabilities. The
$0.7
million balance of the deferred Social Security taxes is expected to be paid in
two
equal annual installments during the years ending
December 31, 2021
and
2022,
respectively. On
April 15, 2020,
the Company received a
$4.1
million loan under the Federal Paycheck Protection Program (“PPP”) created under the CARES Act. In response to revised eligibility guidelines announced by the U.S. Small Business Administration shortly thereafter, the Company repaid this loan in full on
May 7, 2020.
XML 29 R15.htm IDEA: XBRL DOCUMENT v3.21.1
Note 9 - Commitments and Contingencies
12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Commitments and Contingencies Disclosure [Text Block]
9.
         
Commitments and Contingencies
 
From time to time in the ordinary course of its business, the Company
may
be involved in legal and regulatory proceedings, the outcomes of which
may
not
be determinable. The results of litigation and regulatory proceedings are inherently unpredictable. Any claims against the Company, whether meritorious or
not,
could be time consuming, result in costly litigation, require significant amounts of management time and result in diversion of significant resources. The Company is
not
able to estimate an aggregate amount or range of reasonably possible losses for those legal matters for which losses are
not
probable and estimable, primarily for the following reasons: (i) many of the relevant legal proceedings are in preliminary stages, and until such proceedings develop further, there is often uncertainty regarding the relevant facts and circumstances at issue and potential liability; and (ii) many of these proceedings involve matters of which the outcomes are inherently difficult to predict. The Company has insurance policies covering potential losses where such coverage is cost effective.
 
The Company is
not
at this time involved in any proceedings that the Company believes could have a material effect on the Company's financial condition, results of operations or cash flows.
XML 30 R16.htm IDEA: XBRL DOCUMENT v3.21.1
Note 10 - Leases
12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Lessee, Operating Leases [Text Block]
10.
       
Leases
 
The Company has historically entered into a number of lease agreements under which the Company is the lessee for equipment and office leases. During the year ended
December 31, 2020,
the Company entered into
four
leases for equipment.
 
The components of the Company's lease costs consisted of the following as of
December 31 (
in thousands):
 
   
2020
   
2019
 
Operating lease cost
  $
1,617
    $
1,948
 
Variable lease cost
   
315
     
291
 
Total lease cost
  $
1,932
    $
2,239
 
 
Lease costs for the year ended
December 31, 2020
of approximately
$1.3
million and
$0.6
million, were recorded to G&A expenses and cost of revenues, respectively. Lease costs for the year ended
December 31, 2019
of approximately
$1.2
million and
$1.0
million, were recorded to G&A expenses and cost of revenues, respectively.
 
Supplemental cash flow information and non-cash activity related to the Company's leases was as follows (in thousands):
 
   
2020
   
2019
 
Cash paid for amounts included in the measurement of lease liabilities and ROU assets:
               
Operating cash flow from operating leases
  $
1,603
    $
1,610
 
                 
ROU assets obtained in exchange for lease obligations:
               
Operating leases
  $
264
    $
4,545
 
                 
Reductions to ROU assets resulting from reductions to lease obligations:
               
Operating leases
  $
-
    $
22
 
 
Weighted average remaining lease terms and discount rates for the Company's leases as of
December 31, 2019
are as follows:
 
   
2020
   
2019
 
                 
   
Years
   
Years
 
Weighted average remaining lease term:
               
Operating leases
   
7.0
     
7.4
 
   
Rate
   
Rate
 
Weighted average discount rate:
               
Operating leases
   
7.8
%    
7.7
%
 
Future maturities of lease liabilities as of
December 31, 2020
are as follows (in thousands):
 
   
Operating Leases
 
2021
  $
1,108
 
2022
   
1,045
 
2023
   
941
 
2024
   
949
 
2025
   
914
 
Thereafter
   
2,253
 
Total undiscounted lease payments
   
7,210
 
Less: Imputed interest
   
(2,380
)
Total lease liabilities
  $
4,830
 
XML 31 R17.htm IDEA: XBRL DOCUMENT v3.21.1
Note 11 - Share-based Compensation
12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Share-based Payment Arrangement [Text Block]
11.
       
Share-based Compensation
 
All stock option awards are amortized based on their graded vesting over the requisite service period of the awards. Compensation costs are recognized over the requisite service period using the accelerated method and included in general and administrative expenses.
 
Stock Incentive Plan
 
The Company has various stock option and stock-based incentive plans and agreements whereby stock options, restricted stock awards (“RSUs”) and PSUs were made available to certain employees, directors and others approved by the Company's Board of Directors (the “Board”) or Compensation Committee. Stock options are granted at, or above, fair market value and generally expire in
five
to
ten
years from the grant date. RSUs are granted at the fair market value on the date of grant and generally become exercisable over a period of up to
three
years. PSUs are granted at the fair market value on the date of grant and generally become exercisable over a period of up to
three
years based on the performance of a specific achievement. Awards typically vest and are issued only if the participants remain employed by the Company through the vesting date. Stock options, RSUs and PSUs are issued from shares under the Company's plan described below. Grants
may
be made in the form of stock options, restricted stock awards, performance-based restricted stock units, unrestricted common stock or stock appreciation rights (“SARs”).
 
On
April 23, 2014,
the Company's Board adopted the
2014
Amended and Restated Stock Incentive Plan (the
“2014
Plan”). The
2014
Plan was approved by the Company's shareholders at the
2014
Annual Meeting and became effective as of the date it was adopted by the Board of Directors. The
2014
Plan provided for the issuance of a maximum of
2.0
million shares of common stock in connection with the grant of stock-based or stock-denominated awards. On
July 19, 2018,
the Company's stockholders approved the reservation of an additional
1.0
million shares to be issued under the
2014
Plan. On
May 15, 2019,
the Company's stockholders approved the reservation of an additional
1.0
million shares to be issued under the
2014
Plan. As of
December 31, 2020,
a total of approximately
0.4
million common shares remained available for future grant under the
2014
Plan.
 
The Company granted stock options under the
2014
Plan during the years ended
December 31, 2020
and
2019,
respectively.
 
Shares Forgone to Satisfy Minimum Statutory Withholdings
 
During the years ended
December 31, 2020
and
2019,
shares of common stock were issued to employees and directors as their restricted stock awards vested or stock options were exercised. Under the terms of the Company's stock plans, at the election of each employee, the Company can authorize a net settlement of distributable shares to employees after satisfaction of an individual employees' tax withholding obligations. For both of the years ended
December 31, 2020
and
2019,
the Company received
0.1
million shares from employees for tax withholding obligations.
 
Restricted Stock Awards
 
During the year ended
December 31, 2020,
the Company granted
0.2
million restricted stock awards. During the year ended
December 31, 2019,
the Company granted less than
0.1
million restricted stock awards. Restricted stock awards entitle the holder to receive, upon meeting certain time-based vesting criteria, a specified number of shares of the Company's common stock. Stock-based compensation cost of restricted stock awards is measured by the market value of the Company's common stock on the date of grant.
 
The following table summarizes the Company's restricted share activity, excluding the Company's employee stock purchase plan, for the years ended
December 
31:
 
   
 
 
 
 
Weighted
   
 
 
 
   
 
 
 
 
average
   
 
 
 
   
 
 
 
 
grant
   
 
 
 
   
Number of
   
date fair
   
Aggregate
 
   
shares
   
value
   
fair value
 
                         
Unvested at December 31, 2018
   
129,583
    $
1.42
     
 
 
                         
Granted
   
26,000
     
7.04
     
 
 
Vested
   
(58,314
)    
3.17
    $
712,969
 
Vested shares forgone to satisfy minimum statutory withholding
   
(71,269
)    
3.17
    $
422,779
 
Forfeitures
   
-
     
-
     
 
 
                         
Unvested at December 31, 2019
   
26,000
     
7.04
     
 
 
Granted
   
156,250
     
10.12
     
 
 
Vested
   
(28,432
)    
9.28
    $
367,273
 
Vested shares forgone to satisfy minimum statutory withholding
   
(6,818
)    
9.28
    $
62,479
 
Forfeitures
   
(2,000
)    
11.68
     
 
 
Unvested at December 31, 2020
   
145,000
    $
9.78
     
 
 
 
As of
December 31, 2020,
there was
$1.0
million of pre-tax total unrecognized compensation cost related to non-vested restricted stock awards, which will be adjusted for future forfeitures, if any. The Company expects to recognize such cost over the period ending in
2023.
 
Performance-Based Restricted Stock Units
 
During the year ended
December 31, 2020,
the Company granted approximately
0.2
million PSUs. During the year ended
December 31, 2019,
the Company did
not
grant any PSUs. PSUs entitle the holder to receive, upon meeting certain performance-based vesting criteria, a specified number of shares of the Company's common stock. These awards typically vest after the Company's achievement of either Company performance relative to specified performance measure goals for a specific fiscal period or when the Company's stock price reaches a target value for a minimum number of consecutive trading days. Approximately
three
-fourths of the PSUs granted in
2020
are earned based on the market-based condition, while the other
one
-
fourth
are earned based on specified Company performance measure conditions. In the case of the market-based condition, awards are paid in stock immediately upon achievement of the performance condition or expire without any payment after the
third
anniversary of the grant date. In the case of the specified Company performance measure, awards can be earned at
50%
of the target number of shares for achieving a minimum threshold or up to
200%
of the target number of shares for exceeding the target, with a linear adjustment between threshold and target or between target and stretch performance goals.
 
Under FASB ASC Topic
718,
the provisions of the PSUs that vest upon achievement of a target market value are considered a market condition, and therefore the effect of that market condition is reflected in the grant date fair value for this type of award. A
third
-party valuation expert was engaged to complete a “Monte Carlo simulation” to account for the market condition. That simulation takes into account the beginning stock price of the Company's common stock, the expected volatilities for the Company's stock price and the expected risk-free rate of return. The single grant-date fair value computed by this valuation method is recognized by the Company in accounting for the awards regardless of the actual future outcome of the market condition. The grant date fair value of the other PSUs is calculated as the closing price of the Company's common stock on the grant date multiplied by the number of shares subject to the award. Company performance measure goals are considered a performance condition and the grant-date fair value for those PSUs corresponds with management's expectation of the probable outcome of the performance conditions as of the grant date.
 
The following table summarizes the Company's PSU activity for the years ended
December 
31:
 
   
 
 
 
 
Weighted
   
 
 
 
   
 
 
 
 
average
   
 
 
 
   
 
 
 
 
grant
   
 
 
 
   
Number of
   
date fair
   
Aggregate
 
   
shares
   
value
   
fair value
 
                         
Unvested at December 31, 2019
   
-
     
-
     
 
 
Granted
   
232,500
     
9.06
     
 
 
Unvested at December 31, 2020
   
232,500
    $
9.06
     
 
 
 
As of
December 31, 2020,
there was
$1.7
million of pre-tax total unrecognized compensation cost related to non-vested PSUs, which will be adjusted for future forfeitures and changes to management's expectations of the probable outcomes of the performance conditions, if any. The Company expects to recognize such cost over the period ending in
2022.
 
Employee Stock Purchase Plan
 
In
May 2014,
the Company received approval from stockholders to adopt an employee stock purchase plan ("ESPP") effective
October 2014 (
collectively the “Original ESPP”). Under the Original ESPP,
200,000
shares of common stock were authorized for purchase by eligible employees at a
15%
discount through payroll deductions during the
six
-month offering periods. Shares were purchased in whole numbers and generally would be the last day of the offering period. On
September 7, 2016,
the Company received approval from shareholders for an additional
350,000
shares.
No
employee
may
purchase more than
$25,000
worth of fair market value shares in any calendar year. As allowed under the ESPP, a participant
may
elect to withdraw from the plan, effective for the purchase period in progress at the time of the election with all accumulated payroll deductions returned to the participant at the time of withdrawal. As of
December 31, 2020,
there were
187,676
shares remaining available for future issuance. The following table summarizes the activity relating to the Company's ESPP program for the years ended
December 31:
 
   
2020
   
2019
 
Compensation expense
  $
108,589
    $
43,030
 
Shares of stock sold to employees
   
30,012
     
33,742
 
Weighted average fair value per ESPP award
  $
7.43
    $
3.94
 
 
Stock Options
 
The Company calculates the fair value of stock option awards using the Black-Scholes option pricing model, which incorporates various assumptions including volatility, expected term, risk-free interest rates and dividend yields. The expected volatility assumption is based on historical volatility of the Company's common stock over the most recent period commensurate with the expected life of the stock option granted. The Company uses historical volatility because management believes such volatility is representative of prospective trends. The risk-free interest rate assumption is based upon observed interest rates appropriate for the expected life of the stock option awarded. The Company uses historical exercise data to determine the expected lives. Dividend yields have
not
been a factor in determining fair value of stock options granted as the Company has never issued cash dividends and does
not
anticipate issuing cash dividends in the future.
 
During the year ended
December 31, 2020,
the Company granted
0.3
million stock options, of which
0.1
million were issued to Board members at exercise prices based on a preceding
five
-day average price on the date of grant with a vesting period of
12
months. During the year ended
December 31, 2019,
the Company granted
0.7
million stock options, of which
0.1
million were issued to Board members at exercise prices based on the stock price as of the date of grant with a vesting period of
12
months. The following tables detail the various stock option and inducement stock option activity for the years ended
December 31:
 
 
   
 
 
 
 
 
 
 
 
Weighted-
   
 
 
 
   
 
 
 
 
 
 
 
 
Average
   
 
 
 
   
Number
   
Weighted-
   
Remaining
   
Aggregate
 
   
of Authorized
   
Average Exercise
   
Contractual
   
Intrinsic
 
2014 Plan (Options)
 
Shares
   
Price
   
Term (in Years)
   
Value
 
Outstanding at December 31, 2018
   
2,224,167
    $
2.67
     
3.01
    $
-
 
                                 
Granted
   
670,000
    $
3.77
     
4.40
     
 
 
Exercised
   
(213,056
)    
2.33
     
 
     
624,462
 
Exercised shares forgone to satisfy minimum statutory withholding
   
(51,339
)    
2.33
     
 
     
 
 
Cashless exercise
   
(184,493
)    
2.33
     
 
     
 
 
Forfeited
   
(101,946
)    
3.63
     
 
     
 
 
                                 
Outstanding at December 31, 2019
   
2,343,333
    $
2.99
     
1.81
    $
12,989,767
 
                                 
Exercisable at December 31, 2019
   
1,501,750
    $
2.69
     
 
     
 
 
                                 
Granted
   
331,000
     
10.38
     
8.59
     
 
 
Exercised
   
(334,184
)    
2.77
     
 
     
3,135,211
 
Exercised shares forgone to satisfy minimum statutory withholding
   
(125,714
)    
2.77
     
 
     
 
 
Cashless exercise
   
(164,751
)    
2.77
     
 
     
 
 
Forfeited
   
(90,336
)    
3.96
     
 
     
 
 
                                 
Outstanding at December 31, 2020
   
1,959,348
    $
4.26
     
4.42
    $
28,449,362
 
                                 
Exercisable at December 31, 2020
   
1,362,932
    $
3.33
     
 
     
 
 
 
Aggregate Intrinsic Value = Excess of market value over the option exercise price of all in-the-money stock options.
 
   
 
 
 
 
 
 
 
 
Weighted-
   
 
 
 
   
 
 
 
 
 
 
 
 
Average
   
 
 
 
   
Number
   
Weighted-
   
Remaining
   
Aggregate
 
Inducement
 
of Authorized
   
Average Exercise
   
Contractual
   
Intrinsic
 
Options
 
Shares
( 1 )
   
Price
   
Term (in Years)
   
Value
 
Outstanding at December 31, 2018
   
125,000
    $
2.55
     
5.42
    $
111,250
 
                                 
Granted
   
-
     
-
     
-
     
-
 
Exercised
   
-
     
-
     
-
     
-
 
Forfeited
   
-
     
-
     
-
     
-
 
                                 
Outstanding at December 31, 2019
   
125,000
    $
2.55
     
4.42
    $
747,500
 
                                 
Granted
   
-
     
-
     
-
     
-
 
Exercised
   
(27,940
)    
2.55
     
-
     
242,519
 
Exercised shares forgone to satisfy minimum statutory withholding
   
(12,417
)    
2.55
     
-
     
-
 
Cashless exercise
   
(14,330
)    
2.55
     
-
     
-
 
Forfeited
   
(70,313
)    
2.55
     
-
     
-
 
                                 
Outstanding at December 31, 2020
   
-
    $
-
     
-
    $
-
 
                                 
Exercisable at December 31, 2020
   
-
    $
-
     
 
     
 
 
 
Aggregate Intrinsic Value = Excess of market value over the option exercise price of all in-the-money stock options.
 
(
1
) Represents inducement stock options to purchase shares of the Company's Common Stock to executive level managers.
 
The following table summarizes information about stock options outstanding at
December 31, 2020:
 
       
Options Outstanding
   
Options Exercisable
 
2014 Plan (Options):
                                       
Range of Exercise Prices
 
Number of Shares Outstanding
   
Weighted-Average Remaining Contractual Life
   
Weighted-Average Exercise Price
   
Number of Shares Exercisable
   
Weighted-Average Exercise Price
 
                                             
$2.01
-
$3.00
   
870,011
     
3.20
    $
2.26
     
784,178
    $
2.26
 
$3.01
-
$4.00
   
423,336
     
2.74
    $
3.23
     
301,669
    $
3.21
 
$4.01
-
$5.00
   
335,001
     
5.60
    $
4.70
     
198,335
    $
4.70
 
$6.01
-
$7.00
   
50,000
     
4.21
    $
6.82
     
-
    $
-
 
$8.01
-
$9.00
   
20,000
     
9.02
    $
8.55
     
-
    $
-
 
$11.01
-
$12.00
   
245,000
     
9.38
    $
11.07
     
78,750
    $
11.07
 
$13.01
-
$14.00
   
16,000
     
9.62
    $
13.30
     
-
    $
-
 
                                             
Outstanding at December 31, 2020
   
1,959,348
     
4.42
    $
4.26
     
1,362,932
    $
3.33
 
 
The following is the average fair value per share estimated on the date of grant and the assumptions used for options granted during the years ended
December 31:
 
Stock Options:
 
2020
   
2019
 
Expected volatility
 
 42%
to
51%
   
 36%
to
 38%
 
Risk free interest rate
 
 0.20%
to
 1.56%
   
 1.80%
to
2.36%
 
Expected lives at date of grant (in years)
 
 
3.25
 
   
 
4.63
 
 
Weighted average fair value of options granted
 
 
$3.87
 
   
 
$1.61
 
 
 
Stock-based compensation expense
 
The following table presents the total stock-based compensation expense, which is included in selling, general and administrative expenses for the years ended
December 31 (
in thousands):
 
   
2020
   
2019
 
Restricted share expense
  $
1,687
    $
190
 
Stock option and SARs expense
   
923
     
807
 
Total stock-based compensation expense
  $
2,610
    $
997
 
 
Share Repurchase Program
 
On
September 30, 2019,
the Company's Board of Directors approved a stock repurchase program (the “Share Repurchase Program”) authorizing the Company to repurchase up to
$5.0
million of the Company's outstanding common stock through
2020.
Repurchases under the Share Repurchase Program will be subject to market conditions, the periodic capital needs of the Company's operating activities, and the continued satisfaction of all covenants under the Company's credit agreements. The Company's ability to repurchase stock is subject to the restrictions and limitations of its credit agreements. Repurchases under the program
may
take place in the open market or in privately negotiated transactions and
may
be made under a Rule
10b5
-
1
plan. The Share Repurchase Program does
not
obligate the Company to repurchase shares and
may
be suspended, terminated, or modified at any time.
 
As of
December 31, 2020,
the Company had
not
repurchased any shares under the Share Repurchase Program.
XML 32 R18.htm IDEA: XBRL DOCUMENT v3.21.1
Note 12 - Business Segment Information
12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Segment Reporting Disclosure [Text Block]
12.
       
Business Segment Information
 
During the
fourth
quarter of
2019,
the Company reorganized its segment reporting from
one
reportable segment to
two
reportable segments, ITS and DME Services, due to changes in the Company's internal reporting and the information evaluated by its chief operating decision-maker. The Company's reportable segments are organized based on service platforms, with the ITS segment reflecting higher margin rental revenues that generally include payments made by
third
-party and direct payers and the DME Services segment reflecting lower margin product sales and direct payer rental revenues. Resources are allocated and performance is assessed for these segments by the Company's Chief Executive Officer, whom the Company has determined to be its chief operating decision-maker. The Company believes that reporting performance at the gross profit level is the best indicator of segment performance.
 
The financial information summarized below is presented by reportable segment:
 
2020
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
Corporate/
   
 
 
 
(in thousands)
 
ITS
   
DME Services
   
Eliminations
   
Total
 
                                 
Net revenues - external
  $
61,072
    $
36,316
    $
-
    $
97,388
 
Net revenues - internal
   
-
     
5,370
     
(5,370
)    
-
 
Total net revenues
   
61,072
     
41,686
     
(5,370
)    
97,388
 
Gross profit
   
39,773
     
18,986
     
-
     
58,759
 
                                 
Selling , general and administrative expenses
   
 
     
 
     
49,932
     
49,932
 
Interest expense
   
 
     
 
     
(1,255
)    
(1,255
)
Other expense
   
 
     
 
     
(29
)    
(29
)
Benefit from income taxes
   
 
     
 
     
9,789
     
9,789
 
                                 
Net income
   
 
     
 
     
 
    $
17,332
 
                                 
Total assets
  $
68,472
    $
26,519
    $
2,000
    $
96,991
 
Purchases of medical equipment
  $
9,583
    $
6,237
    $
-
    $
15,820
 
Depreciation and amortization of intangible assets
  $
10,708
    $
3,317
    $
-
    $
14,025
 
 
 
2019
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
Corporate/
   
 
 
 
(in thousands)
 
ITS
   
DME Services
   
Eliminations
   
Total
 
                                 
Net revenues - external
  $
51,540
    $
29,575
    $
-
    $
81,115
 
Net revenues - internal
   
-
     
3,788
     
(3,788
)    
-
 
Total net revenues
   
51,540
     
33,363
     
(3,788
)    
81,115
 
Gross profit
   
33,063
     
13,819
     
-
     
46,882
 
                                 
Selling, general and administrative expenses
   
 
     
 
     
43,357
     
43,357
 
Interest expense
   
 
     
 
     
(1,904
)    
(1,904
)
Other expense
   
 
     
 
     
(97
)    
(97
)
Provision for income taxes
   
 
     
 
     
(163
)    
(163
)
                                 
Net income
   
 
     
 
     
 
    $
1,361
 
                                 
Total assets
  $
54,292
    $
22,932
    $
2,000
    $
79,224
 
Purchases of medical equipment
  $
14,216
    $
5,453
    $
-
    $
19,669
 
Depreciation and amortization of intangible assets
  $
9,457
    $
2,885
    $
-
    $
12,342
 
 
The presentation of gross profit above was revised from the
2019
Consolidated Financial Statements to include inter-segment revenues in the DME Services segment column from the prior presentation within the Corporate/Eliminations column. This revision is considered immaterial to the prior period based on the Company's assessment.
XML 33 R19.htm IDEA: XBRL DOCUMENT v3.21.1
Note 13 - Employee Benefit Plans and Other
12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Retirement Benefits [Text Block]
13.
       
Employee Benefit Plans and Other
 
The Company has a defined contribution plan in which the Company makes discretionary matching contributions for a certain percentage of employee contributions. For the years ended
December 31, 2020
and
2019,
the Company's matching contributions were
$0.8
million and
$0.7
million, respectively. The Company does
not
provide other post-retirement or post-employment benefits to its employees. As of
December 31, 2020
and
2019,
accrued payroll liabilities included in Other current liabilities were
$2.8
million and
$3.5
million, respectively.
 
XML 34 R20.htm IDEA: XBRL DOCUMENT v3.21.1
Note 14 - COVID-19
12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Effect of Covid-19 Pandemic [Text Block]
14.
       
COVID-
19
 
On
March 11, 2020,
the World Health Organization declared the outbreak of COVID-
19
as a pandemic, which has spread globally and throughout the United States. With the exception of in-person visits to our customer facilities by our sales staff, the Company has continued to operate despite stay-at-home orders and other government mandated shutdowns across the United States and Canada under exceptions allowed by those orders for the healthcare industry.
 
We have taken a number of precautionary and preemptive steps to protect the safety and well-being of our employees while ensuring continuity of service to our clients, including, transitioning our employees to a remote work environment, suspending employee travel, canceling participation in industry events and in-person group meetings, promoting social distancing and enhanced cleaning and sanitization efforts across office locations, and implementing protocols to quarantine employees who
may
have been exposed to COVID-
19,
or show relevant symptoms. We also continued to undertake preparedness plans at our facilities to maintain continuity of operations, which provide for flexible work arrangements without any significant disruptions to our business or control processes. Our management team is continuing to actively monitor the situation and is in constant communication with our workforce as well as with our customers and vendors. Other specific actions we have taken include purchasing additional inventory of supplies and pumps, as well as purchasing personal protective equipment for our employees. While the Company's business is considered critical, we are unable to predict the impact that the COVID-
19
pandemic will have on future periods due to numerous uncertainties. While the COVID-
19
pandemic has
not
had any material unfavorable effects in our financial results for the year ended
December 31, 2020,
the extent of the impact in the future, if any, will depend on future developments, which are highly uncertain, cannot be predicted and could have a material adverse impact on our financial position, operating results and cash flows. A prolonged outbreak could, among other things, strain our business continuity plans, create delays in our growth and strategic initiatives, reduce our sales and marketing activities, limit our access to financing on favorable terms, increase our exposure to potential impairment charges related to long-lived and intangible assets, hinder our ability to support our clients and operate our business effectively, heighten the risk of disruption to our information and reporting systems and internal controls, including those over financial reporting and other risk management systems, or require us to incur substantial costs. We are closely monitoring the impact of the COVID-
19
pandemic on all aspects of our business and
may
take further actions as
may
be required by federal, state or local authorities, or that we determine are in the best interests of our employees, customers and partners. As the conditions surrounding the COVID-
19
pandemic continue to evolve rapidly, we will continue to actively manage our response in collaboration with customers, government officials and stakeholders, and assess any potential impacts to our financial position and operating results, as well as adverse developments in our business.
XML 35 R21.htm IDEA: XBRL DOCUMENT v3.21.1
Note 15 - Subsequent Events
12 Months Ended
Dec. 31, 2020
Notes to Financial Statements  
Subsequent Events [Text Block]
15.
       
Subsequent Events
 
Acquisition
 
On
February 3, 2021,
the Company announced that it had acquired FilAMed, a privately held biomedical services company based in Bakersfield, California, for an approximate purchase price of
$1.4
million.  The initial accounting for the business combination, including the estimated fair value of the assets and liabilities acquired, is incomplete as a result of the timing of the acquisition. This acquisition will supplement the Company's existing biomedical recertification, maintenance and repair services for acute care facilities and other alternate site settings including home care and home infusion providers, skilled nursing facilities, pain centers and others.
 
Credit Agreement
 
On
February 5, 2021,
the Company entered into a Credit Agreement (the
“2021
Credit Agreement”) with JPMorgan Chase Bank, N.A., as administrative agent (the “Agent”), sole bookrunner and sole lead arranger, and the lenders party thereto. The borrowers under the
2021
Credit Agreement are the Company, InfuSystem Holdings USA, Inc. (“Holdings”), ISI, First Biomedical, , and IFC LLC (“IFC” and, collectively with the Company, Holdings, ISI and First Biomedical, the “Borrowers”).
 
The
2021
Credit Agreement provides for a revolving credit facility (the “Revolving Facility”) of
$75
million, maturing on
February 5, 2026.
The Revolving Facility
may
be increased by
$25
million, subject to certain conditions, including the consent of the Agent and obtaining necessary commitments. The lenders under the
2021
Credit Agreement
may
issue up to
$7
million in letters of credit subject to the satisfaction of certain conditions. On
February 5, 2021,
the Borrowers made an initial borrowing of
$30
million under the Revolving Facility. Proceeds from the loan, along with approximately
$8.2
million in cash, were used to repay all amounts due under the Company's existing credit facility dated
March 23, 2015 (
the
“2015
Credit Agreement”).
 
Amounts outstanding under the Revolving Facility bear interest at a variable rate equal to, at the Company's election, a LIBO Rate for Eurodollar loans or an Alternate Base Rate for ABR loans, as defined by the
2021
Credit Agreement, plus a spread that will vary depending upon the Company's leverage ratio. The spread ranges from
2.00%
to
3.00%
for Eurodollar Loans and
1.00%
to
2.00%
for base rate loans. The initial spread under the
2021
Credit Agreement is
2.00%
for Eurodollar loans and
1.00%
for ABR loans.
 
The
2021
Credit Agreement has customary representations and warranties, and the ability to borrow under the facility is subject to ongoing compliance with a number of customary affirmative and negative covenants, including limitations on indebtedness, liens, mergers, acquisitions, investments, asset sales, affiliate transactions and restricted payments, as well as financial covenants, including the following:
 
 
a minimum fixed charge coverage ratio (defined as the ratio of consolidated EBITDA (as defined in the
2021
Credit Agreement) less
50%
of depreciation expense), to consolidated fixed charges (as defined in the
2021
Credit Agreement)) for the prior
four
most recently ended calendar quarters of
1.20
to
1.00;
and
 
a maximum leverage ratio (defined as total indebtedness to EBITDA for the prior
four
most recently ended calendar quarters) of
3.50
to
1.00.
 
The
2021
Credit Agreement includes customary events of default, and the occurrence of an event of default will permit the lenders to terminate commitments to lend under the Revolving Facility and accelerate payment of all amounts outstanding thereunder.
 
Pledge and Security Agreement
 
Simultaneous with the execution of the
2021
Credit Agreement, the Company entered into a Pledge and Security Agreement to secure repayment of the obligations of the Borrowers. Under the Pledge and Security Agreement, each Borrower has granted to the Agent, for the benefit of various secured parties, a
first
priority security interest in substantially all of the personal property assets of each of the Borrowers, including the shares of each of Holdings, ISI and First Biomedical and the equity interests of IFC.
 
2015
Credit Agreement
 
On
February 5, 2020,
in connection with the execution and closing of the
2021
Credit Agreement, the Company, along with its wholly owned subsidiaries as borrowers, terminated the
2015
Credit Agreement. All outstanding loans under the
2015
Credit Agreement have been repaid and all liens under the
2015
Credit Agreement have been released, except that a letter of credit originally issued under the
2015
Credit Agreement in the amount of approximately
$0.8
million was transferred to the
2021
Credit Agreement.
XML 36 R22.htm IDEA: XBRL DOCUMENT v3.21.1
Significant Accounting Policies (Policies)
12 Months Ended
Dec. 31, 2020
Accounting Policies [Abstract]  
Reclassification, Comparability Adjustment [Policy Text Block]
Reclassifications
 
Certain prior period reclassifications were made to conform with the current period presentation. These reclassifications had
no
effect on reported income (loss), overall cash flows, total assets, total liabilities or stockholders' equity as previously reported.
Presentation in Consolidated Statements [Policy Text Block]
Presentation in the Consolidated Statements
 
The Company rents and sells medical equipment. The Company purchases medical equipment directly for sale as well as medical equipment that is purchased for either rental or sale and that is unallocated at the time of purchase (“Unallocated Assets”). Management believes that the predominant source of revenues and cash flows from the Unallocated Assets is from rentals and most equipment purchased is likely to be rented prior to being sold. The Company concluded that (i) the assets specifically supporting its
two
primary revenue streams should be separately disclosed on the balance sheet; (ii) the purchase and sale of Unallocated Assets should be classified solely in investing cash flows based on their predominant source while medical equipment purchased specifically for sales activity should be classified in operating cash flows; and (iii) other activities ancillary to the rental process should be consistently classified.
Consolidation, Policy [Policy Text Block]
Principles of Consolidation
 
The consolidated financial statements include the accounts of the Company and all wholly owned organizations. All intercompany transactions and account balances have been eliminated in consolidation.
Segment Reporting, Policy [Policy Text Block]
Segments
 
During the
fourth
quarter of
2019,
the Company reorganized its segment reporting from
one
reportable segment to
two
reportable segments, Integrated Therapy Services (“ITS”) and Durable Medical Equipment Services (“DME Services”), due to changes in our internal reporting and the information evaluated by our chief operating decision-maker. See Note
12
for segment disclosures.
 
The Company's approach is to make operational decisions and assess performance based on delivering products and services that together provide solutions to its customer base utilizing a functional management structure. Based upon this business model, the Company's Chief Executive Officer, whom the Company has determined to be its chief operating decision-maker, reviews segment financial information.
Use of Estimates, Policy [Policy Text Block]
Use of Estimates
 
The preparation of financial statements in conformity with GAAP requires management to make estimates, assumptions and judgments that affect the amounts reported in the financial statements, including the notes thereto. The Company considers critical accounting policies to be those that require more significant judgments and estimates in the preparation of its consolidated financial statements, including the following: revenue recognition, leases, accounts receivable and allowance for doubtful accounts, income taxes, and long-lived asset valuations. Management relies on historical experience and other assumptions believed to be reasonable in making its judgments and estimates. Actual results could differ materially from those estimates.
Business Combinations Policy [Policy Text Block]
Business Combinations
 
The Company accounts for all business combinations using the acquisition method of accounting, which allocates the fair value of the purchase consideration to the tangible and intangible assets acquired and liabilities assumed based on their estimated fair values. The excess of the purchase consideration over the fair values of these identifiable assets and liabilities is recorded as goodwill. When determining the fair values of assets acquired and liabilities assumed, management makes significant estimates and assumptions. The Company
may
utilize
third
-party valuation specialists to assist the Company in the allocation. Initial purchase price allocations are subject to revision within the measurement period,
not
to exceed
one
year from the date of acquisition. Acquisition-related expenses and transaction costs associated with business combinations are expensed as incurred.
Cash and Cash Equivalents, Policy [Policy Text Block]
Cash and Cash Equivalents
 
The Company considers all highly liquid investments with original maturities of
three
months or less to be cash equivalents. The Company maintains its cash and cash equivalents primarily with
two
financial institutions that are insured with the Federal Deposit Insurance Corporation (“FDIC”). At times throughout the year, cash and cash equivalents balances might exceed FDIC insurance limits.
Accounts Receivable [Policy Text Block]
Accounts Receivable and Allowance for Doubtful Accounts
 
Amounts billed that have
not
yet been collected that also meet the conditions for unconditional right to payment are presented as accounts receivable. Accounts receivable related to rental service and delivery of products are reported at their estimated transaction prices, inclusive of adjustments for variable consideration, based on the amounts expected to be collected from payers. The Company writes off accounts receivable once collection efforts have been exhausted and an account is deemed to be uncollectible. An allowance for doubtful accounts is established as a result of an adverse change in the Company's payers' ability to pay outstanding billings. The allowance for doubtful accounts was
$1.0
million and
$0.4
million as of
December 31, 2020
and
2019,
respectively.
Inventory, Policy [Policy Text Block]
Inventories
 
The Company's inventories consist of disposable medical supplies, replacement parts and other supplies used in conjunction with medical equipment and are stated at the lower of cost (
first
-in,
first
-out basis) or net realizable value. The Company periodically performs an analysis of slow-moving inventory and records a reserve based on estimated obsolete inventory, which was
$0.1
million as of
December 31, 2020
and
2019.
Medical Equipment [Policy Text Block]
Medical Equipment
 
Medical Equipment (“Equipment”) consists of equipment that the Company purchases from
third
-parties and is (
1
) for sale or rent, and (
2
) used in service to generate rental revenue. Equipment, once placed into service, is depreciated using the straight-line method over the estimated useful lives of the equipment which is typically
seven
years. The Company does
not
depreciate Equipment held for sale or rent. When Equipment in rental service assets are sold, or otherwise disposed, the cost and related accumulated depreciation are removed from the accounts and a sale is recorded in the current period. The Company periodically performs an analysis of slow-moving Equipment used in service to generate rental revenue and records a reserve based on estimated obsolescence, which was
$0.9
and
$0.7
million as of
December 31, 2020
and
2019,
respectively. The Company performs a similar analysis of slow-moving Equipment for sale or rent and records a reserve, which was less than
$0.1
million as of
December 31, 2020
and
2019.
Property, Plant and Equipment, Policy [Policy Text Block]
Property and Equipment
 
Property and equipment is stated at acquired cost and depreciated using the straight-line method over the estimated useful lives of the related assets, ranging from
three
to
seven
years. Externally purchased information technology software and hardware are depreciated over
three
and
five
years, respectively. Leasehold improvements are amortized using the straight-line method over the life of the asset or the remaining term of the lease, whichever is shorter. Maintenance and minor repairs are charged to operations as incurred. When assets are sold, or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts and any gain or loss is recorded in the current period.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]
Intangible Assets
 
Intangible assets consist of trade names, physician and customer relationships and software. The physician and customer relationships arose primarily from previous acquisitions. The Company amortizes the value assigned to the physician and customer relationships on a straight-line basis over the period of expected benefit, which ranges from
fifteen
to
twenty
years. The acquired physician and customer relationship base represents a valuable asset of the Company due to the expectation of future business opportunities to be leveraged from the existing relationship with each physician and customer. The Company has long-standing relationships with numerous oncology clinics, physicians, home care and home infusion providers, skilled nursing facilities, pain centers and others. The useful lives of these relationships are based on minimal attrition experienced to date by the Company and expectations of continued minimal attrition. Acquired software is amortized on a straight-line basis over
three
years. Trade names associated with the original acquisition of InfuSystem are
not
amortized.
 
Management tests indefinite life trade names for impairment annually or more frequently if deemed necessary. The impairment test for intangible assets with indefinite lives consists of a comparison of the fair value of the intangible assets with their carrying amounts. If the carrying value of the intangible assets exceeds the fair value, an impairment loss is recognized in an amount equal to that excess. The Company determines the fair value for trade names with indefinite lives through the royalty relief income valuation approach. The Company performed its annual impairment analysis as of the last day of
October 2020
and determined that the fair value of the trade names with indefinite lives was greater than their carrying value, resulting in
no
impairment.
Capitalization of Internal Costs, Policy [Policy Text Block]
Software Capitalization and Depreciation
 
The Company capitalizes certain costs incurred in connection with obtaining or developing internal-use software, including payroll and payroll-related costs for employees who are directly associated with the internal-use software project, external direct costs of materials and services and interest costs while developing the software. Capitalized software costs are included in intangible assets, net and are amortized using the straight-line method over the estimated useful life of
three
to
five
years. Capitalization of such costs ceases when the project is substantially complete and ready for its intended purpose. Costs incurred during the preliminary project and post-implementation stages, as well as software maintenance and training costs, are expensed in the period in which they are incurred. The Company did
not
capitalize any internal-use software for the years ended
December 31, 2020
and
2019,
respectively. Amortization expense for capitalized software was
$1.9
million in
2020
and
$2.0
million in
2019.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]
Impairment of Long-Lived Assets
 
Long-lived assets held for use, which includes medical equipment in rental service, property and equipment and amortizable intangible assets, are reviewed for impairment when events or changes in circumstances indicate that their carrying value
may
not
be recoverable. If an impairment indicator exists, the Company assesses the asset or asset group for recoverability. Recoverability of these assets is determined based upon the expected undiscounted future net cash flows from the operations to which the assets relate, utilizing management's best estimates, appropriate assumptions and projections at the time. If the carrying value is determined
not
to be recoverable from future operating cash flows, the asset is deemed impaired and an impairment loss would be recognized to the extent the carrying value exceeded the estimated fair market value of the asset or asset group.
 
The Company assesses impairment indicators related to its internally-developed, internal-use software, specifically looking at the effectiveness and useful lives of each project and sub-project to determine if impairment indicators are present. In
December 2020
and
2019,
respectively, the Company assessed the impairment indicators and found
none
to be present.
Lessee, Leases [Policy Text Block]
Leases
 
On
January 1, 2019 (
the “Effective Date”), the Company adopted Accounting Standards Update (“ASU”)
2016
-
02,
Leases (Topic
842
); ASU
2018
-
10,
Codification Improvements to Topic
842,
Leases; and ASU
2018
-
11,
Targeted Improvements (collectively, “Topic
842”
) using a modified retrospective transition approach, which requires Topic
842
to be applied to all leases existing at the date of initial application. Under Topic
842,
lessees are required to recognize a lease liability and right-of-use asset (“ROU asset”) for all leases and to disclose key information about leasing arrangements. Additionally, leases are classified as either financing or operating; the classification determines the pattern of expense recognition and classification within the statement of operations. The Company elected to apply its lease accounting policy only to leases with a term greater than
twelve
months.
 
Topic
842
provides several optional practical expedients that we adopted at transition. The Company elected the “package of practical expedients”, which does
not
require it to reassess its prior conclusions regarding lease identification, lease classification and initial direct costs. The Company did
not
elect the practical expedient of hindsight to the evaluation of lease options (e.g. renewal).
 
Topic
842
also provides practical expedients for an entity's ongoing accounting. The Company elected the “combining lease and non-lease components” practical expedient and also elected to apply the short-term lease recognition exemption to certain leases; therefore, the Company did
not
recognize ROU assets and lease liabilities for these leases.
 
In adopting Topic
842,
the Company determined and will continue to determine whether an arrangement is a lease at inception. The Company's operating leases are primarily for office space, service facility centers and equipment under operating lease arrangements that expire at various dates over the next
ten
years. The Company's leases do
not
contain any restrictive covenants. The Company's office leases generally contain renewal options for periods ranging from
one
to
five
years. Because the Company is
not
reasonably certain to exercise these renewal options, the options are
not
considered in determining the lease term, and payments associated with the option years are excluded from lease payments. The Company's office leases do
not
contain any material residual value guarantees. The Company's equipment leases generally do
not
contain renewal options. The Company is
not
reasonably certain to exercise the renewal options for those equipment leases that do contain renewal options, thus, the options are
not
considered in determining the lease term and payments associated with the option years are excluded from lease payments.
 
For the Company's equipment leases, the Company used and will use the implicit rate in the lease as the discount rate, when available. Otherwise, the Company uses its incremental borrowing rate as the discount rate. For the Company's office leases, the implicit rate is typically
not
available, so the Company used and will use its incremental borrowing rate as the discount rate. The incremental borrowing rate is estimated to approximate the interest rate on a collateralized basis with similar terms and payments. The Company's lease agreements include both lease and non-lease components. The Company elected the practical expedient that allows it to combine lease and non-lease components for all of its leases.
 
Payments due under the Company's operating leases include fixed payments as well as variable payments. For the Company's office leases, variable payments include amounts for the Company's proportionate share of operating expenses, utilities, property taxes, insurance, common area maintenance and other facility-related expenses. For the Company's equipment leases, variable payments
may
consist of sales taxes, property taxes and other fees.
Revenue from Contract with Customer [Policy Text Block]
Revenue Recognition
 
Revenue is recognized at the time and in an amount that reflects the consideration expected to be received for the performance obligations that have been provided. Accounting Standards Codification (“ASC”) Topic
606
– Revenue from Contracts with Customers (“ASC
606”
) defines contracts as written, oral and through customary business practice. Under this definition, the Company considers contracts to be created at the time that the rental service is authorized or an order to purchase product is agreed upon regardless of whether or
not
there is a written contract.
 
The Company has
two
separate and distinct performance obligations offered to its customers: a rental service performance obligation or a product sale performance obligation. A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is defined as the unit of account for revenue recognition under ASC
606.
These performance obligations are related to separate revenue streams and at
no
point are they combined into a single transaction. Sources of net revenues include commercial insurance payers, government insurance payers, medical facilities and patients.
 
The Company generates the majority of its revenue from the rental of infusion pumps to its customers and a minority of its revenue from product sales. For the rental service performance obligation, revenue is based on its standalone price, determined by using reimbursement rates established by
third
-party payer or other contracts. Revenue is recognized in the period in which the related performance obligation is satisfied, which is typically at the point in time that a patient concludes a treatment, or in certain arrangements, based on the number of pumps that a facility has onsite. The Company's revenues related to product sales are recognized at the time that control of the product has been transferred to the customer; either at the time the product is shipped or the time the product has been received by the customer, depending on the delivery terms. The Company does
not
commit to long-term contracts to sell customers a certain minimum quantity of products.
 
The Company employs certain significant judgments to estimate the dollar amount of revenue, and related concessions, allocated to the rental service and sale of products. These judgments include, among others, the estimation of variable consideration. Variable consideration, specifically related to the Company's
third
-party payer rental revenues, is estimated as implied price concessions resulting from differences between the rates charged for services performed and the expected reimbursements for commercial payers and other implied customer concessions. The estimates for variable consideration are based on historical collections with similar payers, aged accounts receivable by payer class and payer correspondence using the portfolio approach, which provide a reasonable basis for estimating the variable portion of a transaction. The Company doesn't believe it is probable that a significant reversal of revenue will occur in future periods because (i) there is
no
significant uncertainty about the amount of considerations that are expected to be collected based on collection history and (ii) the large number of sufficiently similar contracts allows the Company to adequately estimate the component of variable consideration.
 
Net revenues are adjusted when changes in estimates of variable consideration occur. Changes in estimates typically arise as a result of new information obtained, such as actual payment receipt or denial, or pricing adjustments by payers. Subsequent changes to estimates of transaction prices are recorded as adjustments to net revenue in the period of the change. Subsequent changes that are determined to be the result of an adverse change in the payer's ability to pay are recorded as an allowance for doubtful accounts.
 
Due to the nature of the industry and the reimbursement environment in which the Company operates, certain estimates are required to record net revenues and accounts receivable at their net realizable values. Inherent in these estimates is the risk that the estimates will have to be revised or updated as additional information becomes available. Specifically, the complexity of many
third
-party billing arrangements and the uncertainty of reimbursement amounts for certain services from certain payers
may
result in adjustments to amounts originally recorded. Due to continuing changes in the health care industry and
third
-party reimbursement, it is possible that management's estimates could change in the near term, which could have a material impact on the Company's results of operations and cash flows.
Revenue Recognition, Cost of Revenue [Policy Text Block]
Cost of Revenues
 
Cost of revenues include the costs of servicing and maintaining pumps, products sold, shipping and other direct and indirect costs related to net revenues. Shipping and handling costs incurred after control over a product has transferred to a customer are accounted for as a fulfillment cost.
Concentration Risk, Credit Risk, Policy [Policy Text Block]
Customer Concentration
 
For
2020
and
2019,
the Company's largest contracted payer was a national payer which accounted for approximately
14%
and
8%
of ITS net revenues for
2020
and
2019,
respectively, and approximately
9%
and
5%
of total consolidated net revenues for
2020
and
2019,
respectively.
 
The Company also contracts with various other
third
-party payer organizations, Medicaid, commercial Medicare replacement plans, self-insured plans, facilities of our Medicare patients and numerous other insurance carriers. Other than the payer noted above,
no
other single payer represented more than
7%
of the Company's ITS net revenue.
Income Tax, Policy [Policy Text Block]
Income Taxes
 
The Company recognizes deferred income tax liabilities and assets based on (i) the differences between the financial statement carrying amounts and the tax basis of assets and liabilities, using enacted tax rates in effect in the years the differences are expected to reverse and (ii) the tax credit carryforwards. Deferred income tax (expense) benefit results from the change in net deferred tax assets or deferred tax liabilities. A valuation allowance is recorded when it is more likely than
not
that some or all of any deferred tax assets will
not
be realized.
 
Provisions for federal, state and foreign taxes are calculated based on reported pre-tax earnings based on current tax law and include the cumulative effect of any changes in tax rates from those used previously in determining deferred tax assets and liabilities. Certain items of income and expense are recognized in different time periods for financial reporting than for income tax purposes; thus, such provisions differ from the amounts currently receivable or payable.
 
The Company follows a
two
-step approach for recognizing uncertain tax positions. First, it evaluates the tax position for recognition by determining if the weight of available evidence indicates it is more-likely-than-
not
that the position will be sustained upon examination. Second, for positions that are determined are more-likely-than-
not
to be sustained, it recognizes the tax benefits as the largest benefit that has a greater than
50%
likelihood of being sustained. The Company establishes a reserve for uncertain tax positions liability that is comprised of unrecognized tax benefits and related interest and penalties. The Company adjusts this liability in the period in which an uncertain tax position is effectively settled, the statute of limitations expires for the relevant taxing authority to examine the tax position, or more information becomes available.
 
The Company adopted ASU
2019
-
12,
Income Taxes (Topic
740
): Simplifying the Accounting for Income Taxes, in the
fourth
quarter of
2019.
This guidance simplifies various aspects related to accounting for income taxes by removing certain exceptions to the general principles in Topic
740
and also clarifies and amends existing guidance to improve consistent application. The guidance is effective for fiscal years, and interim periods within those fiscal years, beginning after
December 15, 2020.
Early adoption is permitted, including adoption in any interim period for which financial statements have
not
yet been issued. Certain amendments
may
be applied on a retrospective, modified retrospective or prospective basis. As permitted, the Company elected to early adopt this guidance for the year ended
December 31, 2019.
The adoption of this guidance did
not
have a significant impact on the Company's financial statements and primarily resulted in the reclassification of an immaterial amount from non-income tax expense to income tax expense related to the accounting for franchise taxes, with
no
impact to the Company's consolidated net income, equity or cash flows.
Treasury Stock, Policy [Policy Text Block]
Treasury Stock
 
The Company periodically repurchases shares of its common stock. These repurchases take place either as part of a board-authorized program, which
may
include open market transactions or privately negotiated transactions and
may
be made under a Rule
10b5
-
1
plan, or in targeted stock purchase agreements approved by the board. Treasury stock is accounted for using the par value method.
Share-based Payment Arrangement [Policy Text Block]
Share-Based Payments
 
The Company determines the fair value of stock option awards, restricted stock awards and stock appreciation rights (collectively, “Share-Based Awards”) on the date of grant using option-pricing models which are affected by the Company's stock price, as well as assumptions regarding a number of other inputs using the Black-Scholes pricing model. These variables include the Company's expected stock price volatility over the expected term of the Share-Based Awards, actual and projected employee stock option exercise behaviors, risk-free interest rates and expected dividends. The expected volatility is based on the historical volatility. The Company uses historical data to estimate Share-Based Awards exercise rates. The expected term represents the period over which the Share-Based Awards are expected to be outstanding. The dividend yield is an estimate of the expected dividend yield on the Company's stock. The risk-free rate is based on U.S. Treasury yields in effect at the time of the grant for the expected term of the Share-Based Awards. All Share-Based Awards are amortized based on their graded vesting over the requisite service period of the awards. Compensation costs are recognized over the requisite service period using the accelerated method and included in general and administrative expenses.
 
Additionally, the Company also determines the fair value of performance-based restricted stock units (“PSUs”) based upon the type of performance measure. These awards typically vest after the Company's achievement of either Company performance relative to specified performance measure goals for a specific fiscal period or when the market value of the Company's stock price reaches a target value for a minimum number of consecutive trading days. Under Financial Accounting Standards Board (“FASB”) ASC Topic
718,
the provisions of the PSUs that vest upon achievement of a target market value are considered a market condition, and therefore the effect of that market condition is reflected in the grant date fair value for this type of award. A
third
-party valuation expert was engaged to complete a “Monte Carlo simulation” to account for the market condition. That simulation takes into account the beginning stock price of the Company's common stock, the expected volatilities for the Company's stock price and the expected risk-free rate of return. The single grant-date fair value computed by this valuation method is recognized by the Company in accounting for the awards regardless of the actual future outcome of the market condition. The grant date fair value of the other PSUs is calculated as the closing price of the Company's common stock on the grant date multiplied by the number of shares subject to the award. Company performance measure goals are considered a performance condition and the grant-date fair value for those PSUs corresponds with management's expectation of the probable outcome of the performance conditions as of the grant date.
Deferred Charges, Policy [Policy Text Block]
Deferred Debt Issuance Costs
 
Capitalized debt issuance costs as of
December 31, 2020
and
2019
relate to the Company's credit facility. The costs related to the agreement are netted against current and non-current debt. The Company amortizes these costs using the interest method through the maturity date of the underlying debt.
Earnings Per Share, Policy [Policy Text Block]
Earnings Per Share
 
The Company reports its earnings per share in accordance with ASU
2017
-
11,
Earnings Per Share (Topic
260
), which requires the presentation of both basic and diluted earnings per share on the statements of operations. The diluted weighted average common shares include adjustments for the potential effects of outstanding stock options but only in the periods in which such effect is dilutive under the treasury stock method. Included in our basic and diluted weighted average common shares are those stock options and restricted stock awards due to participants granted from the
2014
stock incentive plan. Anti-dilutive stock awards are comprised of stock options and unvested restricted stock awards, which would have been anti-dilutive in the application of the treasury stock method in accordance with ASU
2017
-
11,
Earnings Per Share (Topic
260
). In periods where the Company records a net loss, the diluted per share amount is the same as the basic per share amount.
 
In accordance with this topic, the following table reconciles income and share amounts utilized to calculate basic and diluted net income per common share as of
December 31 (
in thousands, except shares):
 
   
2020
   
2019
 
Numerator:
               
Net income
(in thousands)
  $
17,332
    $
1,361
 
Denominator:
               
Weighted average common shares outstanding:
               
Basic
   
20,106,940
     
19,731,498
 
Dilutive effect of restricted shares and options
   
1,610,276
     
1,107,898
 
Diluted
   
21,717,216
     
20,839,396
 
 
Stock options of less than
0.1
million shares were
not
included in the calculations for both the years ended
December 31, 2020
and
2019
because they would have an anti-dilutive effect.
Fair Value of Financial Instruments, Policy [Policy Text Block]
Fair Value of Financial Instruments
 
The carrying amounts reported in the consolidated balance sheets as of
December 31, 2020
and
2019
for cash, accounts receivable, accounts payable and other current liabilities approximate fair value because of the short-term nature of these instruments (Level I). The carrying value of the Company's long-term debt with variable interest rates approximates fair value based on instruments with similar terms (Level II).
 
The Company has adopted ASC
820,
Fair Value Measurements, which defines fair value, establishes a framework for assets and liabilities being measured and reported at fair value and appends disclosures about fair value measurements.
 
For financial assets and liabilities measured at fair value on a recurring basis, fair value is the price the Company would receive to sell an asset or pay to transfer a liability in an orderly transaction with a market participant at the measurement date. A
three
-level fair value hierarchy prioritizes the inputs used to measure fair value as follows:
 
 
Level I
:
quoted prices in active markets for identical instruments;
 
 
Level II
:
quoted prices in active markets for similar instruments, quoted prices for identical instruments in markets that are
not
active, or other inputs that are observable or can be corroborated by observable data for substantially the full term of the instrument; and
 
 
Level III
:
significant inputs to the valuation model are unobservable.
New Accounting Pronouncements, Policy [Policy Text Block]
Recent Accounting Pronouncements and Developments
 
In
June 2016,
the FASB issued ASU
No.
2016
-
13,
“Financial Instruments (Topic
326
) Credit Losses”. Topic
326
changes the impairment model for most financial assets and certain other instruments. Under the new standard, entities holding financial assets and net investment in leases that are
not
accounted for at fair value through net income are to be presented at the net amount expected to be collected. An allowance for credit losses will be a valuation account that will be deducted from the amortized cost basis of the financial asset to present the net carrying value at the amount expected to be collected on the financial asset. Topic
326
was originally effective as of
January 1, 2020,
although in
November 2019,
the FASB delayed the effective date until fiscal years beginning after
December 15, 2022
for SEC filers eligible to be smaller reporting companies under the SEC's definition. The Company qualifies as a smaller reporting company under the SEC's definition. Early adoption is permitted. The Company is currently evaluating the impact of Topic
326
on its consolidated balance sheets, statements of operations, statements of cash flows and related disclosures.
XML 37 R23.htm IDEA: XBRL DOCUMENT v3.21.1
Note 2 - Summary of Significant Accounting Policies (Tables)
12 Months Ended
Dec. 31, 2020
Notes Tables  
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
   
2020
   
2019
 
Numerator:
               
Net income
(in thousands)
  $
17,332
    $
1,361
 
Denominator:
               
Weighted average common shares outstanding:
               
Basic
   
20,106,940
     
19,731,498
 
Dilutive effect of restricted shares and options
   
1,610,276
     
1,107,898
 
Diluted
   
21,717,216
     
20,839,396
 
XML 38 R24.htm IDEA: XBRL DOCUMENT v3.21.1
Note 3 - Revenue Recognition (Tables)
12 Months Ended
Dec. 31, 2020
Notes Tables  
Disaggregation of Revenue [Table Text Block]
   
2020
   
2019
 
                 
Third-Party Payer Rentals
  $
49,266
    $
40,510
 
Direct Payer Rentals
  $
30,765
    $
26,269
 
Product Sales
  $
17,357
    $
14,336
 
                 
Total - Net revenues
  $
97,388
    $
81,115
 
   
2020
   
2019
 
                 
Third-Party Payer Rentals
   
50.6
%    
49.9
%
Direct Payer Rentals
   
31.6
%    
32.4
%
Product Sales
   
17.8
%    
17.7
%
                 
Total - Net revenues
   
100.0
%    
100.0
%
XML 39 R25.htm IDEA: XBRL DOCUMENT v3.21.1
Note 4 - Medical Equipment (Tables)
12 Months Ended
Dec. 31, 2020
Notes Tables  
Schedule of Medical Equipment [Table Text Block]
   
2020
   
2019
 
Medical Equipment for sale or rental
  $
1,636
    $
1,334
 
Medical Equipment for sale or rental - pump reserve
   
(33
)    
(28
)
Medical Equipment for sale or rental - net
   
1,603
     
1,306
 
                 
Medical Equipment in rental service
   
83,411
     
75,853
 
Medical Equipment in rental service - pump reserve
   
(893
)    
(720
)
Accumulated depreciation
   
(46,907
)    
(41,908
)
Medical Equipment in rental service - net
   
35,611
     
33,225
 
                 
Total
  $
37,214
    $
34,531
 
XML 40 R26.htm IDEA: XBRL DOCUMENT v3.21.1
Note 5 - Property and Equipment (Tables)
12 Months Ended
Dec. 31, 2020
Notes Tables  
Property, Plant and Equipment [Table Text Block]
   
2020
 
   
Gross Assets
   
Accumulated
Depreciation
   
Total
 
Furniture, fixtures, and equipment
  $
3,742
    $
(2,018
)   $
1,724
 
Automobiles
   
117
     
(102
)    
15
 
Leasehold improvements
   
3,416
     
(859
)    
2,557
 
                         
Total
  $
7,275
    $
(2,979
)   $
4,296
 
   
2019
 
   
Gross Assets
   
Accumulated
Depreciation
   
Total
 
Furniture, fixtures, and equipment
  $
3,202
    $
(1,928
)   $
1,274
 
Automobiles
   
117
     
(90
)    
27
 
Leasehold improvements
   
3,366
     
(630
)    
2,736
 
                         
Total
  $
6,685
    $
(2,648
)   $
4,037
 
XML 41 R27.htm IDEA: XBRL DOCUMENT v3.21.1
Note 6 - Intangible Assets (Tables)
12 Months Ended
Dec. 31, 2020
Notes Tables  
Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets [Table Text Block]
   
2020
 
   
Gross Assets
   
Accumulated Amortization
   
Net
 
Nonamortizable intangible assets
                       
Trade names
  $
2,000
    $
-
    $
2,000
 
Amortizable intangible assets
                       
Trade names
   
23
     
(23
)    
-
 
Physician and customer relationships
   
36,534
     
(28,924
)    
7,610
 
Software
   
11,230
     
(9,663
)    
1,567
 
                         
Total nonamortizable and amortizable intangible assets
  $
49,787
    $
(38,610
)   $
11,177
 
   
2019
 
   
Gross Assets
   
Accumulated Amortization
   
Net
 
Nonamortizable intangible assets
                       
Trade names
  $
2,000
    $
-
    $
2,000
 
Amortizable intangible assets
                       
Trade names
   
23
     
(23
)    
-
 
Physician and customer relationships
   
36,534
     
(26,550
)    
9,984
 
Software
   
11,230
     
(7,751
)    
3,479
 
                         
Total nonamortizable and amortizable intangible assets
  $
49,787
    $
(34,324
)   $
15,463
 
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]
   
2021
   
2022
   
2023
   
2024
   
2025
   
2026 and
thereafter
 
Amortization expense
  $
3,930
    $
2,051
    $
548
    $
548
    $
367
    $
1,733
 
XML 42 R28.htm IDEA: XBRL DOCUMENT v3.21.1
Note 7 - Debt (Tables)
12 Months Ended
Dec. 31, 2020
Notes Tables  
Schedule of Line of Credit Facilities [Table Text Block]
   
December 31,
   
December 31,
 
   
2020
   
2019
 
Revolver:
               
Gross availability
  $
11,750
    $
11,750
 
Outstanding draws
   
-
     
-
 
Letters of credit
   
(800
)    
(1,750
)
Landlord reserves
   
(162
)    
(150
)
Availability on Revolver
  $
10,788
    $
9,850
 
Schedule of Maturities of Long-term Debt [Table Text Block]
   
2021
   
2022
   
2023
   
2024
   
2025 and
thereafter
   
Total
 
Term Loan
  $
4,615
    $
4,615
    $
4,615
    $
8,075
    $
-
    $
21,920
 
Equipment Line
   
1,600
     
1,600
     
1,600
     
1,200
     
-
     
6,000
 
2019 Equipment Line
   
2,500
     
2,000
     
2,000
     
3,500
     
-
     
10,000
 
Unamortized value of debt issuance costs
   
(17
)    
(17
)    
(17
)    
(15
)    
-
     
(66
)
Other financing
   
725
     
222
     
-
     
-
     
-
     
947
 
Total
  $
9,423
    $
8,420
    $
8,198
    $
12,760
    $
-
    $
38,801
 
Schedule of Debt [Table Text Block]
   
December 31, 2020
   
December 31, 2019
 
   
Current
Portion
   
Long-Term
Portion
   
Total
   
Current
Portion
   
Long-Term
Portion
   
Total
 
Term Loan
  $
4,615
    $
17,305
    $
21,920
    $
5,768
    $
21,919
    $
27,687
 
Equipment Line
   
1,600
     
4,400
     
6,000
     
1,600
     
6,000
     
7,600
 
2019 Equipment Line
   
2,500
     
7,500
     
10,000
     
79
     
1,495
     
1,574
 
Unamortized value of debt issuance costs
   
(17
)    
(49
)    
(66
)    
(17
)    
(66
)    
(83
)
Other financing
   
725
     
222
     
947
     
652
     
947
     
1,599
 
Total
  $
9,423
    $
29,378
    $
38,801
    $
8,082
    $
30,295
    $
38,377
 
XML 43 R29.htm IDEA: XBRL DOCUMENT v3.21.1
Note 8 - Income Taxes (Tables)
12 Months Ended
Dec. 31, 2020
Notes Tables  
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]
   
2020
   
2019
 
U.S income
  $
6,623
    $
1,413
 
Non-U.S. income
   
920
     
111
 
Income before income taxes
  $
7,543
    $
1,524
 
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]
   
2020
   
2019
 
U.S Federal income tax benefit (expense)
               
Current
  $
(11
)   $
-
 
Deferred
   
8,346
     
(104
)
Total U.S. Federal income tax benefit (expense)
   
8,335
     
(104
)
State and local income tax benefit (expense)
               
Current
   
(66
)    
(29
)
Deferred
   
1,725
     
-
 
Total state and local income tax benefit (expense)
   
1,659
     
(29
)
Foreign income tax expense
               
Current
   
(205
)    
(30
)
Total income tax benefit (expense)
  $
9,789
    $
(163
)
Summary of Valuation Allowance [Table Text Block]
   
2020
   
2019
 
Valuation allowance at the Beginning of Period
  $
(11,250
)   $
(11,370
)
Income tax expense
   
-
     
-
 
Release of valuation allowance
   
11,250
     
120
 
Valuation allowance at the End of Period
  $
-
    $
(11,250
)
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]
   
2020
   
2019
 
Income tax expense at the statutory rate
   
21.0
%    
21.0
%
State and local income tax expense
   
5.1
%    
2.0
%
Foreign income tax
   
0.2
%    
2.0
%
Permanent differences
   
(8.4
%)    
(5.8
%)
Decrease in valuation allowance
   
(149.2
%)    
(7.9
%)
Other adjustments
   
1.5
%    
(0.6
%)
Effective income tax rate
   
(129.8
%)    
10.7
%
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]
   
2020
   
2019
 
Deferred Federal tax assets –
               
Bad debt reserves
  $
1,570
    $
1,459
 
Stock-based compensation
   
656
     
443
 
Net operating loss
   
7,337
     
7,991
 
Operating lease liabilities
   
1,014
     
1,271
 
Accrued compensation
   
757
     
451
 
Inventories
   
214
     
27
 
Goodwill and intangible assets
   
832
     
1,688
 
Research & development credits
   
533
     
533
 
Other credits
   
30
     
25
 
Other
   
54
     
194
 
Total deferred Federal tax assets
   
12,997
     
14,082
 
Less: valuation allowance
   
-
     
(9,553
)
Net deferred Federal tax assets
   
12,997
     
4,529
 
Deferred Federal tax liabilities –
               
Depreciation and asset basis differences
   
(3,393
)    
(3,366
)
Right-of-use assets
   
(937
)    
(1,204
)
Total deferred Federal tax liabilities
   
(4,330
)    
(4,570
)
Net deferred Federal tax assets (liabilities)
   
8,667
     
(41
)
Total deferred state and local tax assets (a)
   
1,300
     
1,634
 
Less: valuation allowance
   
-
     
(1,697
)
Net deferred state and local tax assets (liabilities)
   
1,300
     
(63
)
Net deferred tax assets (liabilities)
  $
9,967
    $
(104
)
XML 44 R30.htm IDEA: XBRL DOCUMENT v3.21.1
Note 10 - Leases (Tables)
12 Months Ended
Dec. 31, 2020
Notes Tables  
Lease, Cost [Table Text Block]
   
2020
   
2019
 
Operating lease cost
  $
1,617
    $
1,948
 
Variable lease cost
   
315
     
291
 
Total lease cost
  $
1,932
    $
2,239
 
   
2020
   
2019
 
Cash paid for amounts included in the measurement of lease liabilities and ROU assets:
               
Operating cash flow from operating leases
  $
1,603
    $
1,610
 
                 
ROU assets obtained in exchange for lease obligations:
               
Operating leases
  $
264
    $
4,545
 
                 
Reductions to ROU assets resulting from reductions to lease obligations:
               
Operating leases
  $
-
    $
22
 
   
2020
   
2019
 
                 
   
Years
   
Years
 
Weighted average remaining lease term:
               
Operating leases
   
7.0
     
7.4
 
   
Rate
   
Rate
 
Weighted average discount rate:
               
Operating leases
   
7.8
%    
7.7
%
Lessee, Operating Lease, Liability, Maturity [Table Text Block]
   
Operating Leases
 
2021
  $
1,108
 
2022
   
1,045
 
2023
   
941
 
2024
   
949
 
2025
   
914
 
Thereafter
   
2,253
 
Total undiscounted lease payments
   
7,210
 
Less: Imputed interest
   
(2,380
)
Total lease liabilities
  $
4,830
 
XML 45 R31.htm IDEA: XBRL DOCUMENT v3.21.1
Note 11 - Share-based Compensation (Tables)
12 Months Ended
Dec. 31, 2020
Notes Tables  
Nonvested Restricted Stock Shares Activity [Table Text Block]
   
 
 
 
 
Weighted
   
 
 
 
   
 
 
 
 
average
   
 
 
 
   
 
 
 
 
grant
   
 
 
 
   
Number of
   
date fair
   
Aggregate
 
   
shares
   
value
   
fair value
 
                         
Unvested at December 31, 2018
   
129,583
    $
1.42
     
 
 
                         
Granted
   
26,000
     
7.04
     
 
 
Vested
   
(58,314
)    
3.17
    $
712,969
 
Vested shares forgone to satisfy minimum statutory withholding
   
(71,269
)    
3.17
    $
422,779
 
Forfeitures
   
-
     
-
     
 
 
                         
Unvested at December 31, 2019
   
26,000
     
7.04
     
 
 
Granted
   
156,250
     
10.12
     
 
 
Vested
   
(28,432
)    
9.28
    $
367,273
 
Vested shares forgone to satisfy minimum statutory withholding
   
(6,818
)    
9.28
    $
62,479
 
Forfeitures
   
(2,000
)    
11.68
     
 
 
Unvested at December 31, 2020
   
145,000
    $
9.78
     
 
 
Share-based Payment Arrangement, Performance Shares, Activity [Table Text Block]
   
 
 
 
 
Weighted
   
 
 
 
   
 
 
 
 
average
   
 
 
 
   
 
 
 
 
grant
   
 
 
 
   
Number of
   
date fair
   
Aggregate
 
   
shares
   
value
   
fair value
 
                         
Unvested at December 31, 2019
   
-
     
-
     
 
 
Granted
   
232,500
     
9.06
     
 
 
Unvested at December 31, 2020
   
232,500
    $
9.06
     
 
 
Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]
   
2020
   
2019
 
Compensation expense
  $
108,589
    $
43,030
 
Shares of stock sold to employees
   
30,012
     
33,742
 
Weighted average fair value per ESPP award
  $
7.43
    $
3.94
 
Schedule of Nonvested Share Activity [Table Text Block]
   
 
 
 
 
 
 
 
 
Weighted-
   
 
 
 
   
 
 
 
 
 
 
 
 
Average
   
 
 
 
   
Number
   
Weighted-
   
Remaining
   
Aggregate
 
   
of Authorized
   
Average Exercise
   
Contractual
   
Intrinsic
 
2014 Plan (Options)
 
Shares
   
Price
   
Term (in Years)
   
Value
 
Outstanding at December 31, 2018
   
2,224,167
    $
2.67
     
3.01
    $
-
 
                                 
Granted
   
670,000
    $
3.77
     
4.40
     
 
 
Exercised
   
(213,056
)    
2.33
     
 
     
624,462
 
Exercised shares forgone to satisfy minimum statutory withholding
   
(51,339
)    
2.33
     
 
     
 
 
Cashless exercise
   
(184,493
)    
2.33
     
 
     
 
 
Forfeited
   
(101,946
)    
3.63
     
 
     
 
 
                                 
Outstanding at December 31, 2019
   
2,343,333
    $
2.99
     
1.81
    $
12,989,767
 
                                 
Exercisable at December 31, 2019
   
1,501,750
    $
2.69
     
 
     
 
 
                                 
Granted
   
331,000
     
10.38
     
8.59
     
 
 
Exercised
   
(334,184
)    
2.77
     
 
     
3,135,211
 
Exercised shares forgone to satisfy minimum statutory withholding
   
(125,714
)    
2.77
     
 
     
 
 
Cashless exercise
   
(164,751
)    
2.77
     
 
     
 
 
Forfeited
   
(90,336
)    
3.96
     
 
     
 
 
                                 
Outstanding at December 31, 2020
   
1,959,348
    $
4.26
     
4.42
    $
28,449,362
 
                                 
Exercisable at December 31, 2020
   
1,362,932
    $
3.33
     
 
     
 
 
   
 
 
 
 
 
 
 
 
Weighted-
   
 
 
 
   
 
 
 
 
 
 
 
 
Average
   
 
 
 
   
Number
   
Weighted-
   
Remaining
   
Aggregate
 
Inducement
 
of Authorized
   
Average Exercise
   
Contractual
   
Intrinsic
 
Options
 
Shares
( 1 )
   
Price
   
Term (in Years)
   
Value
 
Outstanding at December 31, 2018
   
125,000
    $
2.55
     
5.42
    $
111,250
 
                                 
Granted
   
-
     
-
     
-
     
-
 
Exercised
   
-
     
-
     
-
     
-
 
Forfeited
   
-
     
-
     
-
     
-
 
                                 
Outstanding at December 31, 2019
   
125,000
    $
2.55
     
4.42
    $
747,500
 
                                 
Granted
   
-
     
-
     
-
     
-
 
Exercised
   
(27,940
)    
2.55
     
-
     
242,519
 
Exercised shares forgone to satisfy minimum statutory withholding
   
(12,417
)    
2.55
     
-
     
-
 
Cashless exercise
   
(14,330
)    
2.55
     
-
     
-
 
Forfeited
   
(70,313
)    
2.55
     
-
     
-
 
                                 
Outstanding at December 31, 2020
   
-
    $
-
     
-
    $
-
 
                                 
Exercisable at December 31, 2020
   
-
    $
-
     
 
     
 
 
Share-based Payment Arrangement, Option, Exercise Price Range [Table Text Block]
       
Options Outstanding
   
Options Exercisable
 
2014 Plan (Options):
                                       
Range of Exercise Prices
 
Number of Shares Outstanding
   
Weighted-Average Remaining Contractual Life
   
Weighted-Average Exercise Price
   
Number of Shares Exercisable
   
Weighted-Average Exercise Price
 
                                             
$2.01
-
$3.00
   
870,011
     
3.20
    $
2.26
     
784,178
    $
2.26
 
$3.01
-
$4.00
   
423,336
     
2.74
    $
3.23
     
301,669
    $
3.21
 
$4.01
-
$5.00
   
335,001
     
5.60
    $
4.70
     
198,335
    $
4.70
 
$6.01
-
$7.00
   
50,000
     
4.21
    $
6.82
     
-
    $
-
 
$8.01
-
$9.00
   
20,000
     
9.02
    $
8.55
     
-
    $
-
 
$11.01
-
$12.00
   
245,000
     
9.38
    $
11.07
     
78,750
    $
11.07
 
$13.01
-
$14.00
   
16,000
     
9.62
    $
13.30
     
-
    $
-
 
                                             
Outstanding at December 31, 2020
   
1,959,348
     
4.42
    $
4.26
     
1,362,932
    $
3.33
 
Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block]
Stock Options:
 
2020
   
2019
 
Expected volatility
 
 42%
to
51%
   
 36%
to
 38%
 
Risk free interest rate
 
 0.20%
to
 1.56%
   
 1.80%
to
2.36%
 
Expected lives at date of grant (in years)
 
 
3.25
 
   
 
4.63
 
 
Weighted average fair value of options granted
 
 
$3.87
 
   
 
$1.61
 
 
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]
   
2020
   
2019
 
Restricted share expense
  $
1,687
    $
190
 
Stock option and SARs expense
   
923
     
807
 
Total stock-based compensation expense
  $
2,610
    $
997
 
XML 46 R32.htm IDEA: XBRL DOCUMENT v3.21.1
Note 12 - Business Segment Information (Tables)
12 Months Ended
Dec. 31, 2020
Notes Tables  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
2020
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
Corporate/
   
 
 
 
(in thousands)
 
ITS
   
DME Services
   
Eliminations
   
Total
 
                                 
Net revenues - external
  $
61,072
    $
36,316
    $
-
    $
97,388
 
Net revenues - internal
   
-
     
5,370
     
(5,370
)    
-
 
Total net revenues
   
61,072
     
41,686
     
(5,370
)    
97,388
 
Gross profit
   
39,773
     
18,986
     
-
     
58,759
 
                                 
Selling , general and administrative expenses
   
 
     
 
     
49,932
     
49,932
 
Interest expense
   
 
     
 
     
(1,255
)    
(1,255
)
Other expense
   
 
     
 
     
(29
)    
(29
)
Benefit from income taxes
   
 
     
 
     
9,789
     
9,789
 
                                 
Net income
   
 
     
 
     
 
    $
17,332
 
                                 
Total assets
  $
68,472
    $
26,519
    $
2,000
    $
96,991
 
Purchases of medical equipment
  $
9,583
    $
6,237
    $
-
    $
15,820
 
Depreciation and amortization of intangible assets
  $
10,708
    $
3,317
    $
-
    $
14,025
 
2019
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
Corporate/
   
 
 
 
(in thousands)
 
ITS
   
DME Services
   
Eliminations
   
Total
 
                                 
Net revenues - external
  $
51,540
    $
29,575
    $
-
    $
81,115
 
Net revenues - internal
   
-
     
3,788
     
(3,788
)    
-
 
Total net revenues
   
51,540
     
33,363
     
(3,788
)    
81,115
 
Gross profit
   
33,063
     
13,819
     
-
     
46,882
 
                                 
Selling, general and administrative expenses
   
 
     
 
     
43,357
     
43,357
 
Interest expense
   
 
     
 
     
(1,904
)    
(1,904
)
Other expense
   
 
     
 
     
(97
)    
(97
)
Provision for income taxes
   
 
     
 
     
(163
)    
(163
)
                                 
Net income
   
 
     
 
     
 
    $
1,361
 
                                 
Total assets
  $
54,292
    $
22,932
    $
2,000
    $
79,224
 
Purchases of medical equipment
  $
14,216
    $
5,453
    $
-
    $
19,669
 
Depreciation and amortization of intangible assets
  $
9,457
    $
2,885
    $
-
    $
12,342
 
XML 47 R33.htm IDEA: XBRL DOCUMENT v3.21.1
Note 1 - Basis of Presentation and Nature of Operations (Details Textual)
12 Months Ended
Dec. 31, 2020
Number of Operating Locations 5
Supplier Concentration Risk [Member] | Cost of Goods and Service, Product and Service Benchmark [Member] | Ambulatory Pumps [Member] | Smiths Medical, Inc. [Member] | Minimum [Member]  
Concentration Risk, Percentage 10.00%
Supplier Concentration Risk [Member] | Cost of Goods and Service, Product and Service Benchmark [Member] | Ambulatory Pumps [Member] | Moog Medical Devices Group [Member] | Minimum [Member]  
Concentration Risk, Percentage 10.00%
Supplier Concentration Risk [Member] | Cost of Goods and Service, Product and Service Benchmark [Member] | NPWT Medical Equipment [Member] | Cardinal Health, Inc. [Member] | Minimum [Member]  
Concentration Risk, Percentage 10.00%
XML 48 R34.htm IDEA: XBRL DOCUMENT v3.21.1
Note 2 - Summary of Significant Accounting Policies (Details Textual)
$ in Thousands, shares in Millions
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Oct. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Sep. 30, 2019
Dec. 31, 2020
USD ($)
shares
Dec. 31, 2019
USD ($)
shares
Number of Reportable Segments   2 1 2  
Number of Financial Institutions   2     2
Accounts Receivable, Allowance for Credit Loss, Current   $ 400   $ 1,000 $ 400
Inventory Valuation Reserves, Ending Balance   100   $ 100 100
Medical Equipment in Rental Services, Useful Life (Year)       7 years  
Medical Equipment in Rental Services Reserve   720   $ 893 720
Medical Equipment for Sale or Rental, Reserve   28   33 28
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) $ 0        
Impairment of Long-Lived Assets Held-for-use       0 0
Capitalized Computer Software, Net, Ending Balance   0   0 0
Capitalized Computer Software, Amortization       $ 1,900 $ 2,000
Share-based Payment Arrangement, Option [Member]          
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) | shares       0.1 0.1
Revenue, Product and Service Benchmark [Member] | Customer Concentration Risk [Member]          
Concentration Risk, Percentage       17.80% 17.70%
Revenue, Product and Service Benchmark [Member] | Customer Concentration Risk [Member] | National Association 2 [Member] | Oncology Business [Member]          
Concentration Risk, Percentage       14.00% 8.00%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | National Association 2 [Member]          
Concentration Risk, Percentage       9.00% 5.00%
Computer Software, Intangible Asset [Member]          
Finite-Lived Intangible Asset, Useful Life (Year)       3 years  
Information Technology Software [Member]          
Property, Plant and Equipment, Useful Life (Year)       3 years  
Computer Equipment [Member]          
Property, Plant and Equipment, Useful Life (Year)       5 years  
Maximum [Member]          
Medical Equipment for Sale or Rental, Reserve   $ 100   $ 100 $ 100
Property, Plant and Equipment, Useful Life (Year)       7 years  
Lessee, Operating Lease, Renewal Term (Year)       5 years  
Maximum [Member] | Physician and Customer Relationships [Member]          
Finite-Lived Intangible Asset, Useful Life (Year)       20 years  
Maximum [Member] | Software Development [Member]          
Property, Plant and Equipment, Useful Life (Year)       5 years  
Minimum [Member]          
Property, Plant and Equipment, Useful Life (Year)       3 years  
Lessee, Operating Lease, Renewal Term (Year)       1 year  
Minimum [Member] | Physician and Customer Relationships [Member]          
Finite-Lived Intangible Asset, Useful Life (Year)       15 years  
Minimum [Member] | Software Development [Member]          
Property, Plant and Equipment, Useful Life (Year)       3 years  
XML 49 R35.htm IDEA: XBRL DOCUMENT v3.21.1
Note 2 - Summary of Significant Accounting Policies - Summary of Income and Share Amounts Utilized to Calculate Basic and Diluted Net Income Per Common Share (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Numerator:    
Net income (in thousands) $ 17,332 $ 1,361
Weighted average common shares outstanding:    
Basic (in shares) 20,106,940 19,731,498
Dilutive effect of restricted shares and options (in shares) 1,610,276 1,107,898
Diluted (in shares) 21,717,216 20,839,396
XML 50 R36.htm IDEA: XBRL DOCUMENT v3.21.1
Note 3 - Revenue Recognition (Details Textual) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Revenues, Total $ 97,388 $ 81,115
Direct Payer Rentals [Member]    
Revenues, Total 30,765 26,269
ITS Segment [Member] | Direct Payer Rentals [Member]    
Revenues, Total 11,800 11,000
DME Services Segment [Member] | Direct Payer Rentals [Member]    
Revenues, Total $ 19,000 $ 15,300
XML 51 R37.htm IDEA: XBRL DOCUMENT v3.21.1
Note 3 - Revenue Recognition - Disaggregated Revenue by Revenue Stream (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Revenues, Total $ 97,388 $ 81,115
Customer Concentration Risk [Member] | Third-Party Payor Rental Revenue [Member]    
Concentration Risk, Percentage 50.60% 49.90%
Customer Concentration Risk [Member] | Direct Payer Rentals [Member]    
Concentration Risk, Percentage 31.60% 32.40%
Customer Concentration Risk [Member] | Revenue, Product and Service Benchmark [Member]    
Concentration Risk, Percentage 17.80% 17.70%
Customer Concentration Risk [Member] | Revenue from Contract with Customer Benchmark [Member]    
Concentration Risk, Percentage 100.00% 100.00%
Third-Party Payor Rental Revenue [Member]    
Revenues, Total $ 49,266 $ 40,510
Direct Payer Rentals [Member]    
Revenues, Total 30,765 26,269
Product Sales [Member]    
Revenues, Total $ 17,357 $ 14,336
XML 52 R38.htm IDEA: XBRL DOCUMENT v3.21.1
Note 4 - Medical Equipment (Details Textual) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Depreciation Expense Related to Medical Equipment $ 8.9 $ 7.5
XML 53 R39.htm IDEA: XBRL DOCUMENT v3.21.1
Note 4 - Medical Equipment - Summary of Medical Equipment (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Medical Equipment for sale or rental $ 1,636 $ 1,334
Medical Equipment for sale or rental - pump reserve (33) (28)
Medical Equipment for sale or rental - net 1,603 1,306
Medical Equipment in rental service 83,411 75,853
Medical Equipment in rental service - pump reserve (893) (720)
Accumulated depreciation (46,907) (41,908)
Medical Equipment in rental service - net 35,611 33,225
Total $ 37,214 $ 34,531
XML 54 R40.htm IDEA: XBRL DOCUMENT v3.21.1
Note 5 - Property and Equipment (Details Textual) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Depreciation, Nonproduction $ 0.8 $ 0.5
XML 55 R41.htm IDEA: XBRL DOCUMENT v3.21.1
Note 5 - Property and Equipment - Property and Equipment (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Gross Assets $ 7,275 $ 6,685
Accumulated Depreciation (2,979) (2,648)
Total 4,296 4,037
Furniture and Fixtures [Member]    
Gross Assets 3,742 3,202
Accumulated Depreciation (2,018) (1,928)
Total 1,724 1,274
Automobiles [Member]    
Gross Assets 117 117
Accumulated Depreciation (102) (90)
Total 15 27
Leasehold Improvements [Member]    
Gross Assets 3,416 3,366
Accumulated Depreciation (859) (630)
Total $ 2,557 $ 2,736
XML 56 R42.htm IDEA: XBRL DOCUMENT v3.21.1
Note 6 - Intangible Assets (Details Textual) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Impairment of Intangible Assets, Finite-lived $ 0 $ 0
Amortization of Intangible Assets, Total $ 4,285 $ 4,402
Physician and Customer Relationships [Member]    
Finite-Lived Intangible Assets, Remaining Amortization Period (Year) 7 years  
Computer Software, Intangible Asset [Member]    
Finite-Lived Intangible Assets, Remaining Amortization Period (Year) 1 year  
XML 57 R43.htm IDEA: XBRL DOCUMENT v3.21.1
Note 6 - Intangible Assets - Summary of Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Amortizable intangible assets, accumulated amortization $ (38,610) $ (34,324)
Total nonamortizable and amortizable intangible assets, gross assets 49,787 49,787
Total nonamortizable and amortizable intangible assets, net 11,177 15,463
Trade Names [Member]    
Amortizable intangible assets, gross assets 23 23
Amortizable intangible assets, accumulated amortization (23) (23)
Amortizable intangible assets, net
Physician and Customer Relationships [Member]    
Amortizable intangible assets, gross assets 36,534 36,534
Amortizable intangible assets, accumulated amortization (28,924) (26,550)
Amortizable intangible assets, net 7,610 9,984
Computer Software, Intangible Asset [Member]    
Amortizable intangible assets, gross assets 11,230 11,230
Amortizable intangible assets, accumulated amortization (9,663) (7,751)
Amortizable intangible assets, net 1,567 3,479
Trade Names 1 [Member]    
Nonamortizable intangible assets $ 2,000 $ 2,000
XML 58 R44.htm IDEA: XBRL DOCUMENT v3.21.1
Note 6 - Intangible Assets - Expected Annual Amortization Expense for Intangible Assets (Details)
$ in Thousands
Dec. 31, 2020
USD ($)
Amortization expense, 2021 $ 3,930
Amortization expense, 2022 2,051
Amortization expense, 2023 548
Amortization expense, 2024 548
Amortization expense, 2025 367
Amortization expense, 2026 and thereafter $ 1,733
XML 59 R45.htm IDEA: XBRL DOCUMENT v3.21.1
Note 7 - Debt (Details Textual) - USD ($)
$ in Thousands
12 Months Ended
Nov. 07, 2019
Apr. 15, 2019
Dec. 31, 2020
Dec. 31, 2019
Mar. 31, 2019
Feb. 05, 2019
Dec. 31, 2018
Capital Expenditures Incurred but Not yet Paid [1]     $ 793 $ 2,773      
Long-term Debt, Total     38,801 38,377      
Term Loan [Member]              
Long-term Debt, Total     21,920 27,687      
Equipment Line [Member]              
Long-term Debt, Total     6,000 7,600      
Revolving Credit Facility [Member]              
Line of Credit Facility, Current Borrowing Capacity     11,750 11,750      
The 2019 Equipment Line [Member]              
Long-term Debt, Total     10,000 1,574      
Credit Facility [Member] | Term Loan [Member]              
Long-term Debt, Total     $ 21,900        
Credit Facility [Member] | Eurodollar Loan [Member]              
Debt Instrument, Interest Rate, Effective Percentage     2.19%        
LIBOR Rate     0.19%        
Credit Facility [Member] | Eurodollar Loan [Member] | London Interbank Offered Rate (LIBOR) [Member]              
Debt Instrument, Basis Spread on Variable Rate     2.00%        
Credit Facility [Member] | CB Floating Rate Loan [Member]              
Debt Instrument, Interest Rate, Effective Percentage     2.25%        
Credit Facility [Member] | CB Floating Rate Loan [Member] | London Interbank Offered Rate (LIBOR) [Member]              
Debt Instrument, Basis Spread on Variable Rate, Before Margin Rate     2.50%        
Credit Facility [Member] | CB Floating Rate Loan [Member] | CB Floating Rate [Member]              
Debt Instrument, Basis Spread on Variable Rate     (1.00%)        
Lender Prime Rate     3.25%        
Credit Facility [Member] | Maximum [Member] | Eurodollar Loan [Member] | London Interbank Offered Rate (LIBOR) [Member]              
Debt Instrument, Basis Spread on Variable Rate     3.00%        
Credit Facility [Member] | Maximum [Member] | CB Floating Rate Loan [Member] | Greater of Prime Rate or LIBOR Plus 2.5% [Member]              
Debt Instrument, Basis Spread on Variable Rate     0.25%        
Credit Facility [Member] | Minimum [Member] | Eurodollar Loan [Member] | London Interbank Offered Rate (LIBOR) [Member]              
Debt Instrument, Basis Spread on Variable Rate     2.00%        
Credit Facility [Member] | Minimum [Member] | CB Floating Rate Loan [Member] | Greater of Prime Rate or LIBOR Plus 2.5% [Member]              
Debt Instrument, Basis Spread on Variable Rate     (1.00%)        
Credit Facility [Member] | Equipment Line [Member]              
Line of Credit Facility, Maximum Borrowing Capacity           $ 8,000  
Line of Credit Facility Additional Maximum Borrowing Capacity $ 10,000            
Line of Credit Facility, Invoiced Hard Cost Maximum Percent 90.00%            
Line of Credit Facility, Maximum One-time Charges $ 300            
Line of Credit Facility, Maximum Lease Buyout Expenses     $ 200   $ 200   $ 100
Debt Instrument, Periodic Payment, Principal 1,200            
Credit Facility [Member] | Equipment Line [Member] | Maximum [Member]              
Capital Expenditures Incurred but Not yet Paid       7,000      
Credit Facility [Member] | Revolving Credit Facility [Member]              
Line of Credit Facility, Maximum Borrowing Capacity $ 11,800   11,800        
Line of Credit Facility, Borrowing Base     15,600        
Financing Agreement [Member]              
Long-term Debt, Total     947 $ 1,599      
Financing Agreement [Member] | Medical Equipment [Member]              
Line of Credit Facility, Maximum Borrowing Capacity   $ 2,000          
Debt Instrument, Term (Month)   3 years          
Line of Credit Facility, Current Borrowing Capacity     $ 900        
[1] Amounts consist of current liabilities for medical equipment that have not been included in investing activities. These amounts have not been paid for as of December 31, 2020 and 2019, respectively, but will be included as a cash outflow from investing activities for purchases of medical equipment and property when paid.
XML 60 R46.htm IDEA: XBRL DOCUMENT v3.21.1
Note 7 - Debt - Summary of Revolver Based Upon Borrowers' Eligible Accounts Receivable and Inventory (Details) - Revolving Credit Facility [Member] - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Gross availability $ 11,750 $ 11,750
Outstanding draws
Letters of credit (800) (1,750)
Landlord reserves (162) (150)
Availability on Revolver $ 10,788 $ 9,850
XML 61 R47.htm IDEA: XBRL DOCUMENT v3.21.1
Note 7 - Debt - Summary of Future Maturities of Loans (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
2021 $ 9,423  
2022 8,420  
2023 8,198  
2024 12,760  
2025 and thereafter  
Long-term Debt, Total 38,801 $ 38,377
Unamortized value of the debt issuance costs, 2021 (17)  
Unamortized value of the debt issuance costs, 2022 (17)  
Unamortized value of the debt issuance costs, 2023 (17)  
Unamortized value of the debt issuance costs, 2024 (15)  
Unamortized value of the debt issuance costs, 2025 and thereafter  
Unamortized value of debt issuance costs (66)  
Financing Agreement [Member]    
2021 725  
2022 222  
2023  
2024  
2025 and thereafter  
Long-term Debt, Total 947 1,599
Equipment Line [Member]    
2021 1,600  
2022 1,600  
2023 1,600  
2024 1,200  
2025 and thereafter  
Long-term Debt, Total 6,000 7,600
The 2019 Equipment Line [Member]    
2021 2,500  
2022 2,000  
2023 2,000  
2024 3,500  
2025 and thereafter  
Long-term Debt, Total 10,000 1,574
Term Loan [Member]    
2021 4,615  
2022 4,615  
2023 4,615  
2024 8,075  
2025 and thereafter  
Long-term Debt, Total $ 21,920 $ 27,687
XML 62 R48.htm IDEA: XBRL DOCUMENT v3.21.1
Note 7 - Debt - Summary of Company's Current and Long-term Debt (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Current portion of long-term debt $ 9,423 $ 8,082
Long-term debt 29,378 30,295
Total 38,801 38,377
Unamortized value of the debt issuance costs, current portion of long-term debt (17) (17)
Unamortized value of the debt issuance costs, long-term debt (49) (66)
Unamortized value of the debt issuance costs, Total (66) (83)
Financing Agreement [Member]    
Current portion of long-term debt 725 652
Long-term debt 222 947
Total 947 1,599
Equipment Line [Member]    
Current portion of long-term debt 1,600 1,600
Long-term debt 4,400 6,000
Total 6,000 7,600
The 2019 Equipment Line [Member]    
Current portion of long-term debt 2,500 79
Long-term debt 7,500 1,495
Total 10,000 1,574
Term Loan [Member]    
Current portion of long-term debt 4,615 5,768
Long-term debt 17,305 21,919
Total $ 21,920 $ 27,687
XML 63 R49.htm IDEA: XBRL DOCUMENT v3.21.1
Note 8 - Income Taxes (Details Textual) - USD ($)
$ in Thousands
3 Months Ended 12 Months Ended
May 07, 2020
Apr. 15, 2020
Dec. 31, 2020
Dec. 31, 2020
Dec. 31, 2019
Net Operating Loss Carryforwards Limitation on Use       $ 1,800  
Remaining Preownership Net Operating Loss Carryforwards     $ 4,500 4,500  
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount     (11,200)    
Unrecognized Tax Benefits, Ending Balance     0 0 $ 0
Paycheck Protection Program CARES Act [Member]          
Proceeds from Issuance of Long-term Debt, Total   $ 4,100      
Repayments of Long-term Debt, Total $ 4,100        
Other Liabilities [Member]          
Accrued Payroll Taxes     700 700  
State and Local Jurisdiction [Member]          
Operating Loss Carryforwards, Total     1,200 1,200 1,400
Operating Loss Carryforwards with a Definite Life     100 $ 100  
State and Local Jurisdiction [Member] | Minimum [Member]          
Operating Loss Carryforwards Expiration Periods (Year)       5 years  
State and Local Jurisdiction [Member] | Maximum [Member]          
Operating Loss Carryforwards Expiration Periods (Year)       20 years  
Domestic Tax Authority [Member]          
Operating Loss Carryforwards, Total     34,900 $ 34,900  
Deferred Tax Assets, Operating Loss Carryforwards, Total     7,337 7,337 $ 7,991
Operating Loss Carryforwards with a Definite Life     31,500 31,500  
Operating Loss Carryforwards with Indefinite Life     $ 3,400 $ 3,400  
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]          
Open Tax Year       2017 2018 2019 2020  
Income Tax Examination, Year under Examination       2018  
Foreign Tax Authority [Member] | Canada Revenue Agency [Member]          
Open Tax Year       2016 2017 2018 2019 2020  
XML 64 R50.htm IDEA: XBRL DOCUMENT v3.21.1
Note 8 - Income Taxes - Summary of (Loss) Income Before Income Taxes (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
U.S income $ 6,623 $ 1,413
Non-U.S. income 920 111
Income before income taxes $ 7,543 $ 1,524
XML 65 R51.htm IDEA: XBRL DOCUMENT v3.21.1
Note 8 - Income Taxes - Summary of Components of Consolidated Provision for Income Taxes (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
U.S Federal income tax benefit (expense)    
Current, federal $ (11)
Deferred, federal 8,346 (104)
Total U.S. Federal income tax benefit (expense) 8,335 (104)
Current, state and local (66) (29)
Deferred, state and local 1,725
Total state and local income tax benefit (expense) 1,659 (29)
Current (205) (30)
Total income tax benefit (expense) $ 9,789 $ (163)
XML 66 R52.htm IDEA: XBRL DOCUMENT v3.21.1
Note 8 - Income Taxes - Changes in Valuation Allowance (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Valuation allowance at the Beginning of Period $ (11,250) $ (11,370)
Income tax expense
Release of valuation allowance 11,250 120
Valuation allowance at the End of Period $ (11,250)
XML 67 R53.htm IDEA: XBRL DOCUMENT v3.21.1
Note 8 - Income Taxes - Reconciliations of Effective Income Tax Rate to Federal Statutory Rate (Details)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Income tax expense at the statutory rate 21.00% 21.00%
State and local income tax expense 5.10% 2.00%
Foreign income tax 0.20% 2.00%
Permanent differences (8.40%) (5.80%)
Decrease in valuation allowance (149.20%) (7.90%)
Other adjustments 1.50% (0.60%)
Effective income tax rate (129.80%) 10.70%
XML 68 R54.htm IDEA: XBRL DOCUMENT v3.21.1
Note 8 - Income Taxes - Summary of Temporary Differences and Carryforwards That Give Rise to Deferred Tax Assets and Liabilities (Details) - USD ($)
$ in Thousands
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Less: valuation allowance $ (11,250) $ (11,370)
Net deferred tax assets 9,967    
Net deferred tax liabilities   (104)  
Net deferred tax assets 9,967    
Net deferred tax liabilities   104  
Domestic Tax Authority [Member]      
Bad debt reserves 1,570 1,459  
Stock-based compensation 656 443  
Net operating loss 7,337 7,991  
Operating lease liabilities 1,014 1,271  
Accrued compensation 757 451  
Inventories 214 27  
Goodwill and intangible assets 832 1,688  
Research & development credits 533 533  
Other credits 30 25  
Other 54 194  
Total deferred tax assets 12,997 14,082  
Less: valuation allowance (9,553)  
Net deferred Federal tax assets 12,997 4,529  
Depreciation and asset basis differences (3,393) (3,366)  
Right-of-use assets (937) (1,204)  
Total deferred Federal tax liabilities (4,330) (4,570)  
Net deferred tax assets 8,667    
Net deferred tax liabilities   (41)  
Total deferred tax assets 12,997 14,082  
Net deferred tax assets 8,667    
Net deferred tax liabilities   41  
State and Local Jurisdiction [Member]      
Total deferred tax assets [1] 1,300 1,634  
Less: valuation allowance (1,697)  
Net deferred tax assets 1,300    
Net deferred tax liabilities   (63)  
Total deferred tax assets [1] 1,300 1,634  
Net deferred tax assets $ 1,300    
Net deferred tax liabilities   $ 63  
[1] at December 31, 2019, this includes state and local net operating losses of $1.4 million
XML 69 R55.htm IDEA: XBRL DOCUMENT v3.21.1
Note 10 - Leases (Details Textual)
$ in Thousands
12 Months Ended
Dec. 31, 2020
USD ($)
Dec. 31, 2019
USD ($)
Number of Leases Entered Into During the Period for Equipment 4  
Lease, Cost, Total $ 1,932 $ 2,239
General and Administrative Expense [Member]    
Lease, Cost, Total 1,300 1,200
Cost of Sales [Member]    
Lease, Cost, Total $ 600 $ 1,000
XML 70 R56.htm IDEA: XBRL DOCUMENT v3.21.1
Note 10 - Leases - Lease Cost (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Operating lease cost $ 1,617 $ 1,948
Variable lease cost 315 291
Total lease cost 1,932 2,239
Operating cash flow from operating leases 1,603 1,610
ROU assets obtained in exchange for lease obligations: Operating leases 264 4,545
Reductions to ROU assets resulting from reductions to lease obligations: Operating leases $ 22
Weighted average remaining lease term: Operating leases (Year) 7 years 7 years 146 days
Operating leases 7.80% 7.70%
XML 71 R57.htm IDEA: XBRL DOCUMENT v3.21.1
Note 10 - Leases - Maturities of Lease Liabilities (Details)
$ in Thousands
Dec. 31, 2020
USD ($)
2021 $ 1,108
2022 1,045
2023 941
2024 949
2025 914
Thereafter 2,253
Total undiscounted lease payments 7,210
Less: Imputed interest (2,380)
Total lease liabilities $ 4,830
XML 72 R58.htm IDEA: XBRL DOCUMENT v3.21.1
Note 11 - Share-based Compensation (Details Textual) - USD ($)
1 Months Ended 12 Months Ended
May 15, 2019
Jul. 19, 2018
Sep. 07, 2016
May 31, 2014
Dec. 31, 2020
Dec. 31, 2019
Sep. 30, 2019
Apr. 23, 2014
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)     350,000          
Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation (in shares)         100,000 100,000    
Employee Stock Ownership Plan (ESOP), Shares Contributed to ESOP (in shares)       200,000        
Employee Stock Purchase Plan Discount Rate       15.00%        
Employee Stock Ownership Plan ESOP Purchase Per Employee Maximum       $ 25,000        
Stock Issued During Period Shares Employee Stock Ownership Plan Number of Remaining Shares Available for Future Issuance (in shares)         187,676      
Share Repurchase Program, 2020 Repurchases [Member]                
Stock Repurchase Program, Authorized Amount             $ 5,000,000  
2014 Amended and Restated Stock Incentive Plan [Member]                
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)         400,000     2,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares) 1,000,000 1,000,000            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)         331,000 670,000    
Share-based Payment Arrangement, Option [Member]                
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)         1 year 1 year    
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)         300,000 700,000    
Share-based Payment Arrangement, Option [Member] | Chief Executive Officer [Member]                
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)         100,000 100,000    
Share-based Payment Arrangement, Option [Member] | Minimum [Member]                
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)         5 years      
Share-based Payment Arrangement, Option [Member] | Maximum [Member]                
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)         10 years      
Restricted Stock Units (RSUs) [Member] | Maximum [Member]                
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)         3 years      
Performance Shares [Member]                
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)         232,500 0    
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount         $ 1,700,000      
Performance Shares [Member] | Share-based Payment Arrangement, Achieving Minimum Threshold [Member]                
Share-based Compensation Arrangement By Share-based Payment Award Percentage of Target Number of Shares to be Earned         50.00%      
Performance Shares [Member] | Share-based Payment Arrangement, Exceeding Minimum Threshold [Member]                
Share-based Compensation Arrangement By Share-based Payment Award Percentage of Target Number of Shares to be Earned         200.00%      
Performance Shares [Member] | Maximum [Member]                
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)         3 years      
Restricted Stock [Member]                
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)         156,250 26,000    
Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount         $ 1,000,000      
Restricted Stock [Member] | Maximum [Member]                
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)           100,000    
XML 73 R59.htm IDEA: XBRL DOCUMENT v3.21.1
Note 11 - Share-based Compensation - Summary of Restricted Share Activity, Excluding Company's Employee Stock Purchase Plan (Details) - Restricted Stock [Member] - USD ($)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Unvested, number of shares (in shares) 26,000 129,583
Unvested, weighted average grant date fair value (in dollars per share) $ 7.04 $ 1.42
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) 156,250 26,000
Granted, weighted average grant date fair value (in dollars per share) $ 10.12 $ 7.04
Vested, number of shares (in shares) (28,432) (58,314)
Vested, weighted average grant date fair value (in dollars per share) $ 9.28 $ 3.17
Vested, aggregate fair value $ 367,273 $ 712,969
Vested shares forgone to satisfy minimum statutory withholding, number of shares (in shares) (6,818) (71,269)
Vested shares forgone to satisfy minimum statutory withholding, weighted average grant date fair value (in dollars per share) $ 9.28 $ 3.17
Vested shares forgone to satisfy minimum statutory withholding, aggregate fair value $ 62,479 $ 422,779
Forfeitures, number of shares (in shares) (2,000)
Forfeitures, weighted average grant date fair value (in dollars per share) $ 11.68
Unvested, number of shares (in shares) 145,000 26,000
Unvested, weighted average grant date fair value (in dollars per share) $ 9.78 $ 7.04
XML 74 R60.htm IDEA: XBRL DOCUMENT v3.21.1
Note 11 - Share-based Compensation - PSU Activity (Details) - Performance Shares [Member] - $ / shares
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Unvested, number of shares (in shares)  
Unvested, weighted average grant date fair value (in dollars per share)  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares) 232,500 0
Granted, weighted average grant date fair value (in dollars per share) $ 9.06  
Unvested, number of shares (in shares) 232,500
Unvested, weighted average grant date fair value (in dollars per share) $ 9.06
XML 75 R61.htm IDEA: XBRL DOCUMENT v3.21.1
Note 11 - Share-based Compensation - Summary of Activity Relating to Company's ESPP Program (Details) - USD ($)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Compensation expense $ 108,589 $ 43,030
Shares of stock sold to employees (in shares) 30,012 33,742
Weighted average fair value per ESPP award (in dollars per share) $ 7.43 $ 3.94
XML 76 R62.htm IDEA: XBRL DOCUMENT v3.21.1
Note 11 - Share-based Compensation - Summary of Stock Option and Inducement Stock Option Activity (Details) - USD ($)
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation (in shares) (100,000) (100,000)  
Inducement Stock Options [Member]      
Outstanding, number of authorized shares (in shares) [1] 125,000 125,000  
Outstanding, weighted average exercise price (in dollars per share) $ 2.55 $ 2.55  
Outstanding, weighted average remaining contractual term (Year) 4 years 153 days 5 years 153 days
Outstanding, aggregate intrinsic value $ 747,500 $ 111,250
Granted, number of authorized shares (in shares) [1]  
Granted, weighted average exercise price (in dollars per share)  
Granted, weighted average remaining contractual term (Year)  
Exercised, number of authorized shares (in shares) [1] (27,940)  
Cashless exercise, number of authorized shares (in shares) (14,330)    
Cashless exercise, weighted average exercise price (in dollars per share) $ 2.55    
Forfeited, number of authorized shares (in shares) [1] (70,313)  
Exercisable, number of authorized shares (in shares) [1]    
Exercisable, weighted average exercise price (in dollars per share)    
Outstanding, number of authorized shares (in shares) [1] 125,000 125,000
Outstanding, weighted average exercise price (in dollars per share) $ 2.55 $ 2.55
Granted, aggregate intrinsic value  
Common stock repurchased to satisfy minimum statutory withholding on stock-based compensation (in shares) (12,417)    
Exercised shares forgone to satisfy minimum statutory withholding (in dollars per share) $ 2.55    
2014 Amended and Restated Stock Incentive Plan [Member]      
Outstanding, number of authorized shares (in shares) 2,343,333 2,224,167  
Outstanding, weighted average exercise price (in dollars per share) $ 2.99 $ 2.67  
Outstanding, weighted average remaining contractual term (Year) 4 years 153 days 1 year 295 days 3 years 3 days
Outstanding, aggregate intrinsic value $ 28,449,362 $ 12,989,767
Granted, number of authorized shares (in shares) 331,000 670,000  
Granted, weighted average exercise price (in dollars per share) $ 10.38 $ 3.77  
Granted, weighted average remaining contractual term (Year) 8 years 215 days 4 years 146 days  
Exercised, number of authorized shares (in shares) (334,184) (213,056)  
Exercised, weighted average exercise price (in dollars per share) $ 2.77 $ 2.33  
Exercised, aggregate intrinsic value $ 3,135,211 $ 624,462  
Exercised shares forgone to satisfy minimum statutory withholding, number of authorized shares (in shares) (125,714) (51,339)  
Exercised shares forgone to satisfy minimum statutory withholding, weighted average exercise price (in dollars per share) $ 2.77 $ 2.33  
Cashless exercise, number of authorized shares (in shares) (164,751) (184,493)  
Cashless exercise, weighted average exercise price (in dollars per share) $ 2.77 $ 2.33  
Forfeited, number of authorized shares (in shares) (90,336) (101,946)  
Forfeited, weighted average exercise price (in dollars per share) $ 3.96 $ 3.63  
Exercisable, number of authorized shares (in shares) 1,362,932 1,501,750  
Exercisable, weighted average exercise price (in dollars per share) $ 3.33 $ 2.69  
Outstanding, number of authorized shares (in shares) 1,959,348 2,343,333 2,224,167
Outstanding, weighted average exercise price (in dollars per share) $ 4.26 $ 2.99 $ 2.67
[1] Represents inducement stock options to purchase shares of the Company's Common Stock to executive level managers.
XML 77 R63.htm IDEA: XBRL DOCUMENT v3.21.1
Note 11 - Share-based Compensation - Schedule of Stock Options Outstanding (Details) - 2014 Amended and Restated Stock Incentive Plan [Member]
12 Months Ended
Dec. 31, 2020
$ / shares
shares
Options outstanding, number of shares outstanding (in shares) | shares 1,959,348
Options outstanding, weighted-average remaining contractual life (Year) 4 years 153 days
Options outstanding, weighted-average exercise price (in dollars per share) $ 4.26
Options exercisable, number of shares exercisable (in shares) | shares 1,362,932
Options exercisable, weighted-average exercise price (in dollars per share) $ 3.33
Range 1 [Member]  
Exercise price, lower range (in dollars per share) 2.01
Exercise price, upper range (in dollars per share) $ 3
Options outstanding, number of shares outstanding (in shares) | shares 870,011
Options outstanding, weighted-average remaining contractual life (Year) 3 years 73 days
Options outstanding, weighted-average exercise price (in dollars per share) $ 2.26
Options exercisable, number of shares exercisable (in shares) | shares 784,178
Options exercisable, weighted-average exercise price (in dollars per share) $ 2.26
Range 2 [Member]  
Exercise price, lower range (in dollars per share) 3.01
Exercise price, upper range (in dollars per share) $ 4
Options outstanding, number of shares outstanding (in shares) | shares 423,336
Options outstanding, weighted-average remaining contractual life (Year) 2 years 270 days
Options outstanding, weighted-average exercise price (in dollars per share) $ 3.23
Options exercisable, number of shares exercisable (in shares) | shares 301,669
Options exercisable, weighted-average exercise price (in dollars per share) $ 3.21
Range 3 [Member]  
Exercise price, lower range (in dollars per share) 4.01
Exercise price, upper range (in dollars per share) $ 5
Options outstanding, number of shares outstanding (in shares) | shares 335,001
Options outstanding, weighted-average remaining contractual life (Year) 5 years 219 days
Options outstanding, weighted-average exercise price (in dollars per share) $ 4.70
Options exercisable, number of shares exercisable (in shares) | shares 198,335
Options exercisable, weighted-average exercise price (in dollars per share) $ 4.70
Range 4 [Member]  
Exercise price, lower range (in dollars per share) 6.01
Exercise price, upper range (in dollars per share) $ 7
Options outstanding, number of shares outstanding (in shares) | shares 50,000
Options outstanding, weighted-average remaining contractual life (Year) 4 years 76 days
Options outstanding, weighted-average exercise price (in dollars per share) $ 6.82
Options exercisable, number of shares exercisable (in shares) | shares
Options exercisable, weighted-average exercise price (in dollars per share)
Range 5 [Member]  
Exercise price, lower range (in dollars per share) 8.01
Exercise price, upper range (in dollars per share) $ 9
Options outstanding, number of shares outstanding (in shares) | shares 20,000
Options outstanding, weighted-average remaining contractual life (Year) 9 years 7 days
Options outstanding, weighted-average exercise price (in dollars per share) $ 8.55
Options exercisable, number of shares exercisable (in shares) | shares
Options exercisable, weighted-average exercise price (in dollars per share)
Range 6 [Member]  
Exercise price, lower range (in dollars per share) 11.01
Exercise price, upper range (in dollars per share) $ 12
Options outstanding, number of shares outstanding (in shares) | shares 245,000
Options outstanding, weighted-average remaining contractual life (Year) 9 years 138 days
Options outstanding, weighted-average exercise price (in dollars per share) $ 11.07
Options exercisable, number of shares exercisable (in shares) | shares 78,750
Options exercisable, weighted-average exercise price (in dollars per share) $ 11.07
Range 7 [Member]  
Exercise price, lower range (in dollars per share) 13.01
Exercise price, upper range (in dollars per share) $ 14
Options outstanding, number of shares outstanding (in shares) | shares 16,000
Options outstanding, weighted-average remaining contractual life (Year) 9 years 226 days
Options outstanding, weighted-average exercise price (in dollars per share) $ 13.30
Options exercisable, number of shares exercisable (in shares) | shares
Options exercisable, weighted-average exercise price (in dollars per share)
XML 78 R64.htm IDEA: XBRL DOCUMENT v3.21.1
Note 11 - Share-based Compensation - Schedule of Share-based Compensation Expense Based on Fair Value of Options (Details) - $ / shares
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Expected lives at date of grant (in years) (Year) 3 years 91 days 4 years 229 days
Weighted average fair value of options granted (in dollars per share) $ 3.87 $ 1.61
Minimum [Member]    
Expected volatility 42.00% 36.00%
Risk free interest rate 0.20% 1.80%
Maximum [Member]    
Expected volatility 51.00% 38.00%
Risk free interest rate 1.56% 2.36%
XML 79 R65.htm IDEA: XBRL DOCUMENT v3.21.1
Note 11 - Share-based Compensation - Stock-based Compensation (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Restricted share expense $ 1,687 $ 190
Stock option and SARs expense 923 807
Total stock-based compensation expense $ 2,610 $ 997
XML 80 R66.htm IDEA: XBRL DOCUMENT v3.21.1
Note 12 - Business Segment Information (Details Textual)
3 Months Ended 9 Months Ended 12 Months Ended
Dec. 31, 2019
Sep. 30, 2019
Dec. 31, 2020
Number of Reportable Segments 2 1 2
XML 81 R67.htm IDEA: XBRL DOCUMENT v3.21.1
Note 12 - Business Segment Information - Summary of Financial Information By Reportable Segment (Details) - USD ($)
$ in Thousands
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Net revenues - external $ 97,388 $ 81,115
Net revenues - internal
Total net revenues 97,388 81,115
Gross profit 58,759 46,882
Selling , general and administrative expenses 49,932 43,357
Interest expense (1,255) (1,904)
Other expense (29) (97)
Benefit from income taxes 9,789 (163)
Net income 17,332 1,361
Total assets 96,991 79,224
Purchases of medical equipment 15,820 19,669
Depreciation and amortization of intangible assets 14,025 12,342
Corporate and Eliminations [Member]    
Net revenues - external
Net revenues - internal (5,370) (3,788)
Total net revenues (5,370) (3,788)
Gross profit
Selling , general and administrative expenses 49,932 43,357
Interest expense (1,255) (1,904)
Other expense (29) (97)
Benefit from income taxes 9,789 (163)
Total assets 2,000 2,000
Purchases of medical equipment
Depreciation and amortization of intangible assets
ITS Segment [Member] | Operating Segments [Member]    
Net revenues - external 61,072 51,540
Net revenues - internal
Total net revenues 61,072 51,540
Gross profit 39,773 33,063
Other expense  
Benefit from income taxes  
Total assets 68,472 54,292
Purchases of medical equipment 9,583 14,216
Depreciation and amortization of intangible assets 10,708 9,457
DME Services Segment [Member] | Operating Segments [Member]    
Net revenues - external 36,316 29,575
Net revenues - internal 5,370 3,788
Total net revenues 41,686 33,363
Gross profit 18,986 13,819
Other expense  
Benefit from income taxes  
Total assets 26,519 22,932
Purchases of medical equipment 6,237 5,453
Depreciation and amortization of intangible assets $ 3,317 $ 2,885
XML 82 R68.htm IDEA: XBRL DOCUMENT v3.21.1
Note 13 - Employee Benefit Plans and Other (Details Textual) - USD ($)
$ in Millions
12 Months Ended
Dec. 31, 2020
Dec. 31, 2019
Defined Benefit Plan, Plan Assets, Contributions by Employer $ 0.8 $ 0.7
Other Current Liabilities [Member]    
Employee-related Liabilities, Current, Total $ 2.8 $ 3.5
XML 83 R69.htm IDEA: XBRL DOCUMENT v3.21.1
Note 15 - Subsequent Events (Details Textual)
$ in Millions
Feb. 05, 2021
USD ($)
Feb. 03, 2021
USD ($)
Dec. 31, 2020
USD ($)
Feb. 04, 2020
USD ($)
Dec. 31, 2019
USD ($)
Revolving Credit Facility [Member]          
Long-term Line of Credit, Total      
The 2015 Credit Agreement [Member] | Letter of Credit [Member]          
Long-term Line of Credit, Total       $ 0.8  
Subsequent Event [Member] | The 2021 Credit Agreement [Member]          
Percentage of Total Depreciation Expense 50.00%        
Debt Instrument, Covenant, Minimum Fixed Coverage Ratio 1.2        
Debt Instrument, Covenant, Maximum Leverage Ratio 3.5        
Subsequent Event [Member] | The 2021 Credit Agreement [Member] | Eurodollar Loan [Member] | London Interbank Offered Rate (LIBOR) [Member]          
Debt Instrument, Basis Spread on Variable Rate 2.00%        
Subsequent Event [Member] | The 2021 Credit Agreement [Member] | Eurodollar Loan [Member] | Minimum [Member] | London Interbank Offered Rate (LIBOR) [Member]          
Debt Instrument, Basis Spread on Variable Rate 2.00%        
Subsequent Event [Member] | The 2021 Credit Agreement [Member] | Eurodollar Loan [Member] | Maximum [Member] | London Interbank Offered Rate (LIBOR) [Member]          
Debt Instrument, Basis Spread on Variable Rate 3.00%        
Subsequent Event [Member] | The 2021 Credit Agreement [Member] | ABR Loans [Member] | Base Rate [Member]          
Debt Instrument, Basis Spread on Variable Rate 1.00%        
Subsequent Event [Member] | The 2021 Credit Agreement [Member] | ABR Loans [Member] | Minimum [Member] | Base Rate [Member]          
Debt Instrument, Basis Spread on Variable Rate 1.00%        
Subsequent Event [Member] | The 2021 Credit Agreement [Member] | ABR Loans [Member] | Maximum [Member] | Base Rate [Member]          
Debt Instrument, Basis Spread on Variable Rate 2.00%        
Subsequent Event [Member] | The 2021 Credit Agreement [Member] | Revolving Credit Facility [Member]          
Line of Credit Facility, Maximum Borrowing Capacity $ 75.0        
Line of Credit Facility, Additional Borrowing Capacity Subject to Certain Conditions 25.0        
Proceeds from Long-term Lines of Credit 30.0        
Subsequent Event [Member] | The 2021 Credit Agreement [Member] | Letter of Credit [Member]          
Line of Credit Facility, Maximum Borrowing Capacity 7.0        
Subsequent Event [Member] | The 2015 Credit Agreement [Member] | Revolving Credit Facility [Member]          
Repayments of Long-term Lines of Credit $ 8.2        
FilAMed [Member] | Subsequent Event [Member]          
Business Combination, Consideration Transferred, Total   $ 1.4      
EXCEL 84 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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®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end XML 85 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 86 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 87 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.1 html 216 461 1 true 85 0 false 4 false false R1.htm 000 - Document - Document And Entity Information Sheet http://infusystem.com/20201231/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Consolidated Balance Sheets Sheet http://infusystem.com/20201231/role/statement-consolidated-balance-sheets Consolidated Balance Sheets Statements 2 false false R3.htm 002 - Statement - Consolidated Balance Sheets (Parentheticals) Sheet http://infusystem.com/20201231/role/statement-consolidated-balance-sheets-parentheticals Consolidated Balance Sheets (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Consolidated Statements of Operations Sheet http://infusystem.com/20201231/role/statement-consolidated-statements-of-operations Consolidated Statements of Operations Statements 4 false false R5.htm 004 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://infusystem.com/20201231/role/statement-consolidated-statements-of-stockholders-equity Consolidated Statements of Stockholders' Equity Statements 5 false false R6.htm 005 - Statement - Consolidated Statements of Cash Flows Sheet http://infusystem.com/20201231/role/statement-consolidated-statements-of-cash-flows Consolidated Statements of Cash Flows Statements 6 false false R7.htm 006 - Disclosure - Note 1 - Basis of Presentation and Nature of Operations Sheet http://infusystem.com/20201231/role/statement-note-1-basis-of-presentation-and-nature-of-operations Note 1 - Basis of Presentation and Nature of Operations Notes 7 false false R8.htm 007 - Disclosure - Note 2 - Summary of Significant Accounting Policies Sheet http://infusystem.com/20201231/role/statement-note-2-summary-of-significant-accounting-policies Note 2 - Summary of Significant Accounting Policies Notes 8 false false R9.htm 008 - Disclosure - Note 3 - Revenue Recognition Sheet http://infusystem.com/20201231/role/statement-note-3-revenue-recognition Note 3 - Revenue Recognition Notes 9 false false R10.htm 009 - Disclosure - Note 4 - Medical Equipment Sheet http://infusystem.com/20201231/role/statement-note-4-medical-equipment Note 4 - Medical Equipment Notes 10 false false R11.htm 010 - Disclosure - Note 5 - Property and Equipment Sheet http://infusystem.com/20201231/role/statement-note-5-property-and-equipment Note 5 - Property and Equipment Notes 11 false false R12.htm 011 - Disclosure - Note 6 - Intangible Assets Sheet http://infusystem.com/20201231/role/statement-note-6-intangible-assets Note 6 - Intangible Assets Notes 12 false false R13.htm 012 - Disclosure - Note 7 - Debt Sheet http://infusystem.com/20201231/role/statement-note-7-debt Note 7 - Debt Notes 13 false false R14.htm 013 - Disclosure - Note 8 - Income Taxes Sheet http://infusystem.com/20201231/role/statement-note-8-income-taxes Note 8 - Income Taxes Notes 14 false false R15.htm 014 - Disclosure - Note 9 - Commitments and Contingencies Sheet http://infusystem.com/20201231/role/statement-note-9-commitments-and-contingencies Note 9 - Commitments and Contingencies Notes 15 false false R16.htm 015 - Disclosure - Note 10 - Leases Sheet http://infusystem.com/20201231/role/statement-note-10-leases Note 10 - Leases Notes 16 false false R17.htm 016 - Disclosure - Note 11 - Share-based Compensation Sheet http://infusystem.com/20201231/role/statement-note-11-sharebased-compensation Note 11 - Share-based Compensation Notes 17 false false R18.htm 017 - Disclosure - Note 12 - Business Segment Information Sheet http://infusystem.com/20201231/role/statement-note-12-business-segment-information Note 12 - Business Segment Information Notes 18 false false R19.htm 018 - Disclosure - Note 13 - Employee Benefit Plans and Other Sheet http://infusystem.com/20201231/role/statement-note-13-employee-benefit-plans-and-other Note 13 - Employee Benefit Plans and Other Notes 19 false false R20.htm 019 - Disclosure - Note 14 - COVID-19 Sheet http://infusystem.com/20201231/role/statement-note-14-covid19 Note 14 - COVID-19 Notes 20 false false R21.htm 020 - Disclosure - Note 15 - Subsequent Events Sheet http://infusystem.com/20201231/role/statement-note-15-subsequent-events- Note 15 - Subsequent Events Notes 21 false false R22.htm 021 - Disclosure - Significant Accounting Policies (Policies) Sheet http://infusystem.com/20201231/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://infusystem.com/20201231/role/statement-note-2-summary-of-significant-accounting-policies 22 false false R23.htm 022 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Tables) Sheet http://infusystem.com/20201231/role/statement-note-2-summary-of-significant-accounting-policies-tables Note 2 - Summary of Significant Accounting Policies (Tables) Tables http://infusystem.com/20201231/role/statement-note-2-summary-of-significant-accounting-policies 23 false false R24.htm 023 - Disclosure - Note 3 - Revenue Recognition (Tables) Sheet http://infusystem.com/20201231/role/statement-note-3-revenue-recognition-tables Note 3 - Revenue Recognition (Tables) Tables http://infusystem.com/20201231/role/statement-note-3-revenue-recognition 24 false false R25.htm 024 - Disclosure - Note 4 - Medical Equipment (Tables) Sheet http://infusystem.com/20201231/role/statement-note-4-medical-equipment-tables Note 4 - Medical Equipment (Tables) Tables http://infusystem.com/20201231/role/statement-note-4-medical-equipment 25 false false R26.htm 025 - Disclosure - Note 5 - Property and Equipment (Tables) Sheet http://infusystem.com/20201231/role/statement-note-5-property-and-equipment-tables Note 5 - Property and Equipment (Tables) Tables http://infusystem.com/20201231/role/statement-note-5-property-and-equipment 26 false false R27.htm 026 - Disclosure - Note 6 - Intangible Assets (Tables) Sheet http://infusystem.com/20201231/role/statement-note-6-intangible-assets-tables Note 6 - Intangible Assets (Tables) Tables http://infusystem.com/20201231/role/statement-note-6-intangible-assets 27 false false R28.htm 027 - Disclosure - Note 7 - Debt (Tables) Sheet http://infusystem.com/20201231/role/statement-note-7-debt-tables Note 7 - Debt (Tables) Tables http://infusystem.com/20201231/role/statement-note-7-debt 28 false false R29.htm 028 - Disclosure - Note 8 - Income Taxes (Tables) Sheet http://infusystem.com/20201231/role/statement-note-8-income-taxes-tables Note 8 - Income Taxes (Tables) Tables http://infusystem.com/20201231/role/statement-note-8-income-taxes 29 false false R30.htm 029 - Disclosure - Note 10 - Leases (Tables) Sheet http://infusystem.com/20201231/role/statement-note-10-leases-tables Note 10 - Leases (Tables) Tables http://infusystem.com/20201231/role/statement-note-10-leases 30 false false R31.htm 030 - Disclosure - Note 11 - Share-based Compensation (Tables) Sheet http://infusystem.com/20201231/role/statement-note-11-sharebased-compensation-tables Note 11 - Share-based Compensation (Tables) Tables http://infusystem.com/20201231/role/statement-note-11-sharebased-compensation 31 false false R32.htm 031 - Disclosure - Note 12 - Business Segment Information (Tables) Sheet http://infusystem.com/20201231/role/statement-note-12-business-segment-information-tables Note 12 - Business Segment Information (Tables) Tables http://infusystem.com/20201231/role/statement-note-12-business-segment-information 32 false false R33.htm 032 - Disclosure - Note 1 - Basis of Presentation and Nature of Operations (Details Textual) Sheet http://infusystem.com/20201231/role/statement-note-1-basis-of-presentation-and-nature-of-operations-details-textual Note 1 - Basis of Presentation and Nature of Operations (Details Textual) Details http://infusystem.com/20201231/role/statement-note-1-basis-of-presentation-and-nature-of-operations 33 false false R34.htm 033 - Disclosure - Note 2 - Summary of Significant Accounting Policies (Details Textual) Sheet http://infusystem.com/20201231/role/statement-note-2-summary-of-significant-accounting-policies-details-textual Note 2 - Summary of Significant Accounting Policies (Details Textual) Details http://infusystem.com/20201231/role/statement-note-2-summary-of-significant-accounting-policies-tables 34 false false R35.htm 034 - Disclosure - Note 2 - Summary of Significant Accounting Policies - Summary of Income and Share Amounts Utilized to Calculate Basic and Diluted Net Income Per Common Share (Details) Sheet http://infusystem.com/20201231/role/statement-note-2-summary-of-significant-accounting-policies-summary-of-income-and-share-amounts-utilized-to-calculate-basic-and-diluted-net-income-per-common-share-details Note 2 - Summary of Significant Accounting Policies - Summary of Income and Share Amounts Utilized to Calculate Basic and Diluted Net Income Per Common Share (Details) Details 35 false false R36.htm 035 - Disclosure - Note 3 - Revenue Recognition (Details Textual) Sheet http://infusystem.com/20201231/role/statement-note-3-revenue-recognition-details-textual Note 3 - Revenue Recognition (Details Textual) Details http://infusystem.com/20201231/role/statement-note-3-revenue-recognition-tables 36 false false R37.htm 036 - Disclosure - Note 3 - Revenue Recognition - Disaggregated Revenue by Revenue Stream (Details) Sheet http://infusystem.com/20201231/role/statement-note-3-revenue-recognition-disaggregated-revenue-by-revenue-stream-details Note 3 - Revenue Recognition - Disaggregated Revenue by Revenue Stream (Details) Details 37 false false R38.htm 037 - Disclosure - Note 4 - Medical Equipment (Details Textual) Sheet http://infusystem.com/20201231/role/statement-note-4-medical-equipment-details-textual Note 4 - Medical Equipment (Details Textual) Details http://infusystem.com/20201231/role/statement-note-4-medical-equipment-tables 38 false false R39.htm 038 - Disclosure - Note 4 - Medical Equipment - Summary of Medical Equipment (Details) Sheet http://infusystem.com/20201231/role/statement-note-4-medical-equipment-summary-of-medical-equipment-details Note 4 - Medical Equipment - Summary of Medical Equipment (Details) Details 39 false false R40.htm 039 - Disclosure - Note 5 - Property and Equipment (Details Textual) Sheet http://infusystem.com/20201231/role/statement-note-5-property-and-equipment-details-textual Note 5 - Property and Equipment (Details Textual) Details http://infusystem.com/20201231/role/statement-note-5-property-and-equipment-tables 40 false false R41.htm 040 - Disclosure - Note 5 - Property and Equipment - Property and Equipment (Details) Sheet http://infusystem.com/20201231/role/statement-note-5-property-and-equipment-property-and-equipment-details Note 5 - Property and Equipment - Property and Equipment (Details) Details 41 false false R42.htm 041 - Disclosure - Note 6 - Intangible Assets (Details Textual) Sheet http://infusystem.com/20201231/role/statement-note-6-intangible-assets-details-textual Note 6 - Intangible Assets (Details Textual) Details http://infusystem.com/20201231/role/statement-note-6-intangible-assets-tables 42 false false R43.htm 042 - Disclosure - Note 6 - Intangible Assets - Summary of Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets (Details) Sheet http://infusystem.com/20201231/role/statement-note-6-intangible-assets-summary-of-carrying-amount-and-accumulated-amortization-of-identifiable-intangible-assets-details Note 6 - Intangible Assets - Summary of Carrying Amount and Accumulated Amortization of Identifiable Intangible Assets (Details) Details 43 false false R44.htm 043 - Disclosure - Note 6 - Intangible Assets - Expected Annual Amortization Expense for Intangible Assets (Details) Sheet http://infusystem.com/20201231/role/statement-note-6-intangible-assets-expected-annual-amortization-expense-for-intangible-assets-details Note 6 - Intangible Assets - Expected Annual Amortization Expense for Intangible Assets (Details) Details 44 false false R45.htm 044 - Disclosure - Note 7 - Debt (Details Textual) Sheet http://infusystem.com/20201231/role/statement-note-7-debt-details-textual Note 7 - Debt (Details Textual) Details http://infusystem.com/20201231/role/statement-note-7-debt-tables 45 false false R46.htm 045 - Disclosure - Note 7 - Debt - Summary of Revolver Based Upon Borrowers' Eligible Accounts Receivable and Inventory (Details) Sheet http://infusystem.com/20201231/role/statement-note-7-debt-summary-of-revolver-based-upon-borrowers-eligible-accounts-receivable-and-inventory-details Note 7 - Debt - Summary of Revolver Based Upon Borrowers' Eligible Accounts Receivable and Inventory (Details) Details 46 false false R47.htm 046 - Disclosure - Note 7 - Debt - Summary of Future Maturities of Loans (Details) Sheet http://infusystem.com/20201231/role/statement-note-7-debt-summary-of-future-maturities-of-loans-details Note 7 - Debt - Summary of Future Maturities of Loans (Details) Details 47 false false R48.htm 047 - Disclosure - Note 7 - Debt - Summary of Company's Current and Long-term Debt (Details) Sheet http://infusystem.com/20201231/role/statement-note-7-debt-summary-of-companys-current-and-longterm-debt-details Note 7 - Debt - Summary of Company's Current and Long-term Debt (Details) Details 48 false false R49.htm 048 - Disclosure - Note 8 - Income Taxes (Details Textual) Sheet http://infusystem.com/20201231/role/statement-note-8-income-taxes-details-textual Note 8 - Income Taxes (Details Textual) Details http://infusystem.com/20201231/role/statement-note-8-income-taxes-tables 49 false false R50.htm 049 - Disclosure - Note 8 - Income Taxes - Summary of (Loss) Income Before Income Taxes (Details) Sheet http://infusystem.com/20201231/role/statement-note-8-income-taxes-summary-of-loss-income-before-income-taxes-details Note 8 - Income Taxes - Summary of (Loss) Income Before Income Taxes (Details) Details 50 false false R51.htm 050 - Disclosure - Note 8 - Income Taxes - Summary of Components of Consolidated Provision for Income Taxes (Details) Sheet http://infusystem.com/20201231/role/statement-note-8-income-taxes-summary-of-components-of-consolidated-provision-for-income-taxes-details Note 8 - Income Taxes - Summary of Components of Consolidated Provision for Income Taxes (Details) Details 51 false false R52.htm 051 - Disclosure - Note 8 - Income Taxes - Changes in Valuation Allowance (Details) Sheet http://infusystem.com/20201231/role/statement-note-8-income-taxes-changes-in-valuation-allowance-details Note 8 - Income Taxes - Changes in Valuation Allowance (Details) Details 52 false false R53.htm 052 - Disclosure - Note 8 - Income Taxes - Reconciliations of Effective Income Tax Rate to Federal Statutory Rate (Details) Sheet http://infusystem.com/20201231/role/statement-note-8-income-taxes-reconciliations-of-effective-income-tax-rate-to-federal-statutory-rate-details Note 8 - Income Taxes - Reconciliations of Effective Income Tax Rate to Federal Statutory Rate (Details) Details 53 false false R54.htm 053 - Disclosure - Note 8 - Income Taxes - Summary of Temporary Differences and Carryforwards That Give Rise to Deferred Tax Assets and Liabilities (Details) Sheet http://infusystem.com/20201231/role/statement-note-8-income-taxes-summary-of-temporary-differences-and-carryforwards-that-give-rise-to-deferred-tax-assets-and-liabilities-details Note 8 - Income Taxes - Summary of Temporary Differences and Carryforwards That Give Rise to Deferred Tax Assets and Liabilities (Details) Details 54 false false R55.htm 054 - Disclosure - Note 10 - Leases (Details Textual) Sheet http://infusystem.com/20201231/role/statement-note-10-leases-details-textual Note 10 - Leases (Details Textual) Details http://infusystem.com/20201231/role/statement-note-10-leases-tables 55 false false R56.htm 055 - Disclosure - Note 10 - Leases - Lease Cost (Details) Sheet http://infusystem.com/20201231/role/statement-note-10-leases-lease-cost-details Note 10 - Leases - Lease Cost (Details) Details 56 false false R57.htm 056 - Disclosure - Note 10 - Leases - Maturities of Lease Liabilities (Details) Sheet http://infusystem.com/20201231/role/statement-note-10-leases-maturities-of-lease-liabilities-details Note 10 - Leases - Maturities of Lease Liabilities (Details) Details 57 false false R58.htm 057 - Disclosure - Note 11 - Share-based Compensation (Details Textual) Sheet http://infusystem.com/20201231/role/statement-note-11-sharebased-compensation-details-textual Note 11 - Share-based Compensation (Details Textual) Details http://infusystem.com/20201231/role/statement-note-11-sharebased-compensation-tables 58 false false R59.htm 058 - Disclosure - Note 11 - Share-based Compensation - Summary of Restricted Share Activity, Excluding Company's Employee Stock Purchase Plan (Details) Sheet http://infusystem.com/20201231/role/statement-note-11-sharebased-compensation-summary-of-restricted-share-activity-excluding-companys-employee-stock-purchase-plan-details Note 11 - Share-based Compensation - Summary of Restricted Share Activity, Excluding Company's Employee Stock Purchase Plan (Details) Details 59 false false R60.htm 059 - Disclosure - Note 11 - Share-based Compensation - PSU Activity (Details) Sheet http://infusystem.com/20201231/role/statement-note-11-sharebased-compensation-psu-activity-details Note 11 - Share-based Compensation - PSU Activity (Details) Details 60 false false R61.htm 060 - Disclosure - Note 11 - Share-based Compensation - Summary of Activity Relating to Company's ESPP Program (Details) Sheet http://infusystem.com/20201231/role/statement-note-11-sharebased-compensation-summary-of-activity-relating-to-companys-espp-program-details Note 11 - Share-based Compensation - Summary of Activity Relating to Company's ESPP Program (Details) Details 61 false false R62.htm 061 - Disclosure - Note 11 - Share-based Compensation - Summary of Stock Option and Inducement Stock Option Activity (Details) Sheet http://infusystem.com/20201231/role/statement-note-11-sharebased-compensation-summary-of-stock-option-and-inducement-stock-option-activity-details Note 11 - Share-based Compensation - Summary of Stock Option and Inducement Stock Option Activity (Details) Details 62 false false R63.htm 062 - Disclosure - Note 11 - Share-based Compensation - Schedule of Stock Options Outstanding (Details) Sheet http://infusystem.com/20201231/role/statement-note-11-sharebased-compensation-schedule-of-stock-options-outstanding-details Note 11 - Share-based Compensation - Schedule of Stock Options Outstanding (Details) Details 63 false false R64.htm 063 - Disclosure - Note 11 - Share-based Compensation - Schedule of Share-based Compensation Expense Based on Fair Value of Options (Details) Sheet http://infusystem.com/20201231/role/statement-note-11-sharebased-compensation-schedule-of-sharebased-compensation-expense-based-on-fair-value-of-options-details Note 11 - Share-based Compensation - Schedule of Share-based Compensation Expense Based on Fair Value of Options (Details) Details 64 false false R65.htm 064 - Disclosure - Note 11 - Share-based Compensation - Stock-based Compensation (Details) Sheet http://infusystem.com/20201231/role/statement-note-11-sharebased-compensation-stockbased-compensation-details Note 11 - Share-based Compensation - Stock-based Compensation (Details) Details 65 false false R66.htm 065 - Disclosure - Note 12 - Business Segment Information (Details Textual) Sheet http://infusystem.com/20201231/role/statement-note-12-business-segment-information-details-textual Note 12 - Business Segment Information (Details Textual) Details http://infusystem.com/20201231/role/statement-note-12-business-segment-information-tables 66 false false R67.htm 066 - Disclosure - Note 12 - Business Segment Information - Summary of Financial Information By Reportable Segment (Details) Sheet http://infusystem.com/20201231/role/statement-note-12-business-segment-information-summary-of-financial-information-by-reportable-segment-details Note 12 - Business Segment Information - Summary of Financial Information By Reportable Segment (Details) Details 67 false false R68.htm 067 - Disclosure - Note 13 - Employee Benefit Plans and Other (Details Textual) Sheet http://infusystem.com/20201231/role/statement-note-13-employee-benefit-plans-and-other-details-textual Note 13 - Employee Benefit Plans and Other (Details Textual) Details http://infusystem.com/20201231/role/statement-note-13-employee-benefit-plans-and-other 68 false false R69.htm 068 - Disclosure - Note 15 - Subsequent Events (Details Textual) Sheet http://infusystem.com/20201231/role/statement-note-15-subsequent-events-details-textual Note 15 - Subsequent Events (Details Textual) Details http://infusystem.com/20201231/role/statement-note-15-subsequent-events- 69 false false All Reports Book All Reports infu-20201231.xml infu-20201231.xsd infu-20201231_cal.xml infu-20201231_def.xml infu-20201231_lab.xml infu-20201231_pre.xml http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2020-01-31 http://fasb.org/srt/2020-01-31 true true ZIP 89 0001437749-21-006778-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-21-006778-xbrl.zip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end

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